

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

TOP RESEARCH PRIORITIES IN LIVER AND GALLBLADDER DISORDERS IN THE UNITED KINGDOM

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-025045
Article Type:	Research
Date Submitted by the Author:	02-Jul-2018
Complete List of Authors:	Gurusamy, Kurinchi; University College London, Walmsley, Martine; PSC Support Davidson, Brian; Royal Free London NHS Foundation Trust, HPB Surgery Frier, Claire; Royal Free London NHS Foundation Trust, HPB Surgery Fuller, Barry; University College London Madden, Angela; University of Hertfordshire Masson, Steven; Freeman Hospital Morley, Richard; Cochrane Collaboration Consumer Network Safarik, Ivana; Carolside Medical Centre Tsochatzis, E; University College London Ahmed, Irfan; NHS Grampian Cowlin, Maxine; Patient representative Dillon, John; University of Dundee Division of Cardiovascular and Diabetes Medicine, Liver Group Ellicott, Graham; Patient representative Elsharkawy, Ahmed; Queen Elizabeth Hospital Birmingham Farrington, Liz; Royal Cornwall Hospitals NHS Trust Glachan, Anthony; Patient representative Kumar, Nagappan; University Hospital of Wales Milne, EJ; Patient representative Rushbrook, Simon; Norfolk and Norwich University Hospitals NHS Foundation Trust, Smith, Amanda; Queen Elizabeth Hospital Birmingham Stafford, Lizzie; John Radcliffe Hospital Yeoman, Andrew; Royal Gwent Hospital
Keywords:	liver, chronic liver disease, research priorities

SCHOLARONE™
Manuscripts

1 TOP RESEARCH PRIORITIES IN LIVER AND

2 GALLBLADDER DISORDERS IN THE UNITED KINGDOM

3 Kurinchi S Gurusamy¹, Martine Walmsley², Brian R Davidson³, Claire Frier⁴, Barry Fuller⁵, Angela
4 Madden⁶, Steven Masson⁷, Richard Morley⁸, Ivana Safarik⁹, Emmanuel A Tsochatzis¹⁰, Irfan Ahmed¹¹,
5 Maxine Cowlin¹², John F Dillon¹³, Graham Ellicott¹², Ahmed M Elsharkawy¹⁴, Liz Farrington¹⁵, Anthony
6 Glachan¹², Nagappan Kumar¹⁶, EJ Milne¹², Simon M Rushbrook¹⁷, Amanda Smith¹⁸, Lizzie Stafford¹⁹,
7 Andrew Yeoman²⁰

8 ¹Reader in Surgery, Royal Free Campus, University College London, United Kingdom

9 ²Chair of Trustees, PSC Support, United Kingdom

10 ³Professor of Surgery, Royal Free Campus, University College London, United Kingdom

11 ⁴Cancer nurse specialist, HPB, Royal Free Hospital, London, United Kingdom

12 ⁵Professor of Surgery, Royal Free Campus, University College London, United Kingdom

13 ⁶Subject Group Lead for Nutrition and Dietetics, University of Hertfordshire, United Kingdom

14 ⁷Consultant hepatologist, Freeman Hospital, Newcastle, United Kingdom

15 ⁸James-Lind Alliance advisor

16 ⁹General Practitioner, Carolside Medical Centre, Clarkston, Glasgow, United Kingdom

17 ¹⁰Senior lecturer in Hepatology/Consultant hepatologist, UCL Institute for Liver and Digestive Health

18 Royal Free Hospital and University College London, United Kingdom

19 ¹¹Professor of Surgery, NHS Grampian, Aberdeen, United Kingdom

20 ¹²Patient and public representative, United Kingdom

21 ¹³Professor of Hepatology & Gastroenterology, NHS Tayside, Gastroenterology Dundee, UK

1
2
3 22 ¹⁴Consultant Hepatologist, Queen Elizabeth Hospital, Birmingham, United Kingdom
4

5 23 ¹⁵Consultant Nurse Hepatology, Royal Cornwall Hospital, Truro, United Kingdom
6
7

8 24 ¹⁶Consultant HPB Surgeon, University Hospital of Wales, Cardiff, United Kingdom
9

10 25 ¹⁷Consultant Hepatologist, Norfolk and Norwich University Hospital, Norwich, United Kingdom
11
12

13 26 ¹⁸Specialist Pharmacist – Liver, Queen Elizabeth Hospital, Birmingham, United Kingdom
14
15

16 27 ¹⁹Hepatology Research Nurse, John Radcliffe Hospital, Oxford, United Kingdom
17
18

19 28 ²⁰Consultant Hepatologist, Royal Gwent Hospital, Newport, United Kingdom
20
21

22 29 Corresponding author: Kurinchi S Gurusamy
23

24 30 Postal address: Floor 9, Royal Free Hospital, Royal Free Campus UCL, Rowland Hill Street, London
25
26

27 31 NW3 2PF; Email: k.gurusamy@ucl.ac.uk
28
29

30 32 Word count: 3569
31

32 33 Keywords: liver, chronic liver disease
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

34 ABSTRACT

35 Objectives: There is a mismatch between research questions considered important by patients,
36 carers, and healthcare professionals and the research performed in many fields of medicine. The
37 Non-Alcohol-Related Liver and gallbladder disorders Priority setting partnership (NARLIP) was
38 established to identify the top research priorities in the prevention, diagnostic, and treatment of
39 gallbladder disorders and liver disorders not covered by the James-Lind Alliance (JLA) Alcohol-related
40 liver disease (ARLD) Priority Setting Partnership.

41 Design: The methods broadly followed the principles of the JLA guidebook. The one major deviation
42 from the JLA methodology was the final step of identifying priorities: instead of prioritisation by
43 group discussions at a consensus workshop involving stakeholders, the prioritisation was achieved
44 by a modified Delphi consensus process.

45 Results: A total of 428 unique valid diagnostic or treatment research questions were identified. A
46 literature review established that none of these questions were considered 'answered' i.e. high
47 quality systematic reviews suggest that further research is not required on the topic. The Delphi
48 panel achieved consensus (at least 80% Delphi panel members agreed) that a research question was
49 a top research priority for six questions. Four additional research questions with highest proportion
50 of Delphi panel members ranking the question as highly important were added to constitute the top
51 10 research priorities.

52 Conclusions: A priority setting process involving patients, carers and healthcare professionals has
53 been used to identify the top ten priority areas for research related to liver and gallbladder
54 disorders. Basic, translational, clinical, and public health research are required to address these
55 uncertainties.

56 Keywords: liver, chronic liver disease

57 Word count: 3618

ARTICLE SUMMARY

Strengths and limitations

- A research prioritisation process involving clinicians, patients and carer, and public representatives was performed in the field of liver and gallbladder disorders. This will help to address the mismatch between research questions that are considered important jointly by patients, carers, and healthcare professionals and the research performed in the field of liver and gallbladder disorders.
- A Delphi consensus method was performed. This prevented dominance of 'loud voices', a problematic issue with small and large group discussions.
- Because of the predominance of people with chronic liver disease on the Delphi panel, many of the top research priorities related to chronic liver diseases.

INTRODUCTION

Failure to address treatment uncertainties by research can lead to significant suffering and deaths [1]. It is important that research in any field of medicine takes into account the shared interests of patients, carers and clinicians [2]. However, there is a mismatch between research questions that are considered important jointly by patients, carers, and healthcare professionals and the research performed in many fields of medicine [3 4]. The James Lind Alliance (JLA) exists to help ensure a patient-centred process and enables the limited research resources to be utilised in addressing the research questions that are considered important jointly by patients, carers, and healthcare professionals [2] ('top research priorities'). This is achieved by forming 'Priority Setting Partnerships' (PSPs) between patients, carers, and healthcare professionals [2].

There has only been one formal research prioritisation process involving patients, carers, and healthcare professionals in the field of liver and gallbladder disorders [5]. However, the scope of that PSP was limited to alcohol-related liver disorders [5]. The Non-Alcohol-Related Liver and

1
2
3 82 gallbladder disorders Priority setting partnership (NARLIP) was established to address the
4
5 83 prevention, diagnostic, and treatment uncertainties related to the majority of liver disorders which
6
7 84 were not covered by the JLA PSP on alcohol-related liver diseases (ARLD) [5] and to include
8
9 85 gallbladder disease.

10
11
12 86 The aims and objectives of the NARLIP were to work with patients, their carers, and
13
14 87 healthcare professionals treating them ('stakeholders') to identify uncertainties about the diagnostic
15
16 88 tests and effects of prevention and treatments for non-alcohol related liver and gallbladder
17
18 89 disorders, to agree by consensus a prioritised list of those uncertainties for research, to publicise the
19
20 90 results and process, and to take the results to research commissioning bodies to be considered for
21
22 91 funding and researchers to encourage them to submit grant applications addressing these
23
24 92 uncertainties.

27 93 **METHODS**

28
29
30 94 The methods broadly followed the principles of the JLA guidebook.[6] The broad steps involved the
31
32 95 following and are summarised in Figure 1.

- 33
34
35 96 1. Formation of the partnership: organisations and individuals representing people affected by
36
37 97 non-alcohol related liver or gallbladder disorders, their carers, and healthcare professionals
38
39 98 treating people with non-alcohol related liver and gallbladder disorders. A partnership was
40
41 99 formed between KG representing University College London and the British Liver Trust
42
43
44 100 initially, but following reorganisation in the British Liver Trust, PSC Support [7] became the
45
46 101 leading patient organisation partner of this process. A steering committee was formed. The
47
48 102 members of the steering committee who participated in the complete process were KG,
49
50 103 MW, BRD, CF, BF, AM, RM, SM, IS, and ET.
- 51
52 104 2. Establishment of the scope: the steering committee members discussed and decided that
53
54 105 the scope should include adult and paediatric liver and gallbladder disorders which required

- 1
2
3 106 medical and surgical treatments. The protocol was registered with James-Lind Alliance
4
5 107 Priority Setting Partnership.
6
7 108 3. Identifying potential research questions: research questions were collected through online
8
9 109 surveys and searching UK Database of Uncertainties about the Effects of Treatments (UK
10
11 110 DUETs), research recommendations in high quality systematic reviews and clinical
12
13 111 guidelines, and registers of ongoing research.
14
15 112 4. Refining research questions: the research questions identified in the above step were
16
17 113 reviewed and where necessary combined to result in a set of unique research questions.
18
19 114 Research questions were considered 'answered' when recent high-quality systematic
20
21 115 reviews (based on low risk of bias studies) concluded that further research was not required.
22
23 116 Removal of such 'answered' research questions was planned. The remaining questions were
24
25 117 'uncertainties'.
26
27
28 118 5. Interim prioritisation: To shortlist the set of questions to manageable levels for the final
29
30 119 prioritisation process, the members of the steering committee ranked the uncertainties after
31
32 120 stratifying the questions as medical and surgical questions. The members of the steering
33
34 121 committee agreed that the interim prioritisation list should consist of 75% medical questions
35
36 122 and 25% surgical questions. This decision was an arbitrary decision made by the steering
37
38 123 committee based on the rationale that majority of individuals with liver and gallbladder
39
40 124 disorders are treated medically but a minority require surgery which have a major impact on
41
42 125 patients' lives.
43
44
45 126 6. Final prioritisation by consensus: A modified Delphi consensus method was followed to
46
47 127 identify the top priorities using methods described by Jones et al [8]. The steps in the
48
49 128 modified Delphi consensus method were as follows.
50
51 129 a. A Delphi panel consisting of patients, their carers, and healthcare professionals
52
53 130 treating them was formed. A total of 42 people expressed interest in joining the
54
55
56
57
58
59
60

1
2
3 131 Delphi panel and 33 panel members completed all three rounds. Details of the
4
5 132 Delphi panel composition and drop-outs are reported in the results section.
6
7 133 b. A total of three rounds were conducted.
8
9 134 c. Delphi panel members scored the short-listed questions in the interim prioritisation
10
11 135 process on a scale of 1 to 9 with 1 being considered least important and 9 being
12
13 136 considered most important. Scores of 1 to 3 were categorised as 'less important', 4
14
15 137 to 6 as 'moderately important', and 7 to 9 as 'highly important'. Panel members
16
17 138 were requested to score the questions according to the importance of the question
18
19 139 to them/the persons that they represent or treat and could leave questions that
20
21 140 they were unable to score empty. Each Delphi panel member could add a maximum
22
23 141 of two questions in the first round to ensure that the questions most important to
24
25 142 the Delphi panel members were included in the prioritisation process even if they
26
27 143 were not identified in the earlier steps. In the subsequent rounds, the panel
28
29 144 members were shown the summary scores and their previous score for each
30
31 145 question. They were able to retain or change their score in each of the rounds after
32
33 146 the first round. For calculation of the summary scores and the proportion
34
35 147 considering a question 'highly important', non-responses were excluded.
36
37 148 d. Consensus about a specific research question being a top research priority was
38
39 149 reached when 80% or more Delphi panel members considered the research question
40
41 150 as highly important (allocated scores between 7 and 9).
42
43 151 e. When fewer than 10 research priorities were obtained by consensus, the remaining
44
45 152 priorities were completed by uncertainties based on the highest proportions of
46
47 153 panel members agreeing that the research question was highly important (scores
48
49 154 between 7 and 9).
50
51
52
53
54
55
56
57
58
59
60

1
2
3 155 f. There was no restriction on the Delphi panel to consult others while scoring the
4
5 156 questions. However, only one final response on the set of questions was accepted
6
7 157 from each Delphi panel member.
8
9

10 158 When there were no recent high-quality systematic reviews on the research question, we have
11
12 159 recommended high-quality systematic reviews. When recent high-quality systematic reviews
13
14 160 recommended high-quality research, we have recommended randomised controlled trials for
15
16 161 prevention and treatment, as such studies carry the lowest risk of bias if conducted well; we would
17
18 162 have recommended well conducted diagnostic test accuracy studies for diagnostic uncertainties. All
19
20 163 online surveys were completed using Google Forms designed by KG. The Delphi process was
21
22 164 completed using Microsoft Excel and email.
23
24

25 165 Ethical approval was not deemed necessary because no personal identifiable information
26
27 166 was being collected, and the questions were being asked of healthcare professionals, patients and
28
29 167 their carers were not considered sensitive questions. In addition, we had full support of patient
30
31 168 organisations with involvement of patient representatives throughout the whole process rather than
32
33 169 patients visiting the hospitals.
34
35

36 170 **Patient and Public involvement**

37
38 171 Patients and public were involved in all aspects of this project: they were part of the steering
39
40 172 committee and were involved in the definition of the scope, methodology used for the prioritisation
41
42 173 process, identification of further patients and public representatives, participation in the Delphi
43
44 174 panel, interpretation, and critical revisions of the draft report. They will be involved in the
45
46 175 dissemination of the findings through patient websites, patient forums, and to research funders.
47
48
49
50
51
52
53
54
55
56
57
58
59
60

176 RESULTS

177 Identification and refining of research uncertainties

178 A total of 126 patients, carers, and those at risk of developing non-alcohol related liver and
179 gallbladder disorders, and 13 healthcare professionals participated in the first survey which was
180 conducted between July and December 2015. This survey resulted in a total of 209 unique research
181 questions. In addition, 219 unique questions were identified from searching the UK DUETs, Pubmed,
182 and ClinicalTrials.gov on 2nd January 2016. A total of 428 unique valid (i.e. falling within the remit of
183 this priority setting partnership) research questions (247 medical-related and 181 surgery-related)
184 were identified from these sources. None of the research questions had been answered by recent
185 high-quality systematic reviews based on low risk of bias studies which concluded that further
186 research was not required. Therefore, all the 428 research questions were considered research
187 ‘uncertainties’. The complete list of 428 unique valid uncertainties in no particular order is available
188 in Online Supplement Appendix 1. This has been converted to the population, intervention, control,
189 and outcomes (PICO) format whenever possible.

190 Interim priorities

191 To identify a shortlist of questions (from the list of 429 questions) that were to be considered for the
192 next step, a total of 48 research priorities (36 medical questions and 12 surgical questions) were
193 identified on the basis of being selected by at least one patient or carer and healthcare professional
194 of the steering committee (24 questions) and obtaining the highest ranks among the members of the
195 steering committee (additional 24 questions). The list of 48 questions identified as interim priorities
196 in no particular order is available in Online Supplement Appendix 2.

197 Final priorities

198 A total of 42 people expressed interest in joining the Delphi panel and 33 panel members completed
199 all three rounds. Five people dropped out before they returned the scores of the first round, three
200 between first and second rounds, and one between the second and third rounds. Of the 33 panel

201 members who completed all the three rounds, 17 were healthcare professionals and 16 were
 202 patients, carers, and general public. Of the 17 healthcare professionals, six were hepatologists, four
 203 were surgeons, two were hepatology nurses, and the remaining were general practitioner (GP), HPB
 204 surgery (hepato-pancreato biliary) nurse, organ preservation biologist, dietician, and pharmacist
 205 (one each). Of the 16 patients, carers, and general public, there was representation from general
 206 public and various liver diseases including autoimmune diseases such as primary sclerosing
 207 cholangitis, primary biliary cholangitis, autoimmune hepatitis, viral hepatitis, metabolic diseases
 208 such as non-alcohol related fatty liver disease, and other diseases such as hepatocellular carcinoma
 209 and polycystic liver disease. There was also representation of liver transplanted patients in the
 210 Delphi panel. In total, 23 panel members were from England, seven were from Scotland, and three
 211 were from Wales. There were no panel members from Northern Ireland despite attempts to include
 212 panel members from Northern Ireland.

213 A total of 22 additional questions were added by the Delphi panel members in the first
 214 round of the Delphi process. The Delphi panel achieved consensus that an uncertainty was a top
 215 research priority for six research questions. Four additional research questions with the highest
 216 proportion of Delphi panel members scoring the question as highly important (scores between 7 and
 217 9) were added to constitute the top 10 research priorities. The list of the top 10 research priorities
 218 (in the order of proportion who agreed that the uncertainty is a very important research priority) is
 219 available in Table 1. All the top 10 research priorities were prevention and treatment uncertainties,
 220 and none were diagnostic test uncertainties.

221 **Table 1 Treatment uncertainties for which consensus that the**
 222 **uncertainty is a research priority was reached**

Treatment uncertainty (Research question)	Proportion who rated this	Median (interqua
---	------------------------------	---------------------

	question as highly important in the final round	rtile range) in the final round
What is the best treatment for people with early or very early hepatocellular carcinoma (HCC)?	93.5%	8(7,9)
What are the best treatments that cure or delay the progression (worsening) of primary sclerosing cholangitis (PSC)?	93.3%	8(7,9)
What are the best treatments that cure or delay the progression (worsening) of non-alcohol-related fatty liver disease (NAFLD)?	90.3%	9(8,9)
What is the best immunosuppressive regimen in adults undergoing liver transplantation?	90.3%	8(7,9)
Should general public be educated about non-alcohol-related fatty liver disease (NAFLD) with an aim to reduce the numbers of those that have it?	81.8%	8(7,9)
What are the best treatments that cure or delay the progression (worsening) of autoimmune hepatitis (AIH)?	80.6%	8(7,9)
What are the best treatments that cure or delay the progression (worsening) of non-alcohol related steatohepatitis (NASH)?	76.7%	8(6.75,9)
Prior to liver transplantation, is it better to transport the	74.2%	7(6,9)

donor liver using a machine which pumps blood or preservation solution through the liver (machine perfusion) or is it better to transport it in the standard way of transporting it immersed in cold preservation solution (cold storage)?		
What are the best treatments that cure or delay the progression (worsening) of primary biliary cholangitis (PBC)?	74.2%	7(6,8)
Are there any treatments that reverse the liver damage in primary sclerosing cholangitis (PSC)?	72.4%	7(6,9)

223

224 A summary of the availability of systematic review of randomised controlled trials on the topic of the
 225 individual questions, randomised controlled trials on the topic not included in the systematic review
 226 (if one exists), and the outcomes evaluated in these RCTs are listed in Table 2. Table 2 also contains a
 227 suggestion for the next research steps. The list of the existing trials was compiled by searching
 228 ClinicalTrials.gov on 7th April 2018. The references to the trials not included in the systematic reviews
 229 is available in Online Supplement Appendix 3. As seen in Table 2, a well-designed RCT is the next
 230 step for eight of these top 10 research questions. This is because it appears that the outcomes in
 231 those trials will not address the outcomes listed in the research questions.

232 **Table 2 Next step to address the top 10 research priorities based on**
 233 **current best evidence (summary)**

Treatment uncertainty (Research question)	High-quality systematic review ^{a, c}	RCTs not included in the systematic review ^{a, c}	Patient-oriented outcomes assessed in	Next step
---	--	--	---------------------------------------	-----------

	review a,b		trials not included in the systematic review ^d	
What is the best treatment for people with early or very early hepatocellular carcinoma (HCC)?	[9]	8 trials	Survival (7 trials), recurrence (5 trials), morbidity (3 trials)	High-quality RCTs of interventions not covered in ongoing trials and comparison of health-related quality (HRQoL) in different treatments
What are the best treatments that cure or delay the progression (worsening) of	[10]	9 trials	None of the trials include	High-quality

primary sclerosing cholangitis (PSC)?			survival, HRQoL as outcomes ^e	RCTs with clinical outcomes
What are the best treatments that cure or delay the progression (worsening) of non-alcohol-related fatty liver disease (NAFLD)?	[11] (includes only pharmacological interventions)	More than 10 published trials on lifestyle interventions and more than 20 trials on nutritional supplementation with no recent high-quality systematic reviews <u>Pharmacological interventions</u> 44 trials	Lifestyle interventions and nutritional supplementation Not applicable as there are no high quality systematic reviews <u>Pharmacological intervention</u> s Health-related quality of life (2 trials), resolution of fatty liver	High-quality systematic reviews on lifestyle interventions (one review) and nutritional supplementation to cure or delay the progression of NAFLD and high-quality RCTs on

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

			disease (11 trials), mortality (2 trials), cirrhosis (2 trials), cardiovascular events (2 trials) ^e	pharmacological interventions with clinical outcomes
What is the best immunosuppressive regimen in adults undergoing liver transplantation?	[12] (covers only maintenance immunosuppression)	<u>Induction immunosuppression</u> More than 20 published trials <u>Maintenance immunosuppression</u> 4 trials	<u>Induction immunosuppression</u> Not applicable as there is no high quality systematic review <u>Maintenance immunosuppression</u> Graft	High-quality systematic review on induction immunosuppressive regimen and high-quality RCTs on maintenance

			survival (1 trial) Adverse events (1 trial) Hepatocellular carcinoma (1 trial) ^e	immunosuppression with important clinical outcomes
Should general public be educated about non-alcohol-related fatty liver disease (NAFLD) with an aim to reduce the numbers of those that have it?	None	None	-	High-quality RCTs on education to prevent NAFLD
What are the best treatments that cure or delay the progression (worsening) of autoimmune hepatitis (AIH)?	None	15 trials	Survival (1 trial), health-related quality of life (1 trial) ^e	High quality RCTs with clinical outcomes
What are the best treatments that cure or delay the progression (worsening) of non-alcohol related steatohepatitis (NASH)?	The evidence related to this question is covered under non-alcohol related fatty liver disease by performing a subgroup analysis of people with NASH			
Prior to liver transplantation, is it better to transport the donor liver using a machine which pumps blood or	None	5 trials	Overall survival (4 trials), graft	Await results of the RCTs

<p>1 2 3 preservation solution through the liver 4 (machine perfusion) or is it better to 5 transport it in the standard way of 6 transporting it immersed in cold 7 preservation solution (cold storage)? 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27</p>			<p>survival (5 trials), health- related quality of life (2 trials)</p>	<p>(all expected to complete by the end of 2019) and perform a high quality systematic review.</p>
<p>28 What are the best treatments that cure or 29 delay the progression (worsening) of 30 primary biliary cholangitis (PBC)? 31 32 33 34 35 36 37 38 39 40 41 42</p>	[13]	24 trials	<p>Health- related quality of life (5 trials), relief of symptoms (5 trials)^e</p>	<p>High- quality RCTs with clinical outcomes</p>
<p>43 Are there any treatments that reverse the 44 liver damage in primary sclerosing 45 cholangitis (PSC)? 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60</p>	<p>The evidence related to this question is covered under treatments for primary sclerosing cholangitis. The systematic review did not include fibrosis as one of the outcomes. Nine of the trials included in the systematic review reported on fibrosis. Two of the trials not included in the systematic review (and listed above)</p>			

	reported on liver fibrosis.
--	-----------------------------

234

235 a Numbers indicate the reference number.

236 b Further well-designed randomised controlled trials using clinical outcomes were recommended by

237 all these systematic reviews.

238 c Ongoing trials, unpublished trials, or trials published since the search date for the systematic

239 review when a high-quality systematic review based on randomised controlled trials exists. If no

240 systematic reviews based on randomised controlled trials exist, these are either published trials or

241 ongoing studies.

242 d This information is reported to find out whether the important patient-oriented outcomes are

243 reported in the trials not covered by high-quality systematic reviews. This is to help with deciding

244 whether new randomised controlled trials are necessary on the topic.

245 e The remaining trials reported treatment-related adverse events, composite outcomes and

246 surrogate markers.

247

248 The complete list of questions in the Delphi process, the proportion of respondents who

249 considered a research question as very important and the summary scores in each Delphi round is

250 available in Online Supplement Appendix 4.

251 **DISCUSSION**

252 This is the first priority setting partnership on non-alcohol related liver and gallbladder disorders.

253 This included a wide range of disease processes and a total of 428 unique research questions that

254 met the scope of this priority setting partnership were identified. All the research questions were

255 considered unanswered as there had been no high quality systematic reviews which indicated that

256 no further research is required, i.e. all the research questions were uncertainties. Consensus that an

1
2
3 257 uncertainty was a very important research priority was reached for six research questions. Four
4
5 258 additional research questions with the highest proportion of Delphi panel members ranking the
6
7 259 question as highly important were added to constitute the top 10 research priorities.
8
9

10 260 As evident from the online supplement Appendix 1, longevity of life and health-related
11
12 261 quality of life are two major outcomes that appear important to patients, their carers, and
13
14 262 healthcare professionals. However, even when there are ongoing trials, it appears that the outcomes
15
16 263 in those trials will not address the outcomes listed in eight of the top 10 research questions (Table
17
18 264 2). Therefore, the next step in addressing these uncertainties is the design and conduct of
19
20 265 randomised controlled trials. Such randomised controlled trials may involve qualitative studies to
21
22 266 determine the design and should compare the treatments that improve the longevity of life and/or
23
24 267 health-related quality of life.
25
26

27 268 It should be noted that uncertainties ‘what are the best treatments that cure or delay the
28
29 269 progression (worsening) of non-alcohol-related fatty liver disease (NAFLD)?’ and ‘what are the best
30
31 270 treatments that cure or delay the progression (worsening) of non-alcohol related steatohepatitis
32
33 271 (NASH)?’ are related to each other. Although NAFLD includes NASH, most of the panel members felt
34
35 272 that the research questions related to NAFLD and NASH should be kept separate uncertainties.
36
37 273 While the same systematic review can cover both the uncertainties, the primary research study
38
39 274 designed to address these two questions differ in terms of the setting, the outcomes used, and the
40
41 275 period of follow-up. Any primary research that tries to answer these two questions in a single
42
43 276 randomised controlled trial will be inefficient.
44
45

46 277 Similarly, for the uncertainties ‘what are the best treatments that cure or delay the
47
48 278 progression (worsening) of primary sclerosing cholangitis (PSC)’ and ‘are there any treatments that
49
50 279 reverse the liver damage in primary sclerosing cholangitis (PSC)?’, a single randomised controlled
51
52 280 trial will be inefficient and the preference of most of the panel members was to keep these
53
54 281 uncertainties as separate uncertainties.
55
56
57
58
59
60

1
2
3 282 There are several limitations to our priority setting process. The first one is deviation from
4
5 283 the original protocol. To select the final top priorities, the initial plan was to arrive at consensus by
6
7 284 open small group and large group discussions of patients, carers, and healthcare professionals as
8
9 285 suggested by the standard James-Lind Alliance process [6], which provides an opportunity for a
10
11 286 knowledge exchange of viewpoints and experience. However, part of the steering committee with
12
13 287 experience in a similar priority setting partnership felt that open discussions resulted in ‘loud voices’
14
15 288 being given more importance resulting in an unrepresentative list of top priorities. While this can be
16
17 289 mitigated by facilitated group discussions by neutral JLA facilitators to ensure that all voices were
18
19 290 heard in the discussions, this was considered by the steering committee as an important source of
20
21 291 bias based on their prior experience in participating in open discussions. The steering committee
22
23 292 therefore decided to follow the Delphi-consensus method which is one of the major consensus
24
25 293 methods[8]. The advantages of Delphi-consensus method over open discussions include anonymity
26
27 294 of the response and the equal weight given to the opinions of all members [8]. In addition, they are
28
29 295 less costly to conduct without any limitation by geographical location compared to other methods of
30
31 296 consensus[8] because of the lack of necessity to travel and take time off regular work. However,
32
33 297 there is considerable variability in the previous performance of Delphi processes with regards to the
34
35 298 number of rounds and the criteria for achieving consensus [14]. Arriving at consensus depends upon
36
37 299 people revising their scores based on the other’s scores. Our initial plan was to extend the Delphi to
38
39 300 four rounds if consensus on 10 top research priorities was not reached in three rounds. However,
40
41 301 there was minimal change in scores between the rounds for most questions (Online Supplement
42
43 302 Appendix 3) and the Delphi process was completed in three rounds. Consensus on a top research
44
45 303 priority was achieved for six questions only. However, the proportion of Delphi panel members
46
47 304 ranking a question as highly important was greater than 70% for the remaining four questions added
48
49 305 to the list of top research priorities. Previous Delphi consensus processes have used various cut-off
50
51 306 points for defining consensus: greater than 70% agreement among panel members is well within the
52
53 307 definition of consensus used in previous Delphi consensus processes [14].
54
55
56
57
58
59
60

1
2
3 308 The other major limitation of our priority setting process is the representativeness of the
4
5 309 people who completed the survey and took part in the Delphi process. The online survey was shared
6
7 310 among clinicians and members of general and disease-specific patient organisations. Most questions
8
9 311 resulting from the online survey relate to chronic liver disease (in particular, autoimmune liver
10
11 312 diseases), perhaps reflecting the high motivation to support research from those groups. The Delphi
12
13 313 panel also had a high representation of people related to chronic liver disease (in particular,
14
15 314 autoimmune liver diseases) as patients, carers, or healthcare professionals. Whilst people affected
16
17 315 by different liver and gallbladder disorders were actively sought through both general and disease-
18
19 316 specific patient support groups and organisations, only a few responded and completed all three
20
21 317 rounds of the Delphi process. The potential bias towards prioritising chronic liver diseases is evident
22
23 318 as nine of the top 10 research priorities relate to chronic liver diseases (four relate to autoimmune
24
25 319 liver diseases, three related to non-alcohol related fatty liver disease, two related to liver
26
27 320 transplantation). It was surprising that the uncertainties related to the treatment of chronic viral
28
29 321 diseases such as chronic hepatitis B and chronic hepatitis C were not identified within the top 10
30
31 322 research priorities. This may be because of the perception by the some of the panel members that
32
33 323 the research questions related to the treatment of chronic hepatitis C were answered with the
34
35 324 advent of directly acting antivirals (personal communication). The reason for non-prioritisation of
36
37 325 chronic hepatitis B is not entirely clear. This may be because chronic hepatitis B may not have been
38
39 326 considered as important as other chronic liver diseases or under-representation of chronic hepatitis
40
41 327 B in the panel.

42
43
44
45 328 Cancer-related questions, childhood-related liver diseases, and other benign disorders did
46
47 329 not end up in the top research priorities (except for the treatment of very early hepatocellular
48
49 330 carcinoma, which is managed by hepatologists and surgeons) probably for the reasons described
50
51 331 above. We recommend that separate prioritisation processes are carried out for people with
52
53 332 gallstones, a condition that affects approximately 5% to 25% of the population [15], for people with
54
55 333 primary and secondary liver cancer, and childhood liver disorders where significant uncertainties

1
2
3 334 remain on the effectiveness of different treatments in decreasing mortality and improving health-
4
5 335 related quality of life.
6

7
8 336 As well as the above limitation, we are aware of the inherent limitations of using solely
9
10 337 technology to carry out the Delphi exercise. These are limitations that can potentially lead to bias in
11
12 338 any consensus-building method including that of face-to-face consensus methods normally used in a
13
14 339 JLA PSP.
15

16
17 340 One solution which might address the limitations of this priority setting process and the
18
19 341 standard JLA process may be to collect information routinely from patients visiting hospitals using
20
21 342 paper forms and conduct online meetings (video conferencing and presentation) before the final
22
23 343 round of the Delphi (or the standard face-to-face priority setting workshop used by the JLA. Some
24
25 344 JLA PSPs do use methods such as face-to face interviews and group discussions rather than solely
26
27 345 online surveys). By collecting information on paper forms and conducting the meetings in hospitals,
28
29 346 it is possible to engage with people who do not have access to or are not familiar with computers. It
30
31 347 is also possible to engage with people who have concerns regarding data confidentiality with the use
32
33 348 of computers or social media by collecting information using paper forms. Ethical and confidentiality
34
35 349 issues will need to be considered prior to engaging patients attending hospital in the research
36
37 350 prioritisation process.
38

39
40 351 Another limitation of our priority setting process is the drop-outs during the Delphi process.
41
42 352 While some of the drop-outs may be related to the ability to complete online surveys and use
43
44 353 Microsoft Excel, some patient representatives or clinicians may have dropped out because they did
45
46 354 not find any research question to be of direct relevance to them. Other reasons include lack of
47
48 355 understanding of the conditions, feeling that the process was too complicated, feeling that the
49
50 356 process would not work, and the time commitment for the process. This is because of the broad
51
52 357 scope of this research prioritisation process and may be overcome by choosing a narrower focus
53
54
55
56
57
58
59
60

1
2
3 358 while defining the scope of the prioritisation process, and by better explanation of the disease
4
5 359 processes through presentations.
6

7
8 360 It should also be recognised that the Delphi panel was constituted of representatives from
9
10 361 England, Scotland, and Wales. Therefore, the findings are applicable in only these countries.

11 362 However, the findings are likely to be applicable throughout the NHS and in other European and
12
13 363 Western countries with a similar spectrum of chronic liver diseases and similar treatment options
14
15 364 available.
16
17

18
19 365 In summary, there are significant uncertainties in the management of liver and gallbladder
20
21 366 disorders. Further high-quality research is necessary to address these uncertainties which may
22
23 367 require programmes of basic, translational, clinical, and public health research. For issues with
24
25 368 diverse and unproven treatment options, randomised controlled trials may be the only mechanism
26
27 369 for identifying the most effective treatment and the treatments that represent good value for
28
29 370 money for the NHS. Such randomised controlled trials should assess the effect of different
30
31 371 treatments in improving longevity of life and/or health-related quality of life.
32
33

34 372 **ACKNOWLEDGEMENTS**

35
36
37 373 We thank Mr Andrew Langford, previous Chief Executive of British Liver Trust, participants in the
38
39 374 survey, Ms Caroline Whiting and Ms Beccy Maeso, JLA PSP co-ordinators for their advice on the
40
41 375 process and comments on the manuscript, and the Delphi panel members who preferred to remain
42
43 376 anonymous in contributing to this research prioritisation process.
44
45

46 377 **FUNDING**

47
48
49 378 There was no external funding.
50
51
52
53
54
55
56
57
58
59
60

379 CONTRIBUTION OF AUTHORS

380 Kurinchi Gurusamy – conceptualisation, healthcare professional and methodological lead of steering
381 committee, Delphi panel member, analysis, **author** of the manuscript.

382 Martine Walmsley – Patients and carers lead of steering committee, Delphi panel member

383 Brian Davidson, Claire Frier, Barry Fuller, Angela Madden, Steven Masson, Ivana Safarik, Emmanouil

384 Tsochatzis – Steering committee, Delphi panel member, suggested revisions to the manuscript

385 Richard Morley – Steering committee, JLA advisor

386 Irfan Ahmed, Maxine Cowlin, John Dillon, Graham Ellicott, Ahmed Elsharkawy, Liz Farrington,

387 Anthony Glachan, Nagappan Kumar, EJ Milne, Simon Rushbrook, Amanda Smith, Lizzie Stafford,

388 Andrew Yeoman – Delphi panel member, suggested revisions to the manuscript

389 CONFLICTS OF INTEREST

390 The decisions made by healthcare professionals involved in the research prioritisation process might
391 have been influenced by their professional interests, in addition to their own, or family member's
392 experience of health conditions. Decisions made by patients and carers in the research prioritisation
393 process might have been influenced by their particular experiences, health needs and interests.

394 DATA SHARING AGREEMENT

395 All data is available in the manuscript or in the supplementary file.

396 FIGURE 1

397 Research prioritisation steps

398 The major steps in the research prioritisation are shown in the figure.

399 ^aThe protocol was registered with James-Lind Alliance Priority Setting Partnership

1
2
3 400 ^bThe final prioritisation was achieved by modified Delphi consensus method.
4
5

6 401 REFERENCES

- 7
8
9 402 1. Chalmers I. Confronting therapeutic ignorance. *BMJ* 2008;337:a841. doi:
10 403 10.1136/bmj.39555.392627.80 [published Online First: 2008/07/18]
11
12
13 404 2. James Lind Alliance Priority Setting Partnerships. About the James Lind Alliance.
14
15 405 <http://www.jla.nihr.ac.uk/about-the-james-lind-alliance/> (accessed 6th April 2018) 2018
16
17 406 3. Crowe S, Fenton M, Hall M, et al. Patients', clinicians' and the research communities' priorities for
18
19 407 treatment research: there is an important mismatch. *Research Involvement and Engagement*
20
21 408 2015;1(1):2. doi: 10.1186/s40900-015-0003-x
22
23 409 4. Tallon D, Chard J, Dieppe P. Relation between agendas of the research community and the
24
25 410 research consumer. *The Lancet*;355(9220):2037-40. doi: 10.1016/S0140-6736(00)02351-5
26
27 411 5. James Lind Alliance Priority Setting Partnerships. Alcohol-related liver disease.
28
29 412 <http://www.jla.nihr.ac.uk/priority-setting-partnerships/alcohol-related-liver-disease/>
30
31 413 (accessed 6th April 2018) 2018
32
33 414 6. James Lind Alliance Priority Setting Partnerships. JLA guidebook. [http://www.jla.nihr.ac.uk/jla-](http://www.jla.nihr.ac.uk/jla-guidebook/)
34
35 415 [guidebook/](http://www.jla.nihr.ac.uk/jla-guidebook/) (accessed 6th April 2018) 2018
36
37 416 7. PSC Support. Welcome to PSC Support, dedicated to helping people affected by primary sclerosing
38
39 417 cholangitis. <https://www.pscsupport.org.uk/> (accessed 6th April 2018) 2018
40
41 418 8. Jones J, Hunter D. Consensus methods for medical and health services research. *BMJ*
42
43 419 1995;311(7001):376-80.
44
45 420 9. Majumdar A, Roccarina D, Thorburn D, et al. Management of people with early- or very early-
46
47 421 stage hepatocellular carcinoma: an attempted network meta-analysis. *The Cochrane*
48
49 422 *database of systematic reviews* 2017;3:CD011650. doi: 10.1002/14651858.CD011650.pub2
50
51 423 [published Online First: 2017/03/30]
52
53
54
55
56
57
58
59
60

- 1
2
3 424 10. Saffioti F, Gurusamy KS, Hawkins N, et al. Pharmacological interventions for primary sclerosing
4
5 425 cholangitis: an attempted network meta-analysis. *The Cochrane database of systematic*
6
7 426 *reviews* 2017;3:CD011343. doi: 10.1002/14651858.CD011343.pub2 [published Online First:
8
9 427 2017/04/19]
- 10
11 428 11. Lombardi R, Onali S, Thorburn D, et al. Pharmacological interventions for non-alcohol related
12
13 429 fatty liver disease (NAFLD): an attempted network meta-analysis. *The Cochrane database of*
14
15 430 *systematic reviews* 2017;3:CD011640. doi: 10.1002/14651858.CD011640.pub2 [published
16
17 431 Online First: 2017/03/31]
- 18
19 432 12. Rodriguez-Peralvarez M, Guerrero-Misas M, Thorburn D, et al. Maintenance immunosuppression
20
21 433 for adults undergoing liver transplantation: a network meta-analysis. *The Cochrane database*
22
23 434 *of systematic reviews* 2017;3:CD011639. doi: 10.1002/14651858.CD011639.pub2 [published
24
25 435 Online First: 2017/04/01]
- 26
27 436 13. Saffioti F, Gurusamy KS, Eusebi LH, et al. Pharmacological interventions for primary biliary
28
29 437 cholangitis: an attempted network meta-analysis. *The Cochrane database of systematic*
30
31 438 *reviews* 2017;3:CD011648. doi: 10.1002/14651858.CD011648.pub2 [published Online First:
32
33 439 2017/03/30]
- 34
35 440 14. Diamond IR, Grant RC, Feldman BM, et al. Defining consensus: a systematic review recommends
36
37 441 methodologic criteria for reporting of Delphi studies. *J Clin Epidemiol* 2014;67(4):401-9. doi:
38
39 442 10.1016/j.jclinepi.2013.12.002 [published Online First: 2014/03/04]
- 40
41 443 15. Gurusamy KS, Davidson BR. Gallstones. *BMJ* 2014;348:g2669. doi: 10.1136/bmj.g2669
42
43
44
45
46 444
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 1: Research prioritisation steps

The major steps in the research prioritisation are shown in the figure.
aThe protocol was registered with James-Lind Alliance Priority Setting Partnership
bThe final prioritisation was achieved by modified Delphi consensus method.

119x177mm (300 x 300 DPI)

Appendix 1 List of all research questions

Patient/population	Intervention	Control	Outcomes
People with obesity	Lifestyle: diet	No intervention	<ol style="list-style-type: none"> 1. Liver transplantation 2. Improvement in BMI. 3. Improved liver function
People with liver disease	Nurse-led care	Standard care	Ability to self-manage
People with asymptomatic chronic liver disease	Education of people	No intervention	<ol style="list-style-type: none"> 1. Improvement in life style. 2. Fatty liver disease
People with NASH (non-alcoholic steatohepatitis)	Different medical treatments	No intervention	<ol style="list-style-type: none"> 1. Halting disease progression. 2. Reversing disease progression. 3. Slowing disease progression. 4. Cure
People with primary sclerosing cholangitis	Treatment for primary sclerosing cholangitis	No intervention	<ol style="list-style-type: none"> 1. Mortality 2. HRQoL (health-related quality of life)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

			<p>3. Fewer symptoms - pain, itching, fatigue</p> <p>4. improved liver function</p> <p>5. Cure</p> <p>6. Time to liver transplantation</p> <p>7. Improvement (no further details)</p> <p>8. Decreased hospital admission</p> <p>9. Disease progression</p> <p>10. Remission from PSC</p> <p>11. Cancer</p> <p>12. Requirement for liver transplant.</p>
People with liver disease	Methods to improve compliance to treatment	Not applicable	<p>1. HRQoL</p> <p>2. Mortality</p>
General population	Screening: early identification of people at risk of liver disease	No screening	<p>1. HRQoL</p> <p>2. Mortality</p>

<p>1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29</p> <p>People at risk of liver disease</p>	<p>Diagnosis: early identification of people with liver disease</p>	<p>Not applicable</p>	<p>1. HRQoL 2. Mortality 3. Prevention of liver disease 4. Slowing progression of liver disease 5. Reducing requirement for liver transplantation 6. Adverse events of medications</p>
<p>30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60</p> <p>People with primary sclerosing cholangitis and who have had a liver transplant and still have ulcerative colitis even after a sub total colectomy</p>	<p>Symptomatic treatment for primary sclerosing cholangitis</p>	<p>Not applicable</p>	<p>1. HRQoL. 2. Decrease in symptoms (breathlessness and fatigue). 3. Mortality. 4. Decrease in medication. 5. Cure. 6. Decreased progression of primary sclerosing cholangitis.</p>

			7. Improvement in symptoms (unspecified).
People at risk of liver disease (overweight or obese)	Diagnosis: Accurate non-invasive method for diagnosis of chronic liver disease	Not applicable	<ol style="list-style-type: none"> 1. Death 2. Need for liver transplant 3. Requirement for hospital admission. 4. Demonstrating equivalence to biopsy 5. Demonstrating good reproducibility
People at risk of liver disease (overweight or obese)	Screening methods to diagnose liver disease (including history and diagnostic tests)	Not applicable	<ol style="list-style-type: none"> 1. Proportion of people at risk of liver disease 2. Proportion of people at risk who have asymptomatic liver fibrosis 3. Early diagnosis and treatment
People with polycystic liver disease	Treatment for polycystic disease	Not applicable	<ol style="list-style-type: none"> 1. Decrease symptoms 2. Increase quality of

			<p>life</p> <p>3. Decrease size of cyst or preventing cysts to enlarge</p> <p>4. Increased longevity</p> <p>5. Requirement for liver transplant.</p>
<p>People with autoimmune hepatitis</p>	<p>Treatments for autoimmune hepatitis.</p>	<p>Not applicable</p>	<p>1. HRQoL (including ability to carry out normal activities, study, work).</p> <p>2. Fatigue.</p> <p>3. Osteoporosis (treatment-related).</p> <p>4. Cataracts (treatment-related).</p> <p>5. Infections (treatment-related).</p> <p>6. Weight gain (treatment-related).</p> <p>7. Treatment related side-effects (unspecified).</p> <p>8. Brittle teeth</p>

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

			<p>(treatment-related).</p> <p>9. More effective treatment unspecified.</p> <p>10. Complete recovery (unspecified).</p> <p>11. Mortality.</p> <p>12. Measure feeling well (unspecified)</p> <p>13. Fewer flare ups</p> <p>14. Less joint pain.</p> <p>15. Disability</p> <p>16. Liver damage requiring hospital admission</p> <p>17. Quicker recovery</p> <p>18. More monitoring of patients</p> <p>19. Symptom control.</p> <p>20. Side-effects</p>
<p>People with autoimmune hepatitis</p>	<p>Standardised protocol care</p>	<p>Standard care</p>	<p>1. HRQoL.</p> <p>2. Fatigue.</p> <p>3. Osteoporosis</p>

For peer review only

			<p>(treatment-related).</p> <p>4. Cataracts</p> <p>(treatment-related).</p> <p>5. Infections</p> <p>(treatment-related).</p> <p>6. Weight gain</p> <p>(treatment-related).</p>
<p>People with autoimmune hepatitis</p>	<p>Treatment of fatigue/joint pain related to autoimmune hepatitis.</p>	<p>Not applicable</p>	<p>1. HRQoL.</p> <p>2. Fatigue.</p> <p>3. Osteoporosis</p> <p>(treatment-related).</p> <p>4. Cataracts</p> <p>(treatment-related).</p> <p>5. Infections</p> <p>(treatment-related).</p> <p>6. Weight gain</p> <p>(treatment-related).</p> <p>7. Joint pain.</p> <p>8. Symptoms</p> <p>(unspecified).</p>
<p>People with autoimmune hepatitis</p>	<p>Nurse-led care</p>	<p>Standard care</p>	<p>1. Faster recovery.</p> <p>2. HRQoL.</p> <p>3. Symptoms.</p>

1 2 3 4 5 6 7 8 9 10 11	People with autoimmune hepatitis	Education of healthcare professionals and patients	Standard care	1. Faster recovery. 2. HRQoL. 3. Symptoms.
12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43	People with autoimmune hepatitis	Lifestyle: diet	Standard care	1. Treatment related adverse events. 2. Requirements for liver transplantation. 3. NHS (National Health Service, UK) costs 4. HRQoL 5. Mortality. 6. Free from immunosuppressive therapies. 7. Fatigue. 8. Weight.
44 45 46 47 48 49 50 51 52	People with autoimmune hepatitis	Education of people	Standard care	Faster reduction in strong medications. Need for liver transplantation.
53 54 55 56 57 58 59 60	People with autoimmune hepatitis	Cannabis + standard care	Standard care	1. Reduction in immunosuppressants.

			<p>2. Fatigue.</p> <p>3. Treatment related side effects such as serious infections, anxiety, depression, cancer, physical side effects.</p>
<p>General population (> 40 years or >50 years or middle-aged people, particularly overweight/obese and/or have type 2 diabetes and/or a family history of chronic liver disease)</p>	<p>Screening for liver disease by GP using routine blood tests/other methods</p>	<p>Standard care</p>	<p>1. Earlier diagnosis and treatment.</p> <p>2. Preventing liver disease progressing to cirrhosis.</p> <p>3. More cost effective for NHS.</p> <p>4. Preventing the complications of chronic liver disease such as hepatocellular carcinoma and varices.</p>
<p>People with autoimmune hepatitis</p>	<p>Prednisolone</p>	<p>No intervention</p>	<p>1. Obesity.</p> <p>2. Osteoporosis.</p> <p>3. Insomnia.</p> <p>4. Hypertension.</p>

1 2 3 4 5 6 7 8 9	People with genetic markers associated with autoimmune hepatitis.	Methods for prophylaxis	No intervention	Prevention of autoimmune hepatitis
10 11 12 13	People with autoimmune hepatitis	Lifestyle: optimal physical exercise	Not applicable	1. Weight 2. Fatigue
14 15 16 17 18	People with autoimmune hepatitis (stable)	Nurse-led care	Standard care	1. Fatigue
19 20 21 22	People with suspected autoimmune hepatitis	Methods to make a quicker diagnosis	Not applicable	1. Earlier diagnosis
23 24 25 26 27 28 29	People with NASH, diabetes, and gastroparesis	Treatments for breathlessness and pain	Not applicable	1. Breathlessness and pain.
30 31 32 33 34	People with NASH cirrhosis, diabetes, and anaemia	Treatments	Not applicable	HRQoL
35 36 37 38	People with NASH cirrhosis, diabetes, and anaemia	Education of people	Standard care	Better knowledge
39 40 41	General population	Education of people	Standard care	Better knowledge
42 43 44 45 46 47	People with NASH cirrhosis, diabetes, and anaemia	Non-pharmacological treatments to decrease pain and depression	Pharmacological interventions or no intervention	1. Pain 2. Depression
48 49 50 51 52 53 54 55 56 57	People with suspected autoimmune diseases with potential to cause acute liver failure	Diagnosis of autoimmune diseases that cause acute liver failure	Not applicable	Identification of specific autoimmune diseases

<p>1 2 3 4 5 6 7 8 9</p> <p>People with autoimmune diseases with potential to cause acute liver failure</p>	<p>Prophylactic treatments</p>	<p>Not applicable</p>	<p>Prevent acute liver failure</p>
<p>10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36</p> <p>People with primary sclerosing cholangitis</p>	<p>Lifestyle: diet (including alcohol consumption) and physical exercise</p>	<p>Not applicable</p>	<p>1. Reduction in symptoms 2. Overall health benefits (unspecified) 3. Ability to return to useful occupation. 4. Reduce medication. 5. Reduce need for annual investigations.</p>
<p>37 38 39 40</p> <p>People with primary sclerosing cholangitis</p>	<p>Azathioprine</p>	<p>Other interventions</p>	<p>Treatment related adverse events</p>
<p>41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56</p> <p>People with autoimmune hepatitis</p>	<p>Non-pharmacological treatments to treat autoimmune hepatitis</p>	<p>Pharmacological interventions or no intervention</p>	<p>1. Reduction in symptoms 2. HRQoL (including the ability to do everyday tasks/ back into education or employment)</p>

1 2 3 4 5 6 7 8 9	People with primary sclerosing cholangitis	Itching receptor blockers	No intervention/ other interventions	Reduction in itching
10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29	People with primary sclerosing cholangitis with and without Vitamin D deficiency	Vitamin D supplements	Standard care	<ol style="list-style-type: none"> 1. Stop the progress of the disease. 2. Fewer flare ups of inflammatory bowel disease and primary sclerosing cholangitis. 3. Improve HRQoL 4. Less depression
30 31 32 33 34 35 36	People with primary sclerosing cholangitis and autoimmune hepatitis	Ursodeoxycholic acid	No intervention/ other interventions	Reducing symptoms
37 38 39 40 41 42 43	People at risk of primary sclerosing cholangitis and autoimmune hepatitis	Prophylactic treatments	No intervention	Prevention of the condition
44 45 46 47	People with autoimmune hepatitis	Non-steroidal interventions	Steroids	Adverse events
48 49 50 51 52 53 54 55 56 57 58 59 60	People at risk of autoimmune liver diseases	Prophylactic treatments	Not applicable	Reduction in those getting advanced liver disorders

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	People with autoimmune liver diseases (20 to 30 years old)	Treatments	Not applicable	1. Reduction in those getting advanced liver disorders. 2. Stabilisation of disorder. 3. Reduction in liver cancer rates.
19 20 21 22 23 24 25	People with autoimmune liver diseases (> 30 years)	Screening: Early diagnosis of liver cancer	No screening	Early diagnosis of liver cancer
26 27 28 29 30 31 32 33 34	People with NASH and stroke	Nurse-led care	Standard care	1. Recovery time 2. Amount of recovery that is made
35 36 37 38	People with haemochromatosis	Lifestyle: iron avoidance diet	Traditional phlebotomy	Reduction in iron levels
39 40 41 42 43	People with haemochromatosis	Acceleration of phlebotomy	Traditional phlebotomy	Reduction in iron levels
44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60	People with NAFLD	Nurse-led care	Standard care	1. Faster recovery. 2. Symptom relief (unspecified). 3. Prevention of more serious complications. 4. Patient education

			<p>on diet and exercise to lose weight.</p> <p>5. Preventing progression into NASH and cirrhosis.</p> <p>6. Reducing symptoms of aching sides, leg weakness, sickness and nausea.</p> <p>7. Prevent heart attacks and strokes.</p>
People with NAFLD	Treatments for pain	Not applicable	Reducing pain
People with NAFLD	Treatments for itching	Not applicable	Reduction in itching
People at risk of liver disease (overweight or obese)	Education of healthcare professionals about NAFLD	Standard care	<p>1. Prevention of cirrhosis.</p> <p>2. Prevention of other related liver complications.</p> <p>3. Earlier diagnosis and treatment of liver diseases.</p> <p>4. Increased knowledge.</p>
Midwives and healthcare professionals coming into	Education of healthcare	Standard care	1. Prevention of cirrhosis.

contact with children and young adults	professionals about liver disease		2. Prevention of other related liver complications.
People with chronic hepatitis C	Newer treatments	Older interventions	1. Treatment-related complications 2. Ability to perform usual activities such as work, study, housework. 3. Severe liver damage requiring hospital admission. 4. Decreased anxiety.
New-borns	Screening test for biliary atresia	No screening	Earlier diagnosis and treatment
Children who have undergone liver transplantation	Immunosuppressive regimens	Not applicable	Adverse events
People with liver-related disorders	Treatment for itching	Not applicable	Reduction or eradication of itching
People with primary biliary cholangitis	Education of people	Standard care	Knowledge
People with positive AMA (antimitochondrial antibody) M2	Prophylactic treatments	Not applicable	1. Prevention of primary biliary cholangitis.

			2. Reversion to a negative AMA M2 before cirrhosis develops.
People with positive AMA M2	Standardised protocol care by GP	Standard care	1. Prevention of primary biliary cholangitis. 2. Reversion to a negative AMA M2 before cirrhosis develops.
People with liver disease	Stem cell therapy	Standard care	1. Mortality 2. HRQoL (including ability to carry out normal activities including study and work) 3. Prolonging periods of remission 4. Reducing symptoms
People with liver disease	Bio-artificial livers	Standard care	1. Mortality 2. HRQoL (including ability to carry out normal activities

			including study and work)
People with autoimmune hepatitis	Targeted therapy against autoimmunity	Standard care	1. Mortality 2. HRQoL (including ability to carry out normal activities including study and work)
People with primary biliary cholangitis not responding to ursodeoxycholic acid	Different treatments	Not applicable	1. Cure 2. Slowing of disease 3. Improved quality of life with respect to fatigue.
People with primary biliary cholangitis	Antiviral treatment	No intervention/ other interventions	1. Improvement in health (unspecified) 2. Mortality
People with primary biliary cholangitis	Treatment for itching and fatigue	Not applicable	1. HRQoL. 2. Anxiety. 3. Itching. 4. Fatigue. 5. Cure 6. Slowing of disease 7. Symptom relief
People with primary biliary cholangitis	Greater patient involvement	Standard care	1. HRQoL. 2. Anxiety.

1 2 3 4 5 6 7 8 9 10 11 12 13	People with liver and gallbladder disorders	Nurse-led care	Standard care	1. Symptoms. 2. Pain relief. 3. Quicker investigative measures.
14 15 16 17 18 19 20 21 22 23 24 25 26 27	People with pain after cholecystectomy (especially elderly and living alone)	Hospital based investigations to find the cause of pain, treatment of the cause of pain and discharged after pain relief	Symptomatic outpatient intervention	Pain relief
28 29 30 31 32 33 34	People with chronic hepatitis C	Ribavirin	No intervention/ other interventions	Osteoporosis
35 36 37 38 39 40	People with chronic hepatitis C taking ribavirin	Prophylactic treatments for osteoporosis	No prophylactic intervention	Osteoporosis
41 42 43 44 45 46 47 48 49 50 51 52	Healthcare professionals dealing with people with primary biliary cholangitis	Education of healthcare professionals about childhood liver disorders	Standard care	1. Knowledge 2. Better treatment of patients with primary biliary cholangitis
53 54 55 56 57 58 59 60	People with liver disease	Education of people	Standard care	1. Patient knowledge. 2. Visits to the

			hospital. 3. More patient responsibility
People with symptomatic primary sclerosing cholangitis	Different treatments	Not applicable	1. Cure of disease. 2. Delays progression of disease.
People with primary sclerosing cholangitis	Intervention to reverse liver damage	Not applicable	1. Mortality. 2. HRQoL. 3. Requirement for liver transplantation.
People with primary sclerosing cholangitis	Intervention to treat fatigue	Not applicable	1. HRQoL. 2. Fatigue.
People with primary sclerosing cholangitis	Intervention to treat itching	Not applicable	1. HRQoL. 2. Itching.
People with primary sclerosing cholangitis	Specialist interest doctor	Standard care	1. Mortality. 2. HRQoL. 3. Requirement for liver transplantation. 4. Symptom relief.
People at risk of oesophageal varices	Non-invasive assessment of oesophageal varices	Invasive assessment of oesophageal varices	Reduce bleeding oesophageal varices

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60	People at risk of chronic liver disease	Alternative to biopsy for assessment of cirrhosis	Liver biopsy	Assessment of whole liver
	People at risk of primary sclerosing cholangitis (PSC)	Early diagnosis of primary sclerosing cholangitis Alternate to liver biopsy	Not applicable	Not stated
	People with primary sclerosing cholangitis with normal or relatively normal liver function tests	Alternative to UKELD (United Kingdom Model for End-Stage Liver Disease) scores for prioritisation for liver transplantation	UKELD	1. More accurate assessment of transplant need for transplant amongst PSC patients. 2. Reduction in numbers of 'low score' PSC patients becoming too ill for transplant, or not being offered a transplant once 'listed'.
	People with positive AMA M2 with normal liver function tests	Ursodeoxycholic acid	No intervention	Slowing progression of primary biliary cholangitis

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60	<p>People with suspected primary sclerosing cholangitis</p>	<p>Nurse-led care</p>	<p>Standard care</p>	<p>Earlier diagnosis and treatment</p>
<p>People with liver failure of unknown reason</p>	<p>Investigations to find the cause of liver failure of unknown origin</p>	<p>Not applicable</p>	<p>More knowledge.</p>	
<p>People with Gilbert's syndrome</p>	<p>Treatment of fatigue related to Gilbert's syndrome</p>	<p>Not applicable</p>	<p>1. HRQoL. 2. Chronic fatigue. 3. Depression</p>	
<p>People with NAFLD (non-alcoholic fatty liver disease)</p>	<p>Breathing exercises</p>	<p>Standard care</p>	<p>1. Faster recovery. 2. Symptom relief 3. Prevention of more serious complications</p>	
<p>People with NASH cirrhosis</p>	<p>Treatment of symptoms</p>	<p>Not applicable</p>	<p>Improvement of symptoms</p>	
<p>People at risk of liver disease</p>	<p>Screening for autoimmune diseases</p>	<p>No screening</p>	<p>Earlier diagnosis and treatment</p>	
<p>People with autoimmune hepatitis</p>	<p>Treatment of symptoms</p>	<p>Not applicable</p>	<p>1. Measure feeling well (unspecified). 2. Fatigue having energy. 3. Fewer flare ups.</p>	

			4. Less joint pain. 5. Disability.
People with autoimmune hepatitis	Methods to decrease stress	Not applicable	1. Measure feeling well (unspecified). 2. Fatigue having energy. 3. Fewer flare ups. 4. Less joint pain. 5. Disability.
People with liver disease	Counselling for tremors and confusion	No counselling	Coping with symptoms
People with NAFLD	Staging of liver disease	Not applicable	1. Mortality. 2. Reversal of liver damage
People with NAFLD	Metformin	No intervention	1. Mortality. 2. Reversal of liver damage
People with NAFLD	Standardised protocol for diagnosis and treatment of NAFLD	Standard care	1. Mortality. 2. Reversal of liver damage
People with osteoarthritis	Anti-inflammatory drugs	Other interventions	Cirrhosis
People with diabetes	Adequate control of diabetes	Lack of adequate control of diabetes	1. NASH. 2. Cirrhosis.

1 2 3 4 5 6 7	People at risk of NAFLD	Screening: Early identification of causes	Standard care	Prevention of liver disease
8 9 10 11 12 13 14 15 16 17 18 19 20	People with NAFLD	Treatments	Not applicable	1. Cure 2. Prevention of liver disease 3. Disease progression 4. HRQoL
21 22 23 24 25 26 27 28 29 30 31 32	People with upper abdominal pain	Screening: Early scan with ultrasound, blood tests, and urine tests	Standard care	1. Early identification of liver and gallbladder diseases 2. Appropriate advice/treatment
33 34 35 36	People with NAFLD	Lifestyle: diet and exercise	Standard care	1. HRQoL
37 38 39 40	People with NAFLD	Specialist interest doctor	Standard care	1. HRQoL
41 42 43 44 45	People at risk of liver disease	Prophylactic interventions	Not applicable	1. Prevention of liver disease
46 47 48 49 50 51 52	People at risk of NAFLD	Prophylactic treatments	Not applicable	1. Prevention of NAFLD 2. Decrease NAFLD
53 54 55 56 57 58 59 60	People with NASH fibrosis	Lifestyle: exercise	Standard care	None stated

<p>1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36</p> <p>People with cryptogenic liver cirrhosis</p>	<p>Investigations to find the cause of cryptogenic cirrhosis</p>	<p>Not applicable</p>	<p>1. Reduction in liver disease diagnosis of the percentage regarded as cryptogenic.</p> <p>2. Establishment of relevant treatment pathways.</p> <p>3. Reduction in numbers of liver transplant required by earlier intervention using non-invasive treatment regimes.</p>
<p>37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60</p> <p>People with cirrhosis</p>	<p>Community-led psychological support (on lifestyle: diet and exercise, stress, work-life balance, and general well-being)</p>	<p>Standard care</p>	<p>1. Reduction of symptoms such as nausea, fatigue.</p> <p>2. Improved nutrition and healthier weights.</p> <p>3. Improved HRQoL</p> <p>4. Improved sense of wellbeing</p> <p>5. Successful work</p>

			<p>and job retention</p> <p>6. Good sense of self determination/empowerment and motivation</p> <p>7. Improved clinical markers (unspecified)</p>
Newborns	Screening for metabolic liver diseases	No screening	<p>1. Early treatment for people with metabolic liver disease (including dietary advice)</p> <p>2. Mortality.</p> <p>3. HRQoL.</p> <p>4. Prevent type 2 diabetes</p>
People with autoimmune hepatitis	Telephone-based care	Standard care	<p>1. Reduction in time spent in outpatients</p> <p>2. Less spent on car-parking at hospitals</p>
People with NASH and diabetes	Liver transplantation	Standard care	<p>1. Mortality</p>

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60	<p>People with primary biliary cholangitis (newly diagnosed)</p> <p>People with primary sclerosing cholangitis</p> <p>People with bile duct cancer</p> <p>People with gallbladder sludge with digestive symptoms</p> <p>People with NAFLD</p> <p>People with NAFLD</p>	<p>Adequate drinking water</p> <p>Treatment targeted against deformation of bile duct</p> <p>Treatment targeted against deformation of bile duct</p> <p>Avoiding surgery</p> <p>Education of healthcare professionals</p> <p>Education of general public</p>	<p>Standard care</p> <p>Standard care</p> <p>Standard care</p> <p>Standard care</p> <p>Standard care</p> <p>Standard care</p>	<p>1. HRQoL. 2. Liver function tests.</p> <p>1. Time to end-stage liver disease.</p> <p>Not stated</p> <p>1. Symptom relief</p> <p>1. Greater awareness of conditions. 2. Preventative measures. 3. Greater knowledge base.</p> <p>1. Greater awareness of conditions. 2. Preventative measures. 3. Greater knowledge base.</p>
---	--	--	---	---

1 2 3 4 5 6 7 8 9 10 11	People with NAFLD	Methods to make an accurate diagnosis (including liver function tests)	Not applicable	Not stated
12 13 14 15 16	People with NAFLD (overweight)	Interventions to lose weight	Not applicable	Weight loss
17 18 19 20	People with liver disease (newly diagnosed)	Mental health support	Not applicable	Mental health
21 22 23 24 25 26 27	Children with multiple autoimmune disorders related to liver	Genetic testing of telomere lengths	Other tests/ no tests	Not stated
28 29 30 31 32 33 34 35 36	Children with multiple autoimmune disorders related to liver	Stem cell therapy	Standard care	Reduction in all conditions with only one drug with little side effects
37 38 39 40 41 42 43	People with primary biliary cholangitis (especially younger age group)	Treatments based on tools for predicting prognosis	Standard care	Better care for people with high risk of progression
44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60	People with chronic hepatitis C	Lifestyle: diet	Standard care	<ol style="list-style-type: none"> 1. Improvement in overall health. 2. Decrease in liver damage requiring hospital admission. 3. Patient knowledge.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

			<p>4. Healthcare professional knowledge.</p> <p>5. Fewer treatment-related complications.</p> <p>6. Decreasing pain and discomfort.</p> <p>7. Clear guidelines for successful dietary needs.</p>
<p>Healthcare professionals dealing with people with chronic hepatitis C</p>	<p>Education of healthcare professionals (about diet)</p>	<p>Standard care</p>	<p>1. Improvement in overall health.</p> <p>2. Decrease in liver damage requiring hospital admission.</p> <p>3. Patient knowledge.</p> <p>4. Healthcare professional knowledge.</p> <p>5. Fewer treatment-related complications.</p> <p>6. Decreasing pain</p>

			<p>and discomfort.</p> <p>7. Clear guidelines for successful dietary needs.</p>
<p>Healthcare professionals dealing with people with NAFLD</p>	<p>Education of healthcare professionals (around support to patients on weight control, diet, exercise and life style)</p>	<p>Standard care</p>	<ol style="list-style-type: none"> 1. Preventing progression into NASH and cirrhosis. 2. Reducing symptoms of aching sides, leg weakness, sickness and nausea. 3. Prevent heart attacks and strokes.
<p>Family members of people with primary biliary cholangitis</p>	<p>Screening of family members for primary biliary cholangitis</p>	<p>No screening</p>	<ol style="list-style-type: none"> 1. Establishing the genetic link for primary biliary cholangitis. 2. Earlier identification of primary biliary cholangitis who may have PBC or be at risk. 3. Cost-savings.

1 2 3 4 5 6 7 8 9	People with positive AMA M2 with normal liver function tests	Screening for cirrhosis using biopsy	No screening	Accurate diagnosis of primary biliary cholangitis.
10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27	People with primary biliary cholangitis	Screening for other autoimmune conditions associated with primary biliary cholangitis and complications related to primary biliary cholangitis	No screening	1. HRQoL. 2. Costs.
28 29 30 31	People with autoimmune liver disease	Treatment of fatigue and others symptoms	Not applicable	Remission
32 33 34 35 36 37 38 39 40	People with primary sclerosing cholangitis	Standardised protocol for follow-up of patients with primary sclerosing cholangitis	Standard care	1. Reduce need for annual investigations. 2. Costs.
41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60	People with other autoimmune disease	Screening for liver disease	No screening	1. Decreasing risk of severe liver damage and admission to hospital 2. Reducing the need for liver transplants 3. Decreasing the risk of liver cancer

			4. Mortality 5. HRQoL
People with NAFLD	Pathway for managing end of life care	Standard care	1. Patient and carer satisfaction 2. Patient HRQoL 3. Symptom relief.
People with decompensated liver disease	Lifestyle: nutritional treatment	Not applicable	1. Improved survival. 2. Reduced symptoms. 3. Improved nutritional status. 4. Improved Strength.
People with decompensated liver disease	Measuring energy requirements with indirect calorimeters	Current UK guidance on requirements (Parenteral & Enteral Nutrition Group) (high energy requirements)	1. Improved survival. 2. Reduced symptoms. 3. Improved nutritional status. 4. Improved Strength.
People with hepatic encephalopathy	Branch chain amino acids	Standard care	1. Improved survival. 2. Reduced symptoms. 3. Improved

			nutritional status. 4. Improved Strength.
People with decompensated liver disease with muscle wasting	Branch chain amino acids	Standard care	1. Improved survival. 2. Reduced symptoms. 3. Improved nutritional status. 4. Improved Strength.
People with decompensated liver disease with muscle wasting	Lifestyle: exercise	Standard care	1. Improved survival. 2. Reduced symptoms. 3. Improved nutritional status. 4. Improved Strength.
People with decompensated liver disease	Standardised nutritional assessment of patients and outcomes in nutritional intervention trials	Non-standardised assessment	1. Improved survival. 2. Reduced symptoms. 3. Improved nutritional status. 4. Improved Strength.

			5. Better conduct of future trials.
People with NAFLD	Methods to increase self care	Not applicable	Reducing symptoms
People with NAFLD	Methods to decrease shortness of breath	Not applicable	Reducing symptoms
People with liver disease	Interventions to decrease fatigue	Not applicable	Fatigue
Healthcare professionals dealing with people with cirrhosis	Education of healthcare professionals about cirrhosis (complications and benefits and harms of treatment)	Standard care	Better advice to patients by health professionals regarding complications and benefits and harms of different treatments
People with primary biliary cholangitis	Ursodeoxycholic acid (including optimal dose)	No intervention/ other interventions	1. Liver function tests. 2. Minimal effective dose of ursodeoxycholic acid. 3. Good sleep.
People with liver cancer and ascites	Different interventions	Not applicable	HRQoL

1 2 3 4 5 6 7 8 9 10 11	People with primary sclerosing cholangitis	Screening for cancer	No screening	1. Benefits 2. Earlier diagnosis of bile duct cancer 3. Mortality
12 13 14 15 16 17 18	People with primary or metastatic liver cancer	Nurse-led care (follow-up clinic)	Doctor-led follow-up	1. Patient satisfaction 2. Timely surveillance
19 20 21 22	People with cirrhosis	Life-style: nutritional advice	Not applicable	1. Fatigue 2. Muscle wasting
23 24 25 26 27	People with polycystic liver disease	Surgery	Non-surgical management	1. Recurrence 2. HRQoL
28 29 30 31 32 33 34	People with gallstones	Avoiding surgery	Surgery	1. Requirement for surgery 2. Costs to NHS
35 36 37 38 39 40 41 42 43 44 45	People at risk of NASH	Nurse-led care	No intervention	1. Early diagnosis of NASH. 2. Successful treatment of NASH. 3. Mortality
46 47 48 49 50 51 52 53 54 55 56 57 58 59 60	People at risk of NASH	Screening for NASH using Fibroscan	No intervention	1. Early diagnosis of NASH. 2. Successful treatment of NASH. 3. Mortality

1 2 3 4 5 6 7 8 9 10 11 12 13 14	People at risk of NASH	Support group focussed on diet and exercise	No intervention	1. Prevention of NASH. 2. Successful treatment of NASH. 3. Mortality
15 16 17 18	People at risk of NASH	Emotional support group for carers	No intervention	HRQoL
19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36	People with NASH	Nurse-led care	Standard care	1. Mortality. 2. HRQoL. 3. Requirement for liver transplantation. 4. Liver cancer. 5. Liver failure. 6. Treatment-related complications.
37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60	People with NASH	Lifestyle: diet	Standard care	1. Mortality. 2. HRQoL. 3. Requirement for liver transplantation. 4. Liver cancer. 5. Liver failure. 6. Treatment-related complications.

1 2 3 4 5 6 7 8 9	People with NASH	Different interventions to decrease anxiety and depression	Standard care	Anxiety and depression
10 11 12 13	People with NASH	Research design using support group	Standard research design	Help towards better research
14 15 16 17 18	General population	Life style: diet and exercise	No intervention	HRQoL
19 20 21 22 23 24 25	General population	Education of people (patient information leaflet at GP surgeries)	No intervention	1. Prevention of NASH. 2. HRQoL.
26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54	General population	Screening: for liver disease	No intervention	1. Early diagnosis of liver disease 2. Mortality 3. HRQoL 4. Requirement for liver transplantation 5. Costs 6. Requirement for hospital admission for severe liver damage 7. Primary liver cancer
55 56 57 58 59 60	Primary school children	Lifestyle: nutritional and dietary advice	No intervention	1. Adherence to healthy diet and

			exercise to sustain healthy life style.
People undergoing liver resection	Best method to assess function and volume of remnant liver	Not applicable	1. Mortality. 2. HRQoL. 3. Complications.
People undergoing liver resection	Best method to assess cardiopulmonary function?	Not applicable	1. Mortality. 2. HRQoL. 3. Complications.
People undergoing liver resection	Pre-operative education	Standard care	1. Mortality. 2. HRQoL. 3. Complications.
Surgeons treating people undergoing liver resection	Simulation and training of surgeons	Standard care	1. Mortality. 2. HRQoL. 3. Complications.
People undergoing liver resection	Growth factors to optimise muscle and fat content	Standard care	1. Mortality. 2. HRQoL. 3. Complications.
People undergoing liver resection	Pharmacological interventions for weight loss	Not applicable	1. Mortality. 2. HRQoL. 3. Complications.
People undergoing liver resection	Portal vein embolisation	Standard care	1. Mortality. 2. HRQoL. 3. Complications.

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60	People undergoing liver resection	Reducing systemic inflammation using steroids	Standard care	1. Mortality. 2. HRQoL. 3. Complications.
	People undergoing liver resection	Open liver resection	Laparoscopic liver resection	1. Mortality. 2. HRQoL. 3. Complications.
	People undergoing liver resection	Tumour visualisation and localisation of the tumour	Standard care	1. Mortality. 2. HRQoL. 3. Complications.
	People undergoing liver resection	Goal directed therapy during operation	Standard care	1. Mortality. 2. HRQoL. 3. Complications.
	Surgeons treating people undergoing liver resection	Use of magnifying surgical loupes during liver surgery	Standard care	1. Mortality. 2. HRQoL. 3. Complications.
	People undergoing liver resection	Portal vein pressure decrease (by the use of drugs such as vasopressin) during surgery	Standard care	1. Mortality. 2. HRQoL. 3. Complications.
	People undergoing liver resection	Transection techniques	Not applicable	1. Mortality. 2. HRQoL. 3. Complications.

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60	People undergoing liver resection	Vascular occlusion techniques	Not applicable	1. Mortality. 2. HRQoL. 3. Complications.
People undergoing liver resection	Cardiopulmonary and pharmacological interventions for decreasing blood loss	Not applicable	1. Mortality. 2. HRQoL. 3. Complications.	
People undergoing liver resection	Use of peritoneal drains	No drain	1. Mortality. 2. HRQoL. 3. Complications.	
People undergoing liver resection	ALPPS procedure (Associating Liver Partition and Portal vein Ligation for Staged hepatectomy)	Standard care	1. Mortality. 2. HRQoL. 3. Complications.	
People undergoing liver resection	Goal directed therapy (post-operative)	Standard care	1. Mortality. 2. HRQoL. 3. Complications.	
People undergoing liver resection	Pain control protocol	Standard care	1. Mortality. 2. HRQoL. 3. Complications.	
People undergoing liver resection	Early mobilisation protocol	Standard care	1. Mortality. 2. HRQoL. 3. Complications.	

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60	People undergoing liver resection	Early oral intake protocol	Standard care	1. Mortality. 2. HRQoL. 3. Complications.
	People undergoing liver resection	Portal vein pressure decrease (by the use of drugs such as vasopressin) post-operatively	Standard care	1. Mortality. 2. HRQoL. 3. Complications.
	People with unresectable hepatocellular carcinoma	Radioembolisation	No intervention/other interventions	1. Mortality. 2. HRQoL. 3. Complications.
	People with unresectable hepatocellular carcinoma	External beam radiotherapy	No intervention/other interventions	1. Mortality. 2. HRQoL. 3. Complications.
	People with chronic hepatitis B	Screening for cancer	No screening	1. Mortality. 2. HRQoL. 3. Complications.
	People with hepatocellular carcinoma	Cryotherapy	No intervention/other interventions	1. Mortality. 2. HRQoL. 3. Complications.
	People with hepatocellular carcinoma	Systemic chemotherapy	No intervention/other interventions	1. Mortality. 2. HRQoL. 3. Complications.

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60	People with early or very early hepatocellular carcinoma	Treatment	Not applicable	1. Mortality. 2. HRQoL. 3. Complications.
	People with intermediate hepatocellular carcinoma	Treatment	Not applicable	1. Mortality. 2. HRQoL. 3. Complications.
	People with hepatocellular carcinoma	Tamoxifen	No intervention/other interventions	1. Mortality. 2. HRQoL. 3. Complications.
	People with unresectable hepatocellular carcinoma	Transarterial embolisation	No intervention/other interventions	1. Mortality. 2. HRQoL. 3. Complications.
	People with unresectable hepatocellular carcinoma	Tyrosine kinase inhibitors	No intervention/other interventions	1. Mortality. 2. HRQoL. 3. Complications.
	People undergoing liver resection for hepatocellular carcinoma	Neoadjuvant and adjuvant therapy	No intervention/other interventions	1. Mortality. 2. HRQoL. 3. Complications.
	People with unresectable hepatocellular carcinoma	Transarterial chemoembolisation	No intervention/other interventions	1. Mortality. 2. HRQoL. 3. Complications.
	People with hepatocellular carcinoma	Interferon	No intervention/other interventions	1. Mortality. 2. HRQoL. 3. Complications.

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60	<p>People with hepatocellular carcinoma</p> <p>People undergoing liver resection for hepatocellular carcinoma</p> <p>People with hepatocellular carcinoma</p> <p>People undergoing liver resection for hepatocellular carcinoma</p> <p>People undergoing liver resection for hepatocellular carcinoma</p> <p>People with advanced biliary tract carcinoma</p> <p>People with unresectable cholangiocarcinoma</p> <p>People undergoing liver transplantation</p>	<p>Surgical resection</p> <p>Anterior approach</p> <p>Radiofrequency ablation</p> <p>Post-operative transarterial chemoembolisation</p> <p>Post-operative lamivudine with or without adefovir dipivoxil</p> <p>gemcitabine-based chemotherapy</p> <p>Endoscopic treatment</p> <p>Pharmacological interventions for</p>	<p>Liver transplantation</p> <p>Conventional liver resection</p> <p>No intervention/other interventions</p> <p>No intervention/other interventions</p> <p>No intervention/other interventions</p> <p>Surgery</p> <p>No intervention/other interventions</p>	<p>1. Mortality. 2. HRQoL. 3. Complications.</p> <p>1. Mortality. 2. HRQoL. 3. Complications.</p> <p>1. Mortality. 2. HRQoL. 3. Complications.</p> <p>1. Mortality. 2. HRQoL. 3. Complications.</p> <p>1. Mortality. 2. HRQoL. 3. Complications.</p> <p>1. Mortality. 2. HRQoL. 3. Complications.</p> <p>1. Mortality. 2. HRQoL. 3. Complications.</p> <p>1. Mortality. 2. HRQoL. 3. Complications.</p>
---	---	--	---	---

	reducing ischaemia reperfusion injury		
People undergoing liver transplantation for hepatitis B infection	Antibiotic prophylaxis	No intervention/other interventions	1. Mortality. 2. HRQoL. 3. Complications.
People undergoing liver transplantation for hepatitis B infection	Hepatitis B immune globulin	No intervention/other interventions	1. Mortality. 2. HRQoL. 3. Complications.
People undergoing liver transplantation	Prostaglandins	No intervention/other interventions	1. Mortality. 2. HRQoL. 3. Complications.
People undergoing haemopoietic stem cell transplantation	Interventions to prevent hepatic veno-occlusive disease	Not applicable	1. Mortality. 2. HRQoL. 3. Complications.
People undergoing haemopoietic stem cell transplantation	Interventions to treat hepatic veno-occlusive disease	Not applicable	1. Mortality. 2. HRQoL. 3. Complications.
People undergoing liver transplantation	Immunosuppressive regimens	Not applicable	1. Mortality. 2. HRQoL. 3. Complications.
People undergoing liver transplantation	Venovenous bypass	No intervention	1. Mortality. 2. HRQoL. 3. Complications.

1 2 3 4 5 6 7 8 9	People undergoing liver transplantation	Ischaemic preconditioning	No intervention	1. Mortality. 2. HRQoL. 3. Complications.
10 11 12 13 14 15 16	People undergoing liver transplantation	Methods of biliary reconstruction	Not applicable	1. Mortality. 2. HRQoL. 3. Complications.
17 18 19 20 21 22 23 24 25 26 27	People undergoing liver transplantation	Methods of preventing bacterial sepsis and wound complications after liver transplantation	Not applicable	1. Mortality. 2. HRQoL. 3. Complications.
28 29 30 31 32 33 34	People undergoing liver transplantation	Techniques of flushing and reperfusion	Not applicable	1. Mortality. 2. HRQoL. 3. Complications.
35 36 37 38 39 40 41	People undergoing liver transplantation	Abdominal drainage	No intervention	1. Mortality. 2. HRQoL. 3. Complications.
42 43 44 45 46 47	People undergoing liver transplantation	Piggy-back	Conventional liver transplantation	1. Mortality. 2. HRQoL. 3. Complications.
48 49 50 51 52 53 54 55 56 57 58 59 60	People undergoing liver transplantation	Methods to decrease blood loss and transfusion requirements	Not applicable	1. Mortality. 2. HRQoL. 3. Complications.

1 2 3 4 5 6 7 8 9	People undergoing liver transplantation	Antiviral prophylaxis for prevention of hepatitis C infection	Not applicable	1. Mortality. 2. HRQoL. 3. Complications.
10 11 12 13 14 15 16	People undergoing liver transplantation	Antiviral treatment of hepatitis C infection	Not applicable	1. Mortality. 2. HRQoL. 3. Complications.
17 18 19 20 21 22 23 24 25 26 27	People undergoing liver transplantation for hepatitis B infection	Lamivudine or adefovir dipivoxil	No intervention/other interventions including immunoglobulin	1. Mortality. 2. HRQoL. 3. Complications.
28 29 30 31 32 33 34	People undergoing liver transplantation	Nutritional interventions	Not applicable	1. Mortality. 2. HRQoL. 3. Complications.
35 36 37 38 39 40 41	People undergoing liver transplantation	Bile acids	No intervention/other interventions	1. Mortality. 2. HRQoL. 3. Complications.
42 43 44 45 46 47	People undergoing liver transplantation	Celsior solution	UW solution	1. Mortality. 2. HRQoL. 3. Complications.
48 49 50 51 52 53 54 55 56 57 58 59 60	People undergoing liver resection	Pharmacological interventions for reducing ischaemia reperfusion injury	No intervention/other interventions	1. Mortality. 2. HRQoL. 3. Complications.

1 2 3 4 5 6 7 8 9	People undergoing liver resection	Fibrin-based haemostatic agents	No intervention/other interventions	1. Mortality. 2. HRQoL. 3. Complications.
10 11 12 13 14 15 16	People undergoing liver resection for colorectal liver metastases	Neoadjuvant chemotherapy	No intervention/other interventions	1. Mortality. 2. HRQoL. 3. Complications.
17 18 19 20 21 22 23	People with colorectal liver metastases	Resection	Other interventions	1. Mortality. 2. HRQoL. 3. Complications.
24 25 26 27 28 29	People undergoing liver resection	Ischaemic preconditioning	No intervention	1. Mortality. 2. HRQoL. 3. Complications.
30 31 32 33 34 35 36	People undergoing liver resection	Interventions for reducing blood loss	No intervention/other interventions	1. Mortality. 2. HRQoL. 3. Complications.
37 38 39 40 41 42 43	People undergoing liver resection	Methods of decreasing infection	No intervention/other interventions	1. Mortality. 2. HRQoL. 3. Complications.
44 45 46 47 48 49	People with hepatic node positive colorectal liver metastases	Resection	No resection	1. Mortality. 2. HRQoL. 3. Complications.
50 51 52 53 54 55 56 57 58 59 60	People undergoing liver resection for resectable neuroendocrine tumours	Resection	No resection	1. Mortality. 2. HRQoL. 3. Complications.

1 2 3 4 5 6 7 8 9	People undergoing liver resection or ablation of colorectal liver metastases	Hepatic artery adjuvant chemotherapy	No intervention/other interventions	1. Mortality. 2. HRQoL. 3. Complications.
10 11 12 13 14 15 16	People undergoing liver resection	Laparoscopic liver resection	Open liver resection	1. Mortality. 2. HRQoL. 3. Complications.
17 18 19 20 21 22 23	People with hepatic encephalopathy	Nonabsorbable disaccharides	No intervention/other interventions	1. Mortality. 2. HRQoL. 3. Complications.
24 25 26 27 28 29	People with hepatic encephalopathy	Benzodiazepine receptor antagonists	No intervention/other interventions	1. Mortality. 2. HRQoL. 3. Complications.
30 31 32 33 34 35 36	People with hepatic encephalopathy	Antibiotics	No intervention/other interventions	1. Mortality. 2. HRQoL. 3. Complications.
37 38 39 40 41 42 43	People with hepatic encephalopathy	Dopamine agents	No intervention/other interventions	1. Mortality. 2. HRQoL. 3. Complications.
44 45 46 47 48 49	People with hepatic encephalopathy	Rifaximin	No intervention/other interventions	1. Mortality. 2. HRQoL. 3. Complications.
50 51 52 53 54 55 56 57 58 59 60	People with hepatic encephalopathy	Acetyl-L-carnitine	No intervention/other interventions	1. Mortality. 2. HRQoL. 3. Complications.

1 2 3 4 5 6 7 8 9	People with hepatic encephalopathy	Probiotics	No intervention/other interventions	1. Mortality. 2. HRQoL. 3. Complications.
10 11 12 13 14 15 16	People with hepatic encephalopathy	Naloxone	No intervention/other interventions	1. Mortality. 2. HRQoL. 3. Complications.
17 18 19 20 21 22 23	People with hepatic encephalopathy	L-ornithine-L-aspartate	No intervention/other interventions	1. Mortality. 2. HRQoL. 3. Complications.
24 25 26 27 28 29	People with NAFLD	Pharmacological treatments	Not applicable	1. Mortality. 2. HRQoL. 3. Complications.
30 31 32 33 34 35 36	People with NAFLD	Herbal medicines	No intervention/other interventions	1. Mortality. 2. HRQoL. 3. Complications.
37 38 39 40 41 42 43	People with NAFLD	Weight reduction	Not applicable	1. Mortality. 2. HRQoL. 3. Complications.
44 45 46 47 48 49	People with liver metastases	Transarterial (chemo)embolisation	No intervention/other interventions	1. Mortality. 2. HRQoL. 3. Complications.
50 51 52 53 54 55 56 57	People with liver metastases	Microwave coagulation	No intervention/other interventions	1. Mortality. 2. HRQoL. 3. Complications.

1 2 3 4 5 6 7 8 9	People with liver metastases	Cryotherapy	No intervention/oth er interventions	1. Mortality. 2. HRQoL. 3. Complications.
10 11 12 13 14 15 16	People with liver metastases	Radiofrequency ablation	No intervention/oth er interventions	1. Mortality. 2. HRQoL. 3. Complications.
17 18 19 20 21 22 23	People with unresectable neuroendocrine liver metastases	Palliative cytoreductive surgery	Other palliative interventions	1. Mortality. 2. HRQoL. 3. Complications.
24 25 26 27 28 29	People with unresectable colorectal liver metastases	Hepatic arterial infusion	Systemic chemotherapy	1. Mortality. 2. HRQoL. 3. Complications.
30 31 32 33 34 35 36	People with liver metastases	Electro-coagulation	No intervention/oth er interventions	1. Mortality. 2. HRQoL. 3. Complications.
37 38 39 40 41 42 43	People with liver metastases	Percutaneous ethanol injection	No intervention/oth er interventions	1. Mortality. 2. HRQoL. 3. Complications.
44 45 46 47 48 49	People with unresectable colorectal liver metastases	Chemotherapy for downstaging	No intervention/oth er interventions	1. Mortality. 2. HRQoL. 3. Complications.
50 51 52 53 54 55 56 57 58 59 60	People with colorectal liver metastases	Selective internal radiation therapy	No intervention/oth er interventions	1. Mortality. 2. HRQoL. 3. Complications.

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60	People with gallbladder polyp	Cholecystectomy	No cholecystectomy	1. Mortality. 2. HRQoL. 3. Complications.
	People with gallbladder dyskinesia	Cholecystectomy	No cholecystectomy	1. Mortality. 2. HRQoL. 3. Complications.
	People undergoing laparoscopic cholecystectomy	Methods of cystic duct occlusion	Not applicable	1. Mortality. 2. HRQoL. 3. Complications.
	People undergoing laparoscopic cholecystectomy for acute cholecystitis	Early laparoscopic cholecystectomy	Delayed cholecystectomy	1. Mortality. 2. HRQoL. 3. Complications.
	People undergoing cholecystectomy	Laparoscopic cholecystectomy	Open cholecystectomy	1. Mortality. 2. HRQoL. 3. Complications.
	People undergoing cholecystectomy	Laparoscopic cholecystectomy	Mini-incision cholecystectomy	1. Mortality. 2. HRQoL. 3. Complications.
	People undergoing cholecystectomy	Mini-incision cholecystectomy	Open cholecystectomy	1. Mortality. 2. HRQoL. 3. Complications.
	People undergoing laparoscopic cholecystectomy	Abdominal wall lift	Pneumoperitoneum	1. Mortality. 2. HRQoL. 3. Complications.

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60	People undergoing laparoscopic cholecystectomy	Abdominal drainage	No drain	1. Mortality. 2. HRQoL. 3. Complications.
	People undergoing laparoscopic cholecystectomy for biliary colic	Early laparoscopic cholecystectomy	Delayed cholecystectomy	1. Mortality. 2. HRQoL. 3. Complications.
	People undergoing laparoscopic cholecystectomy	Intra-peritoneal saline instillation	No instillation	1. Mortality. 2. HRQoL. 3. Complications.
	People undergoing laparoscopic cholecystectomy	Methods of intraperitoneal local anaesthetic instillation	Not applicable	1. Mortality. 2. HRQoL. 3. Complications.
	People undergoing laparoscopic cholecystectomy	Methods of local anaesthetic wound infiltration	Not applicable	1. Mortality. 2. HRQoL. 3. Complications.
	People undergoing laparoscopic cholecystectomy	Three-dimensional imaging	Two-dimensional imaging	1. Mortality. 2. HRQoL. 3. Complications.
	People with asymptomatic gallstones	Cholecystectomy	No cholecystectomy	1. Mortality. 2. HRQoL. 3. Complications.
	People undergoing open cholecystectomy	Abdominal drainage	No drain	1. Mortality. 2. HRQoL. 3. Complications.

1 2 3 4 5 6 7 8 9	People undergoing laparoscopic cholecystectomy	Robotic assistant	Human assistant	1. Mortality. 2. HRQoL. 3. Complications.
10 11 12 13 14 15 16	People undergoing laparoscopic cholecystectomy	Methods of gallbladder dissection	Not applicable	1. Mortality. 2. HRQoL. 3. Complications.
17 18 19 20 21 22 23 24 25	People undergoing laparoscopic cholecystectomy	Low pressure pneumoperitoneum	Standard pressure pneumoperitoneum	1. Mortality. 2. HRQoL. 3. Complications.
26 27 28 29 30 31 32	People undergoing laparoscopic cholecystectomy	Education of patients	Standard care	1. Mortality. 2. HRQoL. 3. Complications.
33 34 35 36 37 38	People undergoing laparoscopic cholecystectomy	Miniports	Standard ports	1. Mortality. 2. HRQoL. 3. Complications.
39 40 41 42 43 44 45	People undergoing laparoscopic cholecystectomy	Number of ports	Not applicable	1. Mortality. 2. HRQoL. 3. Complications.
46 47 48 49 50 51 52 53 54 55 56 57 58 59 60	People undergoing laparoscopic cholecystectomy	Pharmacological interventions for prevention or treatment of postoperative pain	Not applicable	1. Mortality. 2. HRQoL. 3. Complications.

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60	People undergoing laparoscopic cholecystectomy	Glucocorticoids	No intervention	1. Mortality. 2. HRQoL. 3. Complications.
	People who have undergone endoscopic sphincterotomy for gallstone related complications	Early cholecystectomy	Delayed or no cholecystectomy	1. Mortality. 2. HRQoL. 3. Complications.
	People undergoing laparoscopic cholecystectomy	Antibiotic prophylaxis	Not applicable	1. Mortality. 2. HRQoL. 3. Complications.
	People undergoing laparoscopic cholecystectomy	Day surgery	Overnight stay	1. Mortality. 2. HRQoL. 3. Complications.
	People undergoing day surgery laparoscopic cholecystectomy	Anaesthetic regimens	Not applicable	1. Mortality. 2. HRQoL. 3. Complications.
	People with common bile duct stones undergoing laparoscopic cholecystectomy	Per-operative endoscopic sphincterotomy	Pre-operative endoscopic sphincterotomy	1. Mortality. 2. HRQoL. 3. Complications.
	People with suspected bile duct stenosis	Magnetic resonance cholangiopancreatography	Not applicable	1. Mortality. 2. HRQoL. 3. Complications.

1 2 3 4 5 6 7 8 9 10 11	People with suspected bile duct stones	Endoscopic ultrasound	Magnetic resonance cholangiopancreatography	1. Mortality. 2. HRQoL. 3. Complications.
12 13 14 15 16 17 18	People with suspected bile duct stones	Endoscopic retrograde cholangiopancreatography	Intraoperative cholangiography	1. Mortality. 2. HRQoL. 3. Complications.
19 20 21 22 23 24 25	People with suspected bile duct stones	Liver function tests	Transabdominal ultrasound	1. Mortality. 2. HRQoL. 3. Complications.
26 27 28 29 30 31 32	People undergoing surgery for biliary tract cancer	Pre-operative biliary stenting	No stenting	1. Mortality. 2. HRQoL. 3. Complications.
33 34 35 36 37 38	People with uncomplicated amoebic liver abscess	Percutaneous procedure plus metronidazole	Metronidazole alone	1. Mortality. 2. HRQoL. 3. Complications.
39 40 41 42 43 44 45	People with benign liver tumours	Liver resection	No liver resection	1. Mortality. 2. HRQoL. 3. Complications.
46 47 48 49 50 51 52	People with sphincter of oddi dysfunction	Sphincterotomy	No sphincterotomy	1. Mortality. 2. HRQoL. 3. Complications.
53 54 55 56 57 58 59 60	People with cirrhosis	Colchicine	No intervention/other interventions	1. Mortality. 2. HRQoL. 3. Complications.

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60	People with blunt liver injury	Non-surgical treatment	Surgery	1. Mortality. 2. HRQoL. 3. Complications.
People with common bile duct stones	Surgical treatment	Endoscopic intervention	1. Mortality. 2. HRQoL. 3. Complications.	
People at risk of gallstones	Lifestyle: Diets for primary prevention of gallstones	Not applicable	1. Mortality. 2. HRQoL. 3. Complications.	
People at risk of gallstones	Pharmacological interventions for primary prevention of gallstones	Not applicable	1. Mortality. 2. HRQoL. 3. Complications.	
People with common bile duct stones	Sphincteroplasty	Sphincterotomy	1. Mortality. 2. HRQoL. 3. Complications.	
People with biliary colic	Bile acids	No intervention/other interventions	1. Mortality. 2. HRQoL. 3. Complications.	
People with biliary colic	Non-steroidal anti-inflammatory drugs	No intervention/other interventions	1. Mortality. 2. HRQoL. 3. Complications.	
People with chronic hepatitis C	Pharmacological treatments	Not applicable	1. Mortality. 2. HRQoL. 3. Complications.	

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60	People with chronic hepatitis B	Pharmacological treatments	Not applicable	1. Mortality. 2. HRQoL. 3. Complications.
	People with chronic hepatitis D	Pharmacological treatments	Not applicable	1. Mortality. 2. HRQoL. 3. Complications.
	People exposed to hepatitis A	Post-exposure vaccines	Not applicable	1. Mortality. 2. HRQoL. 3. Complications.
	General population	Immunisation against Hepatitis A	No immunisation	1. Mortality. 2. HRQoL. 3. Complications.
	People exposed to hepatitis A	Post-exposure immunoglobulins	Not applicable	1. Mortality. 2. HRQoL. 3. Complications.
	People with biliary stent	Ursodeoxycholic acid to prevent stent occlusion	No intervention/other interventions	1. Mortality. 2. HRQoL. 3. Complications.
	People with acute hepatitis B	Pharmacological treatments	Not applicable	1. Mortality. 2. HRQoL. 3. Complications.
	Healthcare professionals	Hepatitis B vaccination	Not applicable	1. Mortality. 2. HRQoL. 3. Complications.

Pregnant women with Hepatitis B	Immunoglobulins	No intervention/other interventions	1. Mortality. 2. HRQoL. 3. Complications.
Newborns of HBSAg (hepatitis B surface antigen) positive mothers	Immunisation	No intervention/other interventions	1. Mortality. 2. HRQoL. 3. Complications.
People with chronic hepatitis B	Medicinal herbs	No intervention/other interventions	1. Mortality. 2. HRQoL. 3. Complications.
Asymptomatic Hepatitis B carriers	Medicinal herbs	No intervention/other interventions	1. Mortality. 2. HRQoL. 3. Complications.
People with chronic hepatitis B	Acupuncture	No intervention/other interventions	1. Mortality. 2. HRQoL. 3. Complications.
People with acute hepatitis B	Medicinal herbs	No intervention/other interventions	1. Mortality. 2. HRQoL. 3. Complications.
General population	Hepatitis B vaccination	Not applicable	1. Mortality. 2. HRQoL. 3. Complications.
Pregnant women with Hepatitis B	Lamivudine	No intervention/other interventions	1. Mortality. 2. HRQoL. 3. Complications.

1 2 3 4 5 6 7 8 9	People with HIV infection	Hepatitis B vaccination	Not applicable	1. Mortality. 2. HRQoL. 3. Complications.
10 11 12 13 14 15 16	People who have received Hepatitis B vaccination	Booster dose	No booster dose	1. Mortality. 2. HRQoL. 3. Complications.
17 18 19 20 21 22 23	Pregnant women with Hepatitis B	Hepatitis B vaccination	No intervention/other interventions	1. Mortality. 2. HRQoL. 3. Complications.
24 25 26 27 28 29	People with renal failure	Hepatitis B vaccination	No intervention/other interventions	1. Mortality. 2. HRQoL. 3. Complications.
30 31 32 33 34 35 36	People with chronic hepatitis C and peripheral neuropathy	Treatments	Not applicable	1. Mortality. 2. HRQoL. 3. Complications.
37 38 39 40 41 42 43	People in haemodialysis units	Isolation to prevent Hepatitis C transmission	No isolation	1. Mortality. 2. HRQoL. 3. Complications.
44 45 46 47 48 49 50	People with acute hepatitis C	Pharmacological treatments	Not applicable	1. Mortality. 2. HRQoL. 3. Complications.
51 52 53 54 55 56 57	People with chronic hepatitis C and HIV	Antiviral treatment	Not applicable	1. Mortality. 2. HRQoL. 3. Complications.

1 2 3 4 5 6 7 8 9	People with chronic hepatitis C	Medicinal herbs	No intervention/other interventions	1. Mortality. 2. HRQoL. 3. Complications.
10 11 12 13 14 15 16	Pregnant women with Hepatitis B	Caesarean section	Vaginal delivery	1. Mortality. 2. HRQoL. 3. Complications.
17 18 19 20 21 22 23	People with chronic hepatitis C with vasculitis	Treatments	Not applicable	1. Mortality. 2. HRQoL. 3. Complications.
24 25 26 27 28 29	People with chronic hepatitis C	Staging of liver disease	Not applicable	1. Mortality. 2. HRQoL. 3. Complications.
30 31 32 33 34 35 36	People with primary biliary cholangitis and osteoporosis	Biphosphonates	No intervention/other interventions	1. Mortality. 2. HRQoL. 3. Complications.
37 38 39 40 41 42 43	People with primary biliary cholangitis and osteoporosis	Hormonal replacement therapy	No intervention/other interventions	1. Mortality. 2. HRQoL. 3. Complications.
44 45 46 47 48 49	People with bleeding oesophageal varices	People with portosystemic shunt	No intervention/other interventions	1. Mortality. 2. HRQoL. 3. Complications.
50 51 52 53 54 55 56 57	People with hepatorenal syndrome	Terlipressin	No intervention/other interventions	1. Mortality. 2. HRQoL. 3. Complications.

1 2 3 4 5 6 7 8 9	People with hepatorenal syndrome	Transjugular intrahepatic portosystemic shunts	No intervention/other interventions	1. Mortality. 2. HRQoL. 3. Complications.
10 11 12 13 14 15 16	People undergoing common bile duct exploration	T-tube	No T-tube	1. Mortality. 2. HRQoL. 3. Complications.
17 18 19 20 21 22 23	People with acute calculous cholecystitis (high risk)	Percutaneous cholecystostomy	No intervention/other interventions	1. Mortality. 2. HRQoL. 3. Complications.
24 25 26 27 28 29	People undergoing liver resection	Enhanced recovery protocols	Standard intervention	1. Mortality. 2. HRQoL. 3. Complications.
30 31 32 33 34 35 36	People undergoing liver transplantation	Perfusion techniques in donor	Not applicable	1. Mortality. 2. HRQoL. 3. Complications.
37 38 39 40 41 42 43	People with gallstones	Chinese herbs	Not applicable	1. Mortality. 2. HRQoL. 3. Complications.
44 45 46 47 48 49	Pregnant women with cholestasis	Interventions	Not applicable	1. Mortality. 2. HRQoL. 3. Complications.
50 51 52 53 54 55 56 57 58 59 60	New-borns and infants receiving parenteral nutrition and jaundice	Pharmacological interventions	Not applicable	1. Mortality. 2. HRQoL. 3. Complications.

1 2 3 4 5 6 7 8 9	New-borns and infants receiving parenteral nutrition and jaundice	Alternate interventions	Not applicable	1. Mortality. 2. HRQoL. 3. Complications.
10 11 12 13 14 15 16	People with sickle cell disease and intrahepatic cholestasis	Interventions	Not applicable	1. Mortality. 2. HRQoL. 3. Complications.
17 18 19 20 21 22	People with liver disease with upper gastrointestinal bleeding	Human recombinant activated factor VII	No intervention/other interventions	1. Mortality. 2. HRQoL. 3. Complications.
23 24 25 26 27 28 29	People with liver disease with upper gastrointestinal bleeding	Vitamin K	No intervention/other interventions	1. Mortality. 2. HRQoL. 3. Complications.
30 31 32 33 34 35 36	People with liver disease with upper gastrointestinal bleeding	Antifibrinolytic amino acids	No intervention/other interventions	1. Mortality. 2. HRQoL. 3. Complications.
37 38 39 40 41 42 43	People with liver disease	Antioxidant supplements	No intervention	1. Mortality. 2. HRQoL. 3. Complications.
44 45 46 47 48 49	People with liver disease	Vitamin D supplements	No intervention	1. Mortality. 2. HRQoL. 3. Complications.
50 51 52 53 54 55 56 57 58 59 60	People with liver disease	Lifestyle: Nutritional support	Not applicable	1. Mortality. 2. HRQoL. 3. Complications.

1 2 3 4 5 6 7 8 9 10 11	People with adverse events related to chemoarterial embolisation for primary liver cancer	Chinese herbs	Not applicable	1. Mortality. 2. HRQoL. 3. Complications.
12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27	People with uncomplicated hepatic hydatid cysts	Percutaneous needle aspiration, injection, and re-aspiration with benzimidazole	Percutaneous needle aspiration, injection, and re-aspiration without benzimidazole	1. Mortality. 2. HRQoL. 3. Complications.
28 29 30 31 32 33 34	People with gallbladder cancer	Chemotherapy	Not applicable	1. Mortality. 2. HRQoL. 3. Complications.
35 36 37 38 39 40	People with acute or acute-on-chronic liver failure	Granulocyte-colony stimulating factor	No intervention/other interventions	1. Mortality. 2. HRQoL. 3. Complications.
41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60	People with common bile duct stones	Early laparoscopic cholecystectomy following endoscopic sphincterotomy	Delayed laparoscopic cholecystectomy following endoscopic sphincterotomy	1. Mortality. 2. HRQoL. 3. Complications.

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60	People with gallstones and common-bile duct stones	Model of service delivery	Not applicable	1. Mortality. 2. HRQoL. 3. Complications.
People undergoing cholecystectomy	Routine intraoperative cholangiography	selective cholangiography	1. Mortality. 2. HRQoL. 3. Complications.	
People with gallstone pancreatitis	Early cholecystectomy	Delayed cholecystectomy	1. Mortality. 2. HRQoL. 3. Complications.	
People at risk of gallstones	Non-pharmacological interventions	Not applicable	1. Mortality. 2. HRQoL. 3. Complications.	
People with biliary obstruction due to cholangiocarcinoma	Endoscopic bipolar radiofrequency ablation	Other interventions	1. Mortality. 2. HRQoL. 3. Complications.	
People with colorectal liver metastases	Radiofrequency ablation	Other interventions	1. Mortality. 2. HRQoL. 3. Complications.	
People with suspected bile leak	Magnetic resonance cholangiopancreatography	Endoscopic retrograde cholangiopancreatography	1. Mortality. 2. HRQoL. 3. Complications.	
People with cholangitis	Antibiotics	Not applicable	1. Mortality. 2. HRQoL. 3. Complications.	

1 2 3 4 5 6 7 8 9	People with suspected focal liver lesions	Imaging modalities to distinguish focal liver lesions	Not applicable	1. Mortality. 2. HRQoL. 3. Complications.
10 11 12 13 14 15 16	People with liver cancer who have undergone surgery	Optimal follow-up regimen to detect early recurrence	Not applicable	1. Mortality. 2. HRQoL. 3. Complications.
17 18 19 20 21 22 23	People undergoing laparoscopic cholecystectomy	Evidence-based pain relief protocol	Standard care	1. Mortality. 2. HRQoL. 3. Complications.
24 25 26 27 28 29	People undergoing liver and bile duct resection	Evidence-based pain relief protocol	Standard care	1. Mortality. 2. HRQoL. 3. Complications.
30 31 32 33 34 35 36	People with suspected gallbladder polyp	Imaging modalities to confirm diagnosis of gallbladder polyp	Not applicable	1. Mortality. 2. HRQoL. 3. Complications.
37 38 39 40 41 42 43	People with gallbladder polyp	Imaging modalities to distinguish nature of gallbladder polyp	Not applicable	1. Mortality. 2. HRQoL. 3. Complications.
44 45 46 47 48 49	People with suspected gallstones	Methods to confirm diagnosis of gallstone	Not applicable	1. Mortality. 2. HRQoL. 3. Complications.
50 51 52 53 54 55 56 57 58 59 60	People with suspected acute cholecystitis	Methods to confirm diagnosis of acute cholecystitis	Not applicable	1. Mortality. 2. HRQoL. 3. Complications.

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60	People with suspected gallbladder dyskinesia	Methods to confirm gallbladder dyskinesia	Not applicable	1. Mortality. 2. HRQoL. 3. Complications.
	People with suspected Sphincter of Oddi dysfunction	Methods to confirm Sphincter of Oddi dysfunction	Not applicable	1. Mortality. 2. HRQoL. 3. Complications.
	People at risk of gallstones	Motivational interviewing for lifestyle changes	standard care	1. Mortality. 2. HRQoL. 3. Complications.
	People with gallstones	Motivational interviewing for lifestyle changes	standard care	1. Mortality. 2. HRQoL. 3. Complications.
	People at risk of NAFLD	Motivational interviewing for lifestyle changes	standard care	1. Mortality. 2. HRQoL. 3. Complications.
	People with NAFLD	Motivational interviewing for lifestyle changes	standard care	1. Mortality. 2. HRQoL. 3. Complications.
	People undergoing liver resection for liver cancer	Imaging modalities to confirm resectability	Not applicable	1. Mortality. 2. HRQoL. 3. Complications.
	People undergoing surgery for biliary tract cancer	Imaging modalities to confirm resectability	Not applicable	1. Mortality. 2. HRQoL. 3. Complications.

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60	People undergoing liver resection	Imaging modalities to confirm resectability	Not applicable	1. Mortality. 2. HRQoL. 3. Complications.
People undergoing liver transplantation for hepatocellular carcinoma	Imaging modalities to confirm that cancer is limited to liver	Not applicable	1. Mortality. 2. HRQoL. 3. Complications.	
People undergoing liver transplantation for hepatocellular carcinoma	Bridging ablative therapies	Standard care	1. Mortality. 2. HRQoL. 3. Complications.	
People undergoing liver transplantation for hepatocellular carcinoma	Goal-directed therapy	Standard care	1. Mortality. 2. HRQoL. 3. Complications.	
People with gallstones	Direct access surgery (without seeing a specialist)	Standard care	1. Mortality. 2. HRQoL. 3. Complications.	
People with benign liver and gallbladder conditions	Nurse-led care	Standard care	1. Mortality. 2. HRQoL. 3. Complications.	
People with sphincter of oddi dysfunction	Pharmacological interventions	Standard care	1. Mortality. 2. HRQoL. 3. Complications.	
People with sphincter of oddi dysfunction	Psychological counselling	Standard care	1. Mortality. 2. HRQoL. 3. Complications.	

1 2 3 4 5 6 7 8 9	People with biliary stricture	Different diagnostic tests	Not applicable	1. Mortality. 2. HRQoL. 3. Complications.
10 11 12 13 14 15 16	People with gallstones	Routine magnetic resonance cholangio pancreatography	Standard care	1. Mortality. 2. HRQoL. 3. Complications.
17 18 19 20 21 22 23 24 25 26 27	People with liver and gallbladder disorders	Methods to improve understanding of evidence	Not applicable	1. Improved knowledge. 2. Better involvement in decision making.
28 29 30 31 32 33 34	People undergoing liver transplantation	Routine fat-assessment in donor livers	Standard care	1. Mortality. 2. HRQoL. 3. Complications.
35 36 37 38 39 40	People with NAFLD and obesity	Routine anti-obesity surgery	Standard care	1. Mortality. 2. HRQoL. 3. Complications.
41 42 43 44 45 46 47 48 49	People with severe polycystic liver disease	Pharmacological interventions to improve functional volume	Standard care	1. Mortality. 2. HRQoL. 3. Complications.
50 51 52 53 54 55 56 57 58 59 60	People with liver disease	Interventions to achieve palliation	Not applicable	1. Palliation.

1 2 3 4 5 6 7 8 9	People with liver disease	Interventions to achieve symptom control	Not applicable	Symptom control
10 11 12 13	People with liver disease	Interventions to improve quality of life	Not applicable	Quality of life
14 15 16 17 18 19 20 21 22	Healthcare professionals dealing with people with primary sclerosing cholangitis	Education of healthcare professionals about liver disease	Standard care	1. Early recognition. 2. Appropriate treatment.
23 24 25 26 27 28 29	People with Crohn's disease	Methods for screening for primary sclerosing cholangitis	Not applicable	Diagnosis of primary sclerosing cholangitis
30 31 32 33 34	People with NAFLD	Patient education	Standard care	1. Greater knowledge.
35 36 37 38 39 40 41 42 43	Healthcare professionals dealing with people with polycystic liver disease	Education of healthcare professionals about liver disease	Standard care	1. Early recognition. 2. Appropriate treatment.
44 45 46 47 48 49 50 51 52	People with polycystic liver disease	Early liver transplantation	Standard care	1. Quality of life. 2. Reducing symptoms. 3. Reducing pain.
53 54 55 56 57 58 59 60	People with autoimmune hepatitis	Interventions that affect T cells	No intervention	1. Cure. 2. Improve quality of life

1 2 3 4 5 6 7	People at risk of liver disease	Screening	Not applicable	Early diagnosis and treatment
8 9 10 11	People with polycystic liver disease	Monitoring polycystic liver disease	Not applicable	
12 13 14 15 16	People with polycystic kidney disease	Diagnosis polycystic liver disease	Not applicable	
17 18 19 20 21 22	People with liver disease	Methods to improve early appropriate treatment	Not applicable	Early diagnosis and treatment
23 24 25 26 27 28 29	People with polycystic kidney disease	Methods to prevent symptomatic polycystic liver disease	Not applicable	1. Quality of life. 2. Liver function.
30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45	People undergoing liver transplantation	Various treatments	Not applicable	1. Survival 2. Complications 3. QoL 4. Hospital stay 5. Return to work 6. Improvement of symptoms
46 47 48 49 50 51 52 53 54 55 56 57 58 59 60	People with polycystic liver disease	Diet (specifically soy proteins which contain oestrogen	Standard diet	1. Decrease size of cyst or preventing cysts to enlarge. 2. Decrease symptoms

1 2 3 4 5 6 7 8 9 10 11	People with NAFLD	Various treatments	Not applicable	1. Impact on health (no further details) 2. Progression to liver failure
12 13 14 15 16	People with suspected NAFLD	Diagnosis	Not applicable	1. Early diagnosis
17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34	People with gallstones	Various treatments	Not applicable	1. Impact on health (no further details)
35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60	People with polycystic liver disease	Genetic treatments	Standard therapy	1. Reduce symptoms. 2. Decrease occurrence and size of cysts. 3. Increased longevity
	Healthcare professionals dealing with people with primary biliary cholangitis	Education of healthcare professionals about liver disease	Standard care	1. Early recognition. 2. Appropriate treatment.
	People undergoing treatment for ulcerative colitis	Various treatments	Not applicable	1. Adverse events related to liver
	People with cholangiocarcinoma	Liver transplantation	Standard therapy	1. Survival 2. Complications 3. QoL

			4. Hospital stay 5. Return to work
People undergoing liver transplantation	Machine perfusion of donor organ	Cold storage	1. Survival 2. Complications 3. QoL 4. Hospital stay 5. Return to work
People with liver cancer	Novel treatments (irreversible electroporation, high intensity focused ultrasound)		1. Survival 2. Complications 3. QoL 4. Hospital stay 5. Return to work
People with hepatocellular carcinoma	Liver resection	Liver transplantation	1. Survival 2. Complications 3. QoL 4. Hospital stay 5. Return to work
People with colorectal liver metastases	Ablation	Surgery	1. Survival 2. Complications 3. QoL 4. Hospital stay 5. Return to work
People with liver disease undergoing surgery	Ischaemic preconditioning	No IPC	1. Survival 2. Complications 3. QoL

			4. Hospital stay 5. Return to work
People with liver disease undergoing surgery	Remote ischaemic preconditioning	No RIPC	1. Survival 2. Complications 3. QoL 4. Hospital stay 5. Return to work
People with liver disease undergoing surgery	Goal-directed therapy	standard fluid treatment	1. Survival 2. Complications 3. QoL 4. Hospital stay 5. Return to work
People with compensated liver cirrhosis	Treatments (in particular statins)	Other interventions	1. Decompensation 2. Survival 3. Side effects 4. Quality of life.
People with chronic liver disease/ liver failure	Stem cell therapy	Standard therapy	1. Graft and patient survival 2. QoL. 3. Morbidity compared to conventional transplantation 4. Patient reported outcomes

People with Wilson's disease (and other rare non-alcohol liver related diseases)	Various treatments	Not applicable	Not stated
People with suspected autoimmune hepatitis	Diagnosis of autoimmune diseases	Not applicable	1. Costs of management

Appendix 2 List of unanswered research questions ('uncertainties') prioritised during the interim prioritisation

1. What are the best treatments that cure or delay the progression (worsening) of primary sclerosing cholangitis (PSC)?
2. Should all people above 40 years of age or those considered to be at risk of liver disease (because of family history of liver disease or because of their lifestyle) be tested for the presence of liver disease to identify liver diseases at an early stage?
3. Should people with primary sclerosing cholangitis (PSC) undergo screening (tested routinely) for cancer?
4. Are there any treatments that reverse the liver damage in primary sclerosing cholangitis (PSC)?
5. What are the best treatments that cure or delay the progression (worsening) of non-alcohol-related fatty liver disease (NAFLD)?
6. What are the best symptomatic treatments for itching in people with primary sclerosing cholangitis (PSC)?
7. Are there alternatives to invasive assessment of oesophageal varices in people with chronic liver disease?

- 1
- 2
- 3 8. Does vitamin D supplementation (adding Vitamin D in food or providing it in tablet form)
- 4
- 5 increase the lifespan, health-related quality of life, and decrease complications in people
- 6
- 7 with liver disease?
- 8
- 9
- 10 9. Should new methods to improve the understanding of evidence be developed for people
- 11
- 12 with liver and gallbladder diseases?
- 13
- 14 10. What is the best treatment for people with early or very early hepatocellular carcinoma
- 15
- 16 (HCC)?
- 17
- 18 11. Should the methods used to assess nutrition of patients in liver disease be standardised?
- 19
- 20 12. Does dieting improve liver function and decrease the requirement for liver transplantation in
- 21
- 22 obese people?
- 23
- 24 13. Should general public be educated about non-alcohol-related fatty liver disease (NAFLD)
- 25
- 26 with an aim to reduce the numbers of those that have it?
- 27
- 28 14. What are the best symptomatic treatments for itching in people with chronic liver diseases
- 29
- 30 other than primary sclerosing cholangitis (PSC) and primary biliary cholangitis (PBC)?
- 31
- 32 15. Do treatments targeted against deformation of bile duct (biliary stricture or narrowing of
- 33
- 34 bile duct due to the illness) work better than other treatments in people with primary
- 35
- 36 sclerosing cholangitis (PSC)?
- 37
- 38 16. What are the treatments available to decrease weight in overweight people with non-
- 39
- 40 alcohol-related fatty liver disease (NAFLD)?
- 41
- 42 17. What are the best treatments that cure or delay the progression (worsening) of non-alcohol
- 43
- 44 related steatohepatitis (NASH)?
- 45
- 46 18. Do statins (or other treatments) delay liver failure in people with advanced liver disease?
- 47
- 48 19. What are the best treatments that provide temporary symptom relief in people with
- 49
- 50 advanced liver disease?
- 51
- 52 20. Which is the most suitable antibiotic (or combination of antibiotics) in people with
- 53
- 54 cholangitis (biliary infection)?
- 55
- 56
- 57
- 58
- 59
- 60

- 1
2
3 21. What are the best treatments that cure or delay the progression (worsening) of autoimmune
4 hepatitis (AIH)?
5
6
- 7
8 22. Are there any methods other than liver biopsy (obtaining a piece of liver, usually using a
9
10 needle, for examination under microscope) for the early diagnosis of primary sclerosing
11
12 cholangitis (PSC) in people at risk of developing PSC?
13
- 14 23. What are the best nutritional interventions in people undergoing liver transplantation?
- 15
16 24. What are the best symptomatic treatments for fatigue (tiredness), joint pain, and other
17
18 symptoms in people with people with autoimmune hepatitis (AIH)?
19
- 20
21 25. Prior to liver transplantation, is it better to transport the donor liver using a machine which
22
23 pumps blood or preservation solution through the liver (machine perfusion) or is it better to
24
25 transport it in the standard way of transporting it immersed in cold preservation solution
26
27 (cold storage)?
28
- 29
30 26. What are the best treatments that cure or delay the progression (worsening) of chronic
31
32 hepatitis C virus (HCV) infection?
33
- 34
35 27. Does education of people with liver disease about the natural course and treatment of liver
36
37 disease improve the patient knowledge, patient responsibility, and decrease hospital visits?
38
- 39
40 28. What are the best treatments that cure or delay the progression (worsening) of primary
41
42 biliary cholangitis (PBC)?
43
- 44
45 29. Is nurse-led care as effective or better than doctor-led care for non-alcohol related fatty liver
46
47 disease (NAFLD)?
48
- 49
50 30. Is treatment targeted against deformation of bile duct (biliary stricture or narrowing of bile
51
52 duct due to cancer) better than standard treatment for people with bile duct cancer?
53
- 54
55 31. Is surgery (in the form of removal of gallbladder) required in people with gallstones?
56
- 57
58 32. Should people with non-alcohol-related fatty liver disease (NAFLD) and non-alcohol-related
59
60 steatohepatitis (NASH) receive additional education about the condition?
33. What is the best immunosuppressive regimen in adults undergoing liver transplantation?

- 1
 - 2
 - 3
 - 4
 - 5
 - 6
 - 7
 - 8
 - 9
 - 10
 - 11
 - 12
 - 13
 - 14
 - 15
 - 16
 - 17
 - 18
 - 19
 - 20
 - 21
 - 22
 - 23
 - 24
 - 25
 - 26
 - 27
 - 28
 - 29
 - 30
 - 31
 - 32
 - 33
 - 34
 - 35
 - 36
 - 37
 - 38
 - 39
 - 40
 - 41
 - 42
 - 43
 - 44
 - 45
 - 46
 - 47
 - 48
 - 49
 - 50
 - 51
 - 52
 - 53
 - 54
 - 55
 - 56
 - 57
 - 58
 - 59
 - 60
34. Is endoscopic ultrasound (EUS) (using a ultrasound attached to the end of an endoscope) or magnetic resonance cholangiopancreatography (MRCP, a form of MRI scan) better in the diagnosis of common bile duct (CBD) stones?
35. How can we improve compliance to treatment (adherence to treatment or the degree to which a patient correctly follows medical advice) in people with liver disease?
36. What are the best symptomatic treatments for relief of ulcerative colitis (UC) in people with primary sclerosing cholangitis (PSC) who have undergone liver transplantation?
37. What are the best symptomatic treatments for itching and fatigue (tiredness) in people with primary biliary cholangitis (PBC)?
38. Does education of people with asymptomatic (absence of symptoms) liver disease result in change of life style and cure/delay the progression (worsening) of liver disease?
39. What are the best treatments that are available for the treatment of pregnant women with cholestasis (condition where bile flow from the liver is obstructed)?
40. Is transarterial chemoembolisation (TACE) or transarterial embolisation (TAE) (blocking the blood supply to cancer with or without chemotherapy drugs) effective in the treatment of people with liver metastases?
41. Should people with liver metastases (cancer spread to the liver) from neuroendocrine cancer (a form of cancer that arises from cells that secrete hormones and nervous system) undergo liver resection?
42. What are the best methods available to decrease blood loss during liver resection?
43. What are the best treatments that cure or delay the progression (worsening) of chronic hepatitis B virus (HBV) infection?
44. What are the best treatments for people with polycystic liver disease?
45. Should the healthcare professionals dealing with childhood liver diseases be provided additional education about childhood liver diseases compared to standard education where childhood diseases are learnt as part of overall education?

- 1
2
3 46. What is the best immunosuppressive regimen in children undergoing liver transplantation?
4
5
6 47. Should blood vessels supplying the liver be temporarily blocked in people undergoing liver
7
8 resection? If so, what is the best way of performing this?
9
10 48. What is the best treatment that should be given to people who undergo liver transplantation
11
12 for chronic hepatitis B virus (HBV) infection to prevent reinfection with chronic hepatitis B
13
14 virus (HBV) infection?
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Appendix 3 Next step to address the top 10 uncertainty based on current best evidence (detailed)

Treatment uncertainty (Research question)	High-quality systematic review ^a	Research recommendations of systematic review	RCTs not included in the systematic review ^{a,b,c}	Patient-oriented outcomes assessed in trials not included in the systematic review ^d	Next step
What is the best treatment for people with early or very early hepatocellular carcinoma (HCC)?	[1]	High-quality RCTs designed to assess clinically important differences in all-cause mortality and health-related quality of life, and having an adequate follow-up period (approximately five years) are needed.	NCT02169765 NCT02704130 NCT02728193 NCT02243384 NCT00844454 NCT01918683 NCT01570075 NCT01351194	Survival (7 trials), recurrence (5 trials), morbidity (3 trials)	High-quality RCTs of interventions not covered in ongoing trials and comparison of health-related quality (HRQoL) in different treatments

<p>1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29</p> <p>What are the best treatments that cure or delay the progression (worsening) of primary sclerosing cholangitis (PSC)?</p>	<p>[2]</p>	<p>An urgent need exists to identify an effective medical treatment for primary sclerosing cholangitis through well-designed RCTs with adequate follow-up that aim to identify differences in outcomes important to people with primary sclerosing cholangitis.</p>	<p>NCT03394781 NCT02605213 NCT02943460 NCT02704364 NCT01688024 NCT02177136 NCT01672853 NCT03035058 NCT03333928</p>	<p>None of the trials include survival, HRQoL as outcomes^e</p>	<p>High-quality RCTs with clinical outcomes</p>
<p>30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46</p> <p>What are the best treatments that cure or delay the progression (worsening) of non-</p>	<p>[3] (includes only pharmacological interventions)</p>	<p>Further well-designed randomised clinical trials with sufficiently</p>	<p>More than 10 published trials on lifestyle interventions and more than 20 trials</p>	<p>Lifestyle interventions and nutritional supplementation</p>	<p>High-quality systematic reviews on lifestyle interventions (one review) and nutritional</p>

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

<p>alcohol-related fatty liver disease (NAFLD)?</p>		<p>large sample sizes are necessary.</p>	<p>on nutritional supplementation with no recent high-quality systematic reviews <u>Pharmacological interventions</u> NCT02605616 NCT01002547 NCT02927314 NCT03291249 NCT03166735 NCT03486899 NCT03061721 NCT02784444 NCT02077374 NCT03486912</p>	<p>Not applicable as there are no high quality systematic reviews <u>Pharmacological interventions</u> Health-related quality of life (2 trials), resolution of fatty liver disease (11 trials), mortality (2 trials), cirrhosis (2 trials), cardiovascular events (2 trials)^e</p>	<p>supplementation to cure or delay the progression of NAFLD and high-quality RCTs on pharmacological interventions with clinical outcomes</p>
---	--	--	---	---	--

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

			NCT02854605		
			NCT01963845		
			NCT03437720		
			NCT02684591		
			NCT02787304		
			NCT02466516		
			NCT02633956		
			NCT03008070		
			NCT03205150		
			NCT02923154		
			NCT02913105		
			NCT01899859		
			NCT02548351		
			NCT03053063		
			NCT03053050		
			NCT02413372		

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

			NCT02443116		
			NCT01464801		
			NCT03449446		
			NCT02912260		
			NCT02856555		
			NCT02704403		
			NCT01617772		
			NCT02217475		
			NCT01406704		
			NCT03248882		
			NCT01051219		
			NCT02316717		
			NCT02970942		
			NCT03439254		
			NCT02574325		
			NCT01703260		

			NCT01260246		
			NCT02960204		
<p>1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46</p> <p>What is the best immunosuppressive regimen in adults undergoing liver transplantation?</p>	<p>[4] (covers only maintenance immunosuppression)</p>	<p>Future randomised clinical trials should be adequately powered; performed in people who are generally seen in the clinic rather than in highly selected participants; employ blinding; avoid postrandomisation dropouts or planned cross-overs; and use clinically important outcomes such as</p>	<p><u>Induction immunosuppression</u></p> <p>More than 20 published trials</p> <p><u>Maintenance immunosuppression</u></p> <p>NCT01998789</p> <p>NCT01230502</p> <p>NCT02909335</p> <p>NCT00286871</p>	<p><u>Induction immunosuppression</u></p> <p>Not applicable as there is no high quality systematic review</p> <p><u>Maintenance immunosuppression</u></p> <p>Graft survival (1 trial)</p> <p>Adverse events (1 trial)</p> <p>Hepatocellular carcinoma (1 trial)^e</p>	<p>High-quality systematic review on induction immunosuppressive regimen and high-quality RCTs on maintenance immunosuppression with important clinical outcomes</p>

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

		<p>mortality, graft loss, renal impairment, chronic kidney disease, and retransplantation.</p> <p>Such trials should use tacrolimus as one of the control groups.</p> <p>Moreover, such trials ought to be designed in such a way as to ensure low risk of bias and low risks of random errors.</p>			
Should general public be educated about non-alcohol-related	None	-	None	-	High-quality RCTs on education to prevent NAFLD

<p>fatty liver disease (NAFLD) with an aim to reduce the numbers of those that have it?</p>					
<p>What are the best treatments that cure or delay the progression (worsening) of autoimmune hepatitis (AIH)?</p>	<p>None</p>	<p>-</p>	<p>[5-7] NCT02050646 NCT02463331 NCT00608894 NCT02900443 NCT02239562 NCT01170351 NCT03217422 NCT01661842 NCT00687180 NCT01980745 NCT02878863</p>	<p>Survival (1 trial), health-related quality of life (1 trial)^e</p>	<p>High quality RCTs with clinical outcomes</p>

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

			NCT02936596		
What are the best treatments that cure or delay the progression (worsening) of non-alcohol related steatohepatitis (NASH)?	The evidence related to this question is covered under non-alcohol related fatty liver disease by performing a subgroup analysis of people with NASH				
Prior to liver transplantation, is it better to transport the donor liver using a machine which pumps blood or preservation solution through the liver (machine	None	-	NCT02775162 NCT03124641 NCT02940600 NCT02584283 NCT01317342	Overall survival (4 trials), graft survival (5 trials), health-related quality of life (2 trials)	Await results of the RCTs (all expected to complete by the end of 2019) and perform a high quality systematic review.

<p>perfusion) or is it better to transport it in the standard way of transporting it immersed in cold preservation solution (cold storage)?</p>					
<p>What are the best treatments that cure or delay the progression (worsening) of primary biliary cholangitis (PBC)?</p>	<p>[8]</p>	<p>Further well-designed randomised clinical trials are necessary. Future randomised clinical trials ought to be adequately powered; performed in people who are generally seen in the</p>	<p>NCT02937012 NCT01473524 NCT02823353 NCT02135536 NCT01614405 NCT02609048 NCT00746486 NCT02955602 NCT03226067</p>	<p>Health-related quality of life (5 trials), relief of symptoms (5 trials)^e</p>	<p>High-quality RCTs with clinical outcomes</p>

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

		clinic rather than in	NCT03112681		
		highly selected	NCT01904058		
		participants; employ	NCT02943447		
		blinding; avoid post-	NCT03124108		
		randomisation	NCT03345589		
		dropouts or planned	NCT03092765		
		cross-overs; should	NCT03394924		
		have sufficient follow-	NCT02516605		
		up period (e.g. five or	NCT03253276		
		10 years or more); and	NCT02965911		
		use clinically important	NCT01899703		
		outcomes such as	NCT01654731		
		mortality, health-	NCT02308111		
		related quality of life,	NCT00125281		
		cirrhosis,	NCT02701166		
		decompensated			

		<p>cirrhosis, and liver transplantation.</p> <p>Alternatively, very large groups of participants should be randomised to facilitate shorter trial duration.</p>			
<p>Are there any treatments that reverse the liver damage in primary sclerosing cholangitis (PSC)?</p>	<p>The evidence related to this question is covered under treatments for primary sclerosing cholangitis. The systematic review did not include fibrosis as one of the outcomes. Nine of the trials included in the systematic review reported on fibrosis. Two of the trials not included in the systematic review (and listed above) reported on liver fibrosis.</p>				

a Numbers indicate the reference number.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

b Ongoing trials, unpublished trials, or trials published since the search date for the systematic review when a high-quality systematic review based on randomised controlled trials exists. If no systematic reviews based on randomised controlled trials exist, these are either published trials or ongoing studies.

c NCT followed by a number indicates trial registration number

d This information is reported to find out whether the important patient-oriented outcomes are reported in the trials not covered by high-quality systematic reviews. This is to help with deciding whether new randomised controlled trials are necessary on the topic.

e The remaining trials reported treatment-related adverse events, composite outcomes and surrogate markers.

Appendix 4 Scores obtained by each question in the different Delphi rounds

Questions ^a	Delphi 1: Proportion who rated this question as highly important	Delp hi 1: Medi an (IQR)	Delphi 2: Proportion who rated this question as highly important	Delp hi 2: Medi an (IQR)	Delphi 3: Proportion who rated this question as highly important	Delp hi 3: Medi an (IQR)	Consen sus reache d in Delphi 3? ^b
------------------------	---	--------------------------------------	---	--------------------------------------	---	--------------------------------------	--

1. What are the best treatments that cure or delay the progression (worsening) of primary sclerosing cholangitis (PSC)?	78.8%	8(7,9)	83.9%	8(7,9)	93.3%	8(7,9)	Yes
2. Should all people above 40 years of age or those considered to be at risk of liver disease (because of family history of liver disease or because of their lifestyle) be tested for the presence of liver disease to identify liver diseases at an early stage?	44.4%	6(5,7)	35.3%	6(5,7)	33.3%	6(5,7)	No
3. Should people with primary sclerosing cholangitis (PSC) undergo screening (tested routinely) for cancer?	46.9%	6(5,9)	50.0%	6.5(5.75,8)	44.8%	6(6,7.5)	No
4. Are there any treatments that reverse the liver damage in primary sclerosing cholangitis (PSC)?	59.4%	7.5(5.8,7.5)	70.0%	7.5(6.9)	72.4%	7(6,9)	Yes
5. What are the best treatments that cure or delay the progression (worsening) of non-alcohol-related fatty liver disease (NAFLD)?	76.5%	8(6.7,5,9)	87.5%	8.5(7.9)	90.3%	9(8,9)	Yes
6. What are the best symptomatic treatments for itching in people with primary sclerosing cholangitis (PSC)?	48.5%	6(5,7.5)	48.4%	6(5,7)	50.0%	6.5(5.7)	No

7.Are there alternatives to invasive assessment of oesophageal varices in people with chronic liver disease?	48.6%	6(5,8)	54.5%	7(5.5,8)	56.3%	7(6,8)	No
8.Does vitamin D supplementation (adding Vitamin D in food or providing it in tablet form) increase the lifespan, health-related quality of life, and decrease complications in people with liver disease?	37.1%	6(4,7)	39.4%	6(4,7)	37.5%	6(4.2,5,7,75)	No
9.Should new methods to improve the understanding of evidence be developed for people with liver and gallbladder diseases?	38.2%	6(4,8)	46.9%	6(4,8)	48.4%	6(5,8)	No
10.What is the best treatment for people with early or very early hepatocellular carcinoma (HCC)?	76.5%	8(6.7,5,9)	87.5%	8(7,9)	93.5%	8(7,9)	Yes
11.Should the methods used to assess nutrition of patients in liver disease be standardised?	57.1%	7(5,9)	54.5%	7(5,8)	59.4%	7(5,8)	No
12.Does dieting improve liver function and decrease the requirement for liver transplantation in obese people?	48.6%	6(4,8)	44.1%	6(4,7.25)	48.5%	6(5,7)	No

13.Should general public be educated about non-alcohol-related fatty liver disease (NAFLD) with an aim to reduce the numbers of those that have it?	72.2%	7.5(6,9)	73.5%	8(6,9)	81.8%	8(7,9)	Yes
14.What are the best symptomatic treatments for itching in people with chronic liver diseases other than primary sclerosing cholangitis (PSC) and primary biliary cholangitis (PBC)?	48.5%	6(4.5,7)	48.4%	6(5,7)	50.0%	6.5(5,7)	No
15.Do treatments targeted against deformation of bile duct (biliary stricture or narrowing of bile duct due to the illness) work better than other treatments in people with primary sclerosing cholangitis (PSC)?	19.4%	5(4,6)	20.0%	5(4,6)	20.7%	5(4,6)	No
16.What are the treatments available to decrease weight in overweight people with non-alcohol-related fatty liver disease (NAFLD)?	37.1%	5(4,8)	27.3%	6(4,7)	28.1%	5(4,7)	No
17.What are the best treatments that cure or delay the progression (worsening) of non-alcohol related steatohepatitis (NASH)?	67.6%	8(5,8.25)	71.0%	8(6,9)	76.7%	8(6.7,5,9)	Yes

18.Do statins (or other treatments) delay liver failure in people with advanced liver disease?	45.7%	6(5,7)	39.4%	6(6,7)	43.8%	6(6,7)	No
19.What are the best treatments that provide temporary symptom relief in people with advanced liver disease?	50.0%	6.5(5,7.75)	52.9%	7(5.7,5,7.2)	54.5%	7(6,7)	No
20.Which is the most suitable antibiotic (or combination of antibiotics) in people with cholangitis (biliary infection)?	64.7%	7(5,8)	68.8%	7(5.2,5,8)	67.7%	7(5,8)	No
21.What are the best treatments that cure or delay the progression (worsening) of autoimmune hepatitis (AIH)?	75.8%	7(6.5,9)	81.3%	7.5(7,9)	80.6%	8(7,9)	Yes
22.Are there any methods other than liver biopsy (obtaining a piece of liver, usually using a needle, for examination under microscope) for the early diagnosis of primary sclerosing cholangitis (PSC) in people at risk of developing PSC?	53.1%	7(5,8)	60.0%	7(5,8)	58.6%	7(5,8)	No
23.What are the best nutritional interventions in people undergoing liver transplantation?	52.8%	7(5,8)	51.5%	7(5,8)	53.1%	7(5,8)	No

24. What are the best symptomatic treatments for fatigue (tiredness), joint pain, and other symptoms in people with autoimmune hepatitis (AIH)?	61.8%	7(6,8)	65.6%	7(6,8)	64.5%	7(6,8)	No
25. Prior to liver transplantation, is it better to transport the donor liver using a machine which pumps blood or preservation solution through the liver (machine perfusion) or is it better to transport it in the standard way of transporting it immersed in cold preservation solution (cold storage)?	54.5%	7(5,9)	68.8%	7(6,8 .75)	74.2%	7(6,9)	Yes
26. What are the best treatments that cure or delay the progression (worsening) of chronic hepatitis C virus (HCV) infection?	42.4%	6(2,8)	40.0%	5.5(2 ,7)	37.9%	5(2,7)	No
27. Does education of people with liver disease about the natural course and treatment of liver disease improve the patient knowledge, patient responsibility, and decrease hospital visits?	51.4%	7(4,8)	58.8%	7(4,7 .25)	57.6%	7(4,8)	No
28. What are the best treatments that cure or delay the progression (worsening) of primary biliary cholangitis (PBC)?	61.8%	7(5,7 5,8)	68.8%	7(6,8)	74.2%	7(6,8)	Yes

29. Is nurse-led care as effective or better than doctor-led care for non-alcohol related fatty liver disease (NAFLD)?	38.2%	5(4,8)	31.3%	5(4,7)	25.8%	5(4,7)	No
30. Is treatment targeted against deformation of bile duct (biliary stricture or narrowing of bile duct due to cancer) better than standard treatment for people with bile duct cancer?	35.5%	5(4,7)	22.6%	5(4,6)	20.0%	5(4,6)	No
31. Is surgery (in the form of removal of gallbladder) required in people with gallstones?	24.2%	5(4,6)	30.0%	5(4,7)	24.1%	5(4,5)	No
32. Should people with non-alcohol-related fatty liver disease (NAFLD) and non-alcohol-related steatohepatitis (NASH) receive additional education about the condition?	52.9%	7(4,8)	56.3%	7(4,2)	54.8%	7(5,8)	No
33. What is the best immunosuppressive regimen in adults undergoing liver transplantation?	73.5%	7(6,9)	84.4%	8(7,9)	90.3%	8(7,9)	Yes
34. Is endoscopic ultrasound (EUS) (using a ultrasound attached to the end of an endoscope) or magnetic resonance cholangio pancreatography (MRCP, a form of MRI scan) better in the diagnosis of common bile duct (CBD) stones?	36.7%	5(4,7)	30.0%	5(4,7)	20.7%	5(4,6)	No

35.How can we improve compliance to treatment (adherence to treatment or the degree to which a patient correctly follows medical advice) in people with liver disease?	67.6%	7(5,8)	69.7%	7(5,8)	71.9%	7(5,8)	Yes
36.What are the best symptomatic treatments for relief of ulcerative colitis (UC) in people with primary sclerosing cholangitis (PSC) who have undergone liver transplantation?	51.6%	7(5,8)	56.7%	7(5,8)	55.2%	7(6,8)	No
37.What are the best symptomatic treatments for itching and fatigue (tiredness) in people with primary biliary cholangitis (PBC)?	50.0%	6.5(5 ,7)	43.8%	6(5,7)	41.9%	6(5,7)	No
38.Does education of people with asymptomatic (absence of symptoms) liver disease result in change of life style and cure/delay the progression (worsening) of liver disease?	54.3%	7(5,8)	51.5%	7(4.5 ,8)	53.1%	7(5,7 ,75)	No
39.What are the best treatments that are available for the treatment of pregnant women with cholestasis (condition where bile flow from the liver is obstructed)?	38.7%	6(4,7)	31.0%	6(4.5 ,7)	27.6%	6(5,7)	No
40.Is transarterial chemoembolisation (TACE) or transarterial embolisation (TAE) (blocking the blood supply to cancer with or	40.6%	6(4,8)	34.4%	6(4,7)	32.3%	6(5,7)	No

without chemotherapy drugs) effective in the treatment of people with liver metastases?							
41.Should people with liver metastases (cancer spread to the liver) from neuroendocrine cancer (a form of cancer that arises from cells that secrete hormones and nervous system) undergo liver resection?	36.7%	6(4,7 .25)	40.0%	6(4.7 5,7.2 5)	37.9%	6(5.5 ,7)	No
42.What are the best methods available to decrease blood loss during liver resection?	43.8%	6(5,7 .75)	48.4%	6(5,8)	46.7%	6(5,7 .25)	No
43.What are the best treatments that cure or delay the progression (worsening) of chronic hepatitis B virus (HBV) infection?	51.6%	7(4,8)	46.7%	6(4.7 5,7.2 5)	48.3%	6(5,7 .5)	No
44.What are the best treatments for people with polycystic liver disease?	39.3%	6(4,8)	34.5%	6(4,8)	35.7%	6(5,7)	No
45.Should the healthcare professionals dealing with childhood liver diseases be provided additional education about childhood liver	35.5%	5(3,8)	37.9%	5(3.5 ,7.5)	37.9%	5(4.5 ,7.5)	No

diseases compared to standard education where childhood diseases are learnt as part of overall education?							
46.What is the best immunosuppressive regimen in children undergoing liver transplantation?	65.6%	8(4.2 5,9)	67.7%	8(6,9)	70.0%	8(6,9)	Yes
47.Should blood vessels supplying the liver be temporarily blocked in people undergoing liver resection? If so, what is the best way of performing this?	31.0%	6(4,7)	26.7%	5.5(4 ,7)	27.6%	6(5,7)	No
48.What is the best treatment that should be given to people who undergo liver transplantation for chronic hepatitis B virus (HBV) infection to prevent reinfection with chronic hepatitis B virus (HBV) infection?	46.9%	6(3.5 ,7)	36.7%	6(3,7)	37.9%	6(5,7)	No
49.Are there alternatives to steroids in treating people with autoimmune hepatitis (AIH)?	-	-	51.9%	7(5,8)	50.0%	6.5(5 ,8)	No
50.What impact does the home situation have on recovery from chronic liver disease and its treatment?	-	-	34.5%	5(3.5 ,7.5)	32.1%	5(4,7)	No

51.Does cure of hepatitis C provide benefits to the patient outside reduction in liver related complications?	-	-	29.2%	5.5(3 .25,7)	30.4%	6(4,7)	No
52.How fast does liver fibrosis (scarring) actually progress in non-alcoholic liver disease patients and does this predict overall outcome?	-	-	62.1%	7(6,8)	64.3%	7.5(6 ,8)	No
53.Should direct-acting antiviral treatments therapies be made more easily accessible to GPs and drug service clinics for treatment of hepatitis C virus?	-	-	50.0%	6.5(3 .5,7)	52.2%	7(5,7)	No
54.Should patients diagnosed with liver fibrosis/cirrhosis related to NAFLD (non-alcoholic fatty liver disease) be offered more intensive nutritional support or dietician review?	-	-	60.7%	7(5,8)	63.0%	7(5,8)	No
55.Why have there been no alternatives to surgery in the form of new drug treatments for gall bladder disease & biliary sludge?	-	-	29.2%	4.5(1 .25,7)	26.1%	4(2,7)	No

56. Why is there no proper evidence-based research on nutrition as a way of managing gall bladder disease/biliary sludge?	-	-	36.0%	5(1.5,7)	33.3%	5(2,7)	No
57. Why is there such variability in the natural progression of people with primary sclerosing cholangitis: some are very sick and require a transplant whereas others can remain relatively healthy for a long period?	-	-	56.0%	7(6,7)	54.2%	7(6,7)	No
58. What are the warning signals that primary sclerosing cholangitis will be aggressive or cancerous?	-	-	57.7%	7(5.7,5,8.2,5)	60.0%	7(5.5,8)	No
59. Does information on the impact of the complication on the people's quality of life improve the patient's informed decision-making process about treatment of liver and gallbladder diseases?	-	-	46.4%	6(4,7)	44.4%	6(4,7)	No
60. Will clinical pathways developed with patients and healthcare professionals having an equal say result in greater patient satisfaction and health in people with liver and gallbladder diseases?	-	-	44.8%	6(4.5,8)	46.4%	6(4.2,5,8)	No

<p>61.Should high school teenagers be educated about the risks of hepatitis C?</p>	-	-	53.8%	7(3.7 5,8)	57.7%	7(4.7 5,7.2 5)	No
<p>62.How can patients with end stage liver failure be better prepared for end of life. How can the healthcare professionals supporting them be better prepared to provide that support?</p>	-	-	65.5%	7(6,8)	67.9%	7(6,8)	No
<p>63.Is aggressive control of inflammation on colonic inflammatory bowel disease in primary sclerosing cholangitis associated with improved liver outcomes?</p>	-	-	48.0%	6(5,7)	50.0%	6.5(5 .25,7)	No
<p>64.What is the best way to survey for cholangiocarcinoma in primary sclerosing cholangitis?</p>	-	-	61.5%	7(5.7 5,8)	60.0%	7(6,8)	No
<p>65.Should the criteria for polycystic liver disease and transplantation be changed to take into account the size the liver cysts can grow and the additional pressures on all the internal organs?</p>	-	-	29.2%	4.5(2 ,7)	30.4%	6(3,7)	No

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

66.Does control of colitis at the time of liver transplant reduce the risk of recurrent primary sclerosing cholangitis?	-	-	36.0%	6(5,7)	33.3%	6(5,7)	No
67.Are people with liver disease likely to develop other conditions, if so, what other conditions?	-	-	42.9%	6(3.2, 5,7)	46.4%	6(3.2, 5,7,7)	No
68.Do people with liver disease have a reduced life expectancy?	-	-	30.0%	5.5(3,8)	34.5%	6(3,8)	No
69.Should transjugular intrahepatic portosystemic shunt (TIPS) be used earlier in management of variceal haemorrhage?	-	-	51.9%	7(5,7)	55.6%	7(6,7)	No
70.Should abnormal alanine transaminase (ALT) reference ranges be revised downwards in line with ACG (American College of Gastroenterology) guidance?	-	-	36.0%	6(5,7)	37.5%	6(5,7)	No

a Questions from 49 to 70 were collected during the first round of Delphi.

b Consensus was reached when at least 80% of Delphi-panel members scored between 7 and 9 for the specific question.

Abbreviation: IQR = interquartile range

References

1. Majumdar A, Roccarina D, Thorburn D, Davidson BR, Tsochatzis E, Gurusamy KS. Management of people with early- or very early-stage hepatocellular carcinoma: an attempted network meta-analysis. The Cochrane database of systematic reviews. 2017;3:CD011650. Epub 2017/03/30. doi: 10.1002/14651858.CD011650.pub2. PubMed PMID: 28351116.
2. Saffioti F, Gurusamy KS, Hawkins N, Toon CD, Tsochatzis E, Davidson BR, et al. Pharmacological interventions for primary sclerosing cholangitis: an attempted network meta-analysis. The Cochrane database of systematic reviews. 2017;3:CD011343. Epub 2017/04/19. doi: 10.1002/14651858.CD011343.pub2. PubMed PMID: 28417463.
3. Lombardi R, Onali S, Thorburn D, Davidson BR, Gurusamy KS, Tsochatzis E. Pharmacological interventions for non-alcohol related fatty liver disease (NAFLD): an attempted network meta-analysis. The Cochrane database of systematic reviews. 2017;3:CD011640. Epub 2017/03/31. doi: 10.1002/14651858.CD011640.pub2. PubMed PMID: 28358980.
4. Rodriguez-Peralvarez M, Guerrero-Misas M, Thorburn D, Davidson BR, Tsochatzis E, Gurusamy KS. Maintenance immunosuppression for adults undergoing liver transplantation: a network meta-analysis. The Cochrane database of systematic reviews. 2017;3:CD011639. Epub 2017/04/01. doi: 10.1002/14651858.CD011639.pub2. PubMed PMID: 28362060.
5. Czaja AJ, Carpenter HA, Lindor KD. Ursodeoxycholic acid as adjunctive therapy for problematic type 1 autoimmune hepatitis: a randomized placebo-controlled treatment trial. *Hepatology (Baltimore, Md)*. 1999;30(6):1381-6. Epub 1999/11/26. doi: 10.1002/hep.510300603. PubMed PMID: 10573515.

- 1
2
3 6. Manns MP, Woynarowski M, Kreisel W, Lurie Y, Rust C, Zuckerman E, et al. Budesonide induces remission more effectively than prednisone in a
4 controlled trial of patients with autoimmune hepatitis. *Gastroenterology*. 2010;139(4):1198-206. Epub 2010/07/06. doi: 10.1053/j.gastro.2010.06.046.
5
6 PubMed PMID: 20600032.
7
8
9
10 7. Woynarowski M, Nemeth A, Baruch Y, Koletzko S, Melter M, Rodeck B, et al. Budesonide versus prednisone with azathioprine for the treatment of
11 autoimmune hepatitis in children and adolescents. *The Journal of pediatrics*. 2013;163(5):1347-53.e1. Epub 2013/07/03. doi: 10.1016/j.jpeds.2013.05.042.
12
13 PubMed PMID: 23810723.
14
15
16 8. Saffioti F, Gurusamy KS, Eusebi LH, Tsochatzis E, Davidson BR, Thorburn D. Pharmacological interventions for primary biliary cholangitis: an
17 attempted network meta-analysis. *The Cochrane database of systematic reviews*. 2017;3:CD011648. Epub 2017/03/30. doi:
18
19 10.1002/14651858.CD011648.pub2. PubMed PMID: 28350426.
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

BMJ Open

TOP RESEARCH PRIORITIES IN LIVER AND GALLBLADDER DISORDERS IN THE UNITED KINGDOM

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-025045.R1
Article Type:	Research
Date Submitted by the Author:	13-Dec-2018
Complete List of Authors:	Gurusamy, Kurinchi; University College London, Walmsley, Martine; PSC Support Davidson, Brian; Royal Free London NHS Foundation Trust, HPB Surgery Frier, Claire; Royal Free London NHS Foundation Trust, HPB Surgery Fuller, Barry; University College London Madden, Angela; University of Hertfordshire Masson, Steven; Freeman Hospital Morley, Richard; Cochrane Collaboration Consumer Network Safarik, Ivana; Carolside Medical Centre Tsochatzis, E; University College London Ahmed, Irfan; NHS Grampian Cowlin, Maxine; Patient representative Dillon, John; University of Dundee Division of Cardiovascular and Diabetes Medicine, Liver Group Ellicott, Graham; Patient representative Elsharkawy, Ahmed; Queen Elizabeth Hospital Birmingham Farrington, Liz; Royal Cornwall Hospitals NHS Trust Glachan, Anthony; Patient representative Kumar, Nagappan; University Hospital of Wales Milne, EJ; Patient representative Rushbrook, Simon; Norfolk and Norwich University Hospitals NHS Foundation Trust, Smith, Amanda; Queen Elizabeth Hospital Birmingham Stafford, Lizzie; John Radcliffe Hospital Yeoman, Andrew; Royal Gwent Hospital
Primary Subject Heading:	Gastroenterology and hepatology
Secondary Subject Heading:	Gastroenterology and hepatology
Keywords:	liver, chronic liver disease, research priorities

SCHOLARONE™
Manuscripts

1 TOP RESEARCH PRIORITIES IN LIVER AND

2 GALLBLADDER DISORDERS IN THE UNITED KINGDOM

3 Kurinchi S Gurusamy¹, Martine Walmsley², Brian R Davidson³, Claire Frier⁴, Barry Fuller⁵, Angela
4 Madden⁶, Steven Masson⁷, Richard Morley⁸, Ivana Safarik⁹, Emmanuel A Tsochatzis¹⁰, Irfan Ahmed¹¹,
5 Maxine Cowlin¹², John F Dillon¹³, Graham Ellicott¹², Ahmed M Elsharkawy¹⁴, Liz Farrington¹⁵, Anthony
6 Glachan¹², Nagappan Kumar¹⁶, EJ Milne¹², Simon M Rushbrook¹⁷, Amanda Smith¹⁸, Lizzie Stafford¹⁹,
7 Andrew Yeoman²⁰

8 ¹Professor of Evidence-based Medicine and Surgery, Division of Surgery and Interventional Science,
9 University College London, United Kingdom

10 ²Chair of Trustees, PSC Support, United Kingdom

11 ³Professor of Surgery, Royal Free Campus, University College London, United Kingdom

12 ⁴Cancer nurse specialist, HPB, Royal Free Hospital, London, United Kingdom

13 ⁵Professor of Surgery, Royal Free Campus, University College London, United Kingdom

14 ⁶Subject Group Lead for Nutrition and Dietetics, University of Hertfordshire, United Kingdom

15 ⁷Consultant hepatologist, Freeman Hospital, Newcastle, United Kingdom

16 ⁸James-Lind Alliance advisor

17 ⁹General Practitioner, Carolside Medical Centre, Clarkston, Glasgow, United Kingdom

18 ¹⁰Senior lecturer in Hepatology/Consultant hepatologist, UCL Institute for Liver and Digestive Health
19 Royal Free Hospital and University College London, United Kingdom

20 ¹¹Professor of Surgery, NHS Grampian, Aberdeen, United Kingdom

- 1
2
3 21 ¹²Patient and public representative, United Kingdom
4
5
6 22 ¹³Professor of Hepatology & Gastroenterology, NHS Tayside, Gastroenterology Dundee, UK
7
8
9 23 ¹⁴Consultant Hepatologist, Queen Elizabeth Hospital, Birmingham, United Kingdom
10
11
12 24 ¹⁵Consultant Nurse Hepatology, Royal Cornwall Hospital, Truro, United Kingdom
13
14
15 25 ¹⁶Consultant HPB Surgeon, University Hospital of Wales, Cardiff, United Kingdom
16
17
18 26 ¹⁷Consultant Hepatologist, Norfolk and Norwich University Hospital, Norwich, United Kingdom
19
20
21 27 ¹⁸Specialist Pharmacist – Liver, Queen Elizabeth Hospital, Birmingham, United Kingdom
22
23
24 28 ¹⁹Hepatology Research Nurse, John Radcliffe Hospital, Oxford, United Kingdom
25
26
27 29 ²⁰Consultant Hepatologist, Royal Gwent Hospital, Newport, United Kingdom
28
29
30 30 Corresponding author: Kurinchi S Gurusamy
31
32 31 Postal address: Floor 9, Royal Free Hospital, Royal Free Campus UCL, Rowland Hill Street, London
33
34 32 NW3 2PF; Email: k.gurusamy@ucl.ac.uk
35
36
37 33 Word count: 3569
38
39
40 34 Keywords: liver, chronic liver disease
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

35 ABSTRACT

36 Objectives: There is a mismatch between research questions considered important by patients,
37 carers, and healthcare professionals and the research performed in many fields of medicine. The
38 Non-Alcohol-Related Liver and gallbladder disorders Priority setting partnership (NARLIP) was
39 established to identify the top research priorities in the prevention, diagnostic, and treatment of
40 gallbladder disorders and liver disorders not covered by the James-Lind Alliance (JLA) Alcohol-related
41 liver disease (ARLD) Priority Setting Partnership.

42 Design: The methods broadly followed the principles of the JLA guidebook. The one major deviation
43 from the JLA methodology was the final step of identifying priorities: instead of prioritisation by
44 group discussions at a consensus workshop involving stakeholders, the prioritisation was achieved
45 by a modified Delphi consensus process.

46 Results: A total of 428 unique valid diagnostic or treatment research questions were identified. A
47 literature review established that none of these questions were considered 'answered' i.e. high
48 quality systematic reviews suggest that further research is not required on the topic. The Delphi
49 panel achieved consensus (at least 80% Delphi panel members agreed) that a research question was
50 a top research priority for six questions. Four additional research questions with highest proportion
51 of Delphi panel members ranking the question as highly important were added to constitute the top
52 10 research priorities.

53 Conclusions: A priority setting process involving patients, carers and healthcare professionals has
54 been used to identify the top ten priority areas for research related to liver and gallbladder
55 disorders. Basic, translational, clinical, and public health research are required to address these
56 uncertainties.

57 Keywords: liver, chronic liver disease

1
2
3 58 Word count: 3618
4
5
6

7 59 ARTICLE SUMMARY 8 9

10 11 60 Strengths and limitations 12 13

- 14
15 61 • A research prioritisation process involving clinicians, patients and carer, and public
16
17 62 representatives was performed in the field of liver and gallbladder disorders. This will help to
18
19 63 address the mismatch between research questions that are considered important jointly by
20
21 64 patients, carers, and healthcare professionals and the research performed in the field of liver
22
23 65 and gallbladder disorders.
24
25 66 • A Delphi consensus method was performed. This prevented dominance of 'loud voices', a
26
27 67 problematic issue with small and large group discussions.
28
29 68 • Because of the predominance of people with chronic liver disease on the Delphi panel, many
30
31 69 of the top research priorities related to chronic liver diseases.
32
33
34
35

36 37 70 INTRODUCTION 38 39 40

41 71 Failure to address treatment uncertainties by research can lead to significant suffering and deaths ¹.
42
43 72 It is important that research in any field of medicine takes into account the shared interests of
44
45 73 patients, carers and clinicians ². However, there is a mismatch between research questions that are
46
47 74 considered important jointly by patients, carers, and healthcare professionals and the research
48
49 75 performed in many fields of medicine ^{3,4}. The James Lind Alliance (JLA) exists to help ensure a
50
51 76 patient-centred process and enables the limited research resources to be utilised in addressing the
52
53 77 research questions that are considered important jointly by patients, carers, and healthcare
54
55 78 professionals ² ('top research priorities'). This is achieved by forming 'Priority Setting Partnerships'
56
57
58
59
60

79 (PSPs) between patients, carers, and healthcare professionals². Formal prioritisation of research
80 topics jointly by patients and healthcare professionals can lead to increased research on the topic^{5,6}.

81 There has only been one formal research prioritisation process involving patients, carers,
82 and healthcare professionals in the field of liver and gallbladder disorders⁷. However, the scope of
83 that PSP was limited to alcohol-related liver disorders⁷. The Non-Alcohol-Related Liver and
84 gallbladder disorders Priority setting partnership (NARLIP) was established to address the
85 prevention, diagnostic, and treatment uncertainties related to the majority of liver disorders which
86 were not covered by the JLA PSP on alcohol-related liver diseases (ARLD)⁷ and to include gallbladder
87 disease.

88 The aims and objectives of the NARLIP were to work with patients, their carers, and
89 healthcare professionals treating them ('stakeholders') to identify uncertainties about the diagnostic
90 tests and effects of prevention and treatments for non-alcohol related liver and gallbladder
91 disorders, to agree by consensus a prioritised list of those uncertainties for research, to publicise the
92 results and process, and to take the results to research commissioning bodies to be considered for
93 funding and researchers to encourage them to submit grant applications addressing these
94 uncertainties.

95 METHODS

96 The methods broadly followed the principles of the JLA guidebook.⁸ The broad steps involved the
97 following and are summarised in Figure 1.

- 98 1. Formation of the partnership: organisations and individuals representing people affected by
99 non-alcohol related liver or gallbladder disorders, their carers, and healthcare professionals
100 treating people with non-alcohol related liver and gallbladder disorders. A partnership was
101 formed between KG representing University College London and the British Liver Trust
102 initially, but following reorganisation in the British Liver Trust, PSC Support⁹ became the

1
2
3 103 leading patient organisation partner of this process. A steering committee was formed. The
4
5 104 members of the steering committee who participated in the complete process were KG,
6
7 105 MW, BRD, CF, BF, AM, RM, SM, IS, and ET.
8
9
10 106 2. Establishment of the scope: the steering committee members discussed and decided that
11
12 107 the scope should include adult and paediatric liver and gallbladder disorders which required
13
14 108 medical and surgical treatments. The protocol was registered with James-Lind Alliance
15
16 109 Priority Setting Partnership.
17
18
19 110 3. Identifying potential research questions: research questions were collected through online
20
21 111 surveys and searching UK Database of Uncertainties about the Effects of Treatments (UK
22
23 112 DUETs), research recommendations in high quality systematic reviews and clinical
24
25 113 guidelines, and registers of ongoing research.
26
27
28 114 4. Refining research questions: the research questions identified in the above step were
29
30 115 reviewed and where necessary combined to result in a set of unique research questions.
31
32 116 Research questions were considered 'answered' when recent high-quality systematic
33
34 117 reviews (based on low risk of bias studies) concluded that further research was not required.
35
36 118 Removal of such 'answered' research questions was planned. The remaining questions were
37
38 119 'uncertainties'.
39
40
41 120 5. Interim prioritisation: To shortlist the set of questions to manageable levels for the final
42
43 121 prioritisation process, the members of the steering committee ranked the uncertainties after
44
45 122 stratifying the questions as medical and surgical questions. The members of the steering
46
47 123 committee agreed that the interim prioritisation list should consist of 75% medical questions
48
49 124 and 25% surgical questions. This decision was an arbitrary decision made by the steering
50
51 125 committee based on the rationale that majority of individuals with liver and gallbladder
52
53 126 disorders are treated medically but a minority require surgery which have a major impact on
54
55 127 patients' lives.
56
57
58
59
60

- 1
2
3 128 6. Final prioritisation by consensus: A modified Delphi consensus method was followed to
4
5 129 identify the top priorities using methods described by Jones et al ¹⁰. The Delphi was
6
7 130 performed electronically using Excel for managing the process. The steps in the modified
8
9 Delphi consensus method were as follows.
10 131
11
12 132 a. A Delphi panel consisting of patients, their carers, and healthcare professionals
13
14 133 treating them was formed. The Delphi panel was formed by using 'snowballing'
15
16 134 sampling methods and by contacting people through emails, online liver patient
17
18 135 forums (British Liver Trust Health Unlocked forum), and newsletters. A total of 42
19
20 136 people expressed interest in joining the Delphi panel and 33 panel members
21
22 137 completed all three rounds. Details of the Delphi panel composition and drop-outs
23
24 138 are reported in the results section.
25
26
27 139 b. A total of three rounds were conducted.
28
29
30 140 c. Delphi panel members scored the short-listed questions in the interim prioritisation
31
32 141 process on a scale of 1 to 9 with 1 being considered least important and 9 being
33
34 142 considered most important. Scores of 1 to 3 were categorised as 'less important', 4
35
36 143 to 6 as 'moderately important', and 7 to 9 as 'highly important'. Panel members
37
38 144 were requested to score the questions according to the importance of the question
39
40 145 to them/the persons that they represent or treat and could leave questions that
41
42 146 they were unable to score empty. Each Delphi panel member could add a maximum
43
44 147 of two questions in the first round to ensure that the questions most important to
45
46 148 the Delphi panel members were included in the prioritisation process even if they
47
48 149 were not identified in the earlier steps. In the subsequent rounds, the panel
49
50 150 members were shown the summary scores and their previous score for each
51
52 151 question. They were able to retain or change their score in each of the rounds after
53
54 152 the first round. For calculation of the summary scores and the proportion
55
56 153 considering a question 'highly important', non-responses were excluded.
57
58
59
60

- 1
2
3 154 d. Consensus about a specific research question being a top research priority was
4
5 155 reached when 80% or more Delphi panel members considered the research question
6
7 156 as highly important (allocated scores between 7 and 9).
8
9
10 157 e. When fewer than 10 research priorities were obtained by consensus, the remaining
11
12 158 priorities were completed by uncertainties based on the highest proportions of
13
14 159 panel members agreeing that the research question was highly important (scores
15
16 160 between 7 and 9).
17
18
19 161 f. There was no restriction on the Delphi panel to consult others while scoring the
20
21 162 questions. However, only one final response on the set of questions was accepted
22
23 163 from each Delphi panel member.
24
25

26 164 When there were no recent high-quality systematic reviews on the research question, we have
27
28 165 recommended high-quality systematic reviews. When recent high-quality systematic reviews
29
30 166 recommended high-quality research, we have recommended randomised controlled trials for
31
32
33 167 prevention and treatment, as such studies carry the lowest risk of bias if conducted well; we would
34
35 168 have recommended well conducted diagnostic test accuracy studies for diagnostic uncertainties. All
36
37 169 online surveys were completed using Google Forms designed by KG. The Delphi process was
38
39 170 completed using Microsoft Excel and email.
40
41

42 171 Ethical approval was not deemed necessary because no personal identifiable information
43
44 172 was being collected, and the questions were being asked of healthcare professionals, patients and
45
46 173 their carers were not considered sensitive questions. In addition, we had full support of patient
47
48 174 organisations with involvement of patient representatives throughout the whole process rather than
49
50 175 patients visiting the hospitals.
51
52
53
54
55
56
57
58
59
60

176 Patient and Public involvement

177 Patients and public were involved in all aspects of this project: they were part of the steering
178 committee and were involved in the definition of the scope, methodology used for the prioritisation
179 process, identification of further patients and public representatives, participation in the Delphi
180 panel, interpretation, and critical revisions of the draft report. They will be involved in the
181 dissemination of the findings through patient websites, patient forums, and to research funders.

182 RESULTS

183 Identification and refining of research uncertainties

184 A total of 126 patients, carers, and those at risk of developing non-alcohol related liver and
185 gallbladder disorders, and 13 healthcare professionals participated in the first survey which was
186 conducted between July and December 2015. This survey resulted in a total of 209 unique research
187 questions. In addition, 219 unique questions were identified from searching the UK DUETs, Pubmed,
188 and ClinicalTrials.gov on 2nd January 2016. A total of 428 unique valid (i.e. falling within the remit of
189 this priority setting partnership) research questions (247 medical-related and 181 surgery-related)
190 were identified from these sources. None of the research questions had been answered by recent
191 high-quality systematic reviews based on low risk of bias studies which concluded that further
192 research was not required. Therefore, all the 428 research questions were considered research
193 'uncertainties'. The complete list of 428 unique valid uncertainties in no particular order is available
194 in Online Supplement Appendix 1. This has been converted to the population, intervention, control,
195 and outcomes (PICO) format whenever possible.

196 Interim priorities

197 To identify a shortlist of questions (from the list of 429 questions) that were to be considered for the
198 next step, a total of 48 research priorities (36 medical questions and 12 surgical questions) were
199 identified on the basis of being selected by at least one patient or carer and healthcare professional
200 of the steering committee (24 questions) and obtaining the highest ranks among the members of the
201 steering committee (additional 24 questions). The list of 48 questions identified as interim priorities
202 in no particular order is available in Online Supplement Appendix 2.

203 Final priorities

204 A total of 42 people expressed interest in joining the Delphi panel and 33 panel members completed
205 all three rounds. Five people dropped out before they returned the scores of the first round (all
206 patients, carers, and general public), three between first and second rounds (all healthcare
207 professionals), and one between the second and third rounds (healthcare professional). Of the 33
208 panel members who completed all the three rounds, 17 were healthcare professionals and 16 were
209 patients, carers, and general public. Of the 17 healthcare professionals, six were hepatologists, four
210 were surgeons, two were hepatology nurses, and the remaining were general practitioner (GP), HPB
211 surgery (hepato-pancreato biliary) nurse, organ preservation biologist, dietician, and pharmacist
212 (one each). Of the 16 patients, carers, and general public, there was representation from general
213 public and various liver diseases including autoimmune diseases such as primary sclerosing
214 cholangitis, primary biliary cholangitis, autoimmune hepatitis, viral hepatitis, metabolic diseases
215 such as non-alcohol related fatty liver disease, and other diseases such as hepatocellular carcinoma
216 and polycystic liver disease. There was also representation of liver transplanted patients in the
217 Delphi panel. In total, 23 panel members were from England, seven were from Scotland, and three
218 were from Wales. There were no panel members from Northern Ireland despite attempts to include
219 panel members from Northern Ireland.

220 A total of 22 additional questions were added by the Delphi panel members in the first
 221 round of the Delphi process. The Delphi panel achieved consensus that an uncertainty was a top
 222 research priority for six research questions. Four additional research questions with the highest
 223 proportion of Delphi panel members scoring the question as highly important (scores between 7 and
 224 9) were added to constitute the top 10 research priorities. The list of the top 10 research priorities
 225 (in the order of proportion who agreed that the uncertainty is a very important research priority) is
 226 available in Table 1. All the top 10 research priorities were prevention and treatment uncertainties,
 227 and none were diagnostic test uncertainties. None of the panel members thought the first two
 228 questions as least important (scores of 1 to 3). For the remaining 8 questions, 3% to 6.5% of people
 229 considered the questions to be least important (scores of 1 to 3).

230 **Table 1 Treatment uncertainties for which consensus that the uncertainty is a**
 231 **research priority was reached**

Treatment uncertainty (Research question)	Proportion who rated this question as highly important in the final round	Median (interquartile range) in the final round
What is the best treatment for people with early or very early hepatocellular carcinoma (HCC)?	93.5%	8(7,9)
What are the best treatments that cure or delay the progression (worsening) of primary sclerosing cholangitis (PSC)?	93.3%	8(7,9)

1 2 3 4 5 6 7 8 9	What are the best treatments that cure or delay the progression (worsening) of non-alcohol-related fatty liver disease (NAFLD)?	90.3%	9(8,9)
10 11 12 13 14	What is the best immunosuppressive regimen in adults undergoing liver transplantation?	90.3%	8(7,9)
15 16 17 18 19 20 21 22	Should general public be educated about non-alcohol-related fatty liver disease (NAFLD) with an aim to reduce the numbers of those that have it?	81.8%	8(7,9)
23 24 25 26 27	What are the best treatments that cure or delay the progression (worsening) of autoimmune hepatitis (AIH)?	80.6%	8(7,9)
28 29 30 31 32 33 34	What are the best treatments that cure or delay the progression (worsening) of non-alcohol related steatohepatitis (NASH)?	76.7%	8(6.75,9)
35 36 37 38 39 40 41 42 43 44 45 46 47 48 49	Prior to liver transplantation, is it better to transport the donor liver using a machine which pumps blood or preservation solution through the liver (machine perfusion) or is it better to transport it in the standard way of transporting it immersed in cold preservation solution (cold storage)?	74.2%	7(6,9)
50 51 52 53 54 55 56 57 58 59 60	What are the best treatments that cure or delay the progression (worsening) of primary biliary cholangitis (PBC)?	74.2%	7(6,8)

Are there any treatments that reverse the liver damage in primary sclerosing cholangitis (PSC)?	72.4%	7(6,9)
---	-------	--------

232

233 A summary of the availability of systematic review of randomised controlled trials on the topic of the
 234 individual questions, randomised controlled trials on the topic not included in the systematic review
 235 (if one exists), and the outcomes evaluated in these RCTs are listed in Table 2. Table 2 also contains a
 236 suggestion for the next research steps. The list of the existing trials was compiled by searching
 237 ClinicalTrials.gov on 7th April 2018. The references to the trials not included in the systematic reviews
 238 is available in Online Supplement Appendix 3. As seen in Table 2, a well-designed RCT is the next
 239 step for eight of these top 10 research questions. This is because it appears that the outcomes in
 240 those trials will not address the outcomes listed in the research questions.

241 **Table 2 Next step to address the top 10 research priorities based on current**
 242 **best evidence (summary)**

Treatment uncertainty (Research question)	High-quality systematic review ^{a,b}	RCTs not included in the systematic review ^{a,c}	Patient-oriented outcomes assessed in trials not included in the systematic review ^d	Next step

<p>1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42</p> <p>What is the best treatment for people with early or very early hepatocellular carcinoma (HCC)?</p>	<p>11</p>	<p>8 trials</p>	<p>Survival (7 trials), recurrence (5 trials), morbidity (3 trials)</p>	<p>High-quality RCTs of interventions not covered in ongoing trials and comparison of health-related quality (HRQoL) in different treatments</p>
<p>43 44 45 46 47 48 49 50 51 52 53</p> <p>What are the best treatments that cure or delay the progression (worsening) of primary sclerosing cholangitis (PSC)?</p>	<p>12</p>	<p>9 trials</p>	<p>None of the trials include survival, HRQoL as outcomes^e</p>	<p>High-quality RCTs with clinical outcomes</p>
<p>54 55 56 57 58 59 60</p> <p>What are the best treatments that cure or delay the progression (worsening) of</p>	<p>13 (includ</p>	<p>More than 10 published trials</p>	<p>Lifestyle intervention</p>	<p>High-quality</p>

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

<p>non-alcohol-related fatty liver disease (NAFLD)?</p>	<p>es only pharm acolog ical interv ention s)</p>	<p>on lifestyle interventions and more than 20 trials on nutritional supplementation with no recent high-quality systematic reviews <u>Pharmacological interventions</u> 44 trials</p>	<p>s and nutritional supplement ation Not applicable as there are no high quality systematic reviews <u>Pharmacolo gical intervention s</u> Health- related quality of life (2 trials), resolution of fatty liver disease (11 trials), mortality (2 trials),</p>	<p>systemati c reviews on lifestyle interventi ons (one review) and nutritiona l suppleme ntation to cure or delay the progressio n of NAFLD and high- quality RCTs on pharmaco logical interventi ons with</p>
---	---	--	--	---

			cirrhosis (2 trials), cardiovascular events (2 trials) ^e	clinical outcomes
What is the best immunosuppressive regimen in adults undergoing liver transplantation?	¹⁴ (cover s only maint enanc e immu nosup pressi on)	<u>Induction</u> <u>immunosuppress</u> <u>ion</u> More than 20 published trials <u>Maintenance</u> <u>immunosuppress</u> <u>ion</u> 4 trials	<u>Induction</u> <u>immunosup</u> <u>pression</u> Not applicable as there is no high quality systematic review <u>Maintenanc</u> <u>e</u> <u>immunosup</u> <u>pression</u> Graft survival (1 trial)	High- quality systemati c review on induction immunos uppressiv e regimen and high- quality RCTs on maintena nce immunos uppressio n with

			Adverse events (1 trial) Hepatocellular carcinoma (1 trial) ^e	important clinical outcomes
Should general public be educated about non-alcohol-related fatty liver disease (NAFLD) with an aim to reduce the numbers of those that have it?	None	None	-	High-quality RCTs on education to prevent NAFLD
What are the best treatments that cure or delay the progression (worsening) of autoimmune hepatitis (AIH)?	None	15 trials	Survival (1 trial), health-related quality of life (1 trial) ^e	High quality RCTs with clinical outcomes
What are the best treatments that cure or delay the progression (worsening) of non-alcohol related steatohepatitis (NASH)?	The evidence related to this question is covered under non-alcohol related fatty liver disease by performing a subgroup analysis of people with NASH			

<p>Prior to liver transplantation, is it better to transport the donor liver using a machine which pumps blood or preservation solution through the liver (machine perfusion) or is it better to transport it in the standard way of transporting it immersed in cold preservation solution (cold storage)?</p>	<p>None</p>	<p>5 trials</p>	<p>Overall survival (4 trials), graft survival (5 trials), health-related quality of life (2 trials)</p>	<p>Await results of the RCTs (all expected to complete by the end of 2019) and perform a high quality systematic review.</p>
<p>What are the best treatments that cure or delay the progression (worsening) of primary biliary cholangitis (PBC)?</p>	<p>¹⁵</p>	<p>24 trials</p>	<p>Health-related quality of life (5 trials), relief of symptoms (5 trials)^e</p>	<p>High-quality RCTs with clinical outcomes</p>
<p>Are there any treatments that reverse the liver damage in primary sclerosing cholangitis (PSC)?</p>	<p>The evidence related to this question is covered under treatments for primary sclerosing cholangitis. The systematic review did not include fibrosis as one of the</p>			

	outcomes. Nine of the trials included in the systematic review reported on fibrosis. Two of the trials not included in the systematic review (and listed above) reported on liver fibrosis.
--	---

243

244 a Numbers indicate the reference number.

245 b Further well-designed randomised controlled trials using clinical outcomes were recommended by
246 all these systematic reviews.

247 c Ongoing trials, unpublished trials, or trials published since the search date for the systematic
248 review when a high-quality systematic review based on randomised controlled trials exists. If no
249 systematic reviews based on randomised controlled trials exist, these are either published trials or
250 ongoing studies.

251 d This information is reported to find out whether the important patient-oriented outcomes are
252 reported in the trials not covered by high-quality systematic reviews. This is to help with deciding
253 whether new randomised controlled trials are necessary on the topic.

254 e The remaining trials reported treatment-related adverse events, composite outcomes and
255 surrogate markers.

256

257 The complete list of questions in the Delphi process, the proportion of respondents who
258 considered a research question as very important and the summary scores in each Delphi round is
259 available in Online Supplement Appendix 4.

DISCUSSION

This is the first priority setting partnership on non-alcohol related liver and gallbladder disorders. This included a wide range of disease processes and a total of 428 unique research questions that met the scope of this priority setting partnership were identified. All the research questions were considered unanswered as there had been no high quality systematic reviews which indicated that no further research is required, i.e. all the research questions were uncertainties. Consensus that an uncertainty was a very important research priority was reached for six research questions. Four additional research questions with the highest proportion of Delphi panel members ranking the question as highly important were added to constitute the top 10 research priorities.

As evident from the online supplement Appendix 1, longevity of life and health-related quality of life are two major outcomes that appear important to patients, their carers, and healthcare professionals. However, even when there are ongoing trials, it appears that the outcomes in those trials will not address the outcomes listed in eight of the top 10 research questions (Table 2). Therefore, the next step in addressing these uncertainties is the design and conduct of randomised controlled trials. Such randomised controlled trials may involve qualitative studies to determine the design and should compare the treatments that improve the longevity of life and/or health-related quality of life.

It should be noted that uncertainties 'what are the best treatments that cure or delay the progression (worsening) of non-alcohol-related fatty liver disease (NAFLD)?' and 'what are the best treatments that cure or delay the progression (worsening) of non-alcohol related steatohepatitis (NASH)?' are related to each other. Although NAFLD includes NASH, most of the panel members felt that the research questions related to NAFLD and NASH should be kept separate uncertainties. While the same systematic review can cover both the uncertainties, the primary research study designed to address these two questions differ in terms of the setting, the outcomes used, and the

1
2
3 284 period of follow-up. Any primary research that tries to answer these two questions in a single
4
5 285 randomised controlled trial will be inefficient.

7 286 Similarly, for the uncertainties 'what are the best treatments that cure or delay the
8
9
10 287 progression (worsening) of primary sclerosing cholangitis (PSC)' and 'are there any treatments that
11
12 288 reverse the liver damage in primary sclerosing cholangitis (PSC)?', a single randomised controlled
13
14 289 trial will be inefficient and the preference of most of the panel members was to keep these
15
16 290 uncertainties as separate uncertainties.

18
19 291 There are several limitations to our priority setting process. The first one is deviation from
20
21 292 the original protocol. To select the final top priorities, the initial plan was to arrive at consensus by
22
23 293 open small group and large group discussions of patients, carers, and healthcare professionals as
24
25 294 suggested by the standard James-Lind Alliance process⁸, which provides an opportunity for a
26
27 295 knowledge exchange of viewpoints and experience. However, part of the steering committee with
28
29 296 experience in a similar priority setting partnership felt that open discussions resulted in 'loud voices'
30
31 297 being given more importance resulting in an unrepresentative list of top priorities. While this can be
32
33 298 mitigated by facilitated group discussions by neutral JLA facilitators to ensure that all voices were
34
35 299 heard in the discussions, this was considered by the steering committee as an important source of
36
37 300 bias based on their prior experience in participating in open discussions. The steering committee
38
39 301 therefore decided to follow the Delphi-consensus method which is one of the major consensus
40
41 302 methods¹⁰. The advantages of Delphi-consensus method over open discussions include anonymity of
42
43 303 the response and the equal weight given to the opinions of all members¹⁰. In addition, they are less
44
45 304 costly to conduct without any limitation by geographical location compared to other methods of
46
47 305 consensus¹⁰ because of the lack of necessity to travel and take time off regular work. However, there
48
49 306 is considerable variability in the previous performance of Delphi processes with regards to the
50
51 307 number of rounds and the criteria for achieving consensus¹⁶. Arriving at consensus depends upon
52
53 308 people revising their scores based on the other's scores. Our initial plan was to extend the Delphi to
54
55 309 four rounds if consensus on 10 top research priorities was not reached in three rounds. However,
56
57
58
59
60

1
2
3 310 there was minimal change in scores between the rounds for most questions (Online Supplement
4
5 311 Appendix 3) and the Delphi process was completed in three rounds. Consensus on a top research
6
7 312 priority was achieved for six questions only. However, the proportion of Delphi panel members
8
9 313 ranking a question as highly important was greater than 70% for the remaining four questions added
10
11 314 to the list of top research priorities. Previous Delphi consensus processes have used various cut-off
12
13 315 points for defining consensus: greater than 70% agreement among panel members is well within the
14
15 316 definition of consensus used in previous Delphi consensus processes ¹⁶.

18
19 317 The other major limitation of our priority setting process is the representativeness of the
20
21 318 people who completed the survey and took part in the Delphi process. The online survey was shared
22
23 319 among clinicians and members of general and disease-specific patient organisations. Most questions
24
25 320 resulting from the online survey relate to chronic liver disease (in particular, autoimmune liver
26
27 321 diseases), perhaps reflecting the high motivation to support research from those groups. The Delphi
28
29 322 panel also had a high representation of people related to chronic liver disease (in particular,
30
31 323 autoimmune liver diseases) as patients, carers, or healthcare professionals. Whilst people affected
32
33 324 by different liver and gallbladder disorders were actively sought through both general and disease-
34
35 325 specific patient support groups and organisations, only a few responded and completed all three
36
37 326 rounds of the Delphi process. The potential bias towards prioritising chronic liver diseases is evident
38
39 327 as nine of the top 10 research priorities relate to chronic liver diseases (four relate to autoimmune
40
41 328 liver diseases, three related to non-alcohol related fatty liver disease, two related to liver
42
43 329 transplantation). It was surprising that the uncertainties related to the treatment of chronic viral
44
45 330 diseases such as chronic hepatitis B and chronic hepatitis C were not identified within the top 10
46
47 331 research priorities. This may be because of the perception by the some of the panel members that
48
49 332 the research questions related to the treatment of chronic hepatitis C were answered with the
50
51 333 advent of directly acting antivirals (personal communication). The reason for non-prioritisation of
52
53 334 chronic hepatitis B is not entirely clear. This may be because chronic hepatitis B may not have been
54
55
56
57
58
59
60

1
2
3 335 considered as important as other chronic liver diseases or under-representation of chronic hepatitis
4
5 336 B in the panel.
6
7

8 337 Cancer-related questions, childhood-related liver diseases, and other benign disorders did
9
10 338 not end up in the top research priorities (except for the treatment of very early hepatocellular
11
12 339 carcinoma, which is managed by hepatologists and surgeons) probably for the reasons described
13
14
15 340 above. We recommend that separate prioritisation processes are carried out for people with
16
17 341 gallstones, a condition that affects approximately 5% to 25% of the population ¹⁷, for people with
18
19 342 primary and secondary liver cancer, and childhood liver disorders where significant uncertainties
20
21 343 remain on the effectiveness of different treatments in decreasing mortality and improving health-
22
23 344 related quality of life.
24
25

26
27 345 As well as the above limitation, we are aware of the inherent limitations of using solely
28
29 346 technology to carry out the Delphi exercise. These are limitations that can potentially lead to bias in
30
31 347 any consensus-building method including that of face-to-face consensus methods normally used in a
32
33 348 JLA PSP.
34
35

36 349 One solution which might address the limitations of this priority setting process and the
37
38 350 standard JLA process may be to collect information routinely from patients visiting hospitals using
39
40 351 paper forms and conduct online meetings (video conferencing and presentation) before the final
41
42 352 round of the Delphi (or the standard face-to-face priority setting workshop used by the JLA. Some
43
44 353 JLA PSPs do use methods such as face-to face interviews and group discussions rather than solely
45
46 354 online surveys). By collecting information on paper forms and conducting the meetings in hospitals,
47
48 355 it is possible to engage with people who do not have access to or are not familiar with computers. It
49
50 356 is also possible to engage with people who have concerns regarding data confidentiality with the use
51
52 357 of computers or social media by collecting information using paper forms. Ethical and confidentiality
53
54 358 issues will need to be considered prior to engaging patients attending hospital in the research
55
56 359 prioritisation process.
57
58
59
60

1
2
3 360 Another limitation of our priority setting process is the drop-outs during the Delphi process.
4
5 361 While some of the drop-outs may be related to the ability to complete online surveys and use
6
7 362 Microsoft Excel, some patient representatives or clinicians may have dropped out because they did
8
9 363 not find any research question to be of direct relevance to them. Other reasons include lack of
10
11 364 understanding of the conditions, feeling that the process was too complicated, feeling that the
12
13 365 process would not work, and the time commitment for the process. This is because of the broad
14
15 366 scope of this research prioritisation process and may be overcome by choosing a narrower focus
16
17 367 while defining the scope of the prioritisation process, and by better explanation of the disease
18
19 368 processes through presentations.

20
21
22
23
24 369 It should also be recognised that the Delphi panel was constituted of representatives from
25
26 370 England, Scotland, and Wales. Therefore, the findings are applicable in only these countries.
27
28 371 However, the findings are likely to be applicable throughout the NHS and in other European and
29
30 372 Western countries with a similar spectrum of chronic liver diseases and similar treatment options
31
32 373 available.

33
34
35
36 374 In summary, there are significant uncertainties in the management of liver and gallbladder
37
38 375 disorders. Further high-quality research is necessary to address these uncertainties which may
39
40 376 require programmes of basic, translational, clinical, and public health research. For issues with
41
42 377 diverse and unproven treatment options, randomised controlled trials may be the only mechanism
43
44 378 for identifying the most effective treatment and the treatments that represent good value for
45
46 379 money for the NHS. Such randomised controlled trials should assess the effect of different
47
48 380 treatments in improving longevity of life and/or health-related quality of life.
49
50
51

52 53 381 **ACKNOWLEDGEMENTS**

54
55
56
57 382 We thank Mr Andrew Langford, previous Chief Executive of British Liver Trust, participants in the
58
59 383 survey, Ms Caroline Whiting and Ms Beccy Maeso, JLA PSP co-ordinators for their advice on the
60

1
2
3 384 process and comments on the manuscript, and the Delphi panel members who preferred to remain
4
5 385 anonymous in contributing to this research prioritisation process.
6
7
8

9 386 **FUNDING**

10
11
12
13 387 There was no external funding.
14
15
16

17 388 **CONTRIBUTION OF AUTHORS**

18
19
20
21 389 Kurinchi Gurusamy – conceptualisation, healthcare professional and methodological lead of steering
22
23 390 committee, Delphi panel member, analysis, author of the manuscript.
24
25

26 391 Martine Walmsley – Patients and carers lead of steering committee, Delphi panel member
27
28

29 392 Brian Davidson, Claire Frier, Barry Fuller, Angela Madden, Steven Masson, Ivana Safarik, Emmanouil
30

31 393 Tsochatzis – Steering committee, Delphi panel member, suggested revisions to the manuscript
32
33

34 394 Richard Morley – Steering committee, JLA advisor
35
36

37 395 Irfan Ahmed, Maxine Cowlin, John Dillon, Graham Ellicott, Ahmed Elsharkawy, Liz Farrington,
38

39 396 Anthony Glachan, Nagappan Kumar, EJ Milne, Simon Rushbrook, Amanda Smith, Lizzie Stafford,
40

41 397 Andrew Yeoman – Delphi panel member, suggested revisions to the manuscript
42
43
44

45 398 **CONFLICTS OF INTEREST**

46
47
48
49 399 The decisions made by healthcare professionals involved in the research prioritisation process might
50
51 400 have been influenced by their professional interests, in addition to their own, or family member's
52
53 401 experience of health conditions. Decisions made by patients and carers in the research prioritisation
54
55 402 process might have been influenced by their particular experiences, health needs and interests.
56
57
58
59
60

403 DATA SHARING AGREEMENT

404 All data is available in the manuscript or in the supplementary file.

405 FIGURE 1

406 Research prioritisation steps

407 The major steps in the research prioritisation are shown in the figure.

408 ^aThe protocol was registered with James-Lind Alliance Priority Setting Partnership

409 ^bThe final prioritisation was achieved by modified Delphi consensus method.

410 REFERENCES

- 411 1. Chalmers I. Confronting therapeutic ignorance. *BMJ* 2008;337:a841. doi:
412 10.1136/bmj.39555.392627.80 [published Online First: 2008/07/18]
- 413 2. James Lind Alliance Priority Setting Partnerships. About the James Lind Alliance.
414 <http://www.jlanihracuk/about-the-james-lind-alliance/> (accessed 6th April 2018) 2018
- 415 3. Crowe S, Fenton M, Hall M, et al. Patients', clinicians' and the research communities' priorities for
416 treatment research: there is an important mismatch. *Research Involvement and Engagement*
417 2015;1(1):2. doi: 10.1186/s40900-015-0003-x
- 418 4. Tallon D, Chard J, Dieppe P. Relation between agendas of the research community and the
419 research consumer. *The Lancet*;355(9220):2037-40. doi: 10.1016/S0140-6736(00)02351-5
- 420 5. James Lind Alliance Priority Setting Partnerships. Tinnitus PSP: What's happening to address the
421 priorities more than 4 years later? [http://www.jlanihracuk/news/tinnitus-psp-whats-](http://www.jlanihracuk/news/tinnitus-psp-whats-happening-to-address-the-priorities-more-than-4-years-later/5299)
422 [happening-to-address-the-priorities-more-than-4-years-later/5299](http://www.jlanihracuk/news/tinnitus-psp-whats-happening-to-address-the-priorities-more-than-4-years-later/5299) (accessed on 2 December
423 2018) 2017

- 1
2
3 424 6. National Institute for Health Research. Adding value in research 1: Identifying important research
4
5 425 topics. <https://www.nihr.ac.uk/about-us/documents/pillar-1-identifying-researchpdf> (accessed
6
7 426 on 2 December 2018) 2018
- 8
9
10 427 7. James Lind Alliance Priority Setting Partnerships. Alcohol-related liver disease.
11
12 428 <http://www.jlanihr.ac.uk/priority-setting-partnerships/alcohol-related-liver-disease/> (accessed
13
14 429 6th April 2018) 2018
- 15
16 430 8. James Lind Alliance Priority Setting Partnerships. JLA guidebook. [http://www.jlanihr.ac.uk/jla-](http://www.jlanihr.ac.uk/jla-guidebook/)
17
18 431 [guidebook/](http://www.jlanihr.ac.uk/jla-guidebook/) (accessed 6th April 2018) 2018
- 19
20
21 432 9. PSC Support. Welcome to PSC Support, dedicated to helping people affected by primary sclerosing
22
23 433 cholangitis. <https://www.pscsupport.org.uk/> (accessed 6th April 2018) 2018
- 24
25 434 10. Jones J, Hunter D. Consensus methods for medical and health services research. *BMJ*
26
27 435 1995;311(7001):376-80.
- 28
29
30 436 11. Majumdar A, Roccarina D, Thorburn D, et al. Management of people with early- or very early-
31
32 437 stage hepatocellular carcinoma: an attempted network meta-analysis. *The Cochrane*
33
34 438 *database of systematic reviews* 2017;3:CD011650. doi: 10.1002/14651858.CD011650.pub2
35
36 439 [published Online First: 2017/03/30]
- 37
38
39 440 12. Saffioti F, Gurusamy KS, Hawkins N, et al. Pharmacological interventions for primary sclerosing
40
41 441 cholangitis: an attempted network meta-analysis. *The Cochrane database of systematic*
42
43 442 *reviews* 2017;3:CD011343. doi: 10.1002/14651858.CD011343.pub2 [published Online First:
44
45 443 2017/04/19]
- 46
47
48 444 13. Lombardi R, Onali S, Thorburn D, et al. Pharmacological interventions for non-alcohol related
49
50 445 fatty liver disease (NAFLD): an attempted network meta-analysis. *The Cochrane database of*
51
52 446 *systematic reviews* 2017;3:CD011640. doi: 10.1002/14651858.CD011640.pub2 [published
53
54 447 Online First: 2017/03/31]
- 55
56
57 448 14. Rodriguez-Peralvarez M, Guerrero-Misas M, Thorburn D, et al. Maintenance immunosuppression
58
59 449 for adults undergoing liver transplantation: a network meta-analysis. *The Cochrane database*
60

- 1
2
3 450 *of systematic reviews* 2017;3:CD011639. doi: 10.1002/14651858.CD011639.pub2 [published
4
5 451 Online First: 2017/04/01]
6
7 452 15. Saffioti F, Gurusamy KS, Eusebi LH, et al. Pharmacological interventions for primary biliary
8
9
10 453 cholangitis: an attempted network meta-analysis. *The Cochrane database of systematic*
11
12 454 *reviews* 2017;3:CD011648. doi: 10.1002/14651858.CD011648.pub2 [published Online First:
13
14 455 2017/03/30]
15
16 456 16. Diamond IR, Grant RC, Feldman BM, et al. Defining consensus: a systematic review recommends
17
18
19 457 methodologic criteria for reporting of Delphi studies. *J Clin Epidemiol* 2014;67(4):401-9. doi:
20
21 458 10.1016/j.jclinepi.2013.12.002 [published Online First: 2014/03/04]
22
23 459 17. Gurusamy KS, Davidson BR. Gallstones. *BMJ* 2014;348:g2669. doi: 10.1136/bmj.g2669
24
25
26
27 460
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 1: Research prioritisation steps

The major steps in the research prioritisation are shown in the figure.

^aThe protocol was registered with James-Lind Alliance Priority Setting Partnership

^bThe final prioritisation was achieved by modified Delphi consensus method.

119x177mm (300 x 300 DPI)

Appendix 1 List of all research questions

Patient/population	Intervention	Control	Outcomes
People with obesity	Lifestyle: diet	No intervention	<ol style="list-style-type: none"> 1. Liver transplantation 2. Improvement in BMI. 3. Improved liver function
People with liver disease	Nurse-led care	Standard care	Ability to self-manage
People with asymptomatic chronic liver disease	Education of people	No intervention	<ol style="list-style-type: none"> 1. Improvement in life style. 2. Fatty liver disease
People with NASH (non-alcoholic steatohepatitis)	Different medical treatments	No intervention	<ol style="list-style-type: none"> 1. Halting disease progression. 2. Reversing disease progression. 3. Slowing disease progression. 4. Cure
People with primary sclerosing cholangitis	Treatment for primary sclerosing cholangitis	No intervention	<ol style="list-style-type: none"> 1. Mortality 2. HRQoL (health-related quality of life)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

			<ol style="list-style-type: none"> 3. Fewer symptoms - pain, itching, fatigue 4. improved liver function 5. Cure 6. Time to liver transplantation 7. Improvement (no further details) 8. Decreased hospital admission 9. Disease progression 10. Remission from PSC 11. Cancer 12. Requirement for liver transplant.
People with liver disease	Methods to improve compliance to treatment	Not applicable	<ol style="list-style-type: none"> 1. HRQoL 2. Mortality
General population	Screening: early identification of people at risk of liver disease	No screening	<ol style="list-style-type: none"> 1. HRQoL 2. Mortality

<p>1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29</p> <p>People at risk of liver disease</p>	<p>Diagnosis: early identification of people with liver disease</p>	<p>Not applicable</p>	<p>1. HRQoL 2. Mortality 3. Prevention of liver disease 4. Slowing progression of liver disease 5. Reducing requirement for liver transplantation 6. Adverse events of medications</p>
<p>30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60</p> <p>People with primary sclerosing cholangitis and who have had a liver transplant and still have ulcerative colitis even after a sub total colectomy</p>	<p>Symptomatic treatment for primary sclerosing cholangitis</p>	<p>Not applicable</p>	<p>1. HRQoL. 2. Decrease in symptoms (breathlessness and fatigue). 3. Mortality. 4. Decrease in medication. 5. Cure. 6. Decreased progression of primary sclerosing cholangitis.</p>

			7. Improvement in symptoms (unspecified).
People at risk of liver disease (overweight or obese)	Diagnosis: Accurate non-invasive method for diagnosis of chronic liver disease	Not applicable	<ol style="list-style-type: none"> 1. Death 2. Need for liver transplant 3. Requirement for hospital admission. 4. Demonstrating equivalence to biopsy 5. Demonstrating good reproducibility
People at risk of liver disease (overweight or obese)	Screening methods to diagnose liver disease (including history and diagnostic tests)	Not applicable	<ol style="list-style-type: none"> 1. Proportion of people at risk of liver disease 2. Proportion of people at risk who have asymptomatic liver fibrosis 3. Early diagnosis and treatment
People with polycystic liver disease	Treatment for polycystic disease	Not applicable	<ol style="list-style-type: none"> 1. Decrease symptoms 2. Increase quality of

			<p>life</p> <p>3. Decrease size of cyst or preventing cysts to enlarge</p> <p>4. Increased longevity</p> <p>5. Requirement for liver transplant.</p>
<p>People with autoimmune hepatitis</p>	<p>Treatments for autoimmune hepatitis.</p>	<p>Not applicable</p>	<p>1. HRQoL (including ability to carry out normal activities, study, work).</p> <p>2. Fatigue.</p> <p>3. Osteoporosis (treatment-related).</p> <p>4. Cataracts (treatment-related).</p> <p>5. Infections (treatment-related).</p> <p>6. Weight gain (treatment-related).</p> <p>7. Treatment related side-effects (unspecified).</p> <p>8. Brittle teeth</p>

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

			<p>(treatment-related).</p> <p>9. More effective treatment unspecified.</p> <p>10. Complete recovery (unspecified).</p> <p>11. Mortality.</p> <p>12. Measure feeling well (unspecified)</p> <p>13. Fewer flare ups</p> <p>14. Less joint pain.</p> <p>15. Disability</p> <p>16. Liver damage requiring hospital admission</p> <p>17. Quicker recovery</p> <p>18. More monitoring of patients</p> <p>19. Symptom control.</p> <p>20. Side-effects</p>
<p>People with autoimmune hepatitis</p>	<p>Standardised protocol care</p>	<p>Standard care</p>	<p>1. HRQoL.</p> <p>2. Fatigue.</p> <p>3. Osteoporosis</p>

For peer review only

			<p>(treatment-related).</p> <p>4. Cataracts</p> <p>(treatment-related).</p> <p>5. Infections</p> <p>(treatment-related).</p> <p>6. Weight gain</p> <p>(treatment-related).</p>
<p>People with autoimmune hepatitis</p>	<p>Treatment of fatigue/joint pain related to autoimmune hepatitis.</p>	<p>Not applicable</p>	<p>1. HRQoL.</p> <p>2. Fatigue.</p> <p>3. Osteoporosis</p> <p>(treatment-related).</p> <p>4. Cataracts</p> <p>(treatment-related).</p> <p>5. Infections</p> <p>(treatment-related).</p> <p>6. Weight gain</p> <p>(treatment-related).</p> <p>7. Joint pain.</p> <p>8. Symptoms</p> <p>(unspecified).</p>
<p>People with autoimmune hepatitis</p>	<p>Nurse-led care</p>	<p>Standard care</p>	<p>1. Faster recovery.</p> <p>2. HRQoL.</p> <p>3. Symptoms.</p>

1 2 3 4 5 6 7 8 9 10 11	People with autoimmune hepatitis	Education of healthcare professionals and patients	Standard care	<ol style="list-style-type: none"> 1. Faster recovery. 2. HRQoL. 3. Symptoms.
12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43	People with autoimmune hepatitis	Lifestyle: diet	Standard care	<ol style="list-style-type: none"> 1. Treatment related adverse events. 2. Requirements for liver transplantation. 3. NHS (National Health Service, UK) costs 4. HRQoL 5. Mortality. 6. Free from immunosuppressive therapies. 7. Fatigue. 8. Weight.
44 45 46 47 48 49 50 51 52	People with autoimmune hepatitis	Education of people	Standard care	<ol style="list-style-type: none"> Faster reduction in strong medications. Need for liver transplantation.
53 54 55 56 57 58 59 60	People with autoimmune hepatitis	Cannabis + standard care	Standard care	<ol style="list-style-type: none"> 1. Reduction in immunosuppressants.

			<ol style="list-style-type: none"> 2. Fatigue. 3. Treatment related side effects such as serious infections, anxiety, depression, cancer, physical side effects.
<p>General population (> 40 years or >50 years or middle-aged people, particularly overweight/obese and/or have type 2 diabetes and/or a family history of chronic liver disease)</p>	<p>Screening for liver disease by GP using routine blood tests/other methods</p>	<p>Standard care</p>	<ol style="list-style-type: none"> 1. Earlier diagnosis and treatment. 2. Preventing liver disease progressing to cirrhosis. 3. More cost effective for NHS. 4. Preventing the complications of chronic liver disease such as hepatocellular carcinoma and varices.
<p>People with autoimmune hepatitis</p>	<p>Prednisolone</p>	<p>No intervention</p>	<ol style="list-style-type: none"> 1. Obesity. 2. Osteoporosis. 3. Insomnia. 4. Hypertension.

1 2 3 4 5 6 7 8 9	People with genetic markers associated with autoimmune hepatitis.	Methods for prophylaxis	No intervention	Prevention of autoimmune hepatitis
10 11 12 13	People with autoimmune hepatitis	Lifestyle: optimal physical exercise	Not applicable	1. Weight 2. Fatigue
14 15 16 17 18	People with autoimmune hepatitis (stable)	Nurse-led care	Standard care	1. Fatigue
19 20 21 22	People with suspected autoimmune hepatitis	Methods to make a quicker diagnosis	Not applicable	1. Earlier diagnosis
23 24 25 26 27 28 29	People with NASH, diabetes, and gastroparesis	Treatments for breathlessness and pain	Not applicable	1. Breathlessness and pain.
30 31 32 33 34	People with NASH cirrhosis, diabetes, and anaemia	Treatments	Not applicable	HRQoL
35 36 37 38	People with NASH cirrhosis, diabetes, and anaemia	Education of people	Standard care	Better knowledge
39 40 41	General population	Education of people	Standard care	Better knowledge
42 43 44 45 46 47	People with NASH cirrhosis, diabetes, and anaemia	Non-pharmacological treatments to decrease pain and depression	Pharmacological interventions or no intervention	1. Pain 2. Depression
48 49 50 51 52 53 54 55 56 57	People with suspected autoimmune diseases with potential to cause acute liver failure	Diagnosis of autoimmune diseases that cause acute liver failure	Not applicable	Identification of specific autoimmune diseases

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60	People with autoimmune diseases with potential to cause acute liver failure	Prophylactic treatments	Not applicable	Prevent acute liver failure
	People with primary sclerosing cholangitis	Lifestyle: diet (including alcohol consumption) and physical exercise	Not applicable	<ol style="list-style-type: none"> 1. Reduction in symptoms 2. Overall health benefits (unspecified) 3. Ability to return to useful occupation. 4. Reduce medication. 5. Reduce need for annual investigations.
	People with primary sclerosing cholangitis	Azathioprine	Other interventions	Treatment related adverse events
	People with autoimmune hepatitis	Non-pharmacological treatments to treat autoimmune hepatitis	Pharmacological interventions or no intervention	<ol style="list-style-type: none"> 1. Reduction in symptoms 2. HRQoL (including the ability to do everyday tasks/ back into education or employment)

1 2 3 4 5 6 7 8 9	People with primary sclerosing cholangitis	Itching receptor blockers	No intervention/ other interventions	Reduction in itching
10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29	People with primary sclerosing cholangitis with and without Vitamin D deficiency	Vitamin D supplements	Standard care	<ol style="list-style-type: none"> 1. Stop the progress of the disease. 2. Fewer flare ups of inflammatory bowel disease and primary sclerosing cholangitis. 3. Improve HRQoL 4. Less depression
30 31 32 33 34 35 36	People with primary sclerosing cholangitis and autoimmune hepatitis	Ursodeoxycholic acid	No intervention/ other interventions	Reducing symptoms
37 38 39 40 41 42 43	People at risk of primary sclerosing cholangitis and autoimmune hepatitis	Prophylactic treatments	No intervention	Prevention of the condition
44 45 46 47	People with autoimmune hepatitis	Non-steroidal interventions	Steroids	Adverse events
48 49 50 51 52 53 54 55 56 57 58 59 60	People at risk of autoimmune liver diseases	Prophylactic treatments	Not applicable	Reduction in those getting advanced liver disorders

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	People with autoimmune liver diseases (20 to 30 years old)	Treatments	Not applicable	1. Reduction in those getting advanced liver disorders. 2. Stabilisation of disorder. 3. Reduction in liver cancer rates.
19 20 21 22 23 24 25	People with autoimmune liver diseases (> 30 years)	Screening: Early diagnosis of liver cancer	No screening	Early diagnosis of liver cancer
26 27 28 29 30 31 32 33 34	People with NASH and stroke	Nurse-led care	Standard care	1. Recovery time 2. Amount of recovery that is made
35 36 37 38	People with haemochromatosis	Lifestyle: iron avoidance diet	Traditional phlebotomy	Reduction in iron levels
39 40 41 42 43	People with haemochromatosis	Acceleration of phlebotomy	Traditional phlebotomy	Reduction in iron levels
44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60	People with NAFLD	Nurse-led care	Standard care	1. Faster recovery. 2. Symptom relief (unspecified). 3. Prevention of more serious complications. 4. Patient education

			<p>on diet and exercise to lose weight.</p> <p>5. Preventing progression into NASH and cirrhosis.</p> <p>6. Reducing symptoms of aching sides, leg weakness, sickness and nausea.</p> <p>7. Prevent heart attacks and strokes.</p>
People with NAFLD	Treatments for pain	Not applicable	Reducing pain
People with NAFLD	Treatments for itching	Not applicable	Reduction in itching
People at risk of liver disease (overweight or obese)	Education of healthcare professionals about NAFLD	Standard care	<p>1. Prevention of cirrhosis.</p> <p>2. Prevention of other related liver complications.</p> <p>3. Earlier diagnosis and treatment of liver diseases.</p> <p>4. Increased knowledge.</p>
Midwives and healthcare professionals coming into	Education of healthcare	Standard care	1. Prevention of cirrhosis.

contact with children and young adults	professionals about liver disease		2. Prevention of other related liver complications.
People with chronic hepatitis C	Newer treatments	Older interventions	1. Treatment-related complications 2. Ability to perform usual activities such as work, study, housework. 3. Severe liver damage requiring hospital admission. 4. Decreased anxiety.
New-borns	Screening test for biliary atresia	No screening	Earlier diagnosis and treatment
Children who have undergone liver transplantation	Immunosuppressive regimens	Not applicable	Adverse events
People with liver-related disorders	Treatment for itching	Not applicable	Reduction or eradication of itching
People with primary biliary cholangitis	Education of people	Standard care	Knowledge
People with positive AMA (antimitochondrial antibody) M2	Prophylactic treatments	Not applicable	1. Prevention of primary biliary cholangitis.

			2. Reversion to a negative AMA M2 before cirrhosis develops.
People with positive AMA M2	Standardised protocol care by GP	Standard care	1. Prevention of primary biliary cholangitis. 2. Reversion to a negative AMA M2 before cirrhosis develops.
People with liver disease	Stem cell therapy	Standard care	1. Mortality 2. HRQoL (including ability to carry out normal activities including study and work) 3. Prolonging periods of remission 4. Reducing symptoms
People with liver disease	Bio-artificial livers	Standard care	1. Mortality 2. HRQoL (including ability to carry out normal activities

			including study and work)
People with autoimmune hepatitis	Targeted therapy against autoimmunity	Standard care	1. Mortality 2. HRQoL (including ability to carry out normal activities including study and work)
People with primary biliary cholangitis not responding to ursodeoxycholic acid	Different treatments	Not applicable	1. Cure 2. Slowing of disease 3. Improved quality of life with respect to fatigue.
People with primary biliary cholangitis	Antiviral treatment	No intervention/ other interventions	1. Improvement in health (unspecified) 2. Mortality
People with primary biliary cholangitis	Treatment for itching and fatigue	Not applicable	1. HRQoL. 2. Anxiety. 3. Itching. 4. Fatigue. 5. Cure 6. Slowing of disease 7. Symptom relief
People with primary biliary cholangitis	Greater patient involvement	Standard care	1. HRQoL. 2. Anxiety.

1 2 3 4 5 6 7 8 9 10 11 12 13	People with liver and gallbladder disorders	Nurse-led care	Standard care	1. Symptoms. 2. Pain relief. 3. Quicker investigative measures.
14 15 16 17 18 19 20 21 22 23 24 25 26 27	People with pain after cholecystectomy (especially elderly and living alone)	Hospital based investigations to find the cause of pain, treatment of the cause of pain and discharged after pain relief	Symptomatic outpatient intervention	Pain relief
28 29 30 31 32 33 34	People with chronic hepatitis C	Ribavirin	No intervention/ other interventions	Osteoporosis
35 36 37 38 39 40	People with chronic hepatitis C taking ribavirin	Prophylactic treatments for osteoporosis	No prophylactic intervention	Osteoporosis
41 42 43 44 45 46 47 48 49 50 51 52	Healthcare professionals dealing with people with primary biliary cholangitis	Education of healthcare professionals about childhood liver disorders	Standard care	1. Knowledge 2. Better treatment of patients with primary biliary cholangitis
53 54 55 56 57 58 59 60	People with liver disease	Education of people	Standard care	1. Patient knowledge. 2. Visits to the

			hospital. 3. More patient responsibility
People with symptomatic primary sclerosing cholangitis	Different treatments	Not applicable	1. Cure of disease. 2. Delays progression of disease.
People with primary sclerosing cholangitis	Intervention to reverse liver damage	Not applicable	1. Mortality. 2. HRQoL. 3. Requirement for liver transplantation.
People with primary sclerosing cholangitis	Intervention to treat fatigue	Not applicable	1. HRQoL. 2. Fatigue.
People with primary sclerosing cholangitis	Intervention to treat itching	Not applicable	1. HRQoL. 2. Itching.
People with primary sclerosing cholangitis	Specialist interest doctor	Standard care	1. Mortality. 2. HRQoL. 3. Requirement for liver transplantation. 4. Symptom relief.
People at risk of oesophageal varices	Non-invasive assessment of oesophageal varices	Invasive assessment of oesophageal varices	Reduce bleeding oesophageal varices

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60	<p>People at risk of chronic liver disease</p>	<p>Alternative to biopsy for assessment of cirrhosis</p>	<p>Liver biopsy</p>	<p>Assessment of whole liver</p>
	<p>People at risk of primary sclerosing cholangitis (PSC)</p>	<p>Early diagnosis of primary sclerosing cholangitis Alternate to liver biopsy</p>	<p>Not applicable</p>	<p>Not stated</p>
	<p>People with primary sclerosing cholangitis with normal or relatively normal liver function tests</p>	<p>Alternative to UKELD (United Kingdom Model for End-Stage Liver Disease) scores for prioritisation for liver transplantation</p>	<p>UKELD</p>	<p>1. More accurate assessment of transplant need for transplant amongst PSC patients. 2. Reduction in numbers of 'low score' PSC patients becoming too ill for transplant, or not being offered a transplant once 'listed'.</p>
	<p>People with positive AMA M2 with normal liver function tests</p>	<p>Ursodeoxycholic acid</p>	<p>No intervention</p>	<p>Slowing progression of primary biliary cholangitis</p>

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60	People with suspected primary sclerosing cholangitis	Nurse-led care	Standard care	Earlier diagnosis and treatment
	People with liver failure of unknown reason	Investigations to find the cause of liver failure of unknown origin	Not applicable	More knowledge.
	People with Gilbert's syndrome	Treatment of fatigue related to Gilbert's syndrome	Not applicable	1. HRQoL. 2. Chronic fatigue. 3. Depression
	People with NAFLD (non-alcoholic fatty liver disease)	Breathing exercises	Standard care	1. Faster recovery. 2. Symptom relief 3. Prevention of more serious complications
	People with NASH cirrhosis	Treatment of symptoms	Not applicable	Improvement of symptoms
	People at risk of liver disease	Screening for autoimmune diseases	No screening	Earlier diagnosis and treatment
	People with autoimmune hepatitis	Treatment of symptoms	Not applicable	1. Measure feeling well (unspecified). 2. Fatigue having energy. 3. Fewer flare ups.

			4. Less joint pain. 5. Disability.
People with autoimmune hepatitis	Methods to decrease stress	Not applicable	1. Measure feeling well (unspecified). 2. Fatigue having energy. 3. Fewer flare ups. 4. Less joint pain. 5. Disability.
People with liver disease	Counselling for tremors and confusion	No counselling	Coping with symptoms
People with NAFLD	Staging of liver disease	Not applicable	1. Mortality. 2. Reversal of liver damage
People with NAFLD	Metformin	No intervention	1. Mortality. 2. Reversal of liver damage
People with NAFLD	Standardised protocol for diagnosis and treatment of NAFLD	Standard care	1. Mortality. 2. Reversal of liver damage
People with osteoarthritis	Anti-inflammatory drugs	Other interventions	Cirrhosis
People with diabetes	Adequate control of diabetes	Lack of adequate control of diabetes	1. NASH. 2. Cirrhosis.

1 2 3 4 5 6 7	People at risk of NAFLD	Screening: Early identification of causes	Standard care	Prevention of liver disease
8 9 10 11 12 13 14 15 16 17 18	People with NAFLD	Treatments	Not applicable	1. Cure 2. Prevention of liver disease 3. Disease progression 4. HRQoL
19 20 21 22 23 24 25 26 27 28 29 30 31	People with upper abdominal pain	Screening: Early scan with ultrasound, blood tests, and urine tests	Standard care	1. Early identification of liver and gallbladder diseases 2. Appropriate advice/treatment
32 33 34 35 36	People with NAFLD	Lifestyle: diet and exercise	Standard care	1. HRQoL
37 38 39 40	People with NAFLD	Specialist interest doctor	Standard care	1. HRQoL
41 42 43 44 45	People at risk of liver disease	Prophylactic interventions	Not applicable	1. Prevention of liver disease
46 47 48 49 50 51	People at risk of NAFLD	Prophylactic treatments	Not applicable	1. Prevention of NAFLD 2. Decrease NAFLD
52 53 54 55 56 57 58 59 60	People with NASH fibrosis	Lifestyle: exercise	Standard care	None stated

<p>1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36</p> <p>People with cryptogenic liver cirrhosis</p>	<p>Investigations to find the cause of cryptogenic cirrhosis</p>	<p>Not applicable</p>	<p>1. Reduction in liver disease diagnosis of the percentage regarded as cryptogenic.</p> <p>2. Establishment of relevant treatment pathways.</p> <p>3. Reduction in numbers of liver transplant required by earlier intervention using non-invasive treatment regimes.</p>
<p>37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60</p> <p>People with cirrhosis</p>	<p>Community-led psychological support (on lifestyle: diet and exercise, stress, work-life balance, and general well-being)</p>	<p>Standard care</p>	<p>1. Reduction of symptoms such as nausea, fatigue.</p> <p>2. Improved nutrition and healthier weights.</p> <p>3. Improved HRQoL</p> <p>4. Improved sense of wellbeing</p> <p>5. Successful work</p>

			<p>and job retention</p> <p>6. Good sense of self determination/empowerment and motivation</p> <p>7. Improved clinical markers (unspecified)</p>
Newborns	Screening for metabolic liver diseases	No screening	<p>1. Early treatment for people with metabolic liver disease (including dietary advice)</p> <p>2. Mortality.</p> <p>3. HRQoL.</p> <p>4. Prevent type 2 diabetes</p>
People with autoimmune hepatitis	Telephone-based care	Standard care	<p>1. Reduction in time spent in outpatients</p> <p>2. Less spent on car-parking at hospitals</p>
People with NASH and diabetes	Liver transplantation	Standard care	<p>1. Mortality</p>

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60	People with primary biliary cholangitis (newly diagnosed)	Adequate drinking water	Standard care	1. HRQoL. 2. Liver function tests.
	People with primary sclerosing cholangitis	Treatment targeted against deformation of bile duct	Standard care	1. Time to end-stage liver disease.
	People with bile duct cancer	Treatment targeted against deformation of bile duct	Standard care	Not stated
	People with gallbladder sludge with digestive symptoms	Avoiding surgery	Standard care	1. Symptom relief
	People with NAFLD	Education of healthcare professionals	Standard care	1. Greater awareness of conditions. 2. Preventative measures. 3. Greater knowledge base.
	People with NAFLD	Education of general public	Standard care	1. Greater awareness of conditions. 2. Preventative measures. 3. Greater knowledge base.

1 2 3 4 5 6 7 8 9 10 11	People with NAFLD	Methods to make an accurate diagnosis (including liver function tests)	Not applicable	Not stated
12 13 14 15 16	People with NAFLD (overweight)	Interventions to lose weight	Not applicable	Weight loss
17 18 19 20	People with liver disease (newly diagnosed)	Mental health support	Not applicable	Mental health
21 22 23 24 25 26 27	Children with multiple autoimmune disorders related to liver	Genetic testing of telomere lengths	Other tests/ no tests	Not stated
28 29 30 31 32 33 34 35 36	Children with multiple autoimmune disorders related to liver	Stem cell therapy	Standard care	Reduction in all conditions with only one drug with little side effects
37 38 39 40 41 42 43	People with primary biliary cholangitis (especially younger age group)	Treatments based on tools for predicting prognosis	Standard care	Better care for people with high risk of progression
44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60	People with chronic hepatitis C	Lifestyle: diet	Standard care	<ol style="list-style-type: none"> 1. Improvement in overall health. 2. Decrease in liver damage requiring hospital admission. 3. Patient knowledge.

			<p>4. Healthcare professional knowledge.</p> <p>5. Fewer treatment-related complications.</p> <p>6. Decreasing pain and discomfort.</p> <p>7. Clear guidelines for successful dietary needs.</p>
<p>Healthcare professionals dealing with people with chronic hepatitis C</p>	<p>Education of healthcare professionals (about diet)</p>	<p>Standard care</p>	<p>1. Improvement in overall health.</p> <p>2. Decrease in liver damage requiring hospital admission.</p> <p>3. Patient knowledge.</p> <p>4. Healthcare professional knowledge.</p> <p>5. Fewer treatment-related complications.</p> <p>6. Decreasing pain</p>

For peer review only

			<p>and discomfort.</p> <p>7. Clear guidelines for successful dietary needs.</p>
<p>Healthcare professionals dealing with people with NAFLD</p>	<p>Education of healthcare professionals (around support to patients on weight control, diet, exercise and life style)</p>	<p>Standard care</p>	<ol style="list-style-type: none"> 1. Preventing progression into NASH and cirrhosis. 2. Reducing symptoms of aching sides, leg weakness, sickness and nausea. 3. Prevent heart attacks and strokes.
<p>Family members of people with primary biliary cholangitis</p>	<p>Screening of family members for primary biliary cholangitis</p>	<p>No screening</p>	<ol style="list-style-type: none"> 1. Establishing the genetic link for primary biliary cholangitis. 2. Earlier identification of primary biliary cholangitis who may have PBC or be at risk. 3. Cost-savings.

1 2 3 4 5 6 7 8 9	People with positive AMA M2 with normal liver function tests	Screening for cirrhosis using biopsy	No screening	Accurate diagnosis of primary biliary cholangitis.
10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27	People with primary biliary cholangitis	Screening for other autoimmune conditions associated with primary biliary cholangitis and complications related to primary biliary cholangitis	No screening	1. HRQoL. 2. Costs.
28 29 30 31	People with autoimmune liver disease	Treatment of fatigue and others symptoms	Not applicable	Remission
32 33 34 35 36 37 38 39 40	People with primary sclerosing cholangitis	Standardised protocol for follow-up of patients with primary sclerosing cholangitis	Standard care	1. Reduce need for annual investigations. 2. Costs.
41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60	People with other autoimmune disease	Screening for liver disease	No screening	1. Decreasing risk of severe liver damage and admission to hospital 2. Reducing the need for liver transplants 3. Decreasing the risk of liver cancer

			<p>4. Mortality</p> <p>5. HRQoL</p>
<p>People with NAFLD</p>	<p>Pathway for managing end of life care</p>	<p>Standard care</p>	<p>1. Patient and carer satisfaction</p> <p>2. Patient HRQoL</p> <p>3. Symptom relief.</p>
<p>People with decompensated liver disease</p>	<p>Lifestyle: nutritional treatment</p>	<p>Not applicable</p>	<p>1. Improved survival.</p> <p>2. Reduced symptoms.</p> <p>3. Improved nutritional status.</p> <p>4. Improved Strength.</p>
<p>People with decompensated liver disease</p>	<p>Measuring energy requirements with indirect calorimeters</p>	<p>Current UK guidance on requirements (Parenteral & Enteral Nutrition Group) (high energy requirements)</p>	<p>1. Improved survival.</p> <p>2. Reduced symptoms.</p> <p>3. Improved nutritional status.</p> <p>4. Improved Strength.</p>
<p>People with hepatic encephalopathy</p>	<p>Branch chain amino acids</p>	<p>Standard care</p>	<p>1. Improved survival.</p> <p>2. Reduced symptoms.</p> <p>3. Improved</p>

			nutritional status. 4. Improved Strength.
People with decompensated liver disease with muscle wasting	Branch chain amino acids	Standard care	1. Improved survival. 2. Reduced symptoms. 3. Improved nutritional status. 4. Improved Strength.
People with decompensated liver disease with muscle wasting	Lifestyle: exercise	Standard care	1. Improved survival. 2. Reduced symptoms. 3. Improved nutritional status. 4. Improved Strength.
People with decompensated liver disease	Standardised nutritional assessment of patients and outcomes in nutritional intervention trials	Non-standardised assessment	1. Improved survival. 2. Reduced symptoms. 3. Improved nutritional status. 4. Improved Strength.

			5. Better conduct of future trials.
People with NAFLD	Methods to increase self care	Not applicable	Reducing symptoms
People with NAFLD	Methods to decrease shortness of breath	Not applicable	Reducing symptoms
People with liver disease	Interventions to decrease fatigue	Not applicable	Fatigue
Healthcare professionals dealing with people with cirrhosis	Education of healthcare professionals about cirrhosis (complications and benefits and harms of treatment)	Standard care	Better advice to patients by health professionals regarding complications and benefits and harms of different treatments
People with primary biliary cholangitis	Ursodeoxycholic acid (including optimal dose)	No intervention/ other interventions	1. Liver function tests. 2. Minimal effective dose of ursodeoxycholic acid. 3. Good sleep.
People with liver cancer and ascites	Different interventions	Not applicable	HRQoL

1 2 3 4 5 6 7 8 9 10 11	People with primary sclerosing cholangitis	Screening for cancer	No screening	1. Benefits 2. Earlier diagnosis of bile duct cancer 3. Mortality
12 13 14 15 16 17 18	People with primary or metastatic liver cancer	Nurse-led care (follow-up clinic)	Doctor-led follow-up	1. Patient satisfaction 2. Timely surveillance
19 20 21 22	People with cirrhosis	Life-style: nutritional advice	Not applicable	1. Fatigue 2. Muscle wasting
23 24 25 26 27	People with polycystic liver disease	Surgery	Non-surgical management	1. Recurrence 2. HRQoL
28 29 30 31 32 33 34	People with gallstones	Avoiding surgery	Surgery	1. Requirement for surgery 2. Costs to NHS
35 36 37 38 39 40 41 42 43 44 45	People at risk of NASH	Nurse-led care	No intervention	1. Early diagnosis of NASH. 2. Successful treatment of NASH. 3. Mortality
46 47 48 49 50 51 52 53 54 55 56 57 58 59 60	People at risk of NASH	Screening for NASH using Fibroscan	No intervention	1. Early diagnosis of NASH. 2. Successful treatment of NASH. 3. Mortality

<p>1 2 3 4 5 6 7 8 9 10 11 12 13 14</p> <p>People at risk of NASH</p>	<p>Support group focussed on diet and exercise</p>	<p>No intervention</p>	<p>1. Prevention of NASH. 2. Successful treatment of NASH. 3. Mortality</p>
<p>15 16 17 18</p> <p>People at risk of NASH</p>	<p>Emotional support group for carers</p>	<p>No intervention</p>	<p>HRQoL</p>
<p>19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36</p> <p>People with NASH</p>	<p>Nurse-led care</p>	<p>Standard care</p>	<p>1. Mortality. 2. HRQoL. 3. Requirement for liver transplantation. 4. Liver cancer. 5. Liver failure. 6. Treatment-related complications.</p>
<p>37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60</p> <p>People with NASH</p>	<p>Lifestyle: diet</p>	<p>Standard care</p>	<p>1. Mortality. 2. HRQoL. 3. Requirement for liver transplantation. 4. Liver cancer. 5. Liver failure. 6. Treatment-related complications.</p>

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60		Different interventions to decrease anxiety and depression	Standard care	Anxiety and depression
	People with NASH	Research design using support group	Standard research design	Help towards better research
	General population	Life style: diet and exercise	No intervention	HRQoL
	General population	Education of people (patient information leaflet at GP surgeries)	No intervention	1. Prevention of NASH. 2. HRQoL.
	General population	Screening: for liver disease	No intervention	1. Early diagnosis of liver disease 2. Mortality 3. HRQoL 4. Requirement for liver transplantation 5. Costs 6. Requirement for hospital admission for severe liver damage 7. Primary liver cancer
	Primary school children	Lifestyle: nutritional and dietary advice	No intervention	1. Adherence to healthy diet and

			exercise to sustain healthy life style.
People undergoing liver resection	Best method to assess function and volume of remnant liver	Not applicable	1. Mortality. 2. HRQoL. 3. Complications.
People undergoing liver resection	Best method to assess cardiopulmonary function?	Not applicable	1. Mortality. 2. HRQoL. 3. Complications.
People undergoing liver resection	Pre-operative education	Standard care	1. Mortality. 2. HRQoL. 3. Complications.
Surgeons treating people undergoing liver resection	Simulation and training of surgeons	Standard care	1. Mortality. 2. HRQoL. 3. Complications.
People undergoing liver resection	Growth factors to optimise muscle and fat content	Standard care	1. Mortality. 2. HRQoL. 3. Complications.
People undergoing liver resection	Pharmacological interventions for weight loss	Not applicable	1. Mortality. 2. HRQoL. 3. Complications.
People undergoing liver resection	Portal vein embolisation	Standard care	1. Mortality. 2. HRQoL. 3. Complications.

1 2 3 4 5 6 7 8 9	People undergoing liver resection	Reducing systemic inflammation using steroids	Standard care	1. Mortality. 2. HRQoL. 3. Complications.
10 11 12 13 14 15 16	People undergoing liver resection	Open liver resection	Laparoscopic liver resection	1. Mortality. 2. HRQoL. 3. Complications.
17 18 19 20 21 22 23	People undergoing liver resection	Tumour visualisation and localisation of the tumour	Standard care	1. Mortality. 2. HRQoL. 3. Complications.
24 25 26 27 28 29	People undergoing liver resection	Goal directed therapy during operation	Standard care	1. Mortality. 2. HRQoL. 3. Complications.
30 31 32 33 34 35 36	Surgeons treating people undergoing liver resection	Use of magnifying surgical loupes during liver surgery	Standard care	1. Mortality. 2. HRQoL. 3. Complications.
37 38 39 40 41 42 43 44 45 46 47	People undergoing liver resection	Portal vein pressure decrease (by the use of drugs such as vasopressin) during surgery	Standard care	1. Mortality. 2. HRQoL. 3. Complications.
48 49 50 51 52 53 54 55 56 57 58 59 60	People undergoing liver resection	Transection techniques	Not applicable	1. Mortality. 2. HRQoL. 3. Complications.

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60	People undergoing liver resection	Vascular occlusion techniques	Not applicable	1. Mortality. 2. HRQoL. 3. Complications.
People undergoing liver resection	Cardiopulmonary and pharmacological interventions for decreasing blood loss	Not applicable	1. Mortality. 2. HRQoL. 3. Complications.	
People undergoing liver resection	Use of peritoneal drains	No drain	1. Mortality. 2. HRQoL. 3. Complications.	
People undergoing liver resection	ALPPS procedure (Associating Liver Partition and Portal vein Ligation for Staged hepatectomy)	Standard care	1. Mortality. 2. HRQoL. 3. Complications.	
People undergoing liver resection	Goal directed therapy (post-operative)	Standard care	1. Mortality. 2. HRQoL. 3. Complications.	
People undergoing liver resection	Pain control protocol	Standard care	1. Mortality. 2. HRQoL. 3. Complications.	
People undergoing liver resection	Early mobilisation protocol	Standard care	1. Mortality. 2. HRQoL. 3. Complications.	

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60	People undergoing liver resection	Early oral intake protocol	Standard care	1. Mortality. 2. HRQoL. 3. Complications.
	People undergoing liver resection	Portal vein pressure decrease (by the use of drugs such as vasopressin) post-operatively	Standard care	1. Mortality. 2. HRQoL. 3. Complications.
	People with unresectable hepatocellular carcinoma	Radioembolisation	No intervention/other interventions	1. Mortality. 2. HRQoL. 3. Complications.
	People with unresectable hepatocellular carcinoma	External beam radiotherapy	No intervention/other interventions	1. Mortality. 2. HRQoL. 3. Complications.
	People with chronic hepatitis B	Screening for cancer	No screening	1. Mortality. 2. HRQoL. 3. Complications.
	People with hepatocellular carcinoma	Cryotherapy	No intervention/other interventions	1. Mortality. 2. HRQoL. 3. Complications.
	People with hepatocellular carcinoma	Systemic chemotherapy	No intervention/other interventions	1. Mortality. 2. HRQoL. 3. Complications.

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60	People with early or very early hepatocellular carcinoma	Treatment	Not applicable	1. Mortality. 2. HRQoL. 3. Complications.
	People with intermediate hepatocellular carcinoma	Treatment	Not applicable	1. Mortality. 2. HRQoL. 3. Complications.
	People with hepatocellular carcinoma	Tamoxifen	No intervention/other interventions	1. Mortality. 2. HRQoL. 3. Complications.
	People with unresectable hepatocellular carcinoma	Transarterial embolisation	No intervention/other interventions	1. Mortality. 2. HRQoL. 3. Complications.
	People with unresectable hepatocellular carcinoma	Tyrosine kinase inhibitors	No intervention/other interventions	1. Mortality. 2. HRQoL. 3. Complications.
	People undergoing liver resection for hepatocellular carcinoma	Neoadjuvant and adjuvant therapy	No intervention/other interventions	1. Mortality. 2. HRQoL. 3. Complications.
	People with unresectable hepatocellular carcinoma	Transarterial chemoembolisation	No intervention/other interventions	1. Mortality. 2. HRQoL. 3. Complications.
	People with hepatocellular carcinoma	Interferon	No intervention/other interventions	1. Mortality. 2. HRQoL. 3. Complications.

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60	People with hepatocellular carcinoma	Surgical resection	Liver transplantation	1. Mortality. 2. HRQoL. 3. Complications.
People undergoing liver resection for hepatocellular carcinoma	Anterior approach	Conventional liver resection	1. Mortality. 2. HRQoL. 3. Complications.	
People with hepatocellular carcinoma	Radiofrequency ablation	No intervention/other interventions	1. Mortality. 2. HRQoL. 3. Complications.	
People undergoing liver resection for hepatocellular carcinoma	Post-operative transarterial chemoembolisation	No intervention/other interventions	1. Mortality. 2. HRQoL. 3. Complications.	
People undergoing liver resection for hepatocellular carcinoma	Post-operative lamivudine with or without adefovir dipivoxil	No intervention/other interventions	1. Mortality. 2. HRQoL. 3. Complications.	
People with advanced biliary tract carcinoma	gemcitabine-based chemotherapy	No intervention/other interventions	1. Mortality. 2. HRQoL. 3. Complications.	
People with unresectable cholangiocarcinoma	Endoscopic treatment	Surgery	1. Mortality. 2. HRQoL. 3. Complications.	
People undergoing liver transplantation	Pharmacological interventions for	No intervention/other interventions	1. Mortality. 2. HRQoL. 3. Complications.	

	reducing ischaemia reperfusion injury		
People undergoing liver transplantation for hepatitis B infection	Antibiotic prophylaxis	No intervention/other interventions	1. Mortality. 2. HRQoL. 3. Complications.
People undergoing liver transplantation for hepatitis B infection	Hepatitis B immune globulin	No intervention/other interventions	1. Mortality. 2. HRQoL. 3. Complications.
People undergoing liver transplantation	Prostaglandins	No intervention/other interventions	1. Mortality. 2. HRQoL. 3. Complications.
People undergoing haemopoietic stem cell transplantation	Interventions to prevent hepatic veno-occlusive disease	Not applicable	1. Mortality. 2. HRQoL. 3. Complications.
People undergoing haemopoietic stem cell transplantation	Interventions to treat hepatic veno-occlusive disease	Not applicable	1. Mortality. 2. HRQoL. 3. Complications.
People undergoing liver transplantation	Immunosuppressive regimens	Not applicable	1. Mortality. 2. HRQoL. 3. Complications.
People undergoing liver transplantation	Venovenous bypass	No intervention	1. Mortality. 2. HRQoL. 3. Complications.

1 2 3 4 5 6 7 8 9	People undergoing liver transplantation	Ischaemic preconditioning	No intervention	1. Mortality. 2. HRQoL. 3. Complications.
10 11 12 13 14 15 16	People undergoing liver transplantation	Methods of biliary reconstruction	Not applicable	1. Mortality. 2. HRQoL. 3. Complications.
17 18 19 20 21 22 23 24 25 26 27	People undergoing liver transplantation	Methods of preventing bacterial sepsis and wound complications after liver transplantation	Not applicable	1. Mortality. 2. HRQoL. 3. Complications.
28 29 30 31 32 33 34	People undergoing liver transplantation	Techniques of flushing and reperfusion	Not applicable	1. Mortality. 2. HRQoL. 3. Complications.
35 36 37 38 39 40 41	People undergoing liver transplantation	Abdominal drainage	No intervention	1. Mortality. 2. HRQoL. 3. Complications.
42 43 44 45 46 47	People undergoing liver transplantation	Piggy-back	Conventional liver transplantation	1. Mortality. 2. HRQoL. 3. Complications.
48 49 50 51 52 53 54 55 56 57 58 59 60	People undergoing liver transplantation	Methods to decrease blood loss and transfusion requirements	Not applicable	1. Mortality. 2. HRQoL. 3. Complications.

1 2 3 4 5 6 7 8 9	People undergoing liver transplantation	Antiviral prophylaxis for prevention of hepatitis C infection	Not applicable	1. Mortality. 2. HRQoL. 3. Complications.
10 11 12 13 14 15 16	People undergoing liver transplantation	Antiviral treatment of hepatitis C infection	Not applicable	1. Mortality. 2. HRQoL. 3. Complications.
17 18 19 20 21 22 23 24 25 26 27	People undergoing liver transplantation for hepatitis B infection	Lamivudine or adefovir dipivoxil	No intervention/other interventions including immunoglobulin	1. Mortality. 2. HRQoL. 3. Complications.
28 29 30 31 32 33 34	People undergoing liver transplantation	Nutritional interventions	Not applicable	1. Mortality. 2. HRQoL. 3. Complications.
35 36 37 38 39 40 41	People undergoing liver transplantation	Bile acids	No intervention/other interventions	1. Mortality. 2. HRQoL. 3. Complications.
42 43 44 45 46 47	People undergoing liver transplantation	Celsior solution	UW solution	1. Mortality. 2. HRQoL. 3. Complications.
48 49 50 51 52 53 54 55 56 57 58 59 60	People undergoing liver resection	Pharmacological interventions for reducing ischaemia reperfusion injury	No intervention/other interventions	1. Mortality. 2. HRQoL. 3. Complications.

1 2 3 4 5 6 7 8 9	People undergoing liver resection	Fibrin-based haemostatic agents	No intervention/other interventions	1. Mortality. 2. HRQoL. 3. Complications.
10 11 12 13 14 15 16	People undergoing liver resection for colorectal liver metastases	Neoadjuvant chemotherapy	No intervention/other interventions	1. Mortality. 2. HRQoL. 3. Complications.
17 18 19 20 21 22 23	People with colorectal liver metastases	Resection	Other interventions	1. Mortality. 2. HRQoL. 3. Complications.
24 25 26 27 28 29	People undergoing liver resection	Ischaemic preconditioning	No intervention	1. Mortality. 2. HRQoL. 3. Complications.
30 31 32 33 34 35 36	People undergoing liver resection	Interventions for reducing blood loss	No intervention/other interventions	1. Mortality. 2. HRQoL. 3. Complications.
37 38 39 40 41 42 43	People undergoing liver resection	Methods of decreasing infection	No intervention/other interventions	1. Mortality. 2. HRQoL. 3. Complications.
44 45 46 47 48 49	People with hepatic node positive colorectal liver metastases	Resection	No resection	1. Mortality. 2. HRQoL. 3. Complications.
50 51 52 53 54 55 56 57 58 59 60	People undergoing liver resection for resectable neuroendocrine tumours	Resection	No resection	1. Mortality. 2. HRQoL. 3. Complications.

1 2 3 4 5 6 7 8 9	People undergoing liver resection or ablation of colorectal liver metastases	Hepatic artery adjuvant chemotherapy	No intervention/other interventions	1. Mortality. 2. HRQoL. 3. Complications.
10 11 12 13 14 15 16	People undergoing liver resection	Laparoscopic liver resection	Open liver resection	1. Mortality. 2. HRQoL. 3. Complications.
17 18 19 20 21 22 23	People with hepatic encephalopathy	Nonabsorbable disaccharides	No intervention/other interventions	1. Mortality. 2. HRQoL. 3. Complications.
24 25 26 27 28 29	People with hepatic encephalopathy	Benzodiazepine receptor antagonists	No intervention/other interventions	1. Mortality. 2. HRQoL. 3. Complications.
30 31 32 33 34 35 36	People with hepatic encephalopathy	Antibiotics	No intervention/other interventions	1. Mortality. 2. HRQoL. 3. Complications.
37 38 39 40 41 42 43	People with hepatic encephalopathy	Dopamine agents	No intervention/other interventions	1. Mortality. 2. HRQoL. 3. Complications.
44 45 46 47 48 49	People with hepatic encephalopathy	Rifaximin	No intervention/other interventions	1. Mortality. 2. HRQoL. 3. Complications.
50 51 52 53 54 55 56 57 58 59 60	People with hepatic encephalopathy	Acetyl-L-carnitine	No intervention/other interventions	1. Mortality. 2. HRQoL. 3. Complications.

1 2 3 4 5 6 7 8 9	People with hepatic encephalopathy	Probiotics	No intervention/other interventions	1. Mortality. 2. HRQoL. 3. Complications.
10 11 12 13 14 15 16	People with hepatic encephalopathy	Naloxone	No intervention/other interventions	1. Mortality. 2. HRQoL. 3. Complications.
17 18 19 20 21 22 23	People with hepatic encephalopathy	L-ornithine-L-aspartate	No intervention/other interventions	1. Mortality. 2. HRQoL. 3. Complications.
24 25 26 27 28 29	People with NAFLD	Pharmacological treatments	Not applicable	1. Mortality. 2. HRQoL. 3. Complications.
30 31 32 33 34 35 36	People with NAFLD	Herbal medicines	No intervention/other interventions	1. Mortality. 2. HRQoL. 3. Complications.
37 38 39 40 41 42 43	People with NAFLD	Weight reduction	Not applicable	1. Mortality. 2. HRQoL. 3. Complications.
44 45 46 47 48 49	People with liver metastases	Transarterial (chemo)embolisation	No intervention/other interventions	1. Mortality. 2. HRQoL. 3. Complications.
50 51 52 53 54 55 56 57 58 59 60	People with liver metastases	Microwave coagulation	No intervention/other interventions	1. Mortality. 2. HRQoL. 3. Complications.

1 2 3 4 5 6 7 8 9	People with liver metastases	Cryotherapy	No intervention/oth er interventions	1. Mortality. 2. HRQoL. 3. Complications.
10 11 12 13 14 15 16	People with liver metastases	Radiofrequency ablation	No intervention/oth er interventions	1. Mortality. 2. HRQoL. 3. Complications.
17 18 19 20 21 22 23	People with unresectable neuroendocrine liver metastases	Palliative cytoreductive surgery	Other palliative interventions	1. Mortality. 2. HRQoL. 3. Complications.
24 25 26 27 28 29	People with unresectable colorectal liver metastases	Hepatic arterial infusion	Systemic chemotherapy	1. Mortality. 2. HRQoL. 3. Complications.
30 31 32 33 34 35 36	People with liver metastases	Electro-coagulation	No intervention/oth er interventions	1. Mortality. 2. HRQoL. 3. Complications.
37 38 39 40 41 42 43	People with liver metastases	Percutaneous ethanol injection	No intervention/oth er interventions	1. Mortality. 2. HRQoL. 3. Complications.
44 45 46 47 48 49	People with unresectable colorectal liver metastases	Chemotherapy for downstaging	No intervention/oth er interventions	1. Mortality. 2. HRQoL. 3. Complications.
50 51 52 53 54 55 56 57 58 59 60	People with colorectal liver metastases	Selective internal radiation therapy	No intervention/oth er interventions	1. Mortality. 2. HRQoL. 3. Complications.

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60	People with gallbladder polyp	Cholecystectomy	No cholecystectomy	1. Mortality. 2. HRQoL. 3. Complications.
	People with gallbladder dyskinesia	Cholecystectomy	No cholecystectomy	1. Mortality. 2. HRQoL. 3. Complications.
	People undergoing laparoscopic cholecystectomy	Methods of cystic duct occlusion	Not applicable	1. Mortality. 2. HRQoL. 3. Complications.
	People undergoing laparoscopic cholecystectomy for acute cholecystitis	Early laparoscopic cholecystectomy	Delayed cholecystectomy	1. Mortality. 2. HRQoL. 3. Complications.
	People undergoing cholecystectomy	Laparoscopic cholecystectomy	Open cholecystectomy	1. Mortality. 2. HRQoL. 3. Complications.
	People undergoing cholecystectomy	Laparoscopic cholecystectomy	Mini-incision cholecystectomy	1. Mortality. 2. HRQoL. 3. Complications.
	People undergoing cholecystectomy	Mini-incision cholecystectomy	Open cholecystectomy	1. Mortality. 2. HRQoL. 3. Complications.
	People undergoing laparoscopic cholecystectomy	Abdominal wall lift	Pneumoperitoneum	1. Mortality. 2. HRQoL. 3. Complications.

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60	People undergoing laparoscopic cholecystectomy	Abdominal drainage	No drain	1. Mortality. 2. HRQoL. 3. Complications.
	People undergoing laparoscopic cholecystectomy for biliary colic	Early laparoscopic cholecystectomy	Delayed cholecystectomy	1. Mortality. 2. HRQoL. 3. Complications.
	People undergoing laparoscopic cholecystectomy	Intra-peritoneal saline instillation	No instillation	1. Mortality. 2. HRQoL. 3. Complications.
	People undergoing laparoscopic cholecystectomy	Methods of intraperitoneal local anaesthetic instillation	Not applicable	1. Mortality. 2. HRQoL. 3. Complications.
	People undergoing laparoscopic cholecystectomy	Methods of local anaesthetic wound infiltration	Not applicable	1. Mortality. 2. HRQoL. 3. Complications.
	People undergoing laparoscopic cholecystectomy	Three-dimensional imaging	Two-dimensional imaging	1. Mortality. 2. HRQoL. 3. Complications.
	People with asymptomatic gallstones	Cholecystectomy	No cholecystectomy	1. Mortality. 2. HRQoL. 3. Complications.
	People undergoing open cholecystectomy	Abdominal drainage	No drain	1. Mortality. 2. HRQoL. 3. Complications.

1 2 3 4 5 6 7 8 9	People undergoing laparoscopic cholecystectomy	Robotic assistant	Human assistant	1. Mortality. 2. HRQoL. 3. Complications.
10 11 12 13 14 15 16	People undergoing laparoscopic cholecystectomy	Methods of gallbladder dissection	Not applicable	1. Mortality. 2. HRQoL. 3. Complications.
17 18 19 20 21 22 23 24 25	People undergoing laparoscopic cholecystectomy	Low pressure pneumoperitoneum	Standard pressure pneumoperitoneum	1. Mortality. 2. HRQoL. 3. Complications.
26 27 28 29 30 31 32	People undergoing laparoscopic cholecystectomy	Education of patients	Standard care	1. Mortality. 2. HRQoL. 3. Complications.
33 34 35 36 37 38	People undergoing laparoscopic cholecystectomy	Miniports	Standard ports	1. Mortality. 2. HRQoL. 3. Complications.
39 40 41 42 43 44 45	People undergoing laparoscopic cholecystectomy	Number of ports	Not applicable	1. Mortality. 2. HRQoL. 3. Complications.
46 47 48 49 50 51 52 53 54 55 56 57 58 59 60	People undergoing laparoscopic cholecystectomy	Pharmacological interventions for prevention or treatment of postoperative pain	Not applicable	1. Mortality. 2. HRQoL. 3. Complications.

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60	<p>People undergoing laparoscopic cholecystectomy</p> <p>Glucocorticoids</p> <p>No intervention</p> <p>1. Mortality. 2. HRQoL. 3. Complications.</p>
<p>People who have undergone endoscopic sphincterotomy for gallstone related complications</p> <p>Early cholecystectomy</p> <p>Delayed or no cholecystectomy</p> <p>1. Mortality. 2. HRQoL. 3. Complications.</p>	
<p>People undergoing laparoscopic cholecystectomy</p> <p>Antibiotic prophylaxis</p> <p>Not applicable</p> <p>1. Mortality. 2. HRQoL. 3. Complications.</p>	
<p>People undergoing laparoscopic cholecystectomy</p> <p>Day surgery</p> <p>Overnight stay</p> <p>1. Mortality. 2. HRQoL. 3. Complications.</p>	
<p>People undergoing day surgery laparoscopic cholecystectomy</p> <p>Anaesthetic regimens</p> <p>Not applicable</p> <p>1. Mortality. 2. HRQoL. 3. Complications.</p>	
<p>People with common bile duct stones undergoing laparoscopic cholecystectomy</p> <p>Per-operative endoscopic sphincterotomy</p> <p>Pre-operative endoscopic sphincterotomy</p> <p>1. Mortality. 2. HRQoL. 3. Complications.</p>	
<p>People with suspected bile duct stenosis</p> <p>Magnetic resonance cholangiopancreatography</p> <p>Not applicable</p> <p>1. Mortality. 2. HRQoL. 3. Complications.</p>	

1 2 3 4 5 6 7 8 9 10 11	People with suspected bile duct stones	Endoscopic ultrasound	Magnetic resonance cholangiopancreatography	1. Mortality. 2. HRQoL. 3. Complications.
12 13 14 15 16 17 18	People with suspected bile duct stones	Endoscopic retrograde cholangiopancreatography	Intraoperative cholangiography	1. Mortality. 2. HRQoL. 3. Complications.
19 20 21 22 23 24 25	People with suspected bile duct stones	Liver function tests	Transabdominal ultrasound	1. Mortality. 2. HRQoL. 3. Complications.
26 27 28 29 30 31 32	People undergoing surgery for biliary tract cancer	Pre-operative biliary stenting	No stenting	1. Mortality. 2. HRQoL. 3. Complications.
33 34 35 36 37 38	People with uncomplicated amoebic liver abscess	Percutaneous procedure plus metronidazole	Metronidazole alone	1. Mortality. 2. HRQoL. 3. Complications.
39 40 41 42 43 44 45	People with benign liver tumours	Liver resection	No liver resection	1. Mortality. 2. HRQoL. 3. Complications.
46 47 48 49 50 51 52	People with sphincter of oddi dysfunction	Sphincterotomy	No sphincterotomy	1. Mortality. 2. HRQoL. 3. Complications.
53 54 55 56 57 58 59 60	People with cirrhosis	Colchicine	No intervention/other interventions	1. Mortality. 2. HRQoL. 3. Complications.

1 2 3 4 5 6 7 8 9	People with blunt liver injury	Non-surgical treatment	Surgery	1. Mortality. 2. HRQoL. 3. Complications.
10 11 12 13 14 15 16	People with common bile duct stones	Surgical treatment	Endoscopic intervention	1. Mortality. 2. HRQoL. 3. Complications.
17 18 19 20 21 22 23	People at risk of gallstones	Lifestyle: Diets for primary prevention of gallstones	Not applicable	1. Mortality. 2. HRQoL. 3. Complications.
24 25 26 27 28 29 30 31 32	People at risk of gallstones	Pharmacological interventions for primary prevention of gallstones	Not applicable	1. Mortality. 2. HRQoL. 3. Complications.
33 34 35 36 37 38	People with common bile duct stones	Sphincteroplasty	Sphincterotomy	1. Mortality. 2. HRQoL. 3. Complications.
39 40 41 42 43 44 45	People with biliary colic	Bile acids	No intervention/other interventions	1. Mortality. 2. HRQoL. 3. Complications.
46 47 48 49 50 51 52	People with biliary colic	Non-steroidal anti-inflammatory drugs	No intervention/other interventions	1. Mortality. 2. HRQoL. 3. Complications.
53 54 55 56 57 58 59 60	People with chronic hepatitis C	Pharmacological treatments	Not applicable	1. Mortality. 2. HRQoL. 3. Complications.

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60	People with chronic hepatitis B	Pharmacological treatments	Not applicable	1. Mortality. 2. HRQoL. 3. Complications.
People with chronic hepatitis D	Pharmacological treatments	Not applicable	1. Mortality. 2. HRQoL. 3. Complications.	
People exposed to hepatitis A	Post-exposure vaccines	Not applicable	1. Mortality. 2. HRQoL. 3. Complications.	
General population	Immunisation against Hepatitis A	No immunisation	1. Mortality. 2. HRQoL. 3. Complications.	
People exposed to hepatitis A	Post-exposure immunoglobulins	Not applicable	1. Mortality. 2. HRQoL. 3. Complications.	
People with biliary stent	Ursodeoxycholic acid to prevent stent occlusion	No intervention/other interventions	1. Mortality. 2. HRQoL. 3. Complications.	
People with acute hepatitis B	Pharmacological treatments	Not applicable	1. Mortality. 2. HRQoL. 3. Complications.	
Healthcare professionals	Hepatitis B vaccination	Not applicable	1. Mortality. 2. HRQoL. 3. Complications.	

Pregnant women with Hepatitis B	Immunoglobulins	No intervention/other interventions	1. Mortality. 2. HRQoL. 3. Complications.
Newborns of HBSAg (hepatitis B surface antigen) positive mothers	Immunisation	No intervention/other interventions	1. Mortality. 2. HRQoL. 3. Complications.
People with chronic hepatitis B	Medicinal herbs	No intervention/other interventions	1. Mortality. 2. HRQoL. 3. Complications.
Asymptomatic Hepatitis B carriers	Medicinal herbs	No intervention/other interventions	1. Mortality. 2. HRQoL. 3. Complications.
People with chronic hepatitis B	Acupuncture	No intervention/other interventions	1. Mortality. 2. HRQoL. 3. Complications.
People with acute hepatitis B	Medicinal herbs	No intervention/other interventions	1. Mortality. 2. HRQoL. 3. Complications.
General population	Hepatitis B vaccination	Not applicable	1. Mortality. 2. HRQoL. 3. Complications.
Pregnant women with Hepatitis B	Lamivudine	No intervention/other interventions	1. Mortality. 2. HRQoL. 3. Complications.

1 2 3 4 5 6 7 8 9	People with HIV infection	Hepatitis B vaccination	Not applicable	1. Mortality. 2. HRQoL. 3. Complications.
10 11 12 13 14 15 16	People who have received Hepatitis B vaccination	Booster dose	No booster dose	1. Mortality. 2. HRQoL. 3. Complications.
17 18 19 20 21 22 23	Pregnant women with Hepatitis B	Hepatitis B vaccination	No intervention/other interventions	1. Mortality. 2. HRQoL. 3. Complications.
24 25 26 27 28 29	People with renal failure	Hepatitis B vaccination	No intervention/other interventions	1. Mortality. 2. HRQoL. 3. Complications.
30 31 32 33 34 35 36	People with chronic hepatitis C and peripheral neuropathy	Treatments	Not applicable	1. Mortality. 2. HRQoL. 3. Complications.
37 38 39 40 41 42 43	People in haemodialysis units	Isolation to prevent Hepatitis C transmission	No isolation	1. Mortality. 2. HRQoL. 3. Complications.
44 45 46 47 48 49	People with acute hepatitis C	Pharmacological treatments	Not applicable	1. Mortality. 2. HRQoL. 3. Complications.
50 51 52 53 54 55 56 57 58 59 60	People with chronic hepatitis C and HIV	Antiviral treatment	Not applicable	1. Mortality. 2. HRQoL. 3. Complications.

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60	People with chronic hepatitis C	Medicinal herbs	No intervention/other interventions	1. Mortality. 2. HRQoL. 3. Complications.
	Pregnant women with Hepatitis B	Caesarean section	Vaginal delivery	1. Mortality. 2. HRQoL. 3. Complications.
	People with chronic hepatitis C with vasculitis	Treatments	Not applicable	1. Mortality. 2. HRQoL. 3. Complications.
	People with chronic hepatitis C	Staging of liver disease	Not applicable	1. Mortality. 2. HRQoL. 3. Complications.
	People with primary biliary cholangitis and osteoporosis	Biphosphonates	No intervention/other interventions	1. Mortality. 2. HRQoL. 3. Complications.
	People with primary biliary cholangitis and osteoporosis	Hormonal replacement therapy	No intervention/other interventions	1. Mortality. 2. HRQoL. 3. Complications.
	People with bleeding oesophageal varices	People with portosystemic shunt	No intervention/other interventions	1. Mortality. 2. HRQoL. 3. Complications.
	People with hepatorenal syndrome	Terlipressin	No intervention/other interventions	1. Mortality. 2. HRQoL. 3. Complications.

1 2 3 4 5 6 7 8 9	People with hepatorenal syndrome	Transjugular intrahepatic portosystemic shunts	No intervention/other interventions	1. Mortality. 2. HRQoL. 3. Complications.
10 11 12 13 14 15 16	People undergoing common bile duct exploration	T-tube	No T-tube	1. Mortality. 2. HRQoL. 3. Complications.
17 18 19 20 21 22 23	People with acute calculous cholecystitis (high risk)	Percutaneous cholecystostomy	No intervention/other interventions	1. Mortality. 2. HRQoL. 3. Complications.
24 25 26 27 28 29	People undergoing liver resection	Enhanced recovery protocols	Standard intervention	1. Mortality. 2. HRQoL. 3. Complications.
30 31 32 33 34 35 36	People undergoing liver transplantation	Perfusion techniques in donor	Not applicable	1. Mortality. 2. HRQoL. 3. Complications.
37 38 39 40 41 42 43	People with gallstones	Chinese herbs	Not applicable	1. Mortality. 2. HRQoL. 3. Complications.
44 45 46 47 48 49	Pregnant women with cholestasis	Interventions	Not applicable	1. Mortality. 2. HRQoL. 3. Complications.
50 51 52 53 54 55 56 57 58 59 60	New-borns and infants receiving parenteral nutrition and jaundice	Pharmacological interventions	Not applicable	1. Mortality. 2. HRQoL. 3. Complications.

1 2 3 4 5 6 7 8 9	New-borns and infants receiving parenteral nutrition and jaundice	Alternate interventions	Not applicable	1. Mortality. 2. HRQoL. 3. Complications.
10 11 12 13 14 15 16	People with sickle cell disease and intrahepatic cholestasis	Interventions	Not applicable	1. Mortality. 2. HRQoL. 3. Complications.
17 18 19 20 21 22	People with liver disease with upper gastrointestinal bleeding	Human recombinant activated factor VII	No intervention/other interventions	1. Mortality. 2. HRQoL. 3. Complications.
23 24 25 26 27 28 29	People with liver disease with upper gastrointestinal bleeding	Vitamin K	No intervention/other interventions	1. Mortality. 2. HRQoL. 3. Complications.
30 31 32 33 34 35 36	People with liver disease with upper gastrointestinal bleeding	Antifibrinolytic amino acids	No intervention/other interventions	1. Mortality. 2. HRQoL. 3. Complications.
37 38 39 40 41 42 43	People with liver disease	Antioxidant supplements	No intervention	1. Mortality. 2. HRQoL. 3. Complications.
44 45 46 47 48 49	People with liver disease	Vitamin D supplements	No intervention	1. Mortality. 2. HRQoL. 3. Complications.
50 51 52 53 54 55 56 57 58 59 60	People with liver disease	Lifestyle: Nutritional support	Not applicable	1. Mortality. 2. HRQoL. 3. Complications.

1 2 3 4 5 6 7 8 9 10 11	People with adverse events related to chemoarterial embolisation for primary liver cancer	Chinese herbs	Not applicable	1. Mortality. 2. HRQoL. 3. Complications.
12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27	People with uncomplicated hepatic hydatid cysts	Percutaneous needle aspiration, injection, and re-aspiration with benzimidazole	Percutaneous needle aspiration, injection, and re-aspiration without benzimidazole	1. Mortality. 2. HRQoL. 3. Complications.
28 29 30 31 32 33 34	People with gallbladder cancer	Chemotherapy	Not applicable	1. Mortality. 2. HRQoL. 3. Complications.
35 36 37 38 39 40	People with acute or acute-on-chronic liver failure	Granulocyte-colony stimulating factor	No intervention/other interventions	1. Mortality. 2. HRQoL. 3. Complications.
41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60	People with common bile duct stones	Early laparoscopic cholecystectomy following endoscopic sphincterotomy	Delayed laparoscopic cholecystectomy following endoscopic sphincterotomy	1. Mortality. 2. HRQoL. 3. Complications.

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60	People with gallstones and common-bile duct stones	Model of service delivery	Not applicable	1. Mortality. 2. HRQoL. 3. Complications.
People undergoing cholecystectomy	Routine intraoperative cholangiography	selective cholangiography	1. Mortality. 2. HRQoL. 3. Complications.	
People with gallstone pancreatitis	Early cholecystectomy	Delayed cholecystectomy	1. Mortality. 2. HRQoL. 3. Complications.	
People at risk of gallstones	Non-pharmacological interventions	Not applicable	1. Mortality. 2. HRQoL. 3. Complications.	
People with biliary obstruction due to cholangiocarcinoma	Endoscopic bipolar radiofrequency ablation	Other interventions	1. Mortality. 2. HRQoL. 3. Complications.	
People with colorectal liver metastases	Radiofrequency ablation	Other interventions	1. Mortality. 2. HRQoL. 3. Complications.	
People with suspected bile leak	Magnetic resonance cholangiopancreatography	Endoscopic retrograde cholangiopancreatography	1. Mortality. 2. HRQoL. 3. Complications.	
People with cholangitis	Antibiotics	Not applicable	1. Mortality. 2. HRQoL. 3. Complications.	

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60	People with suspected focal liver lesions	Imaging modalities to distinguish focal liver lesions	Not applicable	1. Mortality. 2. HRQoL. 3. Complications.
	People with liver cancer who have undergone surgery	Optimal follow-up regimen to detect early recurrence	Not applicable	1. Mortality. 2. HRQoL. 3. Complications.
	People undergoing laparoscopic cholecystectomy	Evidence-based pain relief protocol	Standard care	1. Mortality. 2. HRQoL. 3. Complications.
	People undergoing liver and bile duct resection	Evidence-based pain relief protocol	Standard care	1. Mortality. 2. HRQoL. 3. Complications.
	People with suspected gallbladder polyp	Imaging modalities to confirm diagnosis of gallbladder polyp	Not applicable	1. Mortality. 2. HRQoL. 3. Complications.
	People with gallbladder polyp	Imaging modalities to distinguish nature of gallbladder polyp	Not applicable	1. Mortality. 2. HRQoL. 3. Complications.
	People with suspected gallstones	Methods to confirm diagnosis of gallstone	Not applicable	1. Mortality. 2. HRQoL. 3. Complications.
	People with suspected acute cholecystitis	Methods to confirm diagnosis of acute cholecystitis	Not applicable	1. Mortality. 2. HRQoL. 3. Complications.

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60	People with suspected gallbladder dyskinesia	Methods to confirm gallbladder dyskinesia	Not applicable	1. Mortality. 2. HRQoL. 3. Complications.
	People with suspected Sphincter of Oddi dysfunction	Methods to confirm Sphincter of Oddi dysfunction	Not applicable	1. Mortality. 2. HRQoL. 3. Complications.
	People at risk of gallstones	Motivational interviewing for lifestyle changes	standard care	1. Mortality. 2. HRQoL. 3. Complications.
	People with gallstones	Motivational interviewing for lifestyle changes	standard care	1. Mortality. 2. HRQoL. 3. Complications.
	People at risk of NAFLD	Motivational interviewing for lifestyle changes	standard care	1. Mortality. 2. HRQoL. 3. Complications.
	People with NAFLD	Motivational interviewing for lifestyle changes	standard care	1. Mortality. 2. HRQoL. 3. Complications.
	People undergoing liver resection for liver cancer	Imaging modalities to confirm resectability	Not applicable	1. Mortality. 2. HRQoL. 3. Complications.
	People undergoing surgery for biliary tract cancer	Imaging modalities to confirm resectability	Not applicable	1. Mortality. 2. HRQoL. 3. Complications.

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60	People undergoing liver resection	Imaging modalities to confirm resectability	Not applicable	1. Mortality. 2. HRQoL. 3. Complications.
People undergoing liver transplantation for hepatocellular carcinoma	Imaging modalities to confirm that cancer is limited to liver	Not applicable	1. Mortality. 2. HRQoL. 3. Complications.	
People undergoing liver transplantation for hepatocellular carcinoma	Bridging ablative therapies	Standard care	1. Mortality. 2. HRQoL. 3. Complications.	
People undergoing liver transplantation for hepatocellular carcinoma	Goal-directed therapy	Standard care	1. Mortality. 2. HRQoL. 3. Complications.	
People with gallstones	Direct access surgery (without seeing a specialist)	Standard care	1. Mortality. 2. HRQoL. 3. Complications.	
People with benign liver and gallbladder conditions	Nurse-led care	Standard care	1. Mortality. 2. HRQoL. 3. Complications.	
People with sphincter of oddi dysfunction	Pharmacological interventions	Standard care	1. Mortality. 2. HRQoL. 3. Complications.	
People with sphincter of oddi dysfunction	Psychological counselling	Standard care	1. Mortality. 2. HRQoL. 3. Complications.	

1 2 3 4 5 6 7 8 9	People with biliary stricture	Different diagnostic tests	Not applicable	1. Mortality. 2. HRQoL. 3. Complications.
10 11 12 13 14 15 16	People with gallstones	Routine magnetic resonance cholangio pancreatography	Standard care	1. Mortality. 2. HRQoL. 3. Complications.
17 18 19 20 21 22 23 24 25 26 27	People with liver and gallbladder disorders	Methods to improve understanding of evidence	Not applicable	1. Improved knowledge. 2. Better involvement in decision making.
28 29 30 31 32 33 34	People undergoing liver transplantation	Routine fat-assessment in donor livers	Standard care	1. Mortality. 2. HRQoL. 3. Complications.
35 36 37 38 39 40	People with NAFLD and obesity	Routine anti-obesity surgery	Standard care	1. Mortality. 2. HRQoL. 3. Complications.
41 42 43 44 45 46 47 48 49	People with severe polycystic liver disease	Pharmacological interventions to improve functional volume	Standard care	1. Mortality. 2. HRQoL. 3. Complications.
50 51 52 53 54 55 56 57 58 59 60	People with liver disease	Interventions to achieve palliation	Not applicable	1. Palliation.

1 2 3 4 5 6 7 8 9	People with liver disease	Interventions to achieve symptom control	Not applicable	Symptom control
10 11 12 13	People with liver disease	Interventions to improve quality of life	Not applicable	Quality of life
14 15 16 17 18 19 20 21 22	Healthcare professionals dealing with people with primary sclerosing cholangitis	Education of healthcare professionals about liver disease	Standard care	1. Early recognition. 2. Appropriate treatment.
23 24 25 26 27 28 29	People with Crohn's disease	Methods for screening for primary sclerosing cholangitis	Not applicable	Diagnosis of primary sclerosing cholangitis
30 31 32 33 34	People with NAFLD	Patient education	Standard care	1. Greater knowledge.
35 36 37 38 39 40 41 42 43	Healthcare professionals dealing with people with polycystic liver disease	Education of healthcare professionals about liver disease	Standard care	1. Early recognition. 2. Appropriate treatment.
44 45 46 47 48 49 50 51 52	People with polycystic liver disease	Early liver transplantation	Standard care	1. Quality of life. 2. Reducing symptoms. 3. Reducing pain.
53 54 55 56 57 58 59 60	People with autoimmune hepatitis	Interventions that affect T cells	No intervention	1. Cure. 2. Improve quality of life

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60	People at risk of liver disease	Screening	Not applicable	Early diagnosis and treatment
	People with polycystic liver disease	Monitoring polycystic liver disease	Not applicable	
	People with polycystic kidney disease	Diagnosis polycystic liver disease	Not applicable	
	People with liver disease	Methods to improve early appropriate treatment	Not applicable	Early diagnosis and treatment
	People with polycystic kidney disease	Methods to prevent symptomatic polycystic liver disease	Not applicable	1. Quality of life. 2. Liver function.
	People undergoing liver transplantation	Various treatments	Not applicable	1. Survival 2. Complications 3. QoL 4. Hospital stay 5. Return to work 6. Improvement of symptoms
	People with polycystic liver disease	Diet (specifically soy proteins which contain oestrogen	Standard diet	1. Decrease size of cyst or preventing cysts to enlarge. 2. Decrease symptoms

1 2 3 4 5 6 7 8 9 10 11	People with NAFLD	Various treatments	Not applicable	1. Impact on health (no further details) 2. Progression to liver failure
12 13 14 15 16	People with suspected NAFLD	Diagnosis	Not applicable	1. Early diagnosis
17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34	People with gallstones	Various treatments	Not applicable	1. Impact on health (no further details)
35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60	People with polycystic liver disease	Genetic treatments	Standard therapy	1. Reduce symptoms. 2. Decrease occurrence and size of cysts. 3. Increased longevity
	Healthcare professionals dealing with people with primary biliary cholangitis	Education of healthcare professionals about liver disease	Standard care	1. Early recognition. 2. Appropriate treatment.
	People undergoing treatment for ulcerative colitis	Various treatments	Not applicable	1. Adverse events related to liver
	People with cholangiocarcinoma	Liver transplantation	Standard therapy	1. Survival 2. Complications 3. QoL

			4. Hospital stay 5. Return to work
People undergoing liver transplantation	Machine perfusion of donor organ	Cold storage	1. Survival 2. Complications 3. QoL 4. Hospital stay 5. Return to work
People with liver cancer	Novel treatments (irreversible electroporation, high intensity focused ultrasound)		1. Survival 2. Complications 3. QoL 4. Hospital stay 5. Return to work
People with hepatocellular carcinoma	Liver resection	Liver transplantation	1. Survival 2. Complications 3. QoL 4. Hospital stay 5. Return to work
People with colorectal liver metastases	Ablation	Surgery	1. Survival 2. Complications 3. QoL 4. Hospital stay 5. Return to work
People with liver disease undergoing surgery	Ischaemic preconditioning	No IPC	1. Survival 2. Complications 3. QoL

			4. Hospital stay 5. Return to work
People with liver disease undergoing surgery	Remote ischaemic preconditioning	No RIPC	1. Survival 2. Complications 3. QoL 4. Hospital stay 5. Return to work
People with liver disease undergoing surgery	Goal-directed therapy	standard fluid treatment	1. Survival 2. Complications 3. QoL 4. Hospital stay 5. Return to work
People with compensated liver cirrhosis	Treatments (in particular statins)	Other interventions	1. Decompensation 2. Survival 3. Side effects 4. Quality of life.
People with chronic liver disease/ liver failure	Stem cell therapy	Standard therapy	1. Graft and patient survival 2. QoL. 3. Morbidity compared to conventional transplantation 4. Patient reported outcomes

People with Wilson's disease (and other rare non-alcohol liver related diseases)	Various treatments	Not applicable	Not stated
People with suspected autoimmune hepatitis	Diagnosis of autoimmune diseases	Not applicable	1. Costs of management

Appendix 2 List of unanswered research questions ('uncertainties') prioritised during the interim prioritisation

1. What are the best treatments that cure or delay the progression (worsening) of primary sclerosing cholangitis (PSC)?
2. Should all people above 40 years of age or those considered to be at risk of liver disease (because of family history of liver disease or because of their lifestyle) be tested for the presence of liver disease to identify liver diseases at an early stage?
3. Should people with primary sclerosing cholangitis (PSC) undergo screening (tested routinely) for cancer?
4. Are there any treatments that reverse the liver damage in primary sclerosing cholangitis (PSC)?
5. What are the best treatments that cure or delay the progression (worsening) of non-alcohol-related fatty liver disease (NAFLD)?
6. What are the best symptomatic treatments for itching in people with primary sclerosing cholangitis (PSC)?
7. Are there alternatives to invasive assessment of oesophageal varices in people with chronic liver disease?

- 1
- 2
- 3 8. Does vitamin D supplementation (adding Vitamin D in food or providing it in tablet form)
- 4
- 5 increase the lifespan, health-related quality of life, and decrease complications in people
- 6
- 7 with liver disease?
- 8
- 9
- 10 9. Should new methods to improve the understanding of evidence be developed for people
- 11
- 12 with liver and gallbladder diseases?
- 13
- 14 10. What is the best treatment for people with early or very early hepatocellular carcinoma
- 15
- 16 (HCC)?
- 17
- 18 11. Should the methods used to assess nutrition of patients in liver disease be standardised?
- 19
- 20 12. Does dieting improve liver function and decrease the requirement for liver transplantation in
- 21
- 22 obese people?
- 23
- 24 13. Should general public be educated about non-alcohol-related fatty liver disease (NAFLD)
- 25
- 26 with an aim to reduce the numbers of those that have it?
- 27
- 28 14. What are the best symptomatic treatments for itching in people with chronic liver diseases
- 29
- 30 other than primary sclerosing cholangitis (PSC) and primary biliary cholangitis (PBC)?
- 31
- 32 15. Do treatments targeted against deformation of bile duct (biliary stricture or narrowing of
- 33
- 34 bile duct due to the illness) work better than other treatments in people with primary
- 35
- 36 sclerosing cholangitis (PSC)?
- 37
- 38 16. What are the treatments available to decrease weight in overweight people with non-
- 39
- 40 alcohol-related fatty liver disease (NAFLD)?
- 41
- 42 17. What are the best treatments that cure or delay the progression (worsening) of non-alcohol
- 43
- 44 related steatohepatitis (NASH)?
- 45
- 46 18. Do statins (or other treatments) delay liver failure in people with advanced liver disease?
- 47
- 48 19. What are the best treatments that provide temporary symptom relief in people with
- 49
- 50 advanced liver disease?
- 51
- 52 20. Which is the most suitable antibiotic (or combination of antibiotics) in people with
- 53
- 54 cholangitis (biliary infection)?
- 55
- 56
- 57
- 58
- 59
- 60

- 1
2
3 21. What are the best treatments that cure or delay the progression (worsening) of autoimmune
4 hepatitis (AIH)?
5
6
- 7
8 22. Are there any methods other than liver biopsy (obtaining a piece of liver, usually using a
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
23. What are the best nutritional interventions in people undergoing liver transplantation?
24. What are the best symptomatic treatments for fatigue (tiredness), joint pain, and other
symptoms in people with people with autoimmune hepatitis (AIH)?
25. Prior to liver transplantation, is it better to transport the donor liver using a machine which
pumps blood or preservation solution through the liver (machine perfusion) or is it better to
transport it in the standard way of transporting it immersed in cold preservation solution
(cold storage)?
26. What are the best treatments that cure or delay the progression (worsening) of chronic
hepatitis C virus (HCV) infection?
27. Does education of people with liver disease about the natural course and treatment of liver
disease improve the patient knowledge, patient responsibility, and decrease hospital visits?
28. What are the best treatments that cure or delay the progression (worsening) of primary
biliary cholangitis (PBC)?
29. Is nurse-led care as effective or better than doctor-led care for non-alcohol related fatty liver
disease (NAFLD)?
30. Is treatment targeted against deformation of bile duct (biliary stricture or narrowing of bile
duct due to cancer) better than standard treatment for people with bile duct cancer?
31. Is surgery (in the form of removal of gallbladder) required in people with gallstones?
32. Should people with non-alcohol-related fatty liver disease (NAFLD) and non-alcohol-related
steatohepatitis (NASH) receive additional education about the condition?
33. What is the best immunosuppressive regimen in adults undergoing liver transplantation?

- 1
 - 2
 - 3
 - 4
 - 5
 - 6
 - 7
 - 8
 - 9
 - 10
 - 11
 - 12
 - 13
 - 14
 - 15
 - 16
 - 17
 - 18
 - 19
 - 20
 - 21
 - 22
 - 23
 - 24
 - 25
 - 26
 - 27
 - 28
 - 29
 - 30
 - 31
 - 32
 - 33
 - 34
 - 35
 - 36
 - 37
 - 38
 - 39
 - 40
 - 41
 - 42
 - 43
 - 44
 - 45
 - 46
 - 47
 - 48
 - 49
 - 50
 - 51
 - 52
 - 53
 - 54
 - 55
 - 56
 - 57
 - 58
 - 59
 - 60
34. Is endoscopic ultrasound (EUS) (using a ultrasound attached to the end of an endoscope) or magnetic resonance cholangiopancreatography (MRCP, a form of MRI scan) better in the diagnosis of common bile duct (CBD) stones?
35. How can we improve compliance to treatment (adherence to treatment or the degree to which a patient correctly follows medical advice) in people with liver disease?
36. What are the best symptomatic treatments for relief of ulcerative colitis (UC) in people with primary sclerosing cholangitis (PSC) who have undergone liver transplantation?
37. What are the best symptomatic treatments for itching and fatigue (tiredness) in people with primary biliary cholangitis (PBC)?
38. Does education of people with asymptomatic (absence of symptoms) liver disease result in change of life style and cure/delay the progression (worsening) of liver disease?
39. What are the best treatments that are available for the treatment of pregnant women with cholestasis (condition where bile flow from the liver is obstructed)?
40. Is transarterial chemoembolisation (TACE) or transarterial embolisation (TAE) (blocking the blood supply to cancer with or without chemotherapy drugs) effective in the treatment of people with liver metastases?
41. Should people with liver metastases (cancer spread to the liver) from neuroendocrine cancer (a form of cancer that arises from cells that secrete hormones and nervous system) undergo liver resection?
42. What are the best methods available to decrease blood loss during liver resection?
43. What are the best treatments that cure or delay the progression (worsening) of chronic hepatitis B virus (HBV) infection?
44. What are the best treatments for people with polycystic liver disease?
45. Should the healthcare professionals dealing with childhood liver diseases be provided additional education about childhood liver diseases compared to standard education where childhood diseases are learnt as part of overall education?

- 1
2
3 46. What is the best immunosuppressive regimen in children undergoing liver transplantation?
4
5
6 47. Should blood vessels supplying the liver be temporarily blocked in people undergoing liver
7
8 resection? If so, what is the best way of performing this?
9
10 48. What is the best treatment that should be given to people who undergo liver transplantation
11
12 for chronic hepatitis B virus (HBV) infection to prevent reinfection with chronic hepatitis B
13
14 virus (HBV) infection?
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Appendix 3 Next step to address the top 10 uncertainty based on current best evidence (detailed)

Treatment uncertainty (Research question)	High-quality systematic review ^a	Research recommendations of systematic review	RCTs not included in the systematic review ^{a,b,c}	Patient-oriented outcomes assessed in trials not included in the systematic review ^d	Next step
What is the best treatment for people with early or very early hepatocellular carcinoma (HCC)?	[1]	High-quality RCTs designed to assess clinically important differences in all-cause mortality and health-related quality of life, and having an adequate follow-up period (approximately five years) are needed.	NCT02169765 NCT02704130 NCT02728193 NCT02243384 NCT00844454 NCT01918683 NCT01570075 NCT01351194	Survival (7 trials), recurrence (5 trials), morbidity (3 trials)	High-quality RCTs of interventions not covered in ongoing trials and comparison of health-related quality (HRQoL) in different treatments

<p>1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29</p> <p>What are the best treatments that cure or delay the progression (worsening) of primary sclerosing cholangitis (PSC)?</p>	<p>[2]</p>	<p>An urgent need exists to identify an effective medical treatment for primary sclerosing cholangitis through well-designed RCTs with adequate follow-up that aim to identify differences in outcomes important to people with primary sclerosing cholangitis.</p>	<p>NCT03394781 NCT02605213 NCT02943460 NCT02704364 NCT01688024 NCT02177136 NCT01672853 NCT03035058 NCT03333928</p>	<p>None of the trials include survival, HRQoL as outcomes^e</p>	<p>High-quality RCTs with clinical outcomes</p>
<p>30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46</p> <p>What are the best treatments that cure or delay the progression (worsening) of non-</p>	<p>[3] (includes only pharmacological interventions)</p>	<p>Further well-designed randomised clinical trials with sufficiently</p>	<p>More than 10 published trials on lifestyle interventions and more than 20 trials</p>	<p>Lifestyle interventions and nutritional supplementation</p>	<p>High-quality systematic reviews on lifestyle interventions (one review) and nutritional</p>

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

<p>alcohol-related fatty liver disease (NAFLD)?</p>		<p>large sample sizes are necessary.</p>	<p>on nutritional supplementation with no recent high-quality systematic reviews <u>Pharmacological interventions</u> NCT02605616 NCT01002547 NCT02927314 NCT03291249 NCT03166735 NCT03486899 NCT03061721 NCT02784444 NCT02077374 NCT03486912</p>	<p>Not applicable as there are no high quality systematic reviews <u>Pharmacological interventions</u> Health-related quality of life (2 trials), resolution of fatty liver disease (11 trials), mortality (2 trials), cirrhosis (2 trials), cardiovascular events (2 trials)^e</p>	<p>supplementation to cure or delay the progression of NAFLD and high-quality RCTs on pharmacological interventions with clinical outcomes</p>
---	--	--	---	---	--

			NCT02854605		
			NCT01963845		
			NCT03437720		
			NCT02684591		
			NCT02787304		
			NCT02466516		
			NCT02633956		
			NCT03008070		
			NCT03205150		
			NCT02923154		
			NCT02913105		
			NCT01899859		
			NCT02548351		
			NCT03053063		
			NCT03053050		
			NCT02413372		

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

			NCT02443116		
			NCT01464801		
			NCT03449446		
			NCT02912260		
			NCT02856555		
			NCT02704403		
			NCT01617772		
			NCT02217475		
			NCT01406704		
			NCT03248882		
			NCT01051219		
			NCT02316717		
			NCT02970942		
			NCT03439254		
			NCT02574325		
			NCT01703260		

			NCT01260246		
			NCT02960204		
<p>1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46</p> <p>What is the best immunosuppressive regimen in adults undergoing liver transplantation?</p>	<p>[4] (covers only maintenance immunosuppression)</p>	<p>Future randomised clinical trials should be adequately powered; performed in people who are generally seen in the clinic rather than in highly selected participants; employ blinding; avoid postrandomisation dropouts or planned cross-overs; and use clinically important outcomes such as</p>	<p><u>Induction immunosuppression</u></p> <p>More than 20 published trials</p> <p><u>Maintenance immunosuppression</u></p> <p>NCT01998789</p> <p>NCT01230502</p> <p>NCT02909335</p> <p>NCT00286871</p>	<p><u>Induction immunosuppression</u></p> <p>Not applicable as there is no high quality systematic review</p> <p><u>Maintenance immunosuppression</u></p> <p>Graft survival (1 trial)</p> <p>Adverse events (1 trial)</p> <p>Hepatocellular carcinoma (1 trial)^e</p>	<p>High-quality systematic review on induction immunosuppressive regimen and high-quality RCTs on maintenance immunosuppression with important clinical outcomes</p>

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

		<p>mortality, graft loss, renal impairment, chronic kidney disease, and retransplantation.</p> <p>Such trials should use tacrolimus as one of the control groups.</p> <p>Moreover, such trials ought to be designed in such a way as to ensure low risk of bias and low risks of random errors.</p>			
Should general public be educated about non-alcohol-related	None	-	None	-	High-quality RCTs on education to prevent NAFLD

<p>fatty liver disease (NAFLD) with an aim to reduce the numbers of those that have it?</p>					
<p>What are the best treatments that cure or delay the progression (worsening) of autoimmune hepatitis (AIH)?</p>	None	-	<p>[5-7]</p> <p>NCT02050646</p> <p>NCT02463331</p> <p>NCT00608894</p> <p>NCT02900443</p> <p>NCT02239562</p> <p>NCT01170351</p> <p>NCT03217422</p> <p>NCT01661842</p> <p>NCT00687180</p> <p>NCT01980745</p> <p>NCT02878863</p>	<p>Survival (1 trial), health-related quality of life (1 trial)^e</p>	<p>High quality RCTs with clinical outcomes</p>

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

			NCT02936596		
What are the best treatments that cure or delay the progression (worsening) of non-alcohol related steatohepatitis (NASH)?	The evidence related to this question is covered under non-alcohol related fatty liver disease by performing a subgroup analysis of people with NASH				
Prior to liver transplantation, is it better to transport the donor liver using a machine which pumps blood or preservation solution through the liver (machine	None	-	NCT02775162 NCT03124641 NCT02940600 NCT02584283 NCT01317342	Overall survival (4 trials), graft survival (5 trials), health-related quality of life (2 trials)	Await results of the RCTs (all expected to complete by the end of 2019) and perform a high quality systematic review.

<p>perfusion) or is it better to transport it in the standard way of transporting it immersed in cold preservation solution (cold storage)?</p>					
<p>What are the best treatments that cure or delay the progression (worsening) of primary biliary cholangitis (PBC)?</p>	<p>[8]</p>	<p>Further well-designed randomised clinical trials are necessary. Future randomised clinical trials ought to be adequately powered; performed in people who are generally seen in the</p>	<p>NCT02937012 NCT01473524 NCT02823353 NCT02135536 NCT01614405 NCT02609048 NCT00746486 NCT02955602 NCT03226067</p>	<p>Health-related quality of life (5 trials), relief of symptoms (5 trials)^e</p>	<p>High-quality RCTs with clinical outcomes</p>

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

		clinic rather than in	NCT03112681		
		highly selected	NCT01904058		
		participants; employ	NCT02943447		
		blinding; avoid post-	NCT03124108		
		randomisation	NCT03345589		
		dropouts or planned	NCT03092765		
		cross-overs; should	NCT03394924		
		have sufficient follow-	NCT02516605		
		up period (e.g. five or	NCT03253276		
		10 years or more); and	NCT02965911		
		use clinically important	NCT01899703		
		outcomes such as	NCT01654731		
		mortality, health-	NCT02308111		
		related quality of life,	NCT00125281		
		cirrhosis,	NCT02701166		
		decompensated			

		<p>cirrhosis, and liver transplantation.</p> <p>Alternatively, very large groups of participants should be randomised to facilitate shorter trial duration.</p>			
<p>Are there any treatments that reverse the liver damage in primary sclerosing cholangitis (PSC)?</p>	<p>The evidence related to this question is covered under treatments for primary sclerosing cholangitis. The systematic review did not include fibrosis as one of the outcomes. Nine of the trials included in the systematic review reported on fibrosis. Two of the trials not included in the systematic review (and listed above) reported on liver fibrosis.</p>				

a Numbers indicate the reference number.

b Ongoing trials, unpublished trials, or trials published since the search date for the systematic review when a high-quality systematic review based on randomised controlled trials exists. If no systematic reviews based on randomised controlled trials exist, these are either published trials or ongoing studies.

c NCT followed by a number indicates trial registration number

d This information is reported to find out whether the important patient-oriented outcomes are reported in the trials not covered by high-quality systematic reviews. This is to help with deciding whether new randomised controlled trials are necessary on the topic.

e The remaining trials reported treatment-related adverse events, composite outcomes and surrogate markers.

Appendix 4 Scores obtained by each question in the different Delphi rounds

Questions ^a	Delphi 1: Proportion who rated this question as highly important	Delphi 1: Median (IQR)	Delphi 2: Proportion who rated this question as highly important	Delphi 2: Median (IQR)	Delphi 3: Proportion who rated this question as highly important	Delphi 3: Median (IQR)	Consensus reached in Delphi 3? ^b
------------------------	---	------------------------------	---	------------------------------	---	------------------------------	---

1.What are the best treatments that cure or delay the progression (worsening) of primary sclerosing cholangitis (PSC)?	All: 78.8% HCP: 80.0% PCP: 76.9%	All: 8(7,9) HCP: 8.5(7,9) PCP: 8(6.5,9)	All: 83.9% HCP: 83.3% PCP: 84.6%	All: 8(7,9) HCP: 8(7,9) PCP: 8(7,9)	All: 93.3% HCP: 94.1% PCP: 92.3%	All: 8(7,9) HCP: 8(7,9) PCP: 8(7,9)	Yes
2.Should all people above 40 years of age or those considered to be at risk of liver disease (because of family history of liver disease or because of their lifestyle) be tested for the presence of liver disease to identify liver diseases at an early stage?	All: 44.4% HCP: 40.0% PCP: 50.0%	All: 6(5,7) HCP: 6(5,7) PCP: 6(4,7.75)	All: 35.3% HCP: 27.8% PCP: 43.8%	All: 6(5,7) HCP: 6(5,7) PCP: 6(5,7.75)	All: 33.3% HCP: 29.4% PCP: 37.5%	All: 6(5,7) HCP: 6(5,7) PCP: 6(5,7.75)	No
3.Should people with primary sclerosing cholangitis (PSC) undergo screening (tested routinely) for cancer?	All: 46.9% HCP: 40.0% PCP: 58.3%	All: 6(5,9) HCP: 6(5,9) PCP: 6(5,9)	All: 50.0% HCP: 38.9% PCP: 66.7%	All: 6.5(5.75,8) HCP: 6(5.75,7.25) PCP: 6.5(5.25,9)	All: 44.8% HCP: 35.3% PCP: 58.3%	All: 6(6,7.5) HCP: 6(5.5,7) PCP: 6(6,9)	No

4.Are there any treatments that reverse the liver damage in primary sclerosing cholangitis (PSC)?	All: 59.4% HCP: 55.0% PCP: 66.7%	All: 7.5(5,8.75) HCP: 7.5(4.25,8) PCP: 7.5(6,9)	All: 70.0% HCP: 61.1% PCP: 83.3%	All: 7.5(6,9) HCP: 7.5(4.75,8.25) PCP: 7.5(7,9)	All: 72.4% HCP: 64.7% PCP: 83.3%	All: 7(6,9) HCP: 7(5,8) PCP: 7(7,9)	No
5.What are the best treatments that cure or delay the progression (worsening) of non-alcohol-related fatty liver disease (NAFLD)?	All: 76.5% HCP: 75.0% PCP: 78.6%	All: 8(6.75,9) HCP: 8.5(6.25,9) PCP: 8(6.75,9)	All: 87.5% HCP: 83.3% PCP: 92.9%	All: 8.5(7,9) HCP: 8.5(7,9) PCP: 8.5(7,9)	All: 90.3% HCP: 88.2% PCP: 92.9%	All: 9(8,9) HCP: 9(7.5,9) PCP: 9(7.75,9)	Yes
6.What are the best symptomatic treatments for itching in people with primary sclerosing cholangitis (PSC)?	All: 48.5% HCP: 45.0% PCP: 53.8%	All: 6(5,7.5) HCP: 6(5,7) PCP: 6(5.5,8)	All: 48.4% HCP: 38.9% PCP: 61.5%	All: 6(5,7) HCP: 6(4.75,7) PCP: 6(6,8)	All: 50.0% HCP: 41.2% PCP: 61.5%	All: 6.5(5,7) HCP: 6(4.5,7) PCP: 6.5(6,8)	No

7.Are there alternatives to invasive assessment of oesophageal varices in people with chronic liver disease?	All: 48.6% HCP: 30.0% PCP: 73.3%	All: 6(5,8) HCP: 6(3,7) PCP: 6(6,9)	All: 54.5% HCP: 33.3% PCP: 80.0%	All: 7(5.5,8) HCP: 6(4,7) PCP: 7(7,9)	All: 56.3% HCP: 29.4% PCP: 86.7%	All: 7(6,8) HCP: 6(4,7) PCP: 7(7,9)	No
8.Does vitamin D supplementation (adding Vitamin D in food or providing it in tablet form) increase the lifespan, health-related quality of life, and decrease complications in people with liver disease?	All: 37.1% HCP: 21.1% PCP: 56.3%	All: 6(4,7) HCP: 4(4,6) PCP: 6(6,9)	All: 39.4% HCP: 23.5% PCP: 56.3%	All: 6(4,7) HCP: 5(4,6.5) PCP: 6(6,9)	All: 37.5% HCP: 18.8% PCP: 56.3%	All: 6(4.25,7.75) HCP: 5(4,6) PCP: 6(6,8.75)	No
9.Should new methods to improve the understanding of evidence be developed for people with liver and gallbladder diseases?	All: 38.2% HCP: 25.0% PCP: 57.1%	All: 6(4,8) HCP: 5(4,6.75) PCP: 6(5,9)	All: 46.9% HCP: 27.8% PCP: 71.4%	All: 6(4,8) HCP: 5(4,7) PCP: 6(5,9)	All: 48.4% HCP: 29.4% PCP: 71.4%	All: 6(5,8) HCP: 6(4.5,7) PCP: 6(5,9)	No
10.What is the best treatment for people with early or very early hepatocellular carcinoma (HCC)?	All: 76.5% HCP: 75.0% PCP: 78.6%	All: 8(6.75,9) HCP: 7(6.25,9)	All: 87.5% HCP: 88.9% PCP: 85.7%	All: 8(7,9) HCP: 8(7,9) PCP: 8(7,9)	All: 93.5% HCP: 94.1% PCP: 92.9%	All: 8(7,9) HCP: 8(7,9)	Yes

		PCP: 8(6.75,9)				PCP: 8(7.75,9)	
11.Should the methods used to assess nutrition of patients in liver disease be standardised?	All: 57.1% HCP: 60.0% PCP: 53.3%	All: 7(5,9) HCP: 7(5,8.75) PCP: 7(5,9)	All: 54.5% HCP: 55.6% PCP: 53.3%	All: 7(5,8) HCP: 7(5,8) PCP: 7(5,9)	All: 59.4% HCP: 58.8% PCP: 60.0%	All: 7(5,8) HCP: 7(5,8) PCP: 7(5,8)	No
12.Does dieting improve liver function and decrease the requirement for liver transplantation in obese people?	All: 48.6% HCP: 38.1% PCP: 62.5%	All: 6(4,8) HCP: 6(3,8) PCP: 6(5.25,7)	All: 44.1% HCP: 27.8% PCP: 62.5%	All: 6(4,7.25) HCP: 6(3.75,7.25) PCP: 6(5.25,7.75)	All: 48.5% HCP: 29.4% PCP: 68.8%	All: 6(5,7) HCP: 6(5,7) PCP: 6(5.25,7)	No
13.Should general public be educated about non-alcohol-related fatty liver disease (NAFLD) with an aim to reduce the numbers of those that have it?	All: 72.2% HCP: 75.0% PCP: 68.8%	All: 7.5(6,9) HCP: 8(6.25,9) PCP: 7.5(6,9)	All: 73.5% HCP: 72.2% PCP: 75.0%	All: 8(6,9) HCP: 7.5(5.75,9) PCP: 8(6.25,9)	All: 81.8% HCP: 82.4% PCP: 81.3%	All: 8(7,9) HCP: 8(7,9) PCP: 8(7,9)	Yes

14. What are the best symptomatic treatments for itching in people with chronic liver diseases other than primary sclerosing cholangitis (PSC) and primary biliary cholangitis (PBC)?	All: 48.5% HCP: 35.0% PCP: 69.2%	All: 6(4.5,7) HCP: 6(4,7) PCP: 6(5,7.5)	All: 48.4% HCP: 27.8% PCP: 76.9%	All: 6(5,7) HCP: 6(4,7) PCP: 6(6,8)	All: 50.0% HCP: 29.4% PCP: 76.9%	All: 6.5(5,7) HCP: 6(4.5,7) PCP: 6.5(6.5,8)	No
15. Do treatments targeted against deformation of bile duct (biliary stricture or narrowing of bile duct due to the illness) work better than other treatments in people with primary sclerosing cholangitis (PSC)?	All: 19.4% HCP: 21.1% PCP: 16.7%	All: 5(4,6) HCP: 5(4,6) PCP: 5(4,6)	All: 20.0% HCP: 16.7% PCP: 25.0%	All: 5(4,6) HCP: 5(3.75,6) PCP: 5(4,6.75)	All: 20.7% HCP: 17.6% PCP: 25.0%	All: 5(4,6) HCP: 5(3.5,6) PCP: 5(4,6.75)	No
16. What are the treatments available to decrease weight in overweight people with non-alcohol-related fatty liver disease (NAFLD)?	All: 37.1% HCP: 35.0% PCP: 40.0%	All: 5(4,8) HCP: 5.5(4,7) PCP: 5(4,8)	All: 27.3% HCP: 22.2% PCP: 33.3%	All: 6(4,7) HCP: 6(4,6.25) PCP: 6(3,8)	All: 28.1% HCP: 23.5% PCP: 33.3%	All: 5(4,7) HCP: 5(5,6.5) PCP: 5(3,7)	No

17. What are the best treatments that cure or delay the progression (worsening) of non-alcohol related steatohepatitis (NASH)?	All: 67.6% HCP: 71.4% PCP: 61.5%	All: 8(5,8.25) HCP: 8(5.5,9) PCP: 8(5,8)	All: 71.0% HCP: 77.8% PCP: 61.5%	All: 8(6,9) HCP: 7.5(6.75,9) PCP: 8(5,8.5)	All: 76.7% HCP: 82.4% PCP: 69.2%	All: 8(6.75,9) HCP: 8(7,9) PCP: 8(5,8.5)	No
18. Do statins (or other treatments) delay liver failure in people with advanced liver disease?	All: 45.7% HCP: 36.8% PCP: 56.3%	All: 6(5,7) HCP: 6(4,7) PCP: 6(6,7.75)	All: 39.4% HCP: 35.3% PCP: 43.8%	All: 6(6,7) HCP: 6(3.5,7) PCP: 6(6,7.75)	All: 43.8% HCP: 37.5% PCP: 50.0%	All: 6(6,7) HCP: 6(5.25,7) PCP: 6(6,7.75)	No
19. What are the best treatments that provide temporary symptom relief in people with advanced liver disease?	All: 50.0% HCP: 35.0% PCP: 68.8%	All: 6.5(5,7.75) HCP: 6(5,7) PCP: 6.5(5.25,8.75))	All: 52.9% HCP: 33.3% PCP: 75.0%	All: 7(5.75,7.25) HCP: 6(5,7) PCP: 7(6.25,8)	All: 54.5% HCP: 35.3% PCP: 75.0%	All: 7(6,7) HCP: 6(5,7) PCP: 7(6.25,8)	No

20. Which is the most suitable antibiotic (or combination of antibiotics) in people with cholangitis (biliary infection)?	All: 64.7% HCP: 70.0% PCP: 57.1%	All: 7(5,8) HCP: 7(6,8) PCP: 7(5,8)	All: 68.8% HCP: 72.2% PCP: 64.3%	All: 7(5.25,8) HCP: 7(6,8) PCP: 7(5,8)	All: 67.7% HCP: 70.6% PCP: 64.3%	All: 7(5,8) HCP: 7(6,8) PCP: 7(5,8)	No
21. What are the best treatments that cure or delay the progression (worsening) of autoimmune hepatitis (AIH)?	All: 75.8% HCP: 68.4% PCP: 85.7%	All: 7(6.5,9) HCP: 7(6,8) PCP: 7(7,9)	All: 81.3% HCP: 77.8% PCP: 85.7%	All: 7.5(7,9) HCP: 7(6.75,8) PCP: 7.5(7,9)	All: 80.6% HCP: 76.5% PCP: 85.7%	All: 8(7,9) HCP: 7(6.5,8) PCP: 8(7,9)	Yes
22. Are there any methods other than liver biopsy (obtaining a piece of liver, usually using a needle, for examination under microscope) for the early diagnosis of primary sclerosing cholangitis (PSC) in people at risk of developing PSC?	All: 53.1% HCP: 36.8% PCP: 76.9%	All: 7(5,8) HCP: 6(5,7) PCP: 7(6.5,8)	All: 60.0% HCP: 47.1% PCP: 76.9%	All: 7(5,8) HCP: 6(5,8) PCP: 7(6.5,8)	All: 58.6% HCP: 43.8% PCP: 76.9%	All: 7(5,8) HCP: 6(5,7.75) PCP: 7(6.5,8)	No
23. What are the best nutritional interventions in people undergoing liver transplantation?	All: 52.8% HCP: 42.9% PCP: 66.7%	All: 7(5,8) HCP: 6(4,8) PCP: 7(5,8)	All: 51.5% HCP: 38.9% PCP: 66.7%	All: 7(5,8) HCP:	All: 53.1% HCP: 41.2% PCP: 66.7%	All: 7(5,8) HCP: 6(5,7) PCP: 7(6,8)	No

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

				6(4,7.25) PCP: 7(5,8)			
24.What are the best symptomatic treatments for fatigue (tiredness), joint pain, and other symptoms in people with people with autoimmune hepatitis (AIH)?	All: 61.8% HCP: 45.0% PCP: 85.7%	All: 7(6,8) HCP: 6(3.25,7) PCP: 7(7,9)	All: 65.6% HCP: 50.0% PCP: 85.7%	All: 7(6,8) HCP: 6.5(3.75,7) PCP: 7(7,9)	All: 64.5% HCP: 47.1% PCP: 85.7%	All: 7(6,8) HCP: 6(4,7) PCP: 7(7,9)	No
25.Prior to liver transplantation, is it better to transport the donor liver using a machine which pumps blood or preservation solution through the liver (machine perfusion) or is it better to transport it in the standard way of transporting it immersed in cold preservation solution (cold storage)?	All: 54.5% HCP: 42.1% PCP: 71.4%	All: 7(5,9) HCP: 6(5,8) PCP: 7(6,9)	All: 68.8% HCP: 61.1% PCP: 78.6%	All: 7(6,8.75) HCP: 7(5,8) PCP: 7(6.75,9)	All: 74.2% HCP: 70.6% PCP: 78.6%	All: 7(6,9) HCP: 7(6,8) PCP: 7(6.75,9)	No

26. What are the best treatments that cure or delay the progression (worsening) of chronic hepatitis C virus (HCV) infection?	All: 42.4% HCP: 42.9% PCP: 41.7%	All: 6(2,8) HCP: 5(1,8) PCP: 6(4.25,7.75)	All: 40.0% HCP: 44.4% PCP: 33.3%	All: 5.5(2,7) HCP: 4.5(1,8) PCP: 5.5(4.25,7)	All: 37.9% HCP: 47.1% PCP: 25.0%	All: 5(2,7) HCP: 5(1,8) PCP: 5(4.25,6.75)	No
27. Does education of people with liver disease about the natural course and treatment of liver disease improve the patient knowledge, patient responsibility, and decrease hospital visits?	All: 51.4% HCP: 52.4% PCP: 50.0%	All: 7(4,8) HCP: 7(4.5,7.5) PCP: 7(3.25,8.75)	All: 58.8% HCP: 50.0% PCP: 68.8%	All: 7(4,7.25) HCP: 6.5(4,7) PCP: 7(4,8.75)	All: 57.6% HCP: 47.1% PCP: 68.8%	All: 7(4,8) HCP: 6(4,7) PCP: 7(4,8)	No
28. What are the best treatments that cure or delay the progression (worsening) of primary biliary cholangitis (PBC)?	All: 61.8% HCP: 60.0% PCP: 64.3%	All: 7(5.75,8) HCP: 7(6,8) PCP: 7(5,8)	All: 68.8% HCP: 66.7% PCP: 71.4%	All: 7(6,8) HCP: 7(5.75,8) PCP: 7(5.75,8.25)	All: 74.2% HCP: 70.6% PCP: 78.6%	All: 7(6,8) HCP: 7(6,8) PCP: 7(6.5,8.25)	No

29. Is nurse-led care as effective or better than doctor-led care for non-alcohol related fatty liver disease (NAFLD)?	All: 38.2% HCP: 35.0% PCP: 42.9%	All: 5(4,8) HCP: 4.5(3,7.75) PCP: 5(4,8)	All: 31.3% HCP: 27.8% PCP: 35.7%	All: 5(4,7) HCP: 4(3,7) PCP: 5(4,7.25)	All: 25.8% HCP: 23.5% PCP: 28.6%	All: 5(4,7) HCP: 4(3.5,6.5) PCP: 5(4,7)	No
30. Is treatment targeted against deformation of bile duct (biliary stricture or narrowing of bile duct due to cancer) better than standard treatment for people with bile duct cancer?	All: 35.5% HCP: 27.8% PCP: 46.2%	All: 5(4,7) HCP: 5(2.75,7) PCP: 5(4,7.5)	All: 22.6% HCP: 11.1% PCP: 38.5%	All: 5(4,6) HCP: 5(3.5,6) PCP: 5(4,7)	All: 20.0% HCP: 11.8% PCP: 30.8%	All: 5(4,6) HCP: 5(3.5,6) PCP: 5(4,7)	No
31. Is surgery (in the form of removal of gallbladder) required in people with gallstones?	All: 24.2% HCP: 23.8% PCP: 25.0%	All: 5(4,6.5) HCP: 5(4,6.5) PCP: 5(4.25,6.75)	All: 30.0% HCP: 33.3% PCP: 25.0%	All: 5(4,7) HCP: 5(4,7) PCP: 5(3.5,6.75)	All: 24.1% HCP: 29.4% PCP: 16.7%	All: 5(4.5,6.5) HCP: 5(4.5,7) PCP: 5(3.5,6)	No
32. Should people with non-alcohol-related fatty liver disease (NAFLD) and non-alcohol-related steatohepatitis	All: 52.9% HCP: 50.0% PCP: 57.1%	All: 7(4,8) HCP: PCP:	All: 56.3% HCP: 50.0% PCP: 64.3%	All: 7(4.25,8) HCP: 6.5(2,7.25)	All: 54.8% HCP: 47.1% PCP: 64.3%	All: 7(5,8) HCP: 6(4,7.5) PCP:	No

(NASH) receive additional education about the condition?		6.5(2.5,7.75) PCP: 7(4,9)		PCP: 7(5.75,8.25)		PCP: 7(5.75,8.25)	
33.What is the best immunosuppressive regimen in adults undergoing liver transplantation?	All: 73.5% HCP: 60.0% PCP: 92.9%	All: 7(6,9) HCP: 7(5,8) PCP: 7(7,9)	All: 84.4% HCP: 77.8% PCP: 92.9%	All: 8(7,9) HCP: 7(6.5,8) PCP: 8(7,9)	All: 90.3% HCP: 82.4% PCP: 100.0%	All: 8(7,9) HCP: 8(7,8) PCP: 8(7.75,9)	Yes
34.Is endoscopic ultrasound (EUS) (using a ultrasound attached to the end of an endoscope) or magnetic resonance cholangio pancreatography (MRCP, a form of MRI scan) better in the diagnosis of common bile duct (CBD) stones?	All: 36.7% HCP: 22.2% PCP: 58.3%	All: 5(4,7) HCP: 4(3.75,6.25) PCP: 5(5,7)	All: 30.0% HCP: 22.2% PCP: 41.7%	All: 5(4,7) HCP: 5(4,6.25) PCP: 5(5,7)	All: 20.7% HCP: 11.8% PCP: 33.3%	All: 5(4,6) HCP: 5(4,6) PCP: 5(5,7)	No
35.How can we improve compliance to treatment (adherence to treatment or the degree to which a patient correctly	All: 67.6% HCP: 75.0% PCP: 57.1%	All: 7(5,8) HCP: 7(6.25,8)	All: 69.7% HCP: 72.2% PCP: 66.7%	All: 7(5,8) HCP: 7(4.75,8) PCP: 7(5,8)	All: 71.9% HCP: 70.6% PCP: 73.3%	All: 7(5,8) HCP: 7(5,8) PCP: 7(5,8)	No

follows medical advice) in people with liver disease?		PCP: 7(4.75,8)					
36.What are the best symptomatic treatments for relief of ulcerative colitis (UC) in people with primary sclerosing cholangitis (PSC) who have undergone liver transplantation?	All: 51.6% HCP: 36.8% PCP: 75.0%	All: 7(5,8) HCP: 6(4,7) PCP: 7(5.5,8.75)	All: 56.7% HCP: 44.4% PCP: 75.0%	All: 7(5,8) HCP: 6(4.75,7) PCP: 7(6.25,8.75)	All: 55.2% HCP: 41.2% PCP: 75.0%	All: 7(6,8) HCP: 6(5.5,7) PCP: 7(6.25,9)	No
37.What are the best symptomatic treatments for itching and fatigue (tiredness) in people with primary biliary cholangitis (PBC)?	All: 50.0% HCP: 45.0% PCP: 57.1%	All: 6.5(5,7) HCP: 6(5,7) PCP: 6.5(5,7.25)	All: 43.8% HCP: 33.3% PCP: 57.1%	All: 6(5,7) HCP: 6(5,7) PCP: 6(5,8)	All: 41.9% HCP: 29.4% PCP: 57.1%	All: 6(5,7) HCP: 6(5,7) PCP: 6(5,8)	No
38.Does education of people with asymptomatic (absence of symptoms) liver disease result in change of life style and cure/delay the progression (worsening) of liver disease?	All: 54.3% HCP: 45.0% PCP: 66.7%	All: 7(5,8) HCP: 6(4.25,7.75) PCP: 7(5,8)	All: 51.5% HCP: 38.9% PCP: 66.7%	All: 7(4.5,8) HCP: 5(3.5,7.25) PCP: 7(5,8)	All: 53.1% HCP: 35.3% PCP: 73.3%	All: 7(5,7.75) HCP: 5(4,7) PCP: 7(5,8)	No

39. What are the best treatments that are available for the treatment of pregnant women with cholestasis (condition where bile flow from the liver is obstructed)?	All: 38.7% HCP: 25.0% PCP: 63.6%	All: 6(4,7) HCP: 5(4,6.75) PCP: 6(6,8)	All: 31.0% HCP: 27.8% PCP: 36.4%	All: 6(4.5,7) HCP: 5(4,7) PCP: 6(6,8)	All: 27.6% HCP: 23.5% PCP: 33.3%	All: 6(5,7) HCP: 5(4.5,6.5) PCP: 6(5.25,7)	No
40. Is transarterial chemoembolisation (TACE) or transarterial embolisation (TAE) (blocking the blood supply to cancer with or without chemotherapy drugs) effective in the treatment of people with liver metastases?	All: 40.6% HCP: 36.8% PCP: 46.2%	All: 6(4,8) HCP: 6(3,8) PCP: 6(5,8.5)	All: 34.4% HCP: 22.2% PCP: 50.0%	All: 6(4,7) HCP: 5.5(3,6.25) PCP: 6(5,7)	All: 32.3% HCP: 23.5% PCP: 42.9%	All: 6(5,7) HCP: 6(3.5,6.5) PCP: 6(5,7)	No
41. Should people with liver metastases (cancer spread to the liver) from neuroendocrine cancer (a form of cancer that arises from cells that secrete	All: 36.7% HCP: 31.6% PCP: 45.5%	All: 6(4,7.25) HCP: 6(4,7) PCP: 6(5,8)	All: 40.0% HCP: 38.9% PCP: 41.7%	All: 6(4.75,7.25) HCP: 6(4,7) PCP: 6(5.25,8)	All: 37.9% HCP: 41.2% PCP: 33.3%	All: 6(5.5,7) HCP: 6(5,7) PCP: 6(5.25,8)	No

hormones and nervous system) undergo liver resection?							
42.What are the best methods available to decrease blood loss during liver resection?	All: 43.8% HCP: 26.3% PCP: 69.2%	All: 6(5,7.75) HCP: 5(3,7) PCP: 6(6,8)	All: 48.4% HCP: 27.8% PCP: 76.9%	All: 6(5,8) HCP: 5.5(4,7) PCP: 6(6.5,8)	All: 46.7% HCP: 29.4% PCP: 69.2%	All: 6(5,7.25) HCP: 6(5,7) PCP: 6(6,8)	No
43.What are the best treatments that cure or delay the progression (worsening) of chronic hepatitis B virus (HBV) infection?	All: 51.6% HCP: 42.1% PCP: 66.7%	All: 7(4,8) HCP: 6(4,7) PCP: 7(6,8)	All: 46.7% HCP: 38.9% PCP: 58.3%	All: 6(4.75,7.25) HCP: 5.5(4,7) PCP: 6(6,8)	All: 48.3% HCP: 41.2% PCP: 58.3%	All: 6(5,7.5) HCP: 6(4.5,7) PCP: 6(6,8)	No
44.What are the best treatments for people with polycystic liver disease?	All: 39.3% HCP: 17.6% PCP: 72.7%	All: 6(4,8) HCP: 5(4,6) PCP: 6(6,8)	All: 34.5% HCP: 16.7% PCP: 63.6%	All: 6(4,8) HCP: 5(3.75,6) PCP: 6(6,8)	All: 35.7% HCP: 17.6% PCP: 63.6%	All: 6(5,7) HCP: 5(4,6) PCP: 6(6,7)	No
45.Should the HCP dealing with childhood liver diseases be provided additional education about childhood liver diseases	All: 35.5% HCP: 15.0% PCP: 72.7%	All: 5(3,8) HCP:	All: 37.9% HCP: 16.7% PCP: 72.7%	All: 5(3.5,7.5) HCP:	All: 37.9% HCP: 17.6% PCP: 66.7%	All: 5(4.5,7.5) HCP: 5(2,5.5)	No

1 2 3 4 5 6 7 8 9	compared to standard education where childhood diseases are learnt as part of overall education?		5(2,5.75) PCP: 5(5,9)		5(2,5.25) PCP: 5(6,9)		PCP: 5(6,8.75)	
10 11 12 13 14 15 16	46.What is the best immunosuppressive regimen in children undergoing liver transplantation?	All: 65.6% HCP: 57.9% PCP: 76.9%	All: 8(4.25,9) HCP: 7(4,8) PCP: 8(6,9)	All: 67.7% HCP: 61.1% PCP: 76.9%	All: 8(6,9) HCP: 7.5(4,8) PCP: 8(6.5,9)	All: 70.0% HCP: 64.7% PCP: 76.9%	All: 8(6,9) HCP: 8(5,8) PCP: 8(6.5,9)	No
17 18 19 20 21 22 23 24 25 26 27 28 29	47.Should blood vessels supplying the liver be temporarily blocked in people undergoing liver resection? If so, what is the best way of performing this?	All: 31.0% HCP: 11.1% PCP: 63.6%	All: 6(4,7) HCP: 5(2.75,6) PCP: 6(5,7)	All: 26.7% HCP: 11.1% PCP: 50.0%	All: 5.5(4,7) HCP: 5(3.75,6) PCP: 5.5(5.25,7.75))	All: 27.6% HCP: 11.8% PCP: 50.0%	All: 6(5,7) HCP: 5(4,6) PCP: 6(5.25,7)	No
30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46	48.What is the best treatment that should be given to people who undergo liver transplantation for chronic hepatitis B virus (HBV) infection to prevent	All: 46.9% HCP: 40.0% PCP: 58.3%	All: 6(3.5,7) HCP: 6(3,7) PCP: 6(6,8)	All: 36.7% HCP: 22.2% PCP: 58.3%	All: 6(3,7) HCP: 6(2.75,6.25)	All: 37.9% HCP: 23.5% PCP: 58.3%	All: 6(5,7) HCP: 6(4,6.5) PCP: 6(6,7.75)	No

1	reinfestation with chronic hepatitis B virus				PCP:			
2	(HBV) infection?				6(6,7.75)			
3	49.Are there alternatives to steroids in	-	-	All: 51.9%	All: 7(5,8)	All: 50.0%	All: 6.5(5,8)	No
4	treating people with autoimmune			HCP: 40.0%	HCP: 6(4,7)	HCP: 35.7%	HCP:	
5	hepatitis (AIH)?			PCP: 66.7%	PCP: 7(6,9)	PCP: 66.7%	5.5(3.75,7)	
6							PCP: 6.5(6,9)	
7	50.What impact does the home situation	-	-	All: 34.5%	All: 5(3.5,7.5)	All: 32.1%	All: 5(4,7)	No
8	have on recovery from chronic liver			HCP: 13.3%	HCP: 4(3,6)	HCP: 0.0%	HCP:	
9	disease and its treatment?			PCP: 57.1%	PCP: 5(5,8)	PCP: 64.3%	4(3,5.25)	
10							PCP: 5(5,8)	
11	51.Does cure of hepatitis C provide	-	-	All: 29.2%	All:	All: 30.4%	All: 6(4,7)	No
12	benefits to the patient outside reduction			HCP: 33.3%	5.5(3.25,7)	HCP: 35.7%	HCP:	
13	in liver related complications?			PCP: 22.2%	HCP: 5(3,7)	PCP: 22.2%	5.5(3,7.25)	
14					PCP:		PCP:	
15					5.5(4.5,6.5)		6(4.5,6.5)	

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

52.How fast does liver fibrosis (scarring) actually progress in non-alcoholic liver disease patients and does this predict overall outcome?	-	-	All: 62.1% HCP: 40.0% PCP: 85.7%	All: 7(6,8) HCP: 6(5,8) PCP: 7(7,8.25)	All: 64.3% HCP: 42.9% PCP: 85.7%	All: 7.5(6,8) HCP: 6(5,8) PCP: 7.5(7,8.25)	No
53.Should direct-acting antiviral treatments therapies be made more easily accessible to GPs and drug service clinics for treatment of hepatitis C virus?	-	-	All: 50.0% HCP: 46.7% PCP: 55.6%	All: 6.5(3.5,7) HCP: 6(3,7) PCP: 6.5(5.5,8)	All: 52.2% HCP: 50.0% PCP: 55.6%	All: 7(5,7) HCP: 6.5(4.5,7.25) PCP: 7(5.5,8)	No
54.Should patients diagnosed with liver fibrosis/cirrhosis related to NAFLD (non-alcoholic fatty liver disease) be offered more intensive nutritional support or dietician review?	-	-	All: 60.7% HCP: 46.7% PCP: 76.9%	All: 7(5,8) HCP: 6(3,8) PCP: 7(6.5,9)	All: 63.0% HCP: 50.0% PCP: 76.9%	All: 7(5,8) HCP: 7(4.5,8) PCP: 7(6.5,8.5)	No
55.Why have there been no alternatives to surgery in the form of new drug	-	-	All: 29.2% HCP: 20.0% PCP: 44.4%	All: 4.5(1.25,7) HCP: 4(1,6)	All: 26.1% HCP: 21.4% PCP: 33.3%	All: 4(2,7) HCP:	No

1 2 3 4 5 6 7	treatments for gall bladder disease & biliary sludge?				PCP: 4.5(2,7.5)		4(1.75,5.5) PCP: 4(2,7.5)	
8 9 10 11 12 13 14 15 16 17 18	56. Why is there no proper evidence-based research on nutrition as a way of managing gall bladder disease/biliary sludge?	-	-	All: 36.0% HCP: 26.7% PCP: 50.0%	All: 5(1.5,7) HCP: 4(1,7) PCP: 5(2.5,7.5)	All: 33.3% HCP: 28.6% PCP: 40.0%	All: 5(2,7) HCP: 4.5(1.75,7) PCP: 5(2.5,7.5)	No
19 20 21 22 23 24 25 26 27 28 29 30 31	57. Why is there such variability in the natural progression of people with primary sclerosing cholangitis: some are very sick and require a transplant whereas others can remain relatively healthy for a long period?	-	-	All: 56.0% HCP: 42.9% PCP: 72.7%	All: 7(6,7) HCP: 6(4,7) PCP: 7(6,8)	All: 54.2% HCP: 38.5% PCP: 72.7%	All: 7(6,7) HCP: 6(4,7) PCP: 7(6,8)	No
32 33 34 35 36 37 38 39 40 41 42 43 44 45 46	58. What are the warning signals that primary sclerosing cholangitis will be aggressive or cancerous?	-	-	All: 57.7% HCP: 53.3% PCP: 63.6%	All: 7(5.75,8.25)	All: 60.0% HCP: 50.0% PCP: 72.7%	All: 7(5.5,8) HCP:	No

				HCP: 7(5,8) PCP: 7(6,9)		6.5(4.75,8) PCP: 7(6,9)	
59.Does information on the impact of the complication on the people's quality of life improve the patient's informed decision- making process about treatment of liver and gallbladder diseases?	-	-	All: 46.4% HCP: 40.0% PCP: 53.8%	All: 6(4,7) HCP: 6(4,7) PCP: 6(4.5,8)	All: 44.4% HCP: 35.7% PCP: 53.8%	All: 6(4,7) HCP: 5.5(4,7) PCP: 6(5,8)	No
60.Will clinical pathways developed with patients and HCP having an equal say result in greater patient satisfaction and health in people with liver and gallbladder diseases?	-	-	All: 44.8% HCP: 33.3% PCP: 57.1%	All: 6(4.5,8) HCP: 5(4,8) PCP: 6(5,8)	All: 46.4% HCP: 35.7% PCP: 57.1%	All: 6(4.25,8) HCP: 5(3.75,8) PCP: 6(5.75,8.25)	No
61.Should high school teenagers be educated about the risks of hepatitis C?	-	-	All: 53.8% HCP: 40.0% PCP: 72.7%	All: 7(3.75,8) HCP: 5(2,7) PCP: 7(6,9)	All: 57.7% HCP: 42.9% PCP: 75.0%	All: 7(4.75,7.25) HCP: 5.5(2,7)	No

						PCP: 7(6.25,8.75)	
62.How can patients with end stage liver failure be better prepared for end of life. How can the HCP supporting them be better prepared to provide that support?	-	-	All: 65.5% HCP: 46.7% PCP: 85.7%	All: 7(6,8) HCP: 6(5,8) PCP: 7(7,9)	All: 67.9% HCP: 50.0% PCP: 85.7%	All: 7(6,8) HCP: 6.5(4.75,8) PCP: 7(7,9)	No
63.Is aggressive control of inflammation on colonic inflammatory bowel disease in primary sclerosing cholangitis associated with improved liver outcomes?	-	-	All: 48.0% HCP: 46.7% PCP: 50.0%	All: 6(5,7) HCP: 6(5,7) PCP: 6(6,8)	All: 50.0% HCP: 42.9% PCP: 60.0%	All: 6.5(5.25,7) HCP: 6(5,7) PCP: 6.5(6,8)	No
64.What is the best way to survey for cholangiocarcinoma in primary sclerosing cholangitis?	-	-	All: 61.5% HCP: 60.0% PCP: 63.6%	All: 7(5.75,8) HCP: 7(5,7) PCP: 7(6,9)	All: 60.0% HCP: 57.1% PCP: 63.6%	All: 7(6,8) HCP: 7(5,7) PCP: 7(6,9)	No
65.Should the criteria for polycystic liver disease and transplantation be changed to take into account the size the liver	-	-	All: 29.2% HCP: 13.3% PCP: 55.6%	All: 4.5(2,7) HCP: 4(2,6)	All: 30.4% HCP: 7.1% PCP: 66.7%	All: 6(3,7) HCP: 4(2,6) PCP: 6(6,7.5)	No

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

cysts can grow and the additional pressures on all the internal organs?				PCP: 4.5(5.5,7)			
66.Does control of colitis at the time of liver transplant reduce the risk of recurrent primary sclerosing cholangitis?	-	-	All: 36.0% HCP: 33.3% PCP: 40.0%	All: 6(5,7) HCP: 6(4,7) PCP: 6(5,8.25)	All: 33.3% HCP: 28.6% PCP: 40.0%	All: 6(5,7) HCP: 6(3.75,7) PCP: 6(5,8.25)	No
67.Are people with liver disease likely to develop other conditions, if so, what other conditions?	-	-	All: 42.9% HCP: 13.3% PCP: 76.9%	All: 6(3.25,7) HCP: 5(2,6) PCP: 6(6.5,8.5)	All: 46.4% HCP: 14.3% PCP: 78.6%	All: 6(3.25,7.75) HCP: 4.5(2,5.25) PCP: 6(6.75,8.25)	No
68.Do people with liver disease have a reduced life expectancy?	-	-	All: 30.0% HCP: 0.0% PCP: 60.0%	All: 5.5(3,8) HCP: 4(1,5) PCP: 5.5(6,9)	All: 34.5% HCP: 0.0% PCP: 66.7%	All: 6(3,8) HCP: 3.5(1.75,5.25)	No

) PCP: 6(6,9)	
69.Should transjugular intrahepatic portosystemic shunt (TIPS) be used earlier in management of variceal haemorrhage?	-	-	All: 51.9% HCP: 53.3% PCP: 50.0%	All: 7(5,7) HCP: 7(5,8) PCP: 7(5,7)	All: 55.6% HCP: 57.1% PCP: 53.8%	All: 7(6,7) HCP: 7(5.75,8) PCP: 7(5.5,7)	No
70.Should abnormal alanine transaminase (ALT) reference ranges be revised downwards in line with ACG (American College of Gastroenterology) guidance?	-	-	All: 36.0% HCP: 33.3% PCP: 40.0%	All: 6(5,7) HCP: 6(5,7) PCP: 6(5,7)	All: 37.5% HCP: 35.7% PCP: 44.4%	All: 6(5,7) HCP: 6(4.5,7.25) PCP: 6(5.875,7)	No

a Questions from 49 to 70 were collected during the first round of Delphi.

b Consensus was reached when at least 80% of Delphi-panel members scored between 7 and 9 for the specific question.

Abbreviations:

HCP = Healthcare professionals

1
2
3 IQR = interquartile range
4
5

6 PCP = Patients, carers, and public
7
8

9 References

- 10
11
12 1. Majumdar A, Roccarina D, Thorburn D, Davidson BR, Tsochatzis E, Gurusamy KS. Management of people with early- or very early-stage
13 hepatocellular carcinoma: an attempted network meta-analysis. The Cochrane database of systematic reviews. 2017;3:CD011650. Epub 2017/03/30. doi:
14 10.1002/14651858.CD011650.pub2. PubMed PMID: 28351116.
15
16 2. Saffioti F, Gurusamy KS, Hawkins N, Toon CD, Tsochatzis E, Davidson BR, et al. Pharmacological interventions for primary sclerosing cholangitis: an
17 attempted network meta-analysis. The Cochrane database of systematic reviews. 2017;3:CD011343. Epub 2017/04/19. doi:
18 10.1002/14651858.CD011343.pub2. PubMed PMID: 28417463.
19
20 3. Lombardi R, Onali S, Thorburn D, Davidson BR, Gurusamy KS, Tsochatzis E. Pharmacological interventions for non-alcohol related fatty liver disease
21 (NAFLD): an attempted network meta-analysis. The Cochrane database of systematic reviews. 2017;3:CD011640. Epub 2017/03/31. doi:
22 10.1002/14651858.CD011640.pub2. PubMed PMID: 28358980.
23
24 4. Rodriguez-Peralvarez M, Guerrero-Misas M, Thorburn D, Davidson BR, Tsochatzis E, Gurusamy KS. Maintenance immunosuppression for adults
25 undergoing liver transplantation: a network meta-analysis. The Cochrane database of systematic reviews. 2017;3:CD011639. Epub 2017/04/01. doi:
26 10.1002/14651858.CD011639.pub2. PubMed PMID: 28362060.
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

- 1
2
3 5. Czaja AJ, Carpenter HA, Lindor KD. Ursodeoxycholic acid as adjunctive therapy for problematic type 1 autoimmune hepatitis: a randomised placebo-
4 controlled treatment trial. *Hepatology (Baltimore, Md)*. 1999;30(6):1381-6. Epub 1999/11/26. doi: 10.1002/hep.510300603. PubMed PMID: 10573515.
5
6
7 6. Manns MP, Woynarowski M, Kreisel W, Lurie Y, Rust C, Zuckerman E, et al. Budesonide induces remission more effectively than prednisone in a
8 controlled trial of patients with autoimmune hepatitis. *Gastroenterology*. 2010;139(4):1198-206. Epub 2010/07/06. doi: 10.1053/j.gastro.2010.06.046.
9 PubMed PMID: 20600032.
10
11
12 7. Woynarowski M, Nemeth A, Baruch Y, Koletzko S, Melter M, Rodeck B, et al. Budesonide versus prednisone with azathioprine for the treatment of
13 autoimmune hepatitis in children and adolescents. *The Journal of pediatrics*. 2013;163(5):1347-53.e1. Epub 2013/07/03. doi: 10.1016/j.jpeds.2013.05.042.
14 PubMed PMID: 23810723.
15
16
17 8. Saffioti F, Gurusamy KS, Eusebi LH, Tsochatzis E, Davidson BR, Thorburn D. Pharmacological interventions for primary biliary cholangitis: an
18 attempted network meta-analysis. *The Cochrane database of systematic reviews*. 2017;3:CD011648. Epub 2017/03/30. doi:
19 10.1002/14651858.CD011648.pub2. PubMed PMID: 28350426.
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

BMJ Open

TOP RESEARCH PRIORITIES IN LIVER AND GALLBLADDER DISORDERS IN THE UNITED KINGDOM

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-025045.R2
Article Type:	Research
Date Submitted by the Author:	05-Feb-2019
Complete List of Authors:	Gurusamy, Kurinchi; University College London, Walmsley, Martine; PSC Support Davidson, Brian; Royal Free London NHS Foundation Trust, HPB Surgery Frier, Claire; Royal Free London NHS Foundation Trust, HPB Surgery Fuller, Barry; University College London Madden, Angela; University of Hertfordshire Masson, Steven; Freeman Hospital Morley, Richard; Cochrane Collaboration Consumer Network Safarik, Ivana; Carolside Medical Centre Tsochatzis, E; University College London Ahmed, Irfan; NHS Grampian Cowlin, Maxine; Patient representative Dillon, John; University of Dundee Division of Cardiovascular and Diabetes Medicine, Liver Group Ellicott, Graham; Patient representative Elsharkawy, Ahmed; Queen Elizabeth Hospital Birmingham Farrington, Liz; Royal Cornwall Hospitals NHS Trust Glachan, Anthony; Patient representative Kumar, Nagappan; University Hospital of Wales Milne, EJ; Patient representative Rushbrook, Simon; Norfolk and Norwich University Hospitals NHS Foundation Trust, Smith, Amanda; Queen Elizabeth Hospital Birmingham Stafford, Lizzie; John Radcliffe Hospital Yeoman, Andrew; Royal Gwent Hospital
Primary Subject Heading:	Gastroenterology and hepatology
Secondary Subject Heading:	Gastroenterology and hepatology
Keywords:	liver, chronic liver disease, research priorities

SCHOLARONE™
Manuscripts

1 TOP RESEARCH PRIORITIES IN LIVER AND

2 GALLBLADDER DISORDERS IN THE UNITED KINGDOM

3 Kurinchi S Gurusamy¹, Martine Walmsley², Brian R Davidson³, Claire Frier⁴, Barry Fuller⁵, Angela
4 Madden⁶, Steven Masson⁷, Richard Morley⁸, Ivana Safarik⁹, Emmanuel A Tsochatzis¹⁰, Irfan Ahmed¹¹,
5 Maxine Cowlin¹², John F Dillon¹³, Graham Ellicott¹², Ahmed M Elsharkawy¹⁴, Liz Farrington¹⁵, Anthony
6 Glachan¹², Nagappan Kumar¹⁶, EJ Milne¹², Simon M Rushbrook¹⁷, Amanda Smith¹⁸, Lizzie Stafford¹⁹,
7 Andrew Yeoman²⁰

8 ¹Professor of Evidence-based Medicine and Surgery, Division of Surgery and Interventional Science,
9 University College London, United Kingdom

10 ²Chair of Trustees, PSC Support, United Kingdom

11 ³Professor of Surgery, Royal Free Campus, University College London, United Kingdom

12 ⁴Cancer nurse specialist, HPB, Royal Free Hospital, London, United Kingdom

13 ⁵Professor of Surgery, Royal Free Campus, University College London, United Kingdom

14 ⁶Subject Group Lead for Nutrition and Dietetics, University of Hertfordshire, United Kingdom

15 ⁷Consultant hepatologist, Freeman Hospital, Newcastle, United Kingdom

16 ⁸James-Lind Alliance advisor

17 ⁹General Practitioner, Carolside Medical Centre, Clarkston, Glasgow, United Kingdom

18 ¹⁰Senior lecturer in Hepatology/Consultant hepatologist, UCL Institute for Liver and Digestive Health
19 Royal Free Hospital and University College London, United Kingdom

20 ¹¹Professor of Surgery, NHS Grampian, Aberdeen, United Kingdom

- 1
2
3 21 ¹²Patient and public representative, United Kingdom
4
5
6 22 ¹³Professor of Hepatology & Gastroenterology, NHS Tayside, Gastroenterology Dundee, UK
7
8
9 23 ¹⁴Consultant Hepatologist, Queen Elizabeth Hospital, Birmingham, United Kingdom
10
11
12 24 ¹⁵Consultant Nurse Hepatology, Royal Cornwall Hospital, Truro, United Kingdom
13
14
15 25 ¹⁶Consultant HPB Surgeon, University Hospital of Wales, Cardiff, United Kingdom
16
17
18 26 ¹⁷Consultant Hepatologist, Norfolk and Norwich University Hospital, Norwich, United Kingdom
19
20
21 27 ¹⁸Specialist Pharmacist – Liver, Queen Elizabeth Hospital, Birmingham, United Kingdom
22
23
24 28 ¹⁹Hepatology Research Nurse, John Radcliffe Hospital, Oxford, United Kingdom
25
26
27 29 ²⁰Consultant Hepatologist, Royal Gwent Hospital, Newport, United Kingdom
28
29
30 30 Corresponding author: Kurinchi S Gurusamy
31
32 31 Postal address: Floor 9, Royal Free Hospital, Royal Free Campus UCL, Rowland Hill Street, London
33
34 32 NW3 2PF; Email: k.gurusamy@ucl.ac.uk
35
36
37 33 Word count: 3569
38
39
40 34 Keywords: liver, chronic liver disease
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

35 ABSTRACT

36 Objectives: There is a mismatch between research questions considered important by patients,
37 carers, and healthcare professionals and the research performed in many fields of medicine. The
38 Non-Alcohol-Related Liver and gallbladder disorders Priority setting partnership (NARLIP) was
39 established to identify the top research priorities in the prevention, diagnostic, and treatment of
40 gallbladder disorders and liver disorders not covered by the James-Lind Alliance (JLA) Alcohol-related
41 liver disease (ARLD) Priority Setting Partnership.

42 Design: The methods broadly followed the principles of the JLA guidebook. The one major deviation
43 from the JLA methodology was the final step of identifying priorities: instead of prioritisation by
44 group discussions at a consensus workshop involving stakeholders, the prioritisation was achieved
45 by a modified Delphi consensus process.

46 Results: A total of 428 unique valid diagnostic or treatment research questions were identified. A
47 literature review established that none of these questions were considered 'answered' i.e. high
48 quality systematic reviews suggest that further research is not required on the topic. The Delphi
49 panel achieved consensus (at least 80% Delphi panel members agreed) that a research question was
50 a top research priority for six questions. Four additional research questions with highest proportion
51 of Delphi panel members ranking the question as highly important were added to constitute the top
52 10 research priorities.

53 Conclusions: A priority setting process involving patients, carers and healthcare professionals has
54 been used to identify the top ten priority areas for research related to liver and gallbladder
55 disorders. Basic, translational, clinical, and public health research are required to address these
56 uncertainties.

57 Keywords: liver, chronic liver disease

1
2
3 58 Word count: 3618
4
5
6

7 59 **ARTICLE SUMMARY**

8
9
10

11 60 **Strengths and limitations**

12
13

- 14 61 • A research prioritisation process involving clinicians, patients and carer, and public
15 62 representatives was performed in the field of liver and gallbladder disorders. This will help to
16 63 address the mismatch between research questions that are considered important jointly by
17 64 patients, carers, and healthcare professionals and the research performed in the field of liver
18 65 and gallbladder disorders.
 - 19 66 • A Delphi consensus method was performed. This prevented dominance of 'loud voices', a
20 67 problematic issue with small and large group discussions.
 - 21 68 • Because of the predominance of people with chronic liver disease on the Delphi panel, many
22 69 of the top research priorities related to chronic liver diseases.
- 23
24
25
26
27
28
29
30
31
32
33
34
35
36

37 70 **INTRODUCTION**

38
39
40

41 71 Failure to address treatment uncertainties by research can lead to significant suffering and deaths ¹.
42 72 It is important that research in any field of medicine takes into account the shared interests of
43 73 patients, carers and clinicians ². However, there is a mismatch between research questions that are
44 74 considered important jointly by patients, carers, and healthcare professionals and the research
45 75 performed in many fields of medicine ^{3,4}. The James Lind Alliance (JLA) exists to help ensure a
46 76 patient-centred process and enables the limited research resources to be utilised in addressing the
47 77 research questions that are considered important jointly by patients, carers, and healthcare
48 78 professionals ² ('top research priorities'). This is achieved by forming 'Priority Setting Partnerships'

49
50
51
52
53
54
55
56
57
58
59
60

79 (PSPs) between patients, carers, and healthcare professionals². Formal prioritisation of research
80 topics jointly by patients and healthcare professionals can lead to increased research on the topic^{5,6}.

81 There has only been one formal research prioritisation process involving patients, carers,
82 and healthcare professionals in the field of liver and gallbladder disorders⁷. However, the scope of
83 that PSP was limited to alcohol-related liver disorders⁷. The Non-Alcohol-Related Liver and
84 gallbladder disorders Priority setting partnership (NARLIP) was established to address the
85 prevention, diagnostic, and treatment uncertainties related to the majority of liver disorders which
86 were not covered by the JLA PSP on alcohol-related liver diseases (ARLD)⁷ and to include gallbladder
87 disease.

88 The aims and objectives of the NARLIP were to work with patients, their carers, and
89 healthcare professionals treating them ('stakeholders') to identify uncertainties about the diagnostic
90 tests and effects of prevention and treatments for non-alcohol related liver and gallbladder
91 disorders, to agree by consensus a prioritised list of those uncertainties for research, to publicise the
92 results and process, and to take the results to research commissioning bodies to be considered for
93 funding and researchers to encourage them to submit grant applications addressing these
94 uncertainties.

95 METHODS

96 The methods broadly followed the principles of the JLA guidebook.⁸ The broad steps involved the
97 following and are summarised in Figure 1.

- 98 1. Formation of the partnership: organisations and individuals representing people affected by
99 non-alcohol related liver or gallbladder disorders, their carers, and healthcare professionals
100 treating people with non-alcohol related liver and gallbladder disorders. A partnership was
101 formed between KG representing University College London and the British Liver Trust
102 initially, but following reorganisation in the British Liver Trust, PSC Support⁹ became the

1
2
3 103 leading patient organisation partner of this process. A steering committee was formed. The
4
5 104 members of the steering committee who participated in the complete process were KG,
6
7 105 MW, BRD, CF, BF, AM, RM, SM, IS, and ET.
8
9
10 106 2. Establishment of the scope: the steering committee members discussed and decided that
11
12 107 the scope should include adult and paediatric liver and gallbladder disorders which required
13
14 108 medical and surgical treatments. The protocol was registered with James-Lind Alliance
15
16 109 Priority Setting Partnership.
17
18
19 110 3. Identifying potential research questions: research questions were collected through online
20
21 111 surveys and searching UK Database of Uncertainties about the Effects of Treatments (UK
22
23 112 DUETs), research recommendations in high quality systematic reviews and clinical
24
25 113 guidelines, and registers of ongoing research.
26
27
28 114 4. Refining research questions: the research questions identified in the above step were
29
30 115 reviewed and where necessary combined to result in a set of unique research questions.
31
32 116 Research questions were considered 'answered' when recent high-quality systematic
33
34 117 reviews (based on low risk of bias studies) concluded that further research was not required.
35
36 118 Removal of such 'answered' research questions was planned. The remaining questions were
37
38 119 'uncertainties'.
39
40
41 120 5. Interim prioritisation: To shortlist the set of questions to manageable levels for the final
42
43 121 prioritisation process, the members of the steering committee ranked the uncertainties after
44
45 122 stratifying the questions as medical and surgical questions. The members of the steering
46
47 123 committee agreed that the interim prioritisation list should consist of 75% medical questions
48
49 124 and 25% surgical questions. This decision was an arbitrary decision made by the steering
50
51 125 committee based on the rationale that majority of individuals with liver and gallbladder
52
53 126 disorders are treated medically but a minority require surgery which have a major impact on
54
55 127 patients' lives.
56
57
58
59
60

- 1
2
3 128 6. Final prioritisation by consensus: A modified Delphi consensus method was followed to
4
5 129 identify the top priorities using methods described by Jones et al ¹⁰. The Delphi was
6
7 130 performed electronically using Excel for managing the process. The steps in the modified
8
9 Delphi consensus method were as follows.
10 131
11
12 132 a. A Delphi panel consisting of patients, their carers, and healthcare professionals
13
14 133 treating them was formed. The Delphi panel was formed by using 'snowballing'
15
16 134 sampling methods and by contacting people through emails, online liver patient
17
18 135 forums (British Liver Trust Health Unlocked forum), and newsletters. A total of 42
19
20 136 people expressed interest in joining the Delphi panel and 33 panel members
21
22 137 completed all three rounds. Details of the Delphi panel composition and drop-outs
23
24 138 are reported in the results section.
25
26
27 139 b. A total of three rounds were conducted.
28
29
30 140 c. Delphi panel members scored the short-listed questions in the interim prioritisation
31
32 141 process on a scale of 1 to 9 with 1 being considered least important and 9 being
33
34 142 considered most important. Scores of 1 to 3 were categorised as 'less important', 4
35
36 143 to 6 as 'moderately important', and 7 to 9 as 'highly important'. Panel members
37
38 144 were requested to score the questions according to the importance of the question
39
40 145 to them/the persons that they represent or treat and could leave questions that
41
42 146 they were unable to score empty. Each Delphi panel member could add a maximum
43
44 147 of two questions in the first round to ensure that the questions most important to
45
46 148 the Delphi panel members were included in the prioritisation process even if they
47
48 149 were not identified in the earlier steps. In the subsequent rounds, the panel
49
50 150 members were shown the summary scores and their previous score for each
51
52 151 question. They were able to retain or change their score in each of the rounds after
53
54 152 the first round. For calculation of the summary scores and the proportion
55
56 153 considering a question 'highly important', non-responses were excluded.
57
58
59
60

- 1
2
3 154 d. Consensus about a specific research question being a top research priority was
4
5 155 reached when 80% or more Delphi panel members considered the research question
6
7 156 as highly important (allocated scores between 7 and 9).
8
9
10 157 e. When fewer than 10 research priorities were obtained by consensus, the remaining
11
12 158 priorities were completed by uncertainties based on the highest proportions of
13
14 159 panel members agreeing that the research question was highly important (scores
15
16 160 between 7 and 9).
17
18
19 161 f. There was no restriction on the Delphi panel to consult others while scoring the
20
21 162 questions. However, only one final response on the set of questions was accepted
22
23 163 from each Delphi panel member.
24
25

26 164 When there were no recent high-quality systematic reviews on the research question, we have
27
28 165 recommended high-quality systematic reviews. When recent high-quality systematic reviews
29
30 166 recommended high-quality research, we have recommended randomised controlled trials for
31
32
33 167 prevention and treatment, as such studies carry the lowest risk of bias if conducted well; we would
34
35 168 have recommended well conducted diagnostic test accuracy studies for diagnostic uncertainties. All
36
37 169 online surveys were completed using Google Forms designed by KG. The Delphi process was
38
39 170 completed using Microsoft Excel and email.
40
41

42 171 Ethical approval was not deemed necessary because no personal identifiable information
43
44 172 was being collected, and the questions were being asked of healthcare professionals, patients and
45
46 173 their carers were not considered sensitive questions. In addition, we had full support of patient
47
48 174 organisations with involvement of patient representatives throughout the whole process rather than
49
50 175 patients visiting the hospitals.
51
52
53
54
55
56
57
58
59
60

176 Patient and Public involvement

177 Patients and public were involved in all aspects of this project: they were part of the steering
178 committee and were involved in the definition of the scope, methodology used for the prioritisation
179 process, identification of further patients and public representatives, participation in the Delphi
180 panel, interpretation, and critical revisions of the draft report. They will be involved in the
181 dissemination of the findings through patient websites, patient forums, and to research funders.

182 RESULTS

183 Identification and refining of research uncertainties

184 A total of 126 patients, carers, and those at risk of developing non-alcohol related liver and
185 gallbladder disorders, and 13 healthcare professionals participated in the first survey which was
186 conducted between July and December 2015. This survey resulted in a total of 209 unique research
187 questions. In addition, 219 unique questions were identified from searching the UK DUETs, Pubmed,
188 and ClinicalTrials.gov on 2nd January 2016. A total of 428 unique valid (i.e. falling within the remit of
189 this priority setting partnership) research questions (247 medical-related and 181 surgery-related)
190 were identified from these sources. None of the research questions had been answered by recent
191 high-quality systematic reviews based on low risk of bias studies which concluded that further
192 research was not required. Therefore, all the 428 research questions were considered research
193 'uncertainties'. The complete list of 428 unique valid uncertainties in no particular order is available
194 in Online Supplement Appendix 1. This has been converted to the population, intervention, control,
195 and outcomes (PICO) format whenever possible.

196 Interim priorities

197 To identify a shortlist of questions (from the list of 429 questions) that were to be considered for the
198 next step, a total of 48 research priorities (36 medical questions and 12 surgical questions) were
199 identified on the basis of being selected by at least one patient or carer and healthcare professional
200 of the steering committee (24 questions) and obtaining the highest ranks among the members of the
201 steering committee (additional 24 questions). The list of 48 questions identified as interim priorities
202 in no particular order is available in Online Supplement Appendix 2.

203 Final priorities

204 A total of 42 people expressed interest in joining the Delphi panel and 33 panel members completed
205 all three rounds. Five people dropped out before they returned the scores of the first round (all
206 patients, carers, and general public), three between first and second rounds (all healthcare
207 professionals), and one between the second and third rounds (healthcare professional). Of the 33
208 panel members who completed all the three rounds, 17 were healthcare professionals and 16 were
209 patients, carers, and general public. Of the 17 healthcare professionals, six were hepatologists, four
210 were surgeons, two were hepatology nurses, and the remaining were general practitioner (GP), HPB
211 surgery (hepato-pancreato biliary) nurse, organ preservation biologist, dietician, and pharmacist
212 (one each). Of the 16 patients, carers, and general public, there was representation from general
213 public and various liver diseases including autoimmune diseases such as primary sclerosing
214 cholangitis, primary biliary cholangitis, autoimmune hepatitis, viral hepatitis, metabolic diseases
215 such as non-alcohol related fatty liver disease, and other diseases such as hepatocellular carcinoma
216 and polycystic liver disease. There was also representation of liver transplanted patients in the
217 Delphi panel. In total, 23 panel members were from England, seven were from Scotland, and three
218 were from Wales. There were no panel members from Northern Ireland despite attempts to include
219 panel members from Northern Ireland.

220 A total of 22 additional questions were added by the Delphi panel members in the first
 221 round of the Delphi process. The Delphi panel achieved consensus that an uncertainty was a top
 222 research priority for six research questions. Four additional research questions with the highest
 223 proportion of Delphi panel members scoring the question as highly important (scores between 7 and
 224 9) were added to constitute the top 10 research priorities. The list of the top 10 research priorities
 225 (in the order of proportion who agreed that the uncertainty is a very important research priority) is
 226 available in Table 1. All the top 10 research priorities were prevention and treatment uncertainties,
 227 and none were diagnostic test uncertainties. None of the panel members thought the first two
 228 questions as least important (scores of 1 to 3). For the remaining 8 questions, 3% to 6.5% of people
 229 considered the questions to be least important (scores of 1 to 3).

230 **Table 1 Treatment uncertainties for which consensus that the uncertainty is a**
 231 **research priority was reached**

Treatment uncertainty (Research question)	Proportion who rated this question as highly important in the final round	Median (interquartile range) in the final round
What is the best treatment for people with early or very early hepatocellular carcinoma (HCC)?	93.5%	8(7,9)
What are the best treatments that cure or delay the progression (worsening) of primary sclerosing cholangitis (PSC)?	93.3%	8(7,9)

1 2 3 4 5 6 7 8 9	What are the best treatments that cure or delay the progression (worsening) of non-alcohol-related fatty liver disease (NAFLD)?	90.3%	9(8,9)
10 11 12 13 14	What is the best immunosuppressive regimen in adults undergoing liver transplantation?	90.3%	8(7,9)
15 16 17 18 19 20 21 22	Should general public be educated about non-alcohol-related fatty liver disease (NAFLD) with an aim to reduce the numbers of those that have it?	81.8%	8(7,9)
23 24 25 26 27	What are the best treatments that cure or delay the progression (worsening) of autoimmune hepatitis (AIH)?	80.6%	8(7,9)
28 29 30 31 32 33 34	What are the best treatments that cure or delay the progression (worsening) of non-alcohol related steatohepatitis (NASH)?	76.7%	8(6.75,9)
35 36 37 38 39 40 41 42 43 44 45 46 47 48 49	Prior to liver transplantation, is it better to transport the donor liver using a machine which pumps blood or preservation solution through the liver (machine perfusion) or is it better to transport it in the standard way of transporting it immersed in cold preservation solution (cold storage)?	74.2%	7(6,9)
50 51 52 53 54 55 56 57 58 59 60	What are the best treatments that cure or delay the progression (worsening) of primary biliary cholangitis (PBC)?	74.2%	7(6,8)

Are there any treatments that reverse the liver damage in primary sclerosing cholangitis (PSC)?	72.4%	7(6,9)
---	-------	--------

232

233 A summary of the availability of systematic review of randomised controlled trials on the topic of the
 234 individual questions, randomised controlled trials on the topic not included in the systematic review
 235 (if one exists), and the outcomes evaluated in these RCTs are listed in Table 2. Table 2 also contains a
 236 suggestion for the next research steps. The list of the existing trials was compiled by searching
 237 ClinicalTrials.gov on 7th April 2018. The references to the trials not included in the systematic reviews
 238 is available in Online Supplement Appendix 3. As seen in Table 2, a well-designed RCT is the next
 239 step for eight of these top 10 research questions. This is because it appears that the outcomes in
 240 those trials will not address the outcomes listed in the research questions.

241 **Table 2 Next step to address the top 10 research priorities based on current**
 242 **best evidence (summary)**

Treatment uncertainty (Research question)	High-quality systematic review ^{a,b}	RCTs not included in the systematic review ^{a,c}	Patient-oriented outcomes assessed in trials not included in the systematic review ^d	Next step

<p>1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40</p> <p>What is the best treatment for people with early or very early hepatocellular carcinoma (HCC)?</p>	<p>11</p>	<p>8 trials</p>	<p>Survival (7 trials), recurrence (5 trials), morbidity (3 trials)</p>	<p>High-quality RCTs of interventions not covered in ongoing trials and comparison of health-related quality (HRQoL) in different treatment</p>
<p>41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60</p> <p>What are the best treatments that cure or delay the progression (worsening) of primary sclerosing cholangitis (PSC)?</p>	<p>12</p>	<p>9 trials</p>	<p>None of the trials include survival, HRQoL as outcomes^e</p>	<p>High-quality RCTs with clinical outcomes (survival, HRQoL)</p>

<p>1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60</p> <p>What are the best treatments that cure or delay the progression (worsening) of non-alcohol-related fatty liver disease (NAFLD)?</p>	<p>13 (include pharmacological interventions)</p>	<p>More than 10 published trials on lifestyle interventions and more than 20 trials on nutritional supplementation with no recent high-quality systematic reviews</p> <p><u>Pharmacological interventions</u> 44 trials</p>	<p>Lifestyle intervention studies and nutritional supplementation</p> <p>Not applicable as there are no high quality systematic reviews</p> <p><u>Pharmacological intervention studies</u> Health-related quality of life (2 trials), resolution of fatty liver disease (11 trials),</p>	<p>High-quality systematic reviews on lifestyle interventions (one review) and nutritional supplementation to cure or delay the progression of NAFLD and high-quality RCTs on pharmacological</p>
--	---	---	--	---

			mortality (2 trials), cirrhosis (2 trials), cardiovascular events (2 trials) ^e	interventions with clinical outcomes (survival, HRQoL)
What is the best immunosuppressive regimen in adults undergoing liver transplantation?	¹⁴ (covers only maintenance immunosuppression)	<u>Induction immunosuppression</u> More than 20 published trials <u>Maintenance immunosuppression</u> 4 trials	<u>Induction immunosuppression</u> Not applicable as there is no high quality systematic review <u>Maintenance immunosuppression</u>	High-quality systematic review on induction immunosuppressive regimen and high-quality RCTs on maintenance immunosuppression

			Graft survival (1 trial) Adverse events (1 trial) Hepatocellular carcinoma (1 trial) ^e	suppression with important clinical outcomes (overall survival, HRQoL)
Should general public be educated about non-alcohol-related fatty liver disease (NAFLD) with an aim to reduce the numbers of those that have it?	None	None	-	High-quality RCTs on education to prevent NAFLD
What are the best treatments that cure or delay the progression (worsening) of autoimmune hepatitis (AIH)?	None	15 trials	Survival (1 trial), health-related quality of life (1 trial) ^e	High quality RCTs with clinical outcomes (survival, HRQoL)

<p>What are the best treatments that cure or delay the progression (worsening) of non-alcohol related steatohepatitis (NASH)?</p>	<p>The evidence related to this question is covered under non-alcohol related fatty liver disease by performing a subgroup analysis of people with NASH</p>			
<p>Prior to liver transplantation, is it better to transport the donor liver using a machine which pumps blood or preservation solution through the liver (machine perfusion) or is it better to transport it in the standard way of transporting it immersed in cold preservation solution (cold storage)?</p>	<p>None</p>	<p>5 trials</p>	<p>Overall survival (4 trials), graft survival (5 trials), health-related quality of life (2 trials)</p>	<p>Await results of the RCTs (all expected to complete by the end of 2019) and perform a high quality systematic review.</p>
<p>What are the best treatments that cure or delay the progression (worsening) of primary biliary cholangitis (PBC)?</p>	<p>¹⁵</p>	<p>24 trials</p>	<p>Health-related quality of life (5 trials), relief of</p>	<p>High-quality RCTs with clinical outcomes</p>

			symptoms (5 trials) ^e	(survival, HRQoL)
Are there any treatments that reverse the liver damage in primary sclerosing cholangitis (PSC)?	The evidence related to this question is covered under treatments for primary sclerosing cholangitis. The systematic review did not include fibrosis as one of the outcomes. Nine of the trials included in the systematic review reported on fibrosis. Two of the trials not included in the systematic review (and listed above) reported on liver fibrosis.			

243

244 a Numbers indicate the reference number.

245 b Further well-designed randomised controlled trials using clinical outcomes were recommended by
246 all these systematic reviews.

247 c Ongoing trials, unpublished trials, or trials published since the search date for the systematic
248 review when a high-quality systematic review based on randomised controlled trials exists. If no
249 systematic reviews based on randomised controlled trials exist, these are either published trials or
250 ongoing studies.

251 d This information is reported to find out whether the important patient-oriented outcomes are
252 reported in the trials not covered by high-quality systematic reviews. This is to help with deciding
253 whether new randomised controlled trials are necessary on the topic.

254 e The remaining trials reported treatment-related adverse events, composite outcomes and
255 surrogate markers.

256

1
2
3 257 The complete list of questions in the Delphi process, the proportion of respondents who
4
5 258 considered a research question as very important and the summary scores in each Delphi round is
6
7 259 available in Online Supplement Appendix 4. This appendix also has the breakdown of the proportion
8
9 260 of patients, carers, and general public who considered a research question as very important and
10
11 261 their summary scores in each Delphi round along with similar summary measures for healthcare
12
13 262 professionals.

17 18 263 **DISCUSSION**

19
20
21
22 264 This is the first priority setting partnership on non-alcohol related liver and gallbladder disorders.
23
24 265 This included a wide range of disease processes and a total of 428 unique research questions that
25
26 266 met the scope of this priority setting partnership were identified. All the research questions were
27
28 267 considered unanswered as there had been no high quality systematic reviews which indicated that
29
30 268 no further research is required, i.e. all the research questions were uncertainties. Consensus that an
31
32 269 uncertainty was a very important research priority was reached for six research questions. Four
33
34 270 additional research questions with the highest proportion of Delphi panel members ranking the
35
36 271 question as highly important were added to constitute the top 10 research priorities.

37
38
39
40 272 As evident from the online supplement Appendix 1, longevity of life and health-related
41
42 273 quality of life are two major outcomes that appear important to patients, their carers, and
43
44 274 healthcare professionals. However, even when there are ongoing trials, it appears that the outcomes
45
46 275 in those trials will not address the outcomes listed in eight of the top 10 research questions (Table
47
48 276 2). Therefore, the next step in addressing these uncertainties is the design and conduct of
49
50 277 randomised controlled trials. Such randomised controlled trials may involve qualitative studies to
51
52 278 determine the design and should compare the treatments that improve the longevity of life and/or
53
54 279 health-related quality of life.

1
2
3 280 It should be noted that uncertainties ‘what are the best treatments that cure or delay the
4
5 281 progression (worsening) of non-alcohol-related fatty liver disease (NAFLD)?’ and ‘what are the best
6
7 282 treatments that cure or delay the progression (worsening) of non-alcohol related steatohepatitis
8
9 283 (NASH)?’ are related to each other. Although NAFLD includes NASH, most of the panel members felt
10
11 284 that the research questions related to NAFLD and NASH should be kept separate uncertainties.
12
13
14 285 While the same systematic review can cover both the uncertainties, the primary research study
15
16 286 designed to address these two questions differ in terms of the setting, the outcomes used, and the
17
18 287 period of follow-up. Any primary research that tries to answer these two questions in a single
19
20 288 randomised controlled trial will be inefficient.

21
22
23 289 Similarly, for the uncertainties ‘what are the best treatments that cure or delay the
24
25 290 progression (worsening) of primary sclerosing cholangitis (PSC)’ and ‘are there any treatments that
26
27 291 reverse the liver damage in primary sclerosing cholangitis (PSC)?’, a single randomised controlled
28
29 292 trial will be inefficient and the preference of most of the panel members was to keep these
30
31 293 uncertainties as separate uncertainties.

32
33
34 294 There are several limitations to our priority setting process. The first one is deviation from
35
36 295 the original protocol. To select the final top priorities, the initial plan was to arrive at consensus by
37
38 296 open small group and large group discussions of patients, carers, and healthcare professionals as
39
40 297 suggested by the standard James-Lind Alliance process⁸, which provides an opportunity for a
41
42 298 knowledge exchange of viewpoints and experience. However, part of the steering committee with
43
44 299 experience in a similar priority setting partnership felt that open discussions resulted in ‘loud voices’
45
46 300 being given more importance resulting in an unrepresentative list of top priorities. While this can be
47
48 301 mitigated by facilitated group discussions by neutral JLA facilitators to ensure that all voices were
49
50 302 heard in the discussions, this was considered by the steering committee as an important source of
51
52 303 bias based on their prior experience in participating in open discussions. The steering committee
53
54 304 therefore decided to follow the Delphi-consensus method which is one of the major consensus
55
56 305 methods¹⁰. The advantages of Delphi-consensus method over open discussions include anonymity of
57
58
59
60

1
2
3 306 the response and the equal weight given to the opinions of all members ¹⁰. In addition, they are less
4
5 307 costly to conduct without any limitation by geographical location compared to other methods of
6
7 308 consensus¹⁰ because of the lack of necessity to travel and take time off regular work. However, there
8
9
10 309 is considerable variability in the previous performance of Delphi processes with regards to the
11
12 310 number of rounds and the criteria for achieving consensus ¹⁶. Arriving at consensus depends upon
13
14 311 people revising their scores based on the other's scores. Our initial plan was to extend the Delphi to
15
16 312 four rounds if consensus on 10 top research priorities was not reached in three rounds. However,
17
18 313 there was minimal change in scores between the rounds for most questions (Online Supplement
19
20 314 Appendix 3) and the Delphi process was completed in three rounds. Consensus on a top research
21
22 315 priority was achieved for six questions only. However, the proportion of Delphi panel members
23
24 316 ranking a question as highly important was greater than 70% for the remaining four questions added
25
26 317 to the list of top research priorities. Previous Delphi consensus processes have used various cut-off
27
28 318 points for defining consensus: greater than 70% agreement among panel members is well within the
29
30 319 definition of consensus used in previous Delphi consensus processes ¹⁶.

35 320 The other major limitation of our priority setting process is the representativeness of the
36
37 321 people who completed the survey and took part in the Delphi process. The online survey was shared
38
39 322 among clinicians and members of general and disease-specific patient organisations. Most questions
40
41 323 resulting from the online survey relate to chronic liver disease (in particular, autoimmune liver
42
43 324 diseases), perhaps reflecting the high motivation to support research from those groups. The Delphi
44
45 325 panel also had a high representation of people related to chronic liver disease (in particular,
46
47 326 autoimmune liver diseases) as patients, carers, or healthcare professionals. Whilst people affected
48
49 327 by different liver and gallbladder disorders were actively sought through both general and disease-
50
51 328 specific patient support groups and organisations, only a few responded and completed all three
52
53 329 rounds of the Delphi process. The potential bias towards prioritising chronic liver diseases is evident
54
55 330 as nine of the top 10 research priorities relate to chronic liver diseases (four relate to autoimmune
56
57 331 liver diseases, three related to non-alcohol related fatty liver disease, two related to liver

1
2
3 332 transplantation). It was surprising that the uncertainties related to the treatment of chronic viral
4
5 333 diseases such as chronic hepatitis B and chronic hepatitis C were not identified within the top 10
6
7 334 research priorities. This may be because of the perception by the some of the panel members that
8
9 335 the research questions related to the treatment of chronic hepatitis C were answered with the
10
11 336 advent of directly acting antivirals (personal communication). The reason for non-prioritisation of
12
13 337 chronic hepatitis B is not entirely clear. This may be because chronic hepatitis B may not have been
14
15 338 considered as important as other chronic liver diseases or under-representation of chronic hepatitis
16
17 339 B in the panel.

20
21 340 Cancer-related questions, childhood-related liver diseases, and other benign disorders did
22
23 341 not end up in the top research priorities (except for the treatment of very early hepatocellular
24
25 342 carcinoma, which is managed by hepatologists and surgeons) probably for the reasons described
26
27 343 above. We recommend that separate prioritisation processes are carried out for people with
28
29 344 gallstones, a condition that affects approximately 5% to 25% of the population ¹⁷, for people with
30
31 345 primary and secondary liver cancer, and childhood liver disorders where significant uncertainties
32
33 346 remain on the effectiveness of different treatments in decreasing mortality and improving health-
34
35 347 related quality of life.

36
37 348 As well as the above limitation, we are aware of the inherent limitations of using solely
38
39 349 technology to carry out the Delphi exercise. These are limitations that can potentially lead to bias in
40
41 350 any consensus-building method including that of face-to-face consensus methods normally used in a
42
43 351 JLA PSP.

44
45 352 One solution which might address the limitations of this priority setting process and the
46
47 353 standard JLA process may be to collect information routinely from patients visiting hospitals using
48
49 354 paper forms and conduct online meetings (video conferencing and presentation) before the final
50
51 355 round of the Delphi (or the standard face-to-face priority setting workshop used by the JLA. Some
52
53 356 JLA PSPs do use methods such as face-to face interviews and group discussions rather than solely
54
55
56
57
58
59
60

1
2
3 357 online surveys). By collecting information on paper forms and conducting the meetings in hospitals,
4
5 358 it is possible to engage with people who do not have access to or are not familiar with computers. It
6
7 359 is also possible to engage with people who have concerns regarding data confidentiality with the use
8
9
10 360 of computers or social media by collecting information using paper forms. Ethical and confidentiality
11
12 361 issues will need to be considered prior to engaging patients attending hospital in the research
13
14 362 prioritisation process.

17 363 Another limitation of our priority setting process is the drop-outs during the Delphi process.
18
19 364 While some of the drop-outs may be related to the ability to complete online surveys and use
20
21 365 Microsoft Excel, some patient representatives or clinicians may have dropped out because they did
22
23 366 not find any research question to be of direct relevance to them. Other reasons include lack of
24
25 367 understanding of the conditions, feeling that the process was too complicated, feeling that the
26
27 368 process would not work, and the time commitment for the process. This is because of the broad
28
29 369 scope of this research prioritisation process and may be overcome by choosing a narrower focus
30
31 370 while defining the scope of the prioritisation process, and by better explanation of the disease
32
33 371 processes through presentations.

38 372 It should also be recognised that the Delphi panel was constituted of representatives from
39
40 373 England, Scotland, and Wales. Therefore, the findings are applicable in only these countries.
41
42 374 However, the findings are likely to be applicable throughout the NHS and in other European and
43
44 375 Western countries with a similar spectrum of chronic liver diseases and similar treatment options
45
46 376 available.

50 377 In summary, there are significant uncertainties in the management of liver and gallbladder
51
52 378 disorders. Further high-quality research is necessary to address these uncertainties which may
53
54 379 require programmes of basic, translational, clinical, and public health research. For issues with
55
56 380 diverse and unproven treatment options, randomised controlled trials may be the only mechanism
57
58 381 for identifying the most effective treatment and the treatments that represent good value for
59
60

1
2
3 382 money for the NHS. Such randomised controlled trials should assess the effect of different
4
5 383 treatments in improving longevity of life and/or health-related quality of life.
6
7
8

9 384 **ACKNOWLEDGEMENTS**

10
11
12
13 385 We thank Mr Andrew Langford, previous Chief Executive of British Liver Trust, participants in the
14
15 386 survey, Ms Caroline Whiting and Ms Beccy Maeso, JLA PSP co-ordinators for their advice on the
16
17 387 process and comments on the manuscript, and the Delphi panel members who preferred to remain
18
19 388 anonymous in contributing to this research prioritisation process.
20
21
22

23 389 **FUNDING**

24
25
26
27
28 390 There was no external funding.
29
30

31 391 **CONTRIBUTION OF AUTHORS**

32
33
34
35
36 392 Kurinchi Gurusamy – conceptualisation, healthcare professional and methodological lead of steering
37
38 393 committee, Delphi panel member, analysis, author of the manuscript.
39

40
41 394 Martine Walmsley – Patients and carers lead of steering committee, Delphi panel member
42

43
44 395 Brian Davidson, Claire Frier, Barry Fuller, Angela Madden, Steven Masson, Ivana Safarik, Emmanouil
45

46 396 Tsochatzis – Steering committee, Delphi panel member, suggested revisions to the manuscript
47

48
49 397 Richard Morley – Steering committee, JLA advisor
50

51
52 398 Irfan Ahmed, Maxine Cowlin, John Dillon, Graham Ellicott, Ahmed Elsharkawy, Liz Farrington,
53

54 399 Anthony Glachan, Nagappan Kumar, EJ Milne, Simon Rushbrook, Amanda Smith, Lizzie Stafford,
55

56 400 Andrew Yeoman – Delphi panel member, suggested revisions to the manuscript
57
58
59
60

401 CONFLICTS OF INTEREST

402 The decisions made by healthcare professionals involved in the research prioritisation process might
403 have been influenced by their professional interests, in addition to their own, or family member's
404 experience of health conditions. Decisions made by patients and carers in the research prioritisation
405 process might have been influenced by their particular experiences, health needs and interests.

406 DATA SHARING AGREEMENT

407 All data is available in the manuscript or in the supplementary file.

408 FIGURE 1

409 Research prioritisation steps

410 The major steps in the research prioritisation are shown in the figure.

411 ^aThe protocol was registered with James-Lind Alliance Priority Setting Partnership

412 ^bThe final prioritisation was achieved by modified Delphi consensus method.

413 REFERENCES

- 414 1. Chalmers I. Confronting therapeutic ignorance. *BMJ* 2008;337:a841. doi:
415 10.1136/bmj.39555.392627.80 [published Online First: 2008/07/18]
- 416 2. James Lind Alliance Priority Setting Partnerships. About the James Lind Alliance.
417 <http://www.jlanihracuk/about-the-james-lind-alliance/> (accessed 6th April 2018) 2018

- 1
2
3 418 3. Crowe S, Fenton M, Hall M, et al. Patients', clinicians' and the research communities' priorities for
4
5 419 treatment research: there is an important mismatch. *Research Involvement and Engagement*
6
7 420 2015;1(1):2. doi: 10.1186/s40900-015-0003-x
8
9
10 421 4. Tallon D, Chard J, Dieppe P. Relation between agendas of the research community and the
11
12 422 research consumer. *The Lancet*;355(9220):2037-40. doi: 10.1016/S0140-6736(00)02351-5
13
14 423 5. James Lind Alliance Priority Setting Partnerships. Tinnitus PSP: What's happening to address the
15
16 424 priorities more than 4 years later? [http://www.jlanihracuk/news/tinnitus-psp-whats-](http://www.jlanihracuk/news/tinnitus-psp-whats-happening-to-address-the-priorities-more-than-4-years-later/5299)
17
18 425 [happening-to-address-the-priorities-more-than-4-years-later/5299](http://www.jlanihracuk/news/tinnitus-psp-whats-happening-to-address-the-priorities-more-than-4-years-later/5299) (accessed on 2 December
19
20 426 2018) 2017
21
22
23 427 6. National Institute for Health Research. Adding value in research 1: Identifying important research
24
25 428 topics. <https://www.nihracuk/about-us/documents/pillar-1-identifying-researchpdf> (accessed
26
27 429 on 2 December 2018) 2018
28
29
30 430 7. James Lind Alliance Priority Setting Partnerships. Alcohol-related liver disease.
31
32 431 <http://www.jlanihracuk/priority-setting-partnerships/alcohol-related-liver-disease/> (accessed
33
34 432 6th April 2018) 2018
35
36
37 433 8. James Lind Alliance Priority Setting Partnerships. JLA guidebook. [http://www.jlanihracuk/jla-](http://www.jlanihracuk/jla-guidebook/)
38
39 434 [guidebook/](http://www.jlanihracuk/jla-guidebook/) (accessed 6th April 2018) 2018
40
41 435 9. PSC Support. Welcome to PSC Support, dedicated to helping people affected by primary sclerosing
42
43 436 cholangitis. <https://www.pscsupportorguk/> (accessed 6th April 2018) 2018
44
45
46 437 10. Jones J, Hunter D. Consensus methods for medical and health services research. *BMJ*
47
48 438 1995;311(7001):376-80.
49
50 439 11. Majumdar A, Roccarina D, Thorburn D, et al. Management of people with early- or very early-
51
52 440 stage hepatocellular carcinoma: an attempted network meta-analysis. *The Cochrane*
53
54 441 *database of systematic reviews* 2017;3:CD011650. doi: 10.1002/14651858.CD011650.pub2
55
56 442 [published Online First: 2017/03/30]
57
58
59
60

- 1
2
3 443 12. Saffioti F, Gurusamy KS, Hawkins N, et al. Pharmacological interventions for primary sclerosing
4
5 444 cholangitis: an attempted network meta-analysis. *The Cochrane database of systematic*
6
7 445 *reviews* 2017;3:CD011343. doi: 10.1002/14651858.CD011343.pub2 [published Online First:
8
9 446 2017/04/19]
- 10
11
12 447 13. Lombardi R, Onali S, Thorburn D, et al. Pharmacological interventions for non-alcohol related
13
14 448 fatty liver disease (NAFLD): an attempted network meta-analysis. *The Cochrane database of*
15
16 449 *systematic reviews* 2017;3:CD011640. doi: 10.1002/14651858.CD011640.pub2 [published
17
18 450 Online First: 2017/03/31]
- 19
20
21 451 14. Rodriguez-Peralvarez M, Guerrero-Misas M, Thorburn D, et al. Maintenance immunosuppression
22
23 452 for adults undergoing liver transplantation: a network meta-analysis. *The Cochrane database*
24
25 453 *of systematic reviews* 2017;3:CD011639. doi: 10.1002/14651858.CD011639.pub2 [published
26
27 454 Online First: 2017/04/01]
- 28
29
30 455 15. Saffioti F, Gurusamy KS, Eusebi LH, et al. Pharmacological interventions for primary biliary
31
32 456 cholangitis: an attempted network meta-analysis. *The Cochrane database of systematic*
33
34 457 *reviews* 2017;3:CD011648. doi: 10.1002/14651858.CD011648.pub2 [published Online First:
35
36 458 2017/03/30]
- 37
38
39 459 16. Diamond IR, Grant RC, Feldman BM, et al. Defining consensus: a systematic review recommends
40
41 460 methodologic criteria for reporting of Delphi studies. *J Clin Epidemiol* 2014;67(4):401-9. doi:
42
43 461 10.1016/j.jclinepi.2013.12.002 [published Online First: 2014/03/04]
- 44
45
46 462 17. Gurusamy KS, Davidson BR. Gallstones. *BMJ* 2014;348:g2669. doi: 10.1136/bmj.g2669
- 47
48
49
50 463
51
52
53
54
55
56
57
58
59
60




Figure 1: Research prioritisation steps

The major steps in the research prioritisation are shown in the figure.

^aThe protocol was registered with James-Lind Alliance Priority Setting Partnership

^bThe final prioritisation was achieved by modified Delphi consensus method.

119x177mm (300 x 300 DPI)

Appendix 1 List of all research questions

Patient/population	Intervention	Control	Outcomes
People with obesity	Lifestyle: diet	No intervention	<ol style="list-style-type: none"> 1. Liver transplantation 2. Improvement in BMI. 3. Improved liver function
People with liver disease	Nurse-led care	Standard care	Ability to self-manage
People with asymptomatic chronic liver disease	Education of people	No intervention	<ol style="list-style-type: none"> 1. Improvement in life style. 2. Fatty liver disease
People with NASH (non-alcoholic steatohepatitis)	Different medical treatments	No intervention	<ol style="list-style-type: none"> 1. Halting disease progression. 2. Reversing disease progression. 3. Slowing disease progression. 4. Cure
People with primary sclerosing cholangitis	Treatment for primary sclerosing cholangitis	No intervention	<ol style="list-style-type: none"> 1. Mortality 2. HRQoL (health-related quality of life)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

			<ul style="list-style-type: none"> 3. Fewer symptoms - pain, itching, fatigue 4. improved liver function 5. Cure 6. Time to liver transplantation 7. Improvement (no further details) 8. Decreased hospital admission 9. Disease progression 10. Remission from PSC 11. Cancer 12. Requirement for liver transplant.
People with liver disease	Methods to improve compliance to treatment	Not applicable	<ul style="list-style-type: none"> 1. HRQoL 2. Mortality
General population	Screening: early identification of people at risk of liver disease	No screening	<ul style="list-style-type: none"> 1. HRQoL 2. Mortality

<p>1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29</p> <p>People at risk of liver disease</p>	<p>Diagnosis: early identification of people with liver disease</p>	<p>Not applicable</p>	<p>1. HRQoL 2. Mortality 3. Prevention of liver disease 4. Slowing progression of liver disease 5. Reducing requirement for liver transplantation 6. Adverse events of medications</p>
<p>30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60</p> <p>People with primary sclerosing cholangitis and who have had a liver transplant and still have ulcerative colitis even after a sub total colectomy</p>	<p>Symptomatic treatment for primary sclerosing cholangitis</p>	<p>Not applicable</p>	<p>1. HRQoL. 2. Decrease in symptoms (breathlessness and fatigue). 3. Mortality. 4. Decrease in medication. 5. Cure. 6. Decreased progression of primary sclerosing cholangitis.</p>

			7. Improvement in symptoms (unspecified).
People at risk of liver disease (overweight or obese)	Diagnosis: Accurate non-invasive method for diagnosis of chronic liver disease	Not applicable	<ol style="list-style-type: none"> 1. Death 2. Need for liver transplant 3. Requirement for hospital admission. 4. Demonstrating equivalence to biopsy 5. Demonstrating good reproducibility
People at risk of liver disease (overweight or obese)	Screening methods to diagnose liver disease (including history and diagnostic tests)	Not applicable	<ol style="list-style-type: none"> 1. Proportion of people at risk of liver disease 2. Proportion of people at risk who have asymptomatic liver fibrosis 3. Early diagnosis and treatment
People with polycystic liver disease	Treatment for polycystic disease	Not applicable	<ol style="list-style-type: none"> 1. Decrease symptoms 2. Increase quality of

			<p>life</p> <p>3. Decrease size of cyst or preventing cysts to enlarge</p> <p>4. Increased longevity</p> <p>5. Requirement for liver transplant.</p>
<p>People with autoimmune hepatitis</p>	<p>Treatments for autoimmune hepatitis.</p>	<p>Not applicable</p>	<p>1. HRQoL (including ability to carry out normal activities, study, work).</p> <p>2. Fatigue.</p> <p>3. Osteoporosis (treatment-related).</p> <p>4. Cataracts (treatment-related).</p> <p>5. Infections (treatment-related).</p> <p>6. Weight gain (treatment-related).</p> <p>7. Treatment related side-effects (unspecified).</p> <p>8. Brittle teeth</p>

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

			<p>(treatment-related).</p> <p>9. More effective treatment unspecified.</p> <p>10. Complete recovery (unspecified).</p> <p>11. Mortality.</p> <p>12. Measure feeling well (unspecified)</p> <p>13. Fewer flare ups</p> <p>14. Less joint pain.</p> <p>15. Disability</p> <p>16. Liver damage requiring hospital admission</p> <p>17. Quicker recovery</p> <p>18. More monitoring of patients</p> <p>19. Symptom control.</p> <p>20. Side-effects</p>
<p>People with autoimmune hepatitis</p>	<p>Standardised protocol care</p>	<p>Standard care</p>	<p>1. HRQoL.</p> <p>2. Fatigue.</p> <p>3. Osteoporosis</p>

			<p>(treatment-related).</p> <p>4. Cataracts</p> <p>(treatment-related).</p> <p>5. Infections</p> <p>(treatment-related).</p> <p>6. Weight gain</p> <p>(treatment-related).</p>
<p>People with autoimmune hepatitis</p>	<p>Treatment of fatigue/joint pain related to autoimmune hepatitis.</p>	<p>Not applicable</p>	<p>1. HRQoL.</p> <p>2. Fatigue.</p> <p>3. Osteoporosis</p> <p>(treatment-related).</p> <p>4. Cataracts</p> <p>(treatment-related).</p> <p>5. Infections</p> <p>(treatment-related).</p> <p>6. Weight gain</p> <p>(treatment-related).</p> <p>7. Joint pain.</p> <p>8. Symptoms</p> <p>(unspecified).</p>
<p>People with autoimmune hepatitis</p>	<p>Nurse-led care</p>	<p>Standard care</p>	<p>1. Faster recovery.</p> <p>2. HRQoL.</p> <p>3. Symptoms.</p>

1 2 3 4 5 6 7 8 9 10 11	People with autoimmune hepatitis	Education of healthcare professionals and patients	Standard care	<ol style="list-style-type: none"> 1. Faster recovery. 2. HRQoL. 3. Symptoms.
12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42	People with autoimmune hepatitis	Lifestyle: diet	Standard care	<ol style="list-style-type: none"> 1. Treatment related adverse events. 2. Requirements for liver transplantation. 3. NHS (National Health Service, UK) costs 4. HRQoL 5. Mortality. 6. Free from immunosuppressive therapies. 7. Fatigue. 8. Weight.
43 44 45 46 47 48 49 50 51 52	People with autoimmune hepatitis	Education of people	Standard care	<ol style="list-style-type: none"> Faster reduction in strong medications. Need for liver transplantation.
53 54 55 56 57 58 59 60	People with autoimmune hepatitis	Cannabis + standard care	Standard care	<ol style="list-style-type: none"> 1. Reduction in immunosuppressants.

			<p>2. Fatigue.</p> <p>3. Treatment related side effects such as serious infections, anxiety, depression, cancer, physical side effects.</p>
<p>General population (> 40 years or >50 years or middle-aged people, particularly overweight/obese and/or have type 2 diabetes and/or a family history of chronic liver disease)</p>	<p>Screening for liver disease by GP using routine blood tests/other methods</p>	<p>Standard care</p>	<p>1. Earlier diagnosis and treatment.</p> <p>2. Preventing liver disease progressing to cirrhosis.</p> <p>3. More cost effective for NHS.</p> <p>4. Preventing the complications of chronic liver disease such as hepatocellular carcinoma and varices.</p>
<p>People with autoimmune hepatitis</p>	<p>Prednisolone</p>	<p>No intervention</p>	<p>1. Obesity.</p> <p>2. Osteoporosis.</p> <p>3. Insomnia.</p> <p>4. Hypertension.</p>

1 2 3 4 5 6 7 8 9	People with genetic markers associated with autoimmune hepatitis.	Methods for prophylaxis	No intervention	Prevention of autoimmune hepatitis
10 11 12 13	People with autoimmune hepatitis	Lifestyle: optimal physical exercise	Not applicable	1. Weight 2. Fatigue
14 15 16 17 18	People with autoimmune hepatitis (stable)	Nurse-led care	Standard care	1. Fatigue
19 20 21 22	People with suspected autoimmune hepatitis	Methods to make a quicker diagnosis	Not applicable	1. Earlier diagnosis
23 24 25 26 27 28 29	People with NASH, diabetes, and gastroparesis	Treatments for breathlessness and pain	Not applicable	1. Breathlessness and pain.
30 31 32 33 34	People with NASH cirrhosis, diabetes, and anaemia	Treatments	Not applicable	HRQoL
35 36 37 38	People with NASH cirrhosis, diabetes, and anaemia	Education of people	Standard care	Better knowledge
39 40 41	General population	Education of people	Standard care	Better knowledge
42 43 44 45 46 47	People with NASH cirrhosis, diabetes, and anaemia	Non-pharmacological treatments to decrease pain and depression	Pharmacological interventions or no intervention	1. Pain 2. Depression
48 49 50 51 52 53 54 55 56 57	People with suspected autoimmune diseases with potential to cause acute liver failure	Diagnosis of autoimmune diseases that cause acute liver failure	Not applicable	Identification of specific autoimmune diseases

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60	People with autoimmune diseases with potential to cause acute liver failure	Prophylactic treatments	Not applicable	Prevent acute liver failure
	People with primary sclerosing cholangitis	Lifestyle: diet (including alcohol consumption) and physical exercise	Not applicable	<ol style="list-style-type: none"> 1. Reduction in symptoms 2. Overall health benefits (unspecified) 3. Ability to return to useful occupation. 4. Reduce medication. 5. Reduce need for annual investigations.
	People with primary sclerosing cholangitis	Azathioprine	Other interventions	Treatment related adverse events
	People with autoimmune hepatitis	Non-pharmacological treatments to treat autoimmune hepatitis	Pharmacological interventions or no intervention	<ol style="list-style-type: none"> 1. Reduction in symptoms 2. HRQoL (including the ability to do everyday tasks/ back into education or employment)

1 2 3 4 5 6 7 8 9	People with primary sclerosing cholangitis	Itching receptor blockers	No intervention/ other interventions	Reduction in itching
10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29	People with primary sclerosing cholangitis with and without Vitamin D deficiency	Vitamin D supplements	Standard care	<ol style="list-style-type: none"> 1. Stop the progress of the disease. 2. Fewer flare ups of inflammatory bowel disease and primary sclerosing cholangitis. 3. Improve HRQoL 4. Less depression
30 31 32 33 34 35 36	People with primary sclerosing cholangitis and autoimmune hepatitis	Ursodeoxycholic acid	No intervention/ other interventions	Reducing symptoms
37 38 39 40 41 42 43	People at risk of primary sclerosing cholangitis and autoimmune hepatitis	Prophylactic treatments	No intervention	Prevention of the condition
44 45 46 47	People with autoimmune hepatitis	Non-steroidal interventions	Steroids	Adverse events
48 49 50 51 52 53 54 55 56 57 58 59 60	People at risk of autoimmune liver diseases	Prophylactic treatments	Not applicable	Reduction in those getting advanced liver disorders

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	People with autoimmune liver diseases (20 to 30 years old)	Treatments	Not applicable	1. Reduction in those getting advanced liver disorders. 2. Stabilisation of disorder. 3. Reduction in liver cancer rates.
19 20 21 22 23 24 25	People with autoimmune liver diseases (> 30 years)	Screening: Early diagnosis of liver cancer	No screening	Early diagnosis of liver cancer
26 27 28 29 30 31 32 33 34	People with NASH and stroke	Nurse-led care	Standard care	1. Recovery time 2. Amount of recovery that is made
35 36 37 38	People with haemochromatosis	Lifestyle: iron avoidance diet	Traditional phlebotomy	Reduction in iron levels
39 40 41 42 43	People with haemochromatosis	Acceleration of phlebotomy	Traditional phlebotomy	Reduction in iron levels
44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60	People with NAFLD	Nurse-led care	Standard care	1. Faster recovery. 2. Symptom relief (unspecified). 3. Prevention of more serious complications. 4. Patient education

			<p>on diet and exercise to lose weight.</p> <p>5. Preventing progression into NASH and cirrhosis.</p> <p>6. Reducing symptoms of aching sides, leg weakness, sickness and nausea.</p> <p>7. Prevent heart attacks and strokes.</p>
People with NAFLD	Treatments for pain	Not applicable	Reducing pain
People with NAFLD	Treatments for itching	Not applicable	Reduction in itching
People at risk of liver disease (overweight or obese)	Education of healthcare professionals about NAFLD	Standard care	<p>1. Prevention of cirrhosis.</p> <p>2. Prevention of other related liver complications.</p> <p>3. Earlier diagnosis and treatment of liver diseases.</p> <p>4. Increased knowledge.</p>
Midwives and healthcare professionals coming into	Education of healthcare	Standard care	1. Prevention of cirrhosis.

1 2 3 4 5 6 7 8 9	contact with children and young adults	professionals about liver disease		2. Prevention of other related liver complications.
10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31	People with chronic hepatitis C	Newer treatments	Older interventions	1. Treatment-related complications 2. Ability to perform usual activities such as work, study, housework. 3. Severe liver damage requiring hospital admission. 4. Decreased anxiety.
32 33 34 35 36	New-borns	Screening test for biliary atresia	No screening	Earlier diagnosis and treatment
37 38 39 40 41 42 43	Children who have undergone liver transplantation	Immunosuppressive regimens	Not applicable	Adverse events
44 45 46 47	People with liver-related disorders	Treatment for itching	Not applicable	Reduction or eradication of itching
48 49 50 51 52	People with primary biliary cholangitis	Education of people	Standard care	Knowledge
53 54 55 56 57 58 59 60	People with positive AMA (antimitochondrial antibody) M2	Prophylactic treatments	Not applicable	1. Prevention of primary biliary cholangitis.

			2. Reversion to a negative AMA M2 before cirrhosis develops.
People with positive AMA M2	Standardised protocol care by GP	Standard care	1. Prevention of primary biliary cholangitis. 2. Reversion to a negative AMA M2 before cirrhosis develops.
People with liver disease	Stem cell therapy	Standard care	1. Mortality 2. HRQoL (including ability to carry out normal activities including study and work) 3. Prolonging periods of remission 4. Reducing symptoms
People with liver disease	Bio-artificial livers	Standard care	1. Mortality 2. HRQoL (including ability to carry out normal activities)

			including study and work)
People with autoimmune hepatitis	Targeted therapy against autoimmunity	Standard care	1. Mortality 2. HRQoL (including ability to carry out normal activities including study and work)
People with primary biliary cholangitis not responding to ursodeoxycholic acid	Different treatments	Not applicable	1. Cure 2. Slowing of disease 3. Improved quality of life with respect to fatigue.
People with primary biliary cholangitis	Antiviral treatment	No intervention/ other interventions	1. Improvement in health (unspecified) 2. Mortality
People with primary biliary cholangitis	Treatment for itching and fatigue	Not applicable	1. HRQoL. 2. Anxiety. 3. Itching. 4. Fatigue. 5. Cure 6. Slowing of disease 7. Symptom relief
People with primary biliary cholangitis	Greater patient involvement	Standard care	1. HRQoL. 2. Anxiety.

1 2 3 4 5 6 7 8 9 10 11 12 13	People with liver and gallbladder disorders	Nurse-led care	Standard care	1. Symptoms. 2. Pain relief. 3. Quicker investigative measures.
14 15 16 17 18 19 20 21 22 23 24 25 26 27	People with pain after cholecystectomy (especially elderly and living alone)	Hospital based investigations to find the cause of pain, treatment of the cause of pain and discharged after pain relief	Symptomatic outpatient intervention	Pain relief
28 29 30 31 32 33 34	People with chronic hepatitis C	Ribavirin	No intervention/ other interventions	Osteoporosis
35 36 37 38 39 40	People with chronic hepatitis C taking ribavirin	Prophylactic treatments for osteoporosis	No prophylactic intervention	Osteoporosis
41 42 43 44 45 46 47 48 49 50 51 52	Healthcare professionals dealing with people with primary biliary cholangitis	Education of healthcare professionals about childhood liver disorders	Standard care	1. Knowledge 2. Better treatment of patients with primary biliary cholangitis
53 54 55 56 57 58 59 60	People with liver disease	Education of people	Standard care	1. Patient knowledge. 2. Visits to the

			hospital. 3. More patient responsibility
People with symptomatic primary sclerosing cholangitis	Different treatments	Not applicable	1. Cure of disease. 2. Delays progression of disease.
People with primary sclerosing cholangitis	Intervention to reverse liver damage	Not applicable	1. Mortality. 2. HRQoL. 3. Requirement for liver transplantation.
People with primary sclerosing cholangitis	Intervention to treat fatigue	Not applicable	1. HRQoL. 2. Fatigue.
People with primary sclerosing cholangitis	Intervention to treat itching	Not applicable	1. HRQoL. 2. Itching.
People with primary sclerosing cholangitis	Specialist interest doctor	Standard care	1. Mortality. 2. HRQoL. 3. Requirement for liver transplantation. 4. Symptom relief.
People at risk of oesophageal varices	Non-invasive assessment of oesophageal varices	Invasive assessment of oesophageal varices	Reduce bleeding oesophageal varices

1 2 3 4 5 6 7 8 9	People at risk of chronic liver disease	Alternative to biopsy for assessment of cirrhosis	Liver biopsy	Assessment of whole liver
10 11 12 13 14 15 16 17 18 19 20	People at risk of primary sclerosing cholangitis (PSC)	Early diagnosis of primary sclerosing cholangitis Alternate to liver biopsy	Not applicable	Not stated
21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49	People with primary sclerosing cholangitis with normal or relatively normal liver function tests	Alternative to UKELD (United Kingdom Model for End-Stage Liver Disease) scores for prioritisation for liver transplantation	UKELD	1. More accurate assessment of transplant need for transplant amongst PSC patients. 2. Reduction in numbers of 'low score' PSC patients becoming too ill for transplant, or not being offered a transplant once 'listed'.
50 51 52 53 54 55 56 57 58 59 60	People with positive AMA M2 with normal liver function tests	Ursodeoxycholic acid	No intervention	Slowing progression of primary biliary cholangitis

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60	People with suspected primary sclerosing cholangitis	Nurse-led care	Standard care	Earlier diagnosis and treatment
	People with liver failure of unknown reason	Investigations to find the cause of liver failure of unknown origin	Not applicable	More knowledge.
	People with Gilbert's syndrome	Treatment of fatigue related to Gilbert's syndrome	Not applicable	1. HRQoL. 2. Chronic fatigue. 3. Depression
	People with NAFLD (non-alcoholic fatty liver disease)	Breathing exercises	Standard care	1. Faster recovery. 2. Symptom relief 3. Prevention of more serious complications
	People with NASH cirrhosis	Treatment of symptoms	Not applicable	Improvement of symptoms
	People at risk of liver disease	Screening for autoimmune diseases	No screening	Earlier diagnosis and treatment
	People with autoimmune hepatitis	Treatment of symptoms	Not applicable	1. Measure feeling well (unspecified). 2. Fatigue having energy. 3. Fewer flare ups.

			4. Less joint pain. 5. Disability.
People with autoimmune hepatitis	Methods to decrease stress	Not applicable	1. Measure feeling well (unspecified). 2. Fatigue having energy. 3. Fewer flare ups. 4. Less joint pain. 5. Disability.
People with liver disease	Counselling for tremors and confusion	No counselling	Coping with symptoms
People with NAFLD	Staging of liver disease	Not applicable	1. Mortality. 2. Reversal of liver damage
People with NAFLD	Metformin	No intervention	1. Mortality. 2. Reversal of liver damage
People with NAFLD	Standardised protocol for diagnosis and treatment of NAFLD	Standard care	1. Mortality. 2. Reversal of liver damage
People with osteoarthritis	Anti-inflammatory drugs	Other interventions	Cirrhosis
People with diabetes	Adequate control of diabetes	Lack of adequate control of diabetes	1. NASH. 2. Cirrhosis.

1 2 3 4 5 6 7	People at risk of NAFLD	Screening: Early identification of causes	Standard care	Prevention of liver disease
8 9 10 11 12 13 14 15 16 17 18 19 20	People with NAFLD	Treatments	Not applicable	1. Cure 2. Prevention of liver disease 3. Disease progression 4. HRQoL
21 22 23 24 25 26 27 28 29 30 31 32	People with upper abdominal pain	Screening: Early scan with ultrasound, blood tests, and urine tests	Standard care	1. Early identification of liver and gallbladder diseases 2. Appropriate advice/treatment
33 34 35 36	People with NAFLD	Lifestyle: diet and exercise	Standard care	1. HRQoL
37 38 39 40	People with NAFLD	Specialist interest doctor	Standard care	1. HRQoL
41 42 43 44 45	People at risk of liver disease	Prophylactic interventions	Not applicable	1. Prevention of liver disease
46 47 48 49 50 51 52	People at risk of NAFLD	Prophylactic treatments	Not applicable	1. Prevention of NAFLD 2. Decrease NAFLD
53 54 55 56 57 58 59 60	People with NASH fibrosis	Lifestyle: exercise	Standard care	None stated

<p>1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36</p> <p>People with cryptogenic liver cirrhosis</p>	<p>Investigations to find the cause of cryptogenic cirrhosis</p>	<p>Not applicable</p>	<p>1. Reduction in liver disease diagnosis of the percentage regarded as cryptogenic.</p> <p>2. Establishment of relevant treatment pathways.</p> <p>3. Reduction in numbers of liver transplant required by earlier intervention using non-invasive treatment regimes.</p>
<p>37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60</p> <p>People with cirrhosis</p>	<p>Community-led psychological support (on lifestyle: diet and exercise, stress, work-life balance, and general well-being)</p>	<p>Standard care</p>	<p>1. Reduction of symptoms such as nausea, fatigue.</p> <p>2. Improved nutrition and healthier weights.</p> <p>3. Improved HRQoL</p> <p>4. Improved sense of wellbeing</p> <p>5. Successful work</p>

			<p>and job retention</p> <p>6. Good sense of self determination/empowerment and motivation</p> <p>7. Improved clinical markers (unspecified)</p>
Newborns	Screening for metabolic liver diseases	No screening	<p>1. Early treatment for people with metabolic liver disease (including dietary advice)</p> <p>2. Mortality.</p> <p>3. HRQoL.</p> <p>4. Prevent type 2 diabetes</p>
People with autoimmune hepatitis	Telephone-based care	Standard care	<p>1. Reduction in time spent in outpatients</p> <p>2. Less spent on car-parking at hospitals</p>
People with NASH and diabetes	Liver transplantation	Standard care	<p>1. Mortality</p>

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60	People with primary biliary cholangitis (newly diagnosed)	Adequate drinking water	Standard care	1. HRQoL. 2. Liver function tests.
	People with primary sclerosing cholangitis	Treatment targeted against deformation of bile duct	Standard care	1. Time to end-stage liver disease.
	People with bile duct cancer	Treatment targeted against deformation of bile duct	Standard care	Not stated
	People with gallbladder sludge with digestive symptoms	Avoiding surgery	Standard care	1. Symptom relief
	People with NAFLD	Education of healthcare professionals	Standard care	1. Greater awareness of conditions. 2. Preventative measures. 3. Greater knowledge base.
	People with NAFLD	Education of general public	Standard care	1. Greater awareness of conditions. 2. Preventative measures. 3. Greater knowledge base.

1 2 3 4 5 6 7 8 9 10 11	People with NAFLD	Methods to make an accurate diagnosis (including liver function tests)	Not applicable	Not stated
12 13 14 15 16	People with NAFLD (overweight)	Interventions to lose weight	Not applicable	Weight loss
17 18 19 20	People with liver disease (newly diagnosed)	Mental health support	Not applicable	Mental health
21 22 23 24 25 26 27	Children with multiple autoimmune disorders related to liver	Genetic testing of telomere lengths	Other tests/ no tests	Not stated
28 29 30 31 32 33 34 35 36	Children with multiple autoimmune disorders related to liver	Stem cell therapy	Standard care	Reduction in all conditions with only one drug with little side effects
37 38 39 40 41 42 43	People with primary biliary cholangitis (especially younger age group)	Treatments based on tools for predicting prognosis	Standard care	Better care for people with high risk of progression
44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60	People with chronic hepatitis C	Lifestyle: diet	Standard care	1. Improvement in overall health. 2. Decrease in liver damage requiring hospital admission. 3. Patient knowledge.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

			<p>4. Healthcare professional knowledge.</p> <p>5. Fewer treatment-related complications.</p> <p>6. Decreasing pain and discomfort.</p> <p>7. Clear guidelines for successful dietary needs.</p>
<p>Healthcare professionals dealing with people with chronic hepatitis C</p>	<p>Education of healthcare professionals (about diet)</p>	<p>Standard care</p>	<p>1. Improvement in overall health.</p> <p>2. Decrease in liver damage requiring hospital admission.</p> <p>3. Patient knowledge.</p> <p>4. Healthcare professional knowledge.</p> <p>5. Fewer treatment-related complications.</p> <p>6. Decreasing pain</p>

			and discomfort. 7. Clear guidelines for successful dietary needs.
Healthcare professionals dealing with people with NAFLD	Education of healthcare professionals (around support to patients on weight control, diet, exercise and life style)	Standard care	<ol style="list-style-type: none"> 1. Preventing progression into NASH and cirrhosis. 2. Reducing symptoms of aching sides, leg weakness, sickness and nausea. 3. Prevent heart attacks and strokes.
Family members of people with primary biliary cholangitis	Screening of family members for primary biliary cholangitis	No screening	<ol style="list-style-type: none"> 1. Establishing the genetic link for primary biliary cholangitis. 2. Earlier identification of primary biliary cholangitis who may have PBC or be at risk. 3. Cost-savings.

1 2 3 4 5 6 7 8 9	People with positive AMA M2 with normal liver function tests	Screening for cirrhosis using biopsy	No screening	Accurate diagnosis of primary biliary cholangitis.
10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27	People with primary biliary cholangitis	Screening for other autoimmune conditions associated with primary biliary cholangitis and complications related to primary biliary cholangitis	No screening	1. HRQoL. 2. Costs.
28 29 30 31	People with autoimmune liver disease	Treatment of fatigue and others symptoms	Not applicable	Remission
32 33 34 35 36 37 38 39 40	People with primary sclerosing cholangitis	Standardised protocol for follow-up of patients with primary sclerosing cholangitis	Standard care	1. Reduce need for annual investigations. 2. Costs.
41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60	People with other autoimmune disease	Screening for liver disease	No screening	1. Decreasing risk of severe liver damage and admission to hospital 2. Reducing the need for liver transplants 3. Decreasing the risk of liver cancer

			4. Mortality 5. HRQoL
People with NAFLD	Pathway for managing end of life care	Standard care	1. Patient and carer satisfaction 2. Patient HRQoL 3. Symptom relief.
People with decompensated liver disease	Lifestyle: nutritional treatment	Not applicable	1. Improved survival. 2. Reduced symptoms. 3. Improved nutritional status. 4. Improved Strength.
People with decompensated liver disease	Measuring energy requirements with indirect calorimeters	Current UK guidance on requirements (Parenteral & Enteral Nutrition Group) (high energy requirements)	1. Improved survival. 2. Reduced symptoms. 3. Improved nutritional status. 4. Improved Strength.
People with hepatic encephalopathy	Branch chain amino acids	Standard care	1. Improved survival. 2. Reduced symptoms. 3. Improved

			nutritional status. 4. Improved Strength.
People with decompensated liver disease with muscle wasting	Branch chain amino acids	Standard care	1. Improved survival. 2. Reduced symptoms. 3. Improved nutritional status. 4. Improved Strength.
People with decompensated liver disease with muscle wasting	Lifestyle: exercise	Standard care	1. Improved survival. 2. Reduced symptoms. 3. Improved nutritional status. 4. Improved Strength.
People with decompensated liver disease	Standardised nutritional assessment of patients and outcomes in nutritional intervention trials	Non-standardised assessment	1. Improved survival. 2. Reduced symptoms. 3. Improved nutritional status. 4. Improved Strength.

			5. Better conduct of future trials.
People with NAFLD	Methods to increase self care	Not applicable	Reducing symptoms
People with NAFLD	Methods to decrease shortness of breath	Not applicable	Reducing symptoms
People with liver disease	Interventions to decrease fatigue	Not applicable	Fatigue
Healthcare professionals dealing with people with cirrhosis	Education of healthcare professionals about cirrhosis (complications and benefits and harms of treatment)	Standard care	Better advice to patients by health professionals regarding complications and benefits and harms of different treatments
People with primary biliary cholangitis	Ursodeoxycholic acid (including optimal dose)	No intervention/ other interventions	1. Liver function tests. 2. Minimal effective dose of ursodeoxycholic acid. 3. Good sleep.
People with liver cancer and ascites	Different interventions	Not applicable	HRQoL

1 2 3 4 5 6 7 8 9 10 11	People with primary sclerosing cholangitis	Screening for cancer	No screening	1. Benefits 2. Earlier diagnosis of bile duct cancer 3. Mortality
12 13 14 15 16 17 18	People with primary or metastatic liver cancer	Nurse-led care (follow-up clinic)	Doctor-led follow-up	1. Patient satisfaction 2. Timely surveillance
19 20 21 22	People with cirrhosis	Life-style: nutritional advice	Not applicable	1. Fatigue 2. Muscle wasting
23 24 25 26 27	People with polycystic liver disease	Surgery	Non-surgical management	1. Recurrence 2. HRQoL
28 29 30 31 32 33 34	People with gallstones	Avoiding surgery	Surgery	1. Requirement for surgery 2. Costs to NHS
35 36 37 38 39 40 41 42 43 44 45	People at risk of NASH	Nurse-led care	No intervention	1. Early diagnosis of NASH. 2. Successful treatment of NASH. 3. Mortality
46 47 48 49 50 51 52 53 54 55 56 57 58 59 60	People at risk of NASH	Screening for NASH using Fibroscan	No intervention	1. Early diagnosis of NASH. 2. Successful treatment of NASH. 3. Mortality

<p>1 2 3 4 5 6 7 8 9 10 11 12 13 14</p> <p>People at risk of NASH</p>	<p>Support group focussed on diet and exercise</p>	<p>No intervention</p>	<p>1. Prevention of NASH. 2. Successful treatment of NASH. 3. Mortality</p>
<p>15 16 17 18</p> <p>People at risk of NASH</p>	<p>Emotional support group for carers</p>	<p>No intervention</p>	<p>HRQoL</p>
<p>19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36</p> <p>People with NASH</p>	<p>Nurse-led care</p>	<p>Standard care</p>	<p>1. Mortality. 2. HRQoL. 3. Requirement for liver transplantation. 4. Liver cancer. 5. Liver failure. 6. Treatment-related complications.</p>
<p>37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60</p> <p>People with NASH</p>	<p>Lifestyle: diet</p>	<p>Standard care</p>	<p>1. Mortality. 2. HRQoL. 3. Requirement for liver transplantation. 4. Liver cancer. 5. Liver failure. 6. Treatment-related complications.</p>

1 2 3 4 5 6 7 8 9	People with NASH	Different interventions to decrease anxiety and depression	Standard care	Anxiety and depression
10 11 12 13	People with NASH	Research design using support group	Standard research design	Help towards better research
14 15 16 17 18	General population	Life style: diet and exercise	No intervention	HRQoL
19 20 21 22 23 24 25	General population	Education of people (patient information leaflet at GP surgeries)	No intervention	1. Prevention of NASH. 2. HRQoL.
26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54	General population	Screening: for liver disease	No intervention	1. Early diagnosis of liver disease 2. Mortality 3. HRQoL 4. Requirement for liver transplantation 5. Costs 6. Requirement for hospital admission for severe liver damage 7. Primary liver cancer
55 56 57 58 59 60	Primary school children	Lifestyle: nutritional and dietary advice	No intervention	1. Adherence to healthy diet and

			exercise to sustain healthy life style.
People undergoing liver resection	Best method to assess function and volume of remnant liver	Not applicable	1. Mortality. 2. HRQoL. 3. Complications.
People undergoing liver resection	Best method to assess cardiopulmonary function?	Not applicable	1. Mortality. 2. HRQoL. 3. Complications.
People undergoing liver resection	Pre-operative education	Standard care	1. Mortality. 2. HRQoL. 3. Complications.
Surgeons treating people undergoing liver resection	Simulation and training of surgeons	Standard care	1. Mortality. 2. HRQoL. 3. Complications.
People undergoing liver resection	Growth factors to optimise muscle and fat content	Standard care	1. Mortality. 2. HRQoL. 3. Complications.
People undergoing liver resection	Pharmacological interventions for weight loss	Not applicable	1. Mortality. 2. HRQoL. 3. Complications.
People undergoing liver resection	Portal vein embolisation	Standard care	1. Mortality. 2. HRQoL. 3. Complications.

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60	People undergoing liver resection	Reducing systemic inflammation using steroids	Standard care	1. Mortality. 2. HRQoL. 3. Complications.
	People undergoing liver resection	Open liver resection	Laparoscopic liver resection	1. Mortality. 2. HRQoL. 3. Complications.
	People undergoing liver resection	Tumour visualisation and localisation of the tumour	Standard care	1. Mortality. 2. HRQoL. 3. Complications.
	People undergoing liver resection	Goal directed therapy during operation	Standard care	1. Mortality. 2. HRQoL. 3. Complications.
	Surgeons treating people undergoing liver resection	Use of magnifying surgical loupes during liver surgery	Standard care	1. Mortality. 2. HRQoL. 3. Complications.
	People undergoing liver resection	Portal vein pressure decrease (by the use of drugs such as vasopressin) during surgery	Standard care	1. Mortality. 2. HRQoL. 3. Complications.
	People undergoing liver resection	Transection techniques	Not applicable	1. Mortality. 2. HRQoL. 3. Complications.

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60	People undergoing liver resection	Vascular occlusion techniques	Not applicable	1. Mortality. 2. HRQoL. 3. Complications.
People undergoing liver resection	Cardiopulmonary and pharmacological interventions for decreasing blood loss	Not applicable	1. Mortality. 2. HRQoL. 3. Complications.	
People undergoing liver resection	Use of peritoneal drains	No drain	1. Mortality. 2. HRQoL. 3. Complications.	
People undergoing liver resection	ALPPS procedure (Associating Liver Partition and Portal vein Ligation for Staged hepatectomy)	Standard care	1. Mortality. 2. HRQoL. 3. Complications.	
People undergoing liver resection	Goal directed therapy (post-operative)	Standard care	1. Mortality. 2. HRQoL. 3. Complications.	
People undergoing liver resection	Pain control protocol	Standard care	1. Mortality. 2. HRQoL. 3. Complications.	
People undergoing liver resection	Early mobilisation protocol	Standard care	1. Mortality. 2. HRQoL. 3. Complications.	

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60	People undergoing liver resection	Early oral intake protocol	Standard care	1. Mortality. 2. HRQoL. 3. Complications.
	People undergoing liver resection	Portal vein pressure decrease (by the use of drugs such as vasopressin) post-operatively	Standard care	1. Mortality. 2. HRQoL. 3. Complications.
	People with unresectable hepatocellular carcinoma	Radioembolisation	No intervention/other interventions	1. Mortality. 2. HRQoL. 3. Complications.
	People with unresectable hepatocellular carcinoma	External beam radiotherapy	No intervention/other interventions	1. Mortality. 2. HRQoL. 3. Complications.
	People with chronic hepatitis B	Screening for cancer	No screening	1. Mortality. 2. HRQoL. 3. Complications.
	People with hepatocellular carcinoma	Cryotherapy	No intervention/other interventions	1. Mortality. 2. HRQoL. 3. Complications.
	People with hepatocellular carcinoma	Systemic chemotherapy	No intervention/other interventions	1. Mortality. 2. HRQoL. 3. Complications.

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60	People with early or very early hepatocellular carcinoma	Treatment	Not applicable	1. Mortality. 2. HRQoL. 3. Complications.
	People with intermediate hepatocellular carcinoma	Treatment	Not applicable	1. Mortality. 2. HRQoL. 3. Complications.
	People with hepatocellular carcinoma	Tamoxifen	No intervention/other interventions	1. Mortality. 2. HRQoL. 3. Complications.
	People with unresectable hepatocellular carcinoma	Transarterial embolisation	No intervention/other interventions	1. Mortality. 2. HRQoL. 3. Complications.
	People with unresectable hepatocellular carcinoma	Tyrosine kinase inhibitors	No intervention/other interventions	1. Mortality. 2. HRQoL. 3. Complications.
	People undergoing liver resection for hepatocellular carcinoma	Neoadjuvant and adjuvant therapy	No intervention/other interventions	1. Mortality. 2. HRQoL. 3. Complications.
	People with unresectable hepatocellular carcinoma	Transarterial chemoembolisation	No intervention/other interventions	1. Mortality. 2. HRQoL. 3. Complications.
	People with hepatocellular carcinoma	Interferon	No intervention/other interventions	1. Mortality. 2. HRQoL. 3. Complications.

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60	People with hepatocellular carcinoma	Surgical resection	Liver transplantation	1. Mortality. 2. HRQoL. 3. Complications.
People undergoing liver resection for hepatocellular carcinoma	Anterior approach	Conventional liver resection	1. Mortality. 2. HRQoL. 3. Complications.	
People with hepatocellular carcinoma	Radiofrequency ablation	No intervention/other interventions	1. Mortality. 2. HRQoL. 3. Complications.	
People undergoing liver resection for hepatocellular carcinoma	Post-operative transarterial chemoembolisation	No intervention/other interventions	1. Mortality. 2. HRQoL. 3. Complications.	
People undergoing liver resection for hepatocellular carcinoma	Post-operative lamivudine with or without adefovir dipivoxil	No intervention/other interventions	1. Mortality. 2. HRQoL. 3. Complications.	
People with advanced biliary tract carcinoma	gemcitabine-based chemotherapy	No intervention/other interventions	1. Mortality. 2. HRQoL. 3. Complications.	
People with unresectable cholangiocarcinoma	Endoscopic treatment	Surgery	1. Mortality. 2. HRQoL. 3. Complications.	
People undergoing liver transplantation	Pharmacological interventions for	No intervention/other interventions	1. Mortality. 2. HRQoL. 3. Complications.	

	reducing ischaemia reperfusion injury		
People undergoing liver transplantation for hepatitis B infection	Antibiotic prophylaxis	No intervention/other interventions	1. Mortality. 2. HRQoL. 3. Complications.
People undergoing liver transplantation for hepatitis B infection	Hepatitis B immune globulin	No intervention/other interventions	1. Mortality. 2. HRQoL. 3. Complications.
People undergoing liver transplantation	Prostaglandins	No intervention/other interventions	1. Mortality. 2. HRQoL. 3. Complications.
People undergoing haemopoietic stem cell transplantation	Interventions to prevent hepatic veno-occlusive disease	Not applicable	1. Mortality. 2. HRQoL. 3. Complications.
People undergoing haemopoietic stem cell transplantation	Interventions to treat hepatic veno-occlusive disease	Not applicable	1. Mortality. 2. HRQoL. 3. Complications.
People undergoing liver transplantation	Immunosuppressive regimens	Not applicable	1. Mortality. 2. HRQoL. 3. Complications.
People undergoing liver transplantation	Venovenous bypass	No intervention	1. Mortality. 2. HRQoL. 3. Complications.

1 2 3 4 5 6 7 8 9	People undergoing liver transplantation	Ischaemic preconditioning	No intervention	1. Mortality. 2. HRQoL. 3. Complications.
10 11 12 13 14 15 16	People undergoing liver transplantation	Methods of biliary reconstruction	Not applicable	1. Mortality. 2. HRQoL. 3. Complications.
17 18 19 20 21 22 23 24 25 26 27	People undergoing liver transplantation	Methods of preventing bacterial sepsis and wound complications after liver transplantation	Not applicable	1. Mortality. 2. HRQoL. 3. Complications.
28 29 30 31 32 33 34	People undergoing liver transplantation	Techniques of flushing and reperfusion	Not applicable	1. Mortality. 2. HRQoL. 3. Complications.
35 36 37 38 39 40 41	People undergoing liver transplantation	Abdominal drainage	No intervention	1. Mortality. 2. HRQoL. 3. Complications.
42 43 44 45 46 47	People undergoing liver transplantation	Piggy-back	Conventional liver transplantation	1. Mortality. 2. HRQoL. 3. Complications.
48 49 50 51 52 53 54 55 56 57 58 59 60	People undergoing liver transplantation	Methods to decrease blood loss and transfusion requirements	Not applicable	1. Mortality. 2. HRQoL. 3. Complications.

1 2 3 4 5 6 7 8 9	People undergoing liver transplantation	Antiviral prophylaxis for prevention of hepatitis C infection	Not applicable	1. Mortality. 2. HRQoL. 3. Complications.
10 11 12 13 14 15 16	People undergoing liver transplantation	Antiviral treatment of hepatitis C infection	Not applicable	1. Mortality. 2. HRQoL. 3. Complications.
17 18 19 20 21 22 23 24 25 26 27	People undergoing liver transplantation for hepatitis B infection	Lamivudine or adefovir dipivoxil	No intervention/other interventions including immunoglobulin	1. Mortality. 2. HRQoL. 3. Complications.
28 29 30 31 32 33 34	People undergoing liver transplantation	Nutritional interventions	Not applicable	1. Mortality. 2. HRQoL. 3. Complications.
35 36 37 38 39 40 41	People undergoing liver transplantation	Bile acids	No intervention/other interventions	1. Mortality. 2. HRQoL. 3. Complications.
42 43 44 45 46 47	People undergoing liver transplantation	Celsior solution	UW solution	1. Mortality. 2. HRQoL. 3. Complications.
48 49 50 51 52 53 54 55 56 57 58 59 60	People undergoing liver resection	Pharmacological interventions for reducing ischaemia reperfusion injury	No intervention/other interventions	1. Mortality. 2. HRQoL. 3. Complications.

1 2 3 4 5 6 7 8 9	People undergoing liver resection	Fibrin-based haemostatic agents	No intervention/other interventions	1. Mortality. 2. HRQoL. 3. Complications.
10 11 12 13 14 15 16	People undergoing liver resection for colorectal liver metastases	Neoadjuvant chemotherapy	No intervention/other interventions	1. Mortality. 2. HRQoL. 3. Complications.
17 18 19 20 21 22 23	People with colorectal liver metastases	Resection	Other interventions	1. Mortality. 2. HRQoL. 3. Complications.
24 25 26 27 28 29	People undergoing liver resection	Ischaemic preconditioning	No intervention	1. Mortality. 2. HRQoL. 3. Complications.
30 31 32 33 34 35 36	People undergoing liver resection	Interventions for reducing blood loss	No intervention/other interventions	1. Mortality. 2. HRQoL. 3. Complications.
37 38 39 40 41 42 43	People undergoing liver resection	Methods of decreasing infection	No intervention/other interventions	1. Mortality. 2. HRQoL. 3. Complications.
44 45 46 47 48 49	People with hepatic node positive colorectal liver metastases	Resection	No resection	1. Mortality. 2. HRQoL. 3. Complications.
50 51 52 53 54 55 56 57 58 59 60	People undergoing liver resection for resectable neuroendocrine tumours	Resection	No resection	1. Mortality. 2. HRQoL. 3. Complications.

1 2 3 4 5 6 7 8 9	People undergoing liver resection or ablation of colorectal liver metastases	Hepatic artery adjuvant chemotherapy	No intervention/other interventions	1. Mortality. 2. HRQoL. 3. Complications.
10 11 12 13 14 15 16	People undergoing liver resection	Laparoscopic liver resection	Open liver resection	1. Mortality. 2. HRQoL. 3. Complications.
17 18 19 20 21 22 23	People with hepatic encephalopathy	Nonabsorbable disaccharides	No intervention/other interventions	1. Mortality. 2. HRQoL. 3. Complications.
24 25 26 27 28 29	People with hepatic encephalopathy	Benzodiazepine receptor antagonists	No intervention/other interventions	1. Mortality. 2. HRQoL. 3. Complications.
30 31 32 33 34 35 36	People with hepatic encephalopathy	Antibiotics	No intervention/other interventions	1. Mortality. 2. HRQoL. 3. Complications.
37 38 39 40 41 42 43	People with hepatic encephalopathy	Dopamine agents	No intervention/other interventions	1. Mortality. 2. HRQoL. 3. Complications.
44 45 46 47 48 49	People with hepatic encephalopathy	Rifaximin	No intervention/other interventions	1. Mortality. 2. HRQoL. 3. Complications.
50 51 52 53 54 55 56 57 58 59 60	People with hepatic encephalopathy	Acetyl-L-carnitine	No intervention/other interventions	1. Mortality. 2. HRQoL. 3. Complications.

1 2 3 4 5 6 7 8 9	People with hepatic encephalopathy	Probiotics	No intervention/other interventions	1. Mortality. 2. HRQoL. 3. Complications.
10 11 12 13 14 15 16	People with hepatic encephalopathy	Naloxone	No intervention/other interventions	1. Mortality. 2. HRQoL. 3. Complications.
17 18 19 20 21 22 23	People with hepatic encephalopathy	L-ornithine-L-aspartate	No intervention/other interventions	1. Mortality. 2. HRQoL. 3. Complications.
24 25 26 27 28 29	People with NAFLD	Pharmacological treatments	Not applicable	1. Mortality. 2. HRQoL. 3. Complications.
30 31 32 33 34 35 36	People with NAFLD	Herbal medicines	No intervention/other interventions	1. Mortality. 2. HRQoL. 3. Complications.
37 38 39 40 41 42 43	People with NAFLD	Weight reduction	Not applicable	1. Mortality. 2. HRQoL. 3. Complications.
44 45 46 47 48 49	People with liver metastases	Transarterial (chemo)embolisation	No intervention/other interventions	1. Mortality. 2. HRQoL. 3. Complications.
50 51 52 53 54 55 56 57 58 59 60	People with liver metastases	Microwave coagulation	No intervention/other interventions	1. Mortality. 2. HRQoL. 3. Complications.

1 2 3 4 5 6 7 8 9	People with liver metastases	Cryotherapy	No intervention/oth er interventions	1. Mortality. 2. HRQoL. 3. Complications.
10 11 12 13 14 15 16	People with liver metastases	Radiofrequency ablation	No intervention/oth er interventions	1. Mortality. 2. HRQoL. 3. Complications.
17 18 19 20 21 22 23	People with unresectable neuroendocrine liver metastases	Palliative cytoreductive surgery	Other palliative interventions	1. Mortality. 2. HRQoL. 3. Complications.
24 25 26 27 28 29	People with unresectable colorectal liver metastases	Hepatic arterial infusion	Systemic chemotherapy	1. Mortality. 2. HRQoL. 3. Complications.
30 31 32 33 34 35 36	People with liver metastases	Electro-coagulation	No intervention/oth er interventions	1. Mortality. 2. HRQoL. 3. Complications.
37 38 39 40 41 42 43	People with liver metastases	Percutaneous ethanol injection	No intervention/oth er interventions	1. Mortality. 2. HRQoL. 3. Complications.
44 45 46 47 48 49	People with unresectable colorectal liver metastases	Chemotherapy for downstaging	No intervention/oth er interventions	1. Mortality. 2. HRQoL. 3. Complications.
50 51 52 53 54 55 56 57 58 59 60	People with colorectal liver metastases	Selective internal radiation therapy	No intervention/oth er interventions	1. Mortality. 2. HRQoL. 3. Complications.

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60	People with gallbladder polyp	Cholecystectomy	No cholecystectomy	1. Mortality. 2. HRQoL. 3. Complications.
	People with gallbladder dyskinesia	Cholecystectomy	No cholecystectomy	1. Mortality. 2. HRQoL. 3. Complications.
	People undergoing laparoscopic cholecystectomy	Methods of cystic duct occlusion	Not applicable	1. Mortality. 2. HRQoL. 3. Complications.
	People undergoing laparoscopic cholecystectomy for acute cholecystitis	Early laparoscopic cholecystectomy	Delayed cholecystectomy	1. Mortality. 2. HRQoL. 3. Complications.
	People undergoing cholecystectomy	Laparoscopic cholecystectomy	Open cholecystectomy	1. Mortality. 2. HRQoL. 3. Complications.
	People undergoing cholecystectomy	Laparoscopic cholecystectomy	Mini-incision cholecystectomy	1. Mortality. 2. HRQoL. 3. Complications.
	People undergoing cholecystectomy	Mini-incision cholecystectomy	Open cholecystectomy	1. Mortality. 2. HRQoL. 3. Complications.
	People undergoing laparoscopic cholecystectomy	Abdominal wall lift	Pneumoperitoneum	1. Mortality. 2. HRQoL. 3. Complications.

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60	People undergoing laparoscopic cholecystectomy	Abdominal drainage	No drain	1. Mortality. 2. HRQoL. 3. Complications.
	People undergoing laparoscopic cholecystectomy for biliary colic	Early laparoscopic cholecystectomy	Delayed cholecystectomy	1. Mortality. 2. HRQoL. 3. Complications.
	People undergoing laparoscopic cholecystectomy	Intra-peritoneal saline instillation	No instillation	1. Mortality. 2. HRQoL. 3. Complications.
	People undergoing laparoscopic cholecystectomy	Methods of intraperitoneal local anaesthetic instillation	Not applicable	1. Mortality. 2. HRQoL. 3. Complications.
	People undergoing laparoscopic cholecystectomy	Methods of local anaesthetic wound infiltration	Not applicable	1. Mortality. 2. HRQoL. 3. Complications.
	People undergoing laparoscopic cholecystectomy	Three-dimensional imaging	Two-dimensional imaging	1. Mortality. 2. HRQoL. 3. Complications.
	People with asymptomatic gallstones	Cholecystectomy	No cholecystectomy	1. Mortality. 2. HRQoL. 3. Complications.
	People undergoing open cholecystectomy	Abdominal drainage	No drain	1. Mortality. 2. HRQoL. 3. Complications.

1 2 3 4 5 6 7 8 9	People undergoing laparoscopic cholecystectomy	Robotic assistant	Human assistant	1. Mortality. 2. HRQoL. 3. Complications.
10 11 12 13 14 15 16	People undergoing laparoscopic cholecystectomy	Methods of gallbladder dissection	Not applicable	1. Mortality. 2. HRQoL. 3. Complications.
17 18 19 20 21 22 23 24 25	People undergoing laparoscopic cholecystectomy	Low pressure pneumoperitoneum	Standard pressure pneumoperitoneum	1. Mortality. 2. HRQoL. 3. Complications.
26 27 28 29 30 31 32	People undergoing laparoscopic cholecystectomy	Education of patients	Standard care	1. Mortality. 2. HRQoL. 3. Complications.
33 34 35 36 37 38	People undergoing laparoscopic cholecystectomy	Miniports	Standard ports	1. Mortality. 2. HRQoL. 3. Complications.
39 40 41 42 43 44 45	People undergoing laparoscopic cholecystectomy	Number of ports	Not applicable	1. Mortality. 2. HRQoL. 3. Complications.
46 47 48 49 50 51 52 53 54 55 56 57 58 59 60	People undergoing laparoscopic cholecystectomy	Pharmacological interventions for prevention or treatment of postoperative pain	Not applicable	1. Mortality. 2. HRQoL. 3. Complications.

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60	People undergoing laparoscopic cholecystectomy	Glucocorticoids	No intervention	1. Mortality. 2. HRQoL. 3. Complications.
	People who have undergone endoscopic sphincterotomy for gallstone related complications	Early cholecystectomy	Delayed or no cholecystectomy	1. Mortality. 2. HRQoL. 3. Complications.
	People undergoing laparoscopic cholecystectomy	Antibiotic prophylaxis	Not applicable	1. Mortality. 2. HRQoL. 3. Complications.
	People undergoing laparoscopic cholecystectomy	Day surgery	Overnight stay	1. Mortality. 2. HRQoL. 3. Complications.
	People undergoing day surgery laparoscopic cholecystectomy	Anaesthetic regimens	Not applicable	1. Mortality. 2. HRQoL. 3. Complications.
	People with common bile duct stones undergoing laparoscopic cholecystectomy	Per-operative endoscopic sphincterotomy	Pre-operative endoscopic sphincterotomy	1. Mortality. 2. HRQoL. 3. Complications.
	People with suspected bile duct stenosis	Magnetic resonance cholangiopancreatography	Not applicable	1. Mortality. 2. HRQoL. 3. Complications.

1 2 3 4 5 6 7 8 9 10 11	People with suspected bile duct stones	Endoscopic ultrasound	Magnetic resonance cholangiopancreatography	1. Mortality. 2. HRQoL. 3. Complications.
12 13 14 15 16 17 18	People with suspected bile duct stones	Endoscopic retrograde cholangiopancreatography	Intraoperative cholangiography	1. Mortality. 2. HRQoL. 3. Complications.
19 20 21 22 23 24 25	People with suspected bile duct stones	Liver function tests	Transabdominal ultrasound	1. Mortality. 2. HRQoL. 3. Complications.
26 27 28 29 30 31 32	People undergoing surgery for biliary tract cancer	Pre-operative biliary stenting	No stenting	1. Mortality. 2. HRQoL. 3. Complications.
33 34 35 36 37 38	People with uncomplicated amoebic liver abscess	Percutaneous procedure plus metronidazole	Metronidazole alone	1. Mortality. 2. HRQoL. 3. Complications.
39 40 41 42 43 44 45	People with benign liver tumours	Liver resection	No liver resection	1. Mortality. 2. HRQoL. 3. Complications.
46 47 48 49 50 51 52	People with sphincter of oddi dysfunction	Sphincterotomy	No sphincterotomy	1. Mortality. 2. HRQoL. 3. Complications.
53 54 55 56 57 58 59 60	People with cirrhosis	Colchicine	No intervention/other interventions	1. Mortality. 2. HRQoL. 3. Complications.

1 2 3 4 5 6 7 8 9	People with blunt liver injury	Non-surgical treatment	Surgery	1. Mortality. 2. HRQoL. 3. Complications.
10 11 12 13 14 15 16	People with common bile duct stones	Surgical treatment	Endoscopic intervention	1. Mortality. 2. HRQoL. 3. Complications.
17 18 19 20 21 22 23	People at risk of gallstones	Lifestyle: Diets for primary prevention of gallstones	Not applicable	1. Mortality. 2. HRQoL. 3. Complications.
24 25 26 27 28 29 30 31 32	People at risk of gallstones	Pharmacological interventions for primary prevention of gallstones	Not applicable	1. Mortality. 2. HRQoL. 3. Complications.
33 34 35 36 37 38	People with common bile duct stones	Sphincteroplasty	Sphincterotomy	1. Mortality. 2. HRQoL. 3. Complications.
39 40 41 42 43 44 45	People with biliary colic	Bile acids	No intervention/other interventions	1. Mortality. 2. HRQoL. 3. Complications.
46 47 48 49 50 51 52	People with biliary colic	Non-steroidal anti-inflammatory drugs	No intervention/other interventions	1. Mortality. 2. HRQoL. 3. Complications.
53 54 55 56 57 58 59 60	People with chronic hepatitis C	Pharmacological treatments	Not applicable	1. Mortality. 2. HRQoL. 3. Complications.

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60	People with chronic hepatitis B	Pharmacological treatments	Not applicable	1. Mortality. 2. HRQoL. 3. Complications.
	People with chronic hepatitis D	Pharmacological treatments	Not applicable	1. Mortality. 2. HRQoL. 3. Complications.
	People exposed to hepatitis A	Post-exposure vaccines	Not applicable	1. Mortality. 2. HRQoL. 3. Complications.
	General population	Immunisation against Hepatitis A	No immunisation	1. Mortality. 2. HRQoL. 3. Complications.
	People exposed to hepatitis A	Post-exposure immunoglobulins	Not applicable	1. Mortality. 2. HRQoL. 3. Complications.
	People with biliary stent	Ursodeoxycholic acid to prevent stent occlusion	No intervention/other interventions	1. Mortality. 2. HRQoL. 3. Complications.
	People with acute hepatitis B	Pharmacological treatments	Not applicable	1. Mortality. 2. HRQoL. 3. Complications.
	Healthcare professionals	Hepatitis B vaccination	Not applicable	1. Mortality. 2. HRQoL. 3. Complications.

Pregnant women with Hepatitis B	Immunoglobulins	No intervention/other interventions	1. Mortality. 2. HRQoL. 3. Complications.
Newborns of HBSAg (hepatitis B surface antigen) positive mothers	Immunisation	No intervention/other interventions	1. Mortality. 2. HRQoL. 3. Complications.
People with chronic hepatitis B	Medicinal herbs	No intervention/other interventions	1. Mortality. 2. HRQoL. 3. Complications.
Asymptomatic Hepatitis B carriers	Medicinal herbs	No intervention/other interventions	1. Mortality. 2. HRQoL. 3. Complications.
People with chronic hepatitis B	Acupuncture	No intervention/other interventions	1. Mortality. 2. HRQoL. 3. Complications.
People with acute hepatitis B	Medicinal herbs	No intervention/other interventions	1. Mortality. 2. HRQoL. 3. Complications.
General population	Hepatitis B vaccination	Not applicable	1. Mortality. 2. HRQoL. 3. Complications.
Pregnant women with Hepatitis B	Lamivudine	No intervention/other interventions	1. Mortality. 2. HRQoL. 3. Complications.

1 2 3 4 5 6 7 8 9	People with HIV infection	Hepatitis B vaccination	Not applicable	1. Mortality. 2. HRQoL. 3. Complications.
10 11 12 13 14 15 16	People who have received Hepatitis B vaccination	Booster dose	No booster dose	1. Mortality. 2. HRQoL. 3. Complications.
17 18 19 20 21 22 23	Pregnant women with Hepatitis B	Hepatitis B vaccination	No intervention/other interventions	1. Mortality. 2. HRQoL. 3. Complications.
24 25 26 27 28 29	People with renal failure	Hepatitis B vaccination	No intervention/other interventions	1. Mortality. 2. HRQoL. 3. Complications.
30 31 32 33 34 35 36	People with chronic hepatitis C and peripheral neuropathy	Treatments	Not applicable	1. Mortality. 2. HRQoL. 3. Complications.
37 38 39 40 41 42 43	People in haemodialysis units	Isolation to prevent Hepatitis C transmission	No isolation	1. Mortality. 2. HRQoL. 3. Complications.
44 45 46 47 48 49	People with acute hepatitis C	Pharmacological treatments	Not applicable	1. Mortality. 2. HRQoL. 3. Complications.
50 51 52 53 54 55 56 57 58 59 60	People with chronic hepatitis C and HIV	Antiviral treatment	Not applicable	1. Mortality. 2. HRQoL. 3. Complications.

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60	People with chronic hepatitis C	Medicinal herbs	No intervention/other interventions	1. Mortality. 2. HRQoL. 3. Complications.
	Pregnant women with Hepatitis B	Caesarean section	Vaginal delivery	1. Mortality. 2. HRQoL. 3. Complications.
	People with chronic hepatitis C with vasculitis	Treatments	Not applicable	1. Mortality. 2. HRQoL. 3. Complications.
	People with chronic hepatitis C	Staging of liver disease	Not applicable	1. Mortality. 2. HRQoL. 3. Complications.
	People with primary biliary cholangitis and osteoporosis	Biphosphonates	No intervention/other interventions	1. Mortality. 2. HRQoL. 3. Complications.
	People with primary biliary cholangitis and osteoporosis	Hormonal replacement therapy	No intervention/other interventions	1. Mortality. 2. HRQoL. 3. Complications.
	People with bleeding oesophageal varices	People with portosystemic shunt	No intervention/other interventions	1. Mortality. 2. HRQoL. 3. Complications.
	People with hepatorenal syndrome	Terlipressin	No intervention/other interventions	1. Mortality. 2. HRQoL. 3. Complications.

1 2 3 4 5 6 7 8 9	People with hepatorenal syndrome	Transjugular intrahepatic portosystemic shunts	No intervention/other interventions	1. Mortality. 2. HRQoL. 3. Complications.
10 11 12 13 14 15 16	People undergoing common bile duct exploration	T-tube	No T-tube	1. Mortality. 2. HRQoL. 3. Complications.
17 18 19 20 21 22 23	People with acute calculous cholecystitis (high risk)	Percutaneous cholecystostomy	No intervention/other interventions	1. Mortality. 2. HRQoL. 3. Complications.
24 25 26 27 28 29	People undergoing liver resection	Enhanced recovery protocols	Standard intervention	1. Mortality. 2. HRQoL. 3. Complications.
30 31 32 33 34 35 36	People undergoing liver transplantation	Perfusion techniques in donor	Not applicable	1. Mortality. 2. HRQoL. 3. Complications.
37 38 39 40 41 42 43	People with gallstones	Chinese herbs	Not applicable	1. Mortality. 2. HRQoL. 3. Complications.
44 45 46 47 48 49	Pregnant women with cholestasis	Interventions	Not applicable	1. Mortality. 2. HRQoL. 3. Complications.
50 51 52 53 54 55 56 57 58 59 60	New-borns and infants receiving parenteral nutrition and jaundice	Pharmacological interventions	Not applicable	1. Mortality. 2. HRQoL. 3. Complications.

1 2 3 4 5 6 7 8 9	New-borns and infants receiving parenteral nutrition and jaundice	Alternate interventions	Not applicable	1. Mortality. 2. HRQoL. 3. Complications.
10 11 12 13 14 15 16	People with sickle cell disease and intrahepatic cholestasis	Interventions	Not applicable	1. Mortality. 2. HRQoL. 3. Complications.
17 18 19 20 21 22	People with liver disease with upper gastrointestinal bleeding	Human recombinant activated factor VII	No intervention/other interventions	1. Mortality. 2. HRQoL. 3. Complications.
23 24 25 26 27 28 29	People with liver disease with upper gastrointestinal bleeding	Vitamin K	No intervention/other interventions	1. Mortality. 2. HRQoL. 3. Complications.
30 31 32 33 34 35 36	People with liver disease with upper gastrointestinal bleeding	Antifibrinolytic amino acids	No intervention/other interventions	1. Mortality. 2. HRQoL. 3. Complications.
37 38 39 40 41 42 43	People with liver disease	Antioxidant supplements	No intervention	1. Mortality. 2. HRQoL. 3. Complications.
44 45 46 47 48 49	People with liver disease	Vitamin D supplements	No intervention	1. Mortality. 2. HRQoL. 3. Complications.
50 51 52 53 54 55 56 57 58 59 60	People with liver disease	Lifestyle: Nutritional support	Not applicable	1. Mortality. 2. HRQoL. 3. Complications.

1 2 3 4 5 6 7 8 9 10 11	People with adverse events related to chemoarterial embolisation for primary liver cancer	Chinese herbs	Not applicable	1. Mortality. 2. HRQoL. 3. Complications.
12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27	People with uncomplicated hepatic hydatid cysts	Percutaneous needle aspiration, injection, and re-aspiration with benzimidazole	Percutaneous needle aspiration, injection, and re-aspiration without benzimidazole	1. Mortality. 2. HRQoL. 3. Complications.
28 29 30 31 32 33 34	People with gallbladder cancer	Chemotherapy	Not applicable	1. Mortality. 2. HRQoL. 3. Complications.
35 36 37 38 39 40	People with acute or acute-on-chronic liver failure	Granulocyte-colony stimulating factor	No intervention/other interventions	1. Mortality. 2. HRQoL. 3. Complications.
41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60	People with common bile duct stones	Early laparoscopic cholecystectomy following endoscopic sphincterotomy	Delayed laparoscopic cholecystectomy following endoscopic sphincterotomy	1. Mortality. 2. HRQoL. 3. Complications.

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60	People with gallstones and common-bile duct stones	Model of service delivery	Not applicable	1. Mortality. 2. HRQoL. 3. Complications.
People undergoing cholecystectomy	Routine intraoperative cholangiography	selective cholangiography	1. Mortality. 2. HRQoL. 3. Complications.	
People with gallstone pancreatitis	Early cholecystectomy	Delayed cholecystectomy	1. Mortality. 2. HRQoL. 3. Complications.	
People at risk of gallstones	Non-pharmacological interventions	Not applicable	1. Mortality. 2. HRQoL. 3. Complications.	
People with biliary obstruction due to cholangiocarcinoma	Endoscopic bipolar radiofrequency ablation	Other interventions	1. Mortality. 2. HRQoL. 3. Complications.	
People with colorectal liver metastases	Radiofrequency ablation	Other interventions	1. Mortality. 2. HRQoL. 3. Complications.	
People with suspected bile leak	Magnetic resonance cholangiopancreatography	Endoscopic retrograde cholangiopancreatography	1. Mortality. 2. HRQoL. 3. Complications.	
People with cholangitis	Antibiotics	Not applicable	1. Mortality. 2. HRQoL. 3. Complications.	

1 2 3 4 5 6 7 8 9	People with suspected focal liver lesions	Imaging modalities to distinguish focal liver lesions	Not applicable	1. Mortality. 2. HRQoL. 3. Complications.
10 11 12 13 14 15 16	People with liver cancer who have undergone surgery	Optimal follow-up regimen to detect early recurrence	Not applicable	1. Mortality. 2. HRQoL. 3. Complications.
17 18 19 20 21 22 23	People undergoing laparoscopic cholecystectomy	Evidence-based pain relief protocol	Standard care	1. Mortality. 2. HRQoL. 3. Complications.
24 25 26 27 28 29	People undergoing liver and bile duct resection	Evidence-based pain relief protocol	Standard care	1. Mortality. 2. HRQoL. 3. Complications.
30 31 32 33 34 35 36	People with suspected gallbladder polyp	Imaging modalities to confirm diagnosis of gallbladder polyp	Not applicable	1. Mortality. 2. HRQoL. 3. Complications.
37 38 39 40 41 42 43	People with gallbladder polyp	Imaging modalities to distinguish nature of gallbladder polyp	Not applicable	1. Mortality. 2. HRQoL. 3. Complications.
44 45 46 47 48 49	People with suspected gallstones	Methods to confirm diagnosis of gallstone	Not applicable	1. Mortality. 2. HRQoL. 3. Complications.
50 51 52 53 54 55 56 57 58 59 60	People with suspected acute cholecystitis	Methods to confirm diagnosis of acute cholecystitis	Not applicable	1. Mortality. 2. HRQoL. 3. Complications.

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60	People with suspected gallbladder dyskinesia	Methods to confirm gallbladder dyskinesia	Not applicable	1. Mortality. 2. HRQoL. 3. Complications.
	People with suspected Sphincter of Oddi dysfunction	Methods to confirm Sphincter of Oddi dysfunction	Not applicable	1. Mortality. 2. HRQoL. 3. Complications.
	People at risk of gallstones	Motivational interviewing for lifestyle changes	standard care	1. Mortality. 2. HRQoL. 3. Complications.
	People with gallstones	Motivational interviewing for lifestyle changes	standard care	1. Mortality. 2. HRQoL. 3. Complications.
	People at risk of NAFLD	Motivational interviewing for lifestyle changes	standard care	1. Mortality. 2. HRQoL. 3. Complications.
	People with NAFLD	Motivational interviewing for lifestyle changes	standard care	1. Mortality. 2. HRQoL. 3. Complications.
	People undergoing liver resection for liver cancer	Imaging modalities to confirm resectability	Not applicable	1. Mortality. 2. HRQoL. 3. Complications.
	People undergoing surgery for biliary tract cancer	Imaging modalities to confirm resectability	Not applicable	1. Mortality. 2. HRQoL. 3. Complications.

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60	People undergoing liver resection	Imaging modalities to confirm resectability	Not applicable	1. Mortality. 2. HRQoL. 3. Complications.
People undergoing liver transplantation for hepatocellular carcinoma	Imaging modalities to confirm that cancer is limited to liver	Not applicable	1. Mortality. 2. HRQoL. 3. Complications.	
People undergoing liver transplantation for hepatocellular carcinoma	Bridging ablative therapies	Standard care	1. Mortality. 2. HRQoL. 3. Complications.	
People undergoing liver transplantation for hepatocellular carcinoma	Goal-directed therapy	Standard care	1. Mortality. 2. HRQoL. 3. Complications.	
People with gallstones	Direct access surgery (without seeing a specialist)	Standard care	1. Mortality. 2. HRQoL. 3. Complications.	
People with benign liver and gallbladder conditions	Nurse-led care	Standard care	1. Mortality. 2. HRQoL. 3. Complications.	
People with sphincter of oddi dysfunction	Pharmacological interventions	Standard care	1. Mortality. 2. HRQoL. 3. Complications.	
People with sphincter of oddi dysfunction	Psychological counselling	Standard care	1. Mortality. 2. HRQoL. 3. Complications.	

1 2 3 4 5 6 7 8 9	People with biliary stricture	Different diagnostic tests	Not applicable	1. Mortality. 2. HRQoL. 3. Complications.
10 11 12 13 14 15 16	People with gallstones	Routine magnetic resonance cholangio pancreatography	Standard care	1. Mortality. 2. HRQoL. 3. Complications.
17 18 19 20 21 22 23 24 25 26 27	People with liver and gallbladder disorders	Methods to improve understanding of evidence	Not applicable	1. Improved knowledge. 2. Better involvement in decision making.
28 29 30 31 32 33 34	People undergoing liver transplantation	Routine fat-assessment in donor livers	Standard care	1. Mortality. 2. HRQoL. 3. Complications.
35 36 37 38 39 40	People with NAFLD and obesity	Routine anti-obesity surgery	Standard care	1. Mortality. 2. HRQoL. 3. Complications.
41 42 43 44 45 46 47 48 49	People with severe polycystic liver disease	Pharmacological interventions to improve functional volume	Standard care	1. Mortality. 2. HRQoL. 3. Complications.
50 51 52 53 54 55 56 57 58 59 60	People with liver disease	Interventions to achieve palliation	Not applicable	1. Palliation.

1 2 3 4 5 6 7 8 9	People with liver disease	Interventions to achieve symptom control	Not applicable	Symptom control
10 11 12 13	People with liver disease	Interventions to improve quality of life	Not applicable	Quality of life
14 15 16 17 18 19 20 21 22	Healthcare professionals dealing with people with primary sclerosing cholangitis	Education of healthcare professionals about liver disease	Standard care	1. Early recognition. 2. Appropriate treatment.
23 24 25 26 27 28 29	People with Crohn's disease	Methods for screening for primary sclerosing cholangitis	Not applicable	Diagnosis of primary sclerosing cholangitis
30 31 32 33 34	People with NAFLD	Patient education	Standard care	1. Greater knowledge.
35 36 37 38 39 40 41 42 43	Healthcare professionals dealing with people with polycystic liver disease	Education of healthcare professionals about liver disease	Standard care	1. Early recognition. 2. Appropriate treatment.
44 45 46 47 48 49 50 51 52	People with polycystic liver disease	Early liver transplantation	Standard care	1. Quality of life. 2. Reducing symptoms. 3. Reducing pain.
53 54 55 56 57 58 59 60	People with autoimmune hepatitis	Interventions that affect T cells	No intervention	1. Cure. 2. Improve quality of life

1 2 3 4 5 6 7	People at risk of liver disease	Screening	Not applicable	Early diagnosis and treatment
8 9 10 11	People with polycystic liver disease	Monitoring polycystic liver disease	Not applicable	
12 13 14 15 16	People with polycystic kidney disease	Diagnosis polycystic liver disease	Not applicable	
17 18 19 20 21 22	People with liver disease	Methods to improve early appropriate treatment	Not applicable	Early diagnosis and treatment
23 24 25 26 27 28 29	People with polycystic kidney disease	Methods to prevent symptomatic polycystic liver disease	Not applicable	1. Quality of life. 2. Liver function.
30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45	People undergoing liver transplantation	Various treatments	Not applicable	1. Survival 2. Complications 3. QoL 4. Hospital stay 5. Return to work 6. Improvement of symptoms
46 47 48 49 50 51 52 53 54 55 56 57 58 59 60	People with polycystic liver disease	Diet (specifically soy proteins which contain oestrogen	Standard diet	1. Decrease size of cyst or preventing cysts to enlarge. 2. Decrease symptoms

1 2 3 4 5 6 7 8 9 10 11	People with NAFLD	Various treatments	Not applicable	1. Impact on health (no further details) 2. Progression to liver failure
12 13 14 15 16	People with suspected NAFLD	Diagnosis	Not applicable	1. Early diagnosis
17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34	People with gallstones	Various treatments	Not applicable	1. Impact on health (no further details)
35 36 37 38 39 40 41 42 43	People with polycystic liver disease	Genetic treatments	Standard therapy	1. Reduce symptoms. 2. Decrease occurrence and size of cysts. 3. Increased longevity
44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60	Healthcare professionals dealing with people with primary biliary cholangitis	Education of healthcare professionals about liver disease	Standard care	1. Early recognition. 2. Appropriate treatment.
	People undergoing treatment for ulcerative colitis	Various treatments	Not applicable	1. Adverse events related to liver
	People with cholangiocarcinoma	Liver transplantation	Standard therapy	1. Survival 2. Complications 3. QoL

			4. Hospital stay 5. Return to work
People undergoing liver transplantation	Machine perfusion of donor organ	Cold storage	1. Survival 2. Complications 3. QoL 4. Hospital stay 5. Return to work
People with liver cancer	Novel treatments (irreversible electroporation, high intensity focused ultrasound)		1. Survival 2. Complications 3. QoL 4. Hospital stay 5. Return to work
People with hepatocellular carcinoma	Liver resection	Liver transplantation	1. Survival 2. Complications 3. QoL 4. Hospital stay 5. Return to work
People with colorectal liver metastases	Ablation	Surgery	1. Survival 2. Complications 3. QoL 4. Hospital stay 5. Return to work
People with liver disease undergoing surgery	Ischaemic preconditioning	No IPC	1. Survival 2. Complications 3. QoL

			4. Hospital stay 5. Return to work
People with liver disease undergoing surgery	Remote ischaemic preconditioning	No RIPC	1. Survival 2. Complications 3. QoL 4. Hospital stay 5. Return to work
People with liver disease undergoing surgery	Goal-directed therapy	standard fluid treatment	1. Survival 2. Complications 3. QoL 4. Hospital stay 5. Return to work
People with compensated liver cirrhosis	Treatments (in particular statins)	Other interventions	1. Decompensation 2. Survival 3. Side effects 4. Quality of life.
People with chronic liver disease/ liver failure	Stem cell therapy	Standard therapy	1. Graft and patient survival 2. QoL. 3. Morbidity compared to conventional transplantation 4. Patient reported outcomes

1 2 3 4 5 6 7 8 9	People with Wilson's disease (and other rare non-alcohol liver related diseases)	Various treatments	Not applicable	Not stated
10 11 12 13 14	People with suspected autoimmune hepatitis	Diagnosis of autoimmune diseases	Not applicable	1. Costs of management

Appendix 2 List of unanswered research questions ('uncertainties') prioritised during the interim prioritisation

1. What are the best treatments that cure or delay the progression (worsening) of primary sclerosing cholangitis (PSC)?
2. Should all people above 40 years of age or those considered to be at risk of liver disease (because of family history of liver disease or because of their lifestyle) be tested for the presence of liver disease to identify liver diseases at an early stage?
3. Should people with primary sclerosing cholangitis (PSC) undergo screening (tested routinely) for cancer?
4. Are there any treatments that reverse the liver damage in primary sclerosing cholangitis (PSC)?
5. What are the best treatments that cure or delay the progression (worsening) of non-alcohol-related fatty liver disease (NAFLD)?
6. What are the best symptomatic treatments for itching in people with primary sclerosing cholangitis (PSC)?
7. Are there alternatives to invasive assessment of oesophageal varices in people with chronic liver disease?

- 1
2
3 8. Does vitamin D supplementation (adding Vitamin D in food or providing it in tablet form)
4
5 increase the lifespan, health-related quality of life, and decrease complications in people
6
7 with liver disease?
8
9
- 10 9. Should new methods to improve the understanding of evidence be developed for people
11
12 with liver and gallbladder diseases?
13
- 14 10. What is the best treatment for people with early or very early hepatocellular carcinoma
15
16 (HCC)?
17
- 18 11. Should the methods used to assess nutrition of patients in liver disease be standardised?
19
- 20 12. Does dieting improve liver function and decrease the requirement for liver transplantation in
21
22 obese people?
23
- 24 13. Should general public be educated about non-alcohol-related fatty liver disease (NAFLD)
25
26 with an aim to reduce the numbers of those that have it?
27
- 28 14. What are the best symptomatic treatments for itching in people with chronic liver diseases
29
30 other than primary sclerosing cholangitis (PSC) and primary biliary cholangitis (PBC)?
31
32
- 33 15. Do treatments targeted against deformation of bile duct (biliary stricture or narrowing of
34
35 bile duct due to the illness) work better than other treatments in people with primary
36
37 sclerosing cholangitis (PSC)?
38
- 39 16. What are the treatments available to decrease weight in overweight people with non-
40
41 alcohol-related fatty liver disease (NAFLD)?
42
- 43 17. What are the best treatments that cure or delay the progression (worsening) of non-alcohol
44
45 related steatohepatitis (NASH)?
46
47
- 48 18. Do statins (or other treatments) delay liver failure in people with advanced liver disease?
49
- 50 19. What are the best treatments that provide temporary symptom relief in people with
51
52 advanced liver disease?
53
- 54 20. Which is the most suitable antibiotic (or combination of antibiotics) in people with
55
56 cholangitis (biliary infection)?
57
58
59
60

- 1
2
3 21. What are the best treatments that cure or delay the progression (worsening) of autoimmune
4 hepatitis (AIH)?
5
6
- 7
8 22. Are there any methods other than liver biopsy (obtaining a piece of liver, usually using a
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
23. What are the best nutritional interventions in people undergoing liver transplantation?
24. What are the best symptomatic treatments for fatigue (tiredness), joint pain, and other symptoms in people with people with autoimmune hepatitis (AIH)?
25. Prior to liver transplantation, is it better to transport the donor liver using a machine which pumps blood or preservation solution through the liver (machine perfusion) or is it better to transport it in the standard way of transporting it immersed in cold preservation solution (cold storage)?
26. What are the best treatments that cure or delay the progression (worsening) of chronic hepatitis C virus (HCV) infection?
27. Does education of people with liver disease about the natural course and treatment of liver disease improve the patient knowledge, patient responsibility, and decrease hospital visits?
28. What are the best treatments that cure or delay the progression (worsening) of primary biliary cholangitis (PBC)?
29. Is nurse-led care as effective or better than doctor-led care for non-alcohol related fatty liver disease (NAFLD)?
30. Is treatment targeted against deformation of bile duct (biliary stricture or narrowing of bile duct due to cancer) better than standard treatment for people with bile duct cancer?
31. Is surgery (in the form of removal of gallbladder) required in people with gallstones?
32. Should people with non-alcohol-related fatty liver disease (NAFLD) and non-alcohol-related steatohepatitis (NASH) receive additional education about the condition?
33. What is the best immunosuppressive regimen in adults undergoing liver transplantation?

- 1
2
3 34. Is endoscopic ultrasound (EUS) (using a ultrasound attached to the end of an endoscope) or
4
5 magnetic resonance cholangiopancreatography (MRCP, a form of MRI scan) better in the
6
7 diagnosis of common bile duct (CBD) stones?
8
9
10 35. How can we improve compliance to treatment (adherence to treatment or the degree to
11
12 which a patient correctly follows medical advice) in people with liver disease?
13
14 36. What are the best symptomatic treatments for relief of ulcerative colitis (UC) in people with
15
16 primary sclerosing cholangitis (PSC) who have undergone liver transplantation?
17
18 37. What are the best symptomatic treatments for itching and fatigue (tiredness) in people with
19
20 primary biliary cholangitis (PBC)?
21
22
23 38. Does education of people with asymptomatic (absence of symptoms) liver disease result in
24
25 change of life style and cure/delay the progression (worsening) of liver disease?
26
27
28 39. What are the best treatments that are available for the treatment of pregnant women with
29
30 cholestasis (condition where bile flow from the liver is obstructed)?
31
32
33 40. Is transarterial chemoembolisation (TACE) or transarterial embolisation (TAE) (blocking the
34
35 blood supply to cancer with or without chemotherapy drugs) effective in the treatment of
36
37 people with liver metastases?
38
39 41. Should people with liver metastases (cancer spread to the liver) from neuroendocrine cancer
40
41 (a form of cancer that arises from cells that secrete hormones and nervous system) undergo
42
43 liver resection?
44
45
46 42. What are the best methods available to decrease blood loss during liver resection?
47
48
49 43. What are the best treatments that cure or delay the progression (worsening) of chronic
50
51 hepatitis B virus (HBV) infection?
52
53
54 44. What are the best treatments for people with polycystic liver disease?
55
56
57 45. Should the healthcare professionals dealing with childhood liver diseases be provided
58
59 additional education about childhood liver diseases compared to standard education where
60
60 childhood diseases are learnt as part of overall education?

- 1
2
3 46. What is the best immunosuppressive regimen in children undergoing liver transplantation?
4
5
6 47. Should blood vessels supplying the liver be temporarily blocked in people undergoing liver
7
8 resection? If so, what is the best way of performing this?
9
10 48. What is the best treatment that should be given to people who undergo liver transplantation
11
12 for chronic hepatitis B virus (HBV) infection to prevent reinfection with chronic hepatitis B
13
14 virus (HBV) infection?
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Appendix 3 Next step to address the top 10 uncertainty based on current best evidence (detailed)

Treatment uncertainty (Research question)	High-quality systematic review ^a	Research recommendations of systematic review	RCTs not included in the systematic review ^{a,b,c}	Patient-oriented outcomes assessed in trials not included in the systematic review ^d	Next step
What is the best treatment for people with early or very early hepatocellular carcinoma (HCC)?	[1]	High-quality RCTs designed to assess clinically important differences in all-cause mortality and health-related quality of life, and having an adequate follow-up period (approximately five years) are needed.	NCT02169765 NCT02704130 NCT02728193 NCT02243384 NCT00844454 NCT01918683 NCT01570075 NCT01351194	Survival (7 trials), recurrence (5 trials), morbidity (3 trials)	High-quality RCTs of interventions not covered in ongoing trials and comparison of health-related quality (HRQoL) in different treatments

<p>1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29</p> <p>What are the best treatments that cure or delay the progression (worsening) of primary sclerosing cholangitis (PSC)?</p>	<p>[2]</p>	<p>An urgent need exists to identify an effective medical treatment for primary sclerosing cholangitis through well-designed RCTs with adequate follow-up that aim to identify differences in outcomes important to people with primary sclerosing cholangitis.</p>	<p>NCT03394781 NCT02605213 NCT02943460 NCT02704364 NCT01688024 NCT02177136 NCT01672853 NCT03035058 NCT03333928</p>	<p>None of the trials include survival, HRQoL as outcomes^e</p>	<p>High-quality RCTs with clinical outcomes (survival, HRQoL)</p>
<p>30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46</p> <p>What are the best treatments that cure or delay the progression (worsening) of non-</p>	<p>[3] (includes only pharmacological interventions)</p>	<p>Further well-designed randomised clinical trials with sufficiently</p>	<p>More than 10 published trials on lifestyle interventions and more than 20 trials</p>	<p>Lifestyle interventions and nutritional supplementation</p>	<p>High-quality systematic reviews on lifestyle interventions (one review) and nutritional</p>

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

<p>alcohol-related fatty liver disease (NAFLD)?</p>		<p>large sample sizes are necessary.</p>	<p>on nutritional supplementation with no recent high-quality systematic reviews <u>Pharmacological interventions</u> NCT02605616 NCT01002547 NCT02927314 NCT03291249 NCT03166735 NCT03486899 NCT03061721 NCT02784444 NCT02077374 NCT03486912</p>	<p>Not applicable as there are no high quality systematic reviews <u>Pharmacological interventions</u> Health-related quality of life (2 trials), resolution of fatty liver disease (11 trials), mortality (2 trials), cirrhosis (2 trials), cardiovascular events (2 trials)^e</p>	<p>supplementation to cure or delay the progression of NAFLD and high-quality RCTs on pharmacological interventions with clinical outcomes (survival, HRQoL)</p>
---	--	--	---	---	--

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

			NCT02854605		
			NCT01963845		
			NCT03437720		
			NCT02684591		
			NCT02787304		
			NCT02466516		
			NCT02633956		
			NCT03008070		
			NCT03205150		
			NCT02923154		
			NCT02913105		
			NCT01899859		
			NCT02548351		
			NCT03053063		
			NCT03053050		
			NCT02413372		

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

			NCT02443116		
			NCT01464801		
			NCT03449446		
			NCT02912260		
			NCT02856555		
			NCT02704403		
			NCT01617772		
			NCT02217475		
			NCT01406704		
			NCT03248882		
			NCT01051219		
			NCT02316717		
			NCT02970942		
			NCT03439254		
			NCT02574325		
			NCT01703260		

			NCT01260246		
			NCT02960204		
<p>1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46</p> <p>What is the best immunosuppressive regimen in adults undergoing liver transplantation?</p>	<p>[4] (covers only maintenance immunosuppression)</p>	<p>Future randomised clinical trials should be adequately powered; performed in people who are generally seen in the clinic rather than in highly selected participants; employ blinding; avoid postrandomisation dropouts or planned cross-overs; and use clinically important outcomes such as</p>	<p><u>Induction immunosuppression</u></p> <p>More than 20 published trials</p> <p><u>Maintenance immunosuppression</u></p> <p>NCT01998789</p> <p>NCT01230502</p> <p>NCT02909335</p> <p>NCT00286871</p>	<p><u>Induction immunosuppression</u></p> <p>Not applicable as there is no high quality systematic review</p> <p><u>Maintenance immunosuppression</u></p> <p>Graft survival (1 trial)</p> <p>Adverse events (1 trial)</p> <p>Hepatocellular carcinoma (1 trial)^e</p>	<p>High-quality systematic review on induction immunosuppressive regimen and high-quality RCTs on maintenance immunosuppression with important clinical outcomes (overall survival, HRQoL)</p>

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

		<p>mortality, graft loss, renal impairment, chronic kidney disease, and retransplantation.</p> <p>Such trials should use tacrolimus as one of the control groups.</p> <p>Moreover, such trials ought to be designed in such a way as to ensure low risk of bias and low risks of random errors.</p>			
Should general public be educated about non-alcohol-related	None	-	None	-	High-quality RCTs on education to prevent NAFLD

<p>fatty liver disease (NAFLD) with an aim to reduce the numbers of those that have it?</p>					
<p>What are the best treatments that cure or delay the progression (worsening) of autoimmune hepatitis (AIH)?</p>	None	-	<p>[5-7]</p> <p>NCT02050646</p> <p>NCT02463331</p> <p>NCT00608894</p> <p>NCT02900443</p> <p>NCT02239562</p> <p>NCT01170351</p> <p>NCT03217422</p> <p>NCT01661842</p> <p>NCT00687180</p> <p>NCT01980745</p> <p>NCT02878863</p>	<p>Survival (1 trial), health-related quality of life (1 trial)^e</p>	<p>High quality RCTs with clinical outcomes (survival, HRQoL)</p>

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

			NCT02936596		
What are the best treatments that cure or delay the progression (worsening) of non-alcohol related steatohepatitis (NASH)?	The evidence related to this question is covered under non-alcohol related fatty liver disease by performing a subgroup analysis of people with NASH				
Prior to liver transplantation, is it better to transport the donor liver using a machine which pumps blood or preservation solution through the liver (machine	None	-	NCT02775162 NCT03124641 NCT02940600 NCT02584283 NCT01317342	Overall survival (4 trials), graft survival (5 trials), health-related quality of life (2 trials)	Await results of the RCTs (all expected to complete by the end of 2019) and perform a high quality systematic review.

<p>perfusion) or is it better to transport it in the standard way of transporting it immersed in cold preservation solution (cold storage)?</p>					
<p>What are the best treatments that cure or delay the progression (worsening) of primary biliary cholangitis (PBC)?</p>	<p>[8]</p>	<p>Further well-designed randomised clinical trials are necessary. Future randomised clinical trials ought to be adequately powered; performed in people who are generally seen in the</p>	<p>NCT02937012 NCT01473524 NCT02823353 NCT02135536 NCT01614405 NCT02609048 NCT00746486 NCT02955602 NCT03226067</p>	<p>Health-related quality of life (5 trials), relief of symptoms (5 trials)^e</p>	<p>High-quality RCTs with clinical outcomes (survival, HRQoL)</p>

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

		clinic rather than in	NCT03112681		
		highly selected	NCT01904058		
		participants; employ	NCT02943447		
		blinding; avoid post-	NCT03124108		
		randomisation	NCT03345589		
		dropouts or planned	NCT03092765		
		cross-overs; should	NCT03394924		
		have sufficient follow-	NCT02516605		
		up period (e.g. five or	NCT03253276		
		10 years or more); and	NCT02965911		
		use clinically important	NCT01899703		
		outcomes such as	NCT01654731		
		mortality, health-	NCT02308111		
		related quality of life,	NCT00125281		
		cirrhosis,	NCT02701166		
		decompensated			

		<p>cirrhosis, and liver transplantation.</p> <p>Alternatively, very large groups of participants should be randomised to facilitate shorter trial duration.</p>			
<p>Are there any treatments that reverse the liver damage in primary sclerosing cholangitis (PSC)?</p>	<p>The evidence related to this question is covered under treatments for primary sclerosing cholangitis. The systematic review did not include fibrosis as one of the outcomes. Nine of the trials included in the systematic review reported on fibrosis. Two of the trials not included in the systematic review (and listed above) reported on liver fibrosis.</p>				

a Numbers indicate the reference number.

b Ongoing trials, unpublished trials, or trials published since the search date for the systematic review when a high-quality systematic review based on randomised controlled trials exists. If no systematic reviews based on randomised controlled trials exist, these are either published trials or ongoing studies.

c NCT followed by a number indicates trial registration number

d This information is reported to find out whether the important patient-oriented outcomes are reported in the trials not covered by high-quality systematic reviews. This is to help with deciding whether new randomised controlled trials are necessary on the topic.

e The remaining trials reported treatment-related adverse events, composite outcomes and surrogate markers.

Appendix 4 Scores obtained by each question in the different Delphi rounds

Questions ^a	Delphi 1: Proportion who rated this question as highly important	Delphi 1: Median (IQR)	Delphi 2: Proportion who rated this question as highly important	Delphi 2: Median (IQR)	Delphi 3: Proportion who rated this question as highly important	Delphi 3: Median (IQR)	Consensus reached in Delphi 3? ^b
------------------------	---	------------------------------	---	------------------------------	---	------------------------------	---

1. What are the best treatments that cure or delay the progression (worsening) of primary sclerosing cholangitis (PSC)?	All: 78.8% HCP: 80.0% PCP: 76.9%	All: 8(7,9) HCP: 8.5(7,9) PCP: 8(6.5,9)	All: 83.9% HCP: 83.3% PCP: 84.6%	All: 8(7,9) HCP: 8(7,9) PCP: 8(7,9)	All: 93.3% HCP: 94.1% PCP: 92.3%	All: 8(7,9) HCP: 8(7,9) PCP: 8(7,9)	Yes
2. Should all people above 40 years of age or those considered to be at risk of liver disease (because of family history of liver disease or because of their lifestyle) be tested for the presence of liver disease to identify liver diseases at an early stage?	All: 44.4% HCP: 40.0% PCP: 50.0%	All: 6(5,7) HCP: 6(5,7) PCP: 6(4,7.75)	All: 35.3% HCP: 27.8% PCP: 43.8%	All: 6(5,7) HCP: 6(5,7) PCP: 6(5,7.75)	All: 33.3% HCP: 29.4% PCP: 37.5%	All: 6(5,7) HCP: 6(5,7) PCP: 6(5,7.75)	No
3. Should people with primary sclerosing cholangitis (PSC) undergo screening (tested routinely) for cancer?	All: 46.9% HCP: 40.0% PCP: 58.3%	All: 6(5,9) HCP: 6(5,9) PCP: 6(5,9)	All: 50.0% HCP: 38.9% PCP: 66.7%	All: 6.5(5.75,8) HCP: 6(5.75,7.25) PCP: 6.5(5.25,9)	All: 44.8% HCP: 35.3% PCP: 58.3%	All: 6(6,7.5) HCP: 6(5.5,7) PCP: 6(6,9)	No

<p>4.Are there any treatments that reverse the liver damage in primary sclerosing cholangitis (PSC)?</p>	<p>All: 59.4% HCP: 55.0% PCP: 66.7%</p>	<p>All: 7.5(5,8.75) HCP: 7.5(4.25,8) PCP: 7.5(6,9)</p>	<p>All: 70.0% HCP: 61.1% PCP: 83.3%</p>	<p>All: 7.5(6,9) HCP: 7.5(4.75,8.25) PCP: 7.5(7,9)</p>	<p>All: 72.4% HCP: 64.7% PCP: 83.3%</p>	<p>All: 7(6,9) HCP: 7(5,8) PCP: 7(7,9)</p>	<p>No</p>
<p>5.What are the best treatments that cure or delay the progression (worsening) of non-alcohol-related fatty liver disease (NAFLD)?</p>	<p>All: 76.5% HCP: 75.0% PCP: 78.6%</p>	<p>All: 8(6.75,9) HCP: 8.5(6.25,9) PCP: 8(6.75,9)</p>	<p>All: 87.5% HCP: 83.3% PCP: 92.9%</p>	<p>All: 8.5(7,9) HCP: 8.5(7,9) PCP: 8.5(7,9)</p>	<p>All: 90.3% HCP: 88.2% PCP: 92.9%</p>	<p>All: 9(8,9) HCP: 9(7.5,9) PCP: 9(7.75,9)</p>	<p>Yes</p>
<p>6.What are the best symptomatic treatments for itching in people with primary sclerosing cholangitis (PSC)?</p>	<p>All: 48.5% HCP: 45.0% PCP: 53.8%</p>	<p>All: 6(5,7.5) HCP: 6(5,7) PCP: 6(5.5,8)</p>	<p>All: 48.4% HCP: 38.9% PCP: 61.5%</p>	<p>All: 6(5,7) HCP: 6(4.75,7) PCP: 6(6,8)</p>	<p>All: 50.0% HCP: 41.2% PCP: 61.5%</p>	<p>All: 6.5(5,7) HCP: 6(4.5,7) PCP: 6.5(6,8)</p>	<p>No</p>

7.Are there alternatives to invasive assessment of oesophageal varices in people with chronic liver disease?	All: 48.6% HCP: 30.0% PCP: 73.3%	All: 6(5,8) HCP: 6(3,7) PCP: 6(6,9)	All: 54.5% HCP: 33.3% PCP: 80.0%	All: 7(5.5,8) HCP: 6(4,7) PCP: 7(7,9)	All: 56.3% HCP: 29.4% PCP: 86.7%	All: 7(6,8) HCP: 6(4,7) PCP: 7(7,9)	No
8.Does vitamin D supplementation (adding Vitamin D in food or providing it in tablet form) increase the lifespan, health-related quality of life, and decrease complications in people with liver disease?	All: 37.1% HCP: 21.1% PCP: 56.3%	All: 6(4,7) HCP: 4(4,6) PCP: 6(6,9)	All: 39.4% HCP: 23.5% PCP: 56.3%	All: 6(4,7) HCP: 5(4,6.5) PCP: 6(6,9)	All: 37.5% HCP: 18.8% PCP: 56.3%	All: 6(4.25,7.75) HCP: 5(4,6) PCP: 6(6,8.75)	No
9.Should new methods to improve the understanding of evidence be developed for people with liver and gallbladder diseases?	All: 38.2% HCP: 25.0% PCP: 57.1%	All: 6(4,8) HCP: 5(4,6.75) PCP: 6(5,9)	All: 46.9% HCP: 27.8% PCP: 71.4%	All: 6(4,8) HCP: 5(4,7) PCP: 6(5,9)	All: 48.4% HCP: 29.4% PCP: 71.4%	All: 6(5,8) HCP: 6(4.5,7) PCP: 6(5,9)	No
10.What is the best treatment for people with early or very early hepatocellular carcinoma (HCC)?	All: 76.5% HCP: 75.0% PCP: 78.6%	All: 8(6.75,9) HCP: 7(6.25,9)	All: 87.5% HCP: 88.9% PCP: 85.7%	All: 8(7,9) HCP: 8(7,9) PCP: 8(7,9)	All: 93.5% HCP: 94.1% PCP: 92.9%	All: 8(7,9) HCP: 8(7,9)	Yes

		PCP: 8(6.75,9)				PCP: 8(7.75,9)	
11.Should the methods used to assess nutrition of patients in liver disease be standardised?	All: 57.1% HCP: 60.0% PCP: 53.3%	All: 7(5,9) HCP: 7(5,8.75) PCP: 7(5,9)	All: 54.5% HCP: 55.6% PCP: 53.3%	All: 7(5,8) HCP: 7(5,8) PCP: 7(5,9)	All: 59.4% HCP: 58.8% PCP: 60.0%	All: 7(5,8) HCP: 7(5,8) PCP: 7(5,8)	No
12.Does dieting improve liver function and decrease the requirement for liver transplantation in obese people?	All: 48.6% HCP: 38.1% PCP: 62.5%	All: 6(4,8) HCP: 6(3,8) PCP: 6(5.25,7)	All: 44.1% HCP: 27.8% PCP: 62.5%	All: 6(4,7.25) HCP: 6(3.75,7.25) PCP: 6(5.25,7.75)	All: 48.5% HCP: 29.4% PCP: 68.8%	All: 6(5,7) HCP: 6(5,7) PCP: 6(5.25,7)	No
13.Should general public be educated about non-alcohol-related fatty liver disease (NAFLD) with an aim to reduce the numbers of those that have it?	All: 72.2% HCP: 75.0% PCP: 68.8%	All: 7.5(6,9) HCP: 8(6.25,9) PCP: 7.5(6,9)	All: 73.5% HCP: 72.2% PCP: 75.0%	All: 8(6,9) HCP: 7.5(5.75,9) PCP: 8(6.25,9)	All: 81.8% HCP: 82.4% PCP: 81.3%	All: 8(7,9) HCP: 8(7,9) PCP: 8(7,9)	Yes

14. What are the best symptomatic treatments for itching in people with chronic liver diseases other than primary sclerosing cholangitis (PSC) and primary biliary cholangitis (PBC)?	All: 48.5% HCP: 35.0% PCP: 69.2%	All: 6(4,5,7) HCP: 6(4,7) PCP: 6(5,7,5)	All: 48.4% HCP: 27.8% PCP: 76.9%	All: 6(5,7) HCP: 6(4,7) PCP: 6(6,8)	All: 50.0% HCP: 29.4% PCP: 76.9%	All: 6.5(5,7) HCP: 6(4,5,7) PCP: 6.5(6.5,8)	No
15. Do treatments targeted against deformation of bile duct (biliary stricture or narrowing of bile duct due to the illness) work better than other treatments in people with primary sclerosing cholangitis (PSC)?	All: 19.4% HCP: 21.1% PCP: 16.7%	All: 5(4,6) HCP: 5(4,6) PCP: 5(4,6)	All: 20.0% HCP: 16.7% PCP: 25.0%	All: 5(4,6) HCP: 5(3,7,5,6) PCP: 5(4,6,7,5)	All: 20.7% HCP: 17.6% PCP: 25.0%	All: 5(4,6) HCP: 5(3,5,6) PCP: 5(4,6,7,5)	No
16. What are the treatments available to decrease weight in overweight people with non-alcohol-related fatty liver disease (NAFLD)?	All: 37.1% HCP: 35.0% PCP: 40.0%	All: 5(4,8) HCP: 5.5(4,7) PCP: 5(4,8)	All: 27.3% HCP: 22.2% PCP: 33.3%	All: 6(4,7) HCP: 6(4,6,2,5) PCP: 6(3,8)	All: 28.1% HCP: 23.5% PCP: 33.3%	All: 5(4,7) HCP: 5(5,6,5) PCP: 5(3,7)	No

17. What are the best treatments that cure or delay the progression (worsening) of non-alcohol related steatohepatitis (NASH)?	All: 67.6% HCP: 71.4% PCP: 61.5%	All: 8(5,8.25) HCP: 8(5.5,9) PCP: 8(5,8)	All: 71.0% HCP: 77.8% PCP: 61.5%	All: 8(6,9) HCP: 7.5(6.75,9) PCP: 8(5,8.5)	All: 76.7% HCP: 82.4% PCP: 69.2%	All: 8(6.75,9) HCP: 8(7,9) PCP: 8(5,8.5)	No
18. Do statins (or other treatments) delay liver failure in people with advanced liver disease?	All: 45.7% HCP: 36.8% PCP: 56.3%	All: 6(5,7) HCP: 6(4,7) PCP: 6(6,7.75)	All: 39.4% HCP: 35.3% PCP: 43.8%	All: 6(6,7) HCP: 6(3.5,7) PCP: 6(6,7.75)	All: 43.8% HCP: 37.5% PCP: 50.0%	All: 6(6,7) HCP: 6(5.25,7) PCP: 6(6,7.75)	No
19. What are the best treatments that provide temporary symptom relief in people with advanced liver disease?	All: 50.0% HCP: 35.0% PCP: 68.8%	All: 6.5(5,7.75) HCP: 6(5,7) PCP: 6.5(5.25,8.75))	All: 52.9% HCP: 33.3% PCP: 75.0%	All: 7(5.75,7.25) HCP: 6(5,7) PCP: 7(6.25,8)	All: 54.5% HCP: 35.3% PCP: 75.0%	All: 7(6,7) HCP: 6(5,7) PCP: 7(6.25,8)	No

20. Which is the most suitable antibiotic (or combination of antibiotics) in people with cholangitis (biliary infection)?	All: 64.7% HCP: 70.0% PCP: 57.1%	All: 7(5,8) HCP: 7(6,8) PCP: 7(5,8)	All: 68.8% HCP: 72.2% PCP: 64.3%	All: 7(5.25,8) HCP: 7(6,8) PCP: 7(5,8)	All: 67.7% HCP: 70.6% PCP: 64.3%	All: 7(5,8) HCP: 7(6,8) PCP: 7(5,8)	No
21. What are the best treatments that cure or delay the progression (worsening) of autoimmune hepatitis (AIH)?	All: 75.8% HCP: 68.4% PCP: 85.7%	All: 7(6.5,9) HCP: 7(6,8) PCP: 7(7,9)	All: 81.3% HCP: 77.8% PCP: 85.7%	All: 7.5(7,9) HCP: 7(6.75,8) PCP: 7.5(7,9)	All: 80.6% HCP: 76.5% PCP: 85.7%	All: 8(7,9) HCP: 7(6.5,8) PCP: 8(7,9)	Yes
22. Are there any methods other than liver biopsy (obtaining a piece of liver, usually using a needle, for examination under microscope) for the early diagnosis of primary sclerosing cholangitis (PSC) in people at risk of developing PSC?	All: 53.1% HCP: 36.8% PCP: 76.9%	All: 7(5,8) HCP: 6(5,7) PCP: 7(6.5,8)	All: 60.0% HCP: 47.1% PCP: 76.9%	All: 7(5,8) HCP: 6(5,8) PCP: 7(6.5,8)	All: 58.6% HCP: 43.8% PCP: 76.9%	All: 7(5,8) HCP: 6(5,7.75) PCP: 7(6.5,8)	No
23. What are the best nutritional interventions in people undergoing liver transplantation?	All: 52.8% HCP: 42.9% PCP: 66.7%	All: 7(5,8) HCP: 6(4,8) PCP: 7(5,8)	All: 51.5% HCP: 38.9% PCP: 66.7%	All: 7(5,8) HCP:	All: 53.1% HCP: 41.2% PCP: 66.7%	All: 7(5,8) HCP: 6(5,7) PCP: 7(6,8)	No

				6(4,7.25) PCP: 7(5,8)			
24.What are the best symptomatic treatments for fatigue (tiredness), joint pain, and other symptoms in people with people with autoimmune hepatitis (AIH)?	All: 61.8% HCP: 45.0% PCP: 85.7%	All: 7(6,8) HCP: 6(3.25,7) PCP: 7(7,9)	All: 65.6% HCP: 50.0% PCP: 85.7%	All: 7(6,8) HCP: 6.5(3.75,7) PCP: 7(7,9)	All: 64.5% HCP: 47.1% PCP: 85.7%	All: 7(6,8) HCP: 6(4,7) PCP: 7(7,9)	No
25.Prior to liver transplantation, is it better to transport the donor liver using a machine which pumps blood or preservation solution through the liver (machine perfusion) or is it better to transport it in the standard way of transporting it immersed in cold preservation solution (cold storage)?	All: 54.5% HCP: 42.1% PCP: 71.4%	All: 7(5,9) HCP: 6(5,8) PCP: 7(6,9)	All: 68.8% HCP: 61.1% PCP: 78.6%	All: 7(6,8.75) HCP: 7(5,8) PCP: 7(6.75,9)	All: 74.2% HCP: 70.6% PCP: 78.6%	All: 7(6,9) HCP: 7(6,8) PCP: 7(6.75,9)	No

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

26.What are the best treatments that cure or delay the progression (worsening) of chronic hepatitis C virus (HCV) infection?	All: 42.4% HCP: 42.9% PCP: 41.7%	All: 6(2,8) HCP: 5(1,8) PCP: 6(4.25,7.75)	All: 40.0% HCP: 44.4% PCP: 33.3%	All: 5.5(2,7) HCP: 4.5(1,8) PCP: 5.5(4.25,7)	All: 37.9% HCP: 47.1% PCP: 25.0%	All: 5(2,7) HCP: 5(1,8) PCP: 5(4.25,6.75)	No
27.Does education of people with liver disease about the natural course and treatment of liver disease improve the patient knowledge, patient responsibility, and decrease hospital visits?	All: 51.4% HCP: 52.4% PCP: 50.0%	All: 7(4,8) HCP: 7(4.5,7.5) PCP: 7(3.25,8.75)	All: 58.8% HCP: 50.0% PCP: 68.8%	All: 7(4,7.25) HCP: 6.5(4,7) PCP: 7(4,8.75)	All: 57.6% HCP: 47.1% PCP: 68.8%	All: 7(4,8) HCP: 6(4,7) PCP: 7(4,8)	No
28.What are the best treatments that cure or delay the progression (worsening) of primary biliary cholangitis (PBC)?	All: 61.8% HCP: 60.0% PCP: 64.3%	All: 7(5.75,8) HCP: 7(6,8) PCP: 7(5,8)	All: 68.8% HCP: 66.7% PCP: 71.4%	All: 7(6,8) HCP: 7(5.75,8) PCP: 7(5.75,8.25)	All: 74.2% HCP: 70.6% PCP: 78.6%	All: 7(6,8) HCP: 7(6,8) PCP: 7(6.5,8.25)	No

29. Is nurse-led care as effective or better than doctor-led care for non-alcohol related fatty liver disease (NAFLD)?	All: 38.2% HCP: 35.0% PCP: 42.9%	All: 5(4,8) HCP: 4.5(3,7.75) PCP: 5(4,8)	All: 31.3% HCP: 27.8% PCP: 35.7%	All: 5(4,7) HCP: 4(3,7) PCP: 5(4,7.25)	All: 25.8% HCP: 23.5% PCP: 28.6%	All: 5(4,7) HCP: 4(3.5,6.5) PCP: 5(4,7)	No
30. Is treatment targeted against deformation of bile duct (biliary stricture or narrowing of bile duct due to cancer) better than standard treatment for people with bile duct cancer?	All: 35.5% HCP: 27.8% PCP: 46.2%	All: 5(4,7) HCP: 5(2.75,7) PCP: 5(4,7.5)	All: 22.6% HCP: 11.1% PCP: 38.5%	All: 5(4,6) HCP: 5(3.5,6) PCP: 5(4,7)	All: 20.0% HCP: 11.8% PCP: 30.8%	All: 5(4,6) HCP: 5(3.5,6) PCP: 5(4,7)	No
31. Is surgery (in the form of removal of gallbladder) required in people with gallstones?	All: 24.2% HCP: 23.8% PCP: 25.0%	All: 5(4,6.5) HCP: 5(4,6.5) PCP: 5(4.25,6.75)	All: 30.0% HCP: 33.3% PCP: 25.0%	All: 5(4,7) HCP: 5(4,7) PCP: 5(3.5,6.75)	All: 24.1% HCP: 29.4% PCP: 16.7%	All: 5(4.5,6.5) HCP: 5(4.5,7) PCP: 5(3.5,6)	No
32. Should people with non-alcohol-related fatty liver disease (NAFLD) and non-alcohol-related steatohepatitis	All: 52.9% HCP: 50.0% PCP: 57.1%	All: 7(4,8) HCP: PCP:	All: 56.3% HCP: 50.0% PCP: 64.3%	All: 7(4.25,8) HCP: 6.5(2,7.25)	All: 54.8% HCP: 47.1% PCP: 64.3%	All: 7(5,8) HCP: 6(4,7.5) PCP:	No

(NASH) receive additional education about the condition?		6.5(2.5,7.75) PCP: 7(4,9)		PCP: 7(5.75,8.25)		PCP: 7(5.75,8.25)	
33.What is the best immunosuppressive regimen in adults undergoing liver transplantation?	All: 73.5% HCP: 60.0% PCP: 92.9%	All: 7(6,9) HCP: 7(5,8) PCP: 7(7,9)	All: 84.4% HCP: 77.8% PCP: 92.9%	All: 8(7,9) HCP: 7(6.5,8) PCP: 8(7,9)	All: 90.3% HCP: 82.4% PCP: 100.0%	All: 8(7,9) HCP: 8(7,8) PCP: 8(7.75,9)	Yes
34.Is endoscopic ultrasound (EUS) (using a ultrasound attached to the end of an endoscope) or magnetic resonance cholangio pancreatography (MRCP, a form of MRI scan) better in the diagnosis of common bile duct (CBD) stones?	All: 36.7% HCP: 22.2% PCP: 58.3%	All: 5(4,7) HCP: 4(3.75,6.25) PCP: 5(5,7)	All: 30.0% HCP: 22.2% PCP: 41.7%	All: 5(4,7) HCP: 5(4,6.25) PCP: 5(5,7)	All: 20.7% HCP: 11.8% PCP: 33.3%	All: 5(4,6) HCP: 5(4,6) PCP: 5(5,7)	No
35.How can we improve compliance to treatment (adherence to treatment or the degree to which a patient correctly	All: 67.6% HCP: 75.0% PCP: 57.1%	All: 7(5,8) HCP: 7(6.25,8)	All: 69.7% HCP: 72.2% PCP: 66.7%	All: 7(5,8) HCP: 7(4.75,8) PCP: 7(5,8)	All: 71.9% HCP: 70.6% PCP: 73.3%	All: 7(5,8) HCP: 7(5,8) PCP: 7(5,8)	No

follows medical advice) in people with liver disease?		PCP: 7(4.75,8)					
36.What are the best symptomatic treatments for relief of ulcerative colitis (UC) in people with primary sclerosing cholangitis (PSC) who have undergone liver transplantation?	All: 51.6% HCP: 36.8% PCP: 75.0%	All: 7(5,8) HCP: 6(4,7) PCP: 7(5.5,8.75)	All: 56.7% HCP: 44.4% PCP: 75.0%	All: 7(5,8) HCP: 6(4.75,7) PCP: 7(6.25,8.75)	All: 55.2% HCP: 41.2% PCP: 75.0%	All: 7(6,8) HCP: 6(5.5,7) PCP: 7(6.25,9)	No
37.What are the best symptomatic treatments for itching and fatigue (tiredness) in people with primary biliary cholangitis (PBC)?	All: 50.0% HCP: 45.0% PCP: 57.1%	All: 6.5(5,7) HCP: 6(5,7) PCP: 6.5(5,7.25)	All: 43.8% HCP: 33.3% PCP: 57.1%	All: 6(5,7) HCP: 6(5,7) PCP: 6(5,8)	All: 41.9% HCP: 29.4% PCP: 57.1%	All: 6(5,7) HCP: 6(5,7) PCP: 6(5,8)	No
38.Does education of people with asymptomatic (absence of symptoms) liver disease result in change of life style and cure/delay the progression (worsening) of liver disease?	All: 54.3% HCP: 45.0% PCP: 66.7%	All: 7(5,8) HCP: 6(4.25,7.75) PCP: 7(5,8)	All: 51.5% HCP: 38.9% PCP: 66.7%	All: 7(4.5,8) HCP: 5(3.5,7.25) PCP: 7(5,8)	All: 53.1% HCP: 35.3% PCP: 73.3%	All: 7(5,7.75) HCP: 5(4,7) PCP: 7(5,8)	No

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

39. What are the best treatments that are available for the treatment of pregnant women with cholestasis (condition where bile flow from the liver is obstructed)?	All: 38.7% HCP: 25.0% PCP: 63.6%	All: 6(4,7) HCP: 5(4,6.75) PCP: 6(6,8)	All: 31.0% HCP: 27.8% PCP: 36.4%	All: 6(4.5,7) HCP: 5(4,7) PCP: 6(6,8)	All: 27.6% HCP: 23.5% PCP: 33.3%	All: 6(5,7) HCP: 5(4.5,6.5) PCP: 6(5.25,7)	No
40. Is transarterial chemoembolisation (TACE) or transarterial embolisation (TAE) (blocking the blood supply to cancer with or without chemotherapy drugs) effective in the treatment of people with liver metastases?	All: 40.6% HCP: 36.8% PCP: 46.2%	All: 6(4,8) HCP: 6(3,8) PCP: 6(5,8.5)	All: 34.4% HCP: 22.2% PCP: 50.0%	All: 6(4,7) HCP: 5.5(3,6.25) PCP: 6(5,7)	All: 32.3% HCP: 23.5% PCP: 42.9%	All: 6(5,7) HCP: 6(3.5,6.5) PCP: 6(5,7)	No
41. Should people with liver metastases (cancer spread to the liver) from neuroendocrine cancer (a form of cancer that arises from cells that secrete	All: 36.7% HCP: 31.6% PCP: 45.5%	All: 6(4,7.25) HCP: 6(4,7) PCP: 6(5,8)	All: 40.0% HCP: 38.9% PCP: 41.7%	All: 6(4.75,7.25) HCP: 6(4,7) PCP: 6(5.25,8)	All: 37.9% HCP: 41.2% PCP: 33.3%	All: 6(5.5,7) HCP: 6(5,7) PCP: 6(5.25,8)	No

hormones and nervous system) undergo liver resection?							
42.What are the best methods available to decrease blood loss during liver resection?	All: 43.8% HCP: 26.3% PCP: 69.2%	All: 6(5,7.75) HCP: 5(3,7) PCP: 6(6,8)	All: 48.4% HCP: 27.8% PCP: 76.9%	All: 6(5,8) HCP: 5.5(4,7) PCP: 6(6.5,8)	All: 46.7% HCP: 29.4% PCP: 69.2%	All: 6(5,7.25) HCP: 6(5,7) PCP: 6(6,8)	No
43.What are the best treatments that cure or delay the progression (worsening) of chronic hepatitis B virus (HBV) infection?	All: 51.6% HCP: 42.1% PCP: 66.7%	All: 7(4,8) HCP: 6(4,7) PCP: 7(6,8)	All: 46.7% HCP: 38.9% PCP: 58.3%	All: 6(4.75,7.25) HCP: 5.5(4,7) PCP: 6(6,8)	All: 48.3% HCP: 41.2% PCP: 58.3%	All: 6(5,7.5) HCP: 6(4.5,7) PCP: 6(6,8)	No
44.What are the best treatments for people with polycystic liver disease?	All: 39.3% HCP: 17.6% PCP: 72.7%	All: 6(4,8) HCP: 5(4,6) PCP: 6(6,8)	All: 34.5% HCP: 16.7% PCP: 63.6%	All: 6(4,8) HCP: 5(3.75,6) PCP: 6(6,8)	All: 35.7% HCP: 17.6% PCP: 63.6%	All: 6(5,7) HCP: 5(4,6) PCP: 6(6,7)	No
45.Should the HCP dealing with childhood liver diseases be provided additional education about childhood liver diseases	All: 35.5% HCP: 15.0% PCP: 72.7%	All: 5(3,8) HCP:	All: 37.9% HCP: 16.7% PCP: 72.7%	All: 5(3.5,7.5) HCP:	All: 37.9% HCP: 17.6% PCP: 66.7%	All: 5(4.5,7.5) HCP: 5(2,5.5)	No

1 2 3 4 5 6 7 8 9	compared to standard education where childhood diseases are learnt as part of overall education?		5(2,5.75) PCP: 5(5,9)		5(2,5.25) PCP: 5(6,9)		PCP: 5(6,8.75)	
10 11 12 13 14 15 16	46.What is the best immunosuppressive regimen in children undergoing liver transplantation?	All: 65.6% HCP: 57.9% PCP: 76.9%	All: 8(4.25,9) HCP: 7(4,8) PCP: 8(6,9)	All: 67.7% HCP: 61.1% PCP: 76.9%	All: 8(6,9) HCP: 7.5(4,8) PCP: 8(6.5,9)	All: 70.0% HCP: 64.7% PCP: 76.9%	All: 8(6,9) HCP: 8(5,8) PCP: 8(6.5,9)	No
17 18 19 20 21 22 23 24 25 26 27 28 29	47.Should blood vessels supplying the liver be temporarily blocked in people undergoing liver resection? If so, what is the best way of performing this?	All: 31.0% HCP: 11.1% PCP: 63.6%	All: 6(4,7) HCP: 5(2.75,6) PCP: 6(5,7)	All: 26.7% HCP: 11.1% PCP: 50.0%	All: 5.5(4,7) HCP: 5(3.75,6) PCP: 5.5(5.25,7.75))	All: 27.6% HCP: 11.8% PCP: 50.0%	All: 6(5,7) HCP: 5(4,6) PCP: 6(5.25,7)	No
30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46	48.What is the best treatment that should be given to people who undergo liver transplantation for chronic hepatitis B virus (HBV) infection to prevent	All: 46.9% HCP: 40.0% PCP: 58.3%	All: 6(3.5,7) HCP: 6(3,7) PCP: 6(6,8)	All: 36.7% HCP: 22.2% PCP: 58.3%	All: 6(3,7) HCP: 6(2.75,6.25)	All: 37.9% HCP: 23.5% PCP: 58.3%	All: 6(5,7) HCP: 6(4,6.5) PCP: 6(6,7.75)	No

1 2 3 4 5 6 7	reinfection with chronic hepatitis B virus (HBV) infection?				PCP: 6(6,7.75)			
8 9 10 11 12 13 14 15 16	49.Are there alternatives to steroids in treating people with autoimmune hepatitis (AIH)?	-	-	All: 51.9% HCP: 40.0% PCP: 66.7%	All: 7(5,8) HCP: 6(4,7) PCP: 7(6,9)	All: 50.0% HCP: 35.7% PCP: 66.7%	All: 6.5(5,8) HCP: 5.5(3.75,7) PCP: 6.5(6,9)	No
17 18 19 20 21 22 23 24 25	50.What impact does the home situation have on recovery from chronic liver disease and its treatment?	-	-	All: 34.5% HCP: 13.3% PCP: 57.1%	All: 5(3.5,7.5) HCP: 4(3,6) PCP: 5(5,8)	All: 32.1% HCP: 0.0% PCP: 64.3%	All: 5(4,7) HCP: 4(3,5.25) PCP: 5(5,8)	No
26 27 28 29 30 31 32 33 34 35 36 37	51.Does cure of hepatitis C provide benefits to the patient outside reduction in liver related complications?	-	-	All: 29.2% HCP: 33.3% PCP: 22.2%	All: 5.5(3.25,7) HCP: 5(3,7) PCP: 5.5(4.5,6.5)	All: 30.4% HCP: 35.7% PCP: 22.2%	All: 6(4,7) HCP: 5.5(3,7.25) PCP: 6(4.5,6.5)	No

1 2 3 4 5 6 7 8 9 10 11	52.How fast does liver fibrosis (scarring) actually progress in non-alcoholic liver disease patients and does this predict overall outcome?	-	-	All: 62.1% HCP: 40.0% PCP: 85.7%	All: 7(6,8) HCP: 6(5,8) PCP: 7(7,8.25)	All: 64.3% HCP: 42.9% PCP: 85.7%	All: 7.5(6,8) HCP: 6(5,8) PCP: 7.5(7,8.25)	No
12 13 14 15 16 17 18 19 20	53.Should direct-acting antiviral treatments therapies be made more easily accessible to GPs and drug service clinics for treatment of hepatitis C virus?	-	-	All: 50.0% HCP: 46.7% PCP: 55.6%	All: 6.5(3.5,7) HCP: 6(3,7) PCP: 6.5(5.5,8)	All: 52.2% HCP: 50.0% PCP: 55.6%	All: 7(5,7) HCP: 6.5(4.5,7.25) PCP: 7(5.5,8)	No
21 22 23 24 25 26 27 28 29 30 31	54.Should patients diagnosed with liver fibrosis/cirrhosis related to NAFLD (non-alcoholic fatty liver disease) be offered more intensive nutritional support or dietician review?	-	-	All: 60.7% HCP: 46.7% PCP: 76.9%	All: 7(5,8) HCP: 6(3,8) PCP: 7(6.5,9)	All: 63.0% HCP: 50.0% PCP: 76.9%	All: 7(5,8) HCP: 7(4.5,8) PCP: 7(6.5,8.5)	No
32 33 34 35 36 37 38 39 40 41 42 43 44 45 46	55.Why have there been no alternatives to surgery in the form of new drug	-	-	All: 29.2% HCP: 20.0% PCP: 44.4%	All: 4.5(1.25,7) HCP: 4(1,6)	All: 26.1% HCP: 21.4% PCP: 33.3%	All: 4(2,7) HCP:	No

<p>treatments for gall bladder disease & biliary sludge?</p>				<p>PCP: 4.5(2,7.5)</p>		<p>4(1.75,5.5) PCP: 4(2,7.5)</p>	
<p>56. Why is there no proper evidence-based research on nutrition as a way of managing gall bladder disease/biliary sludge?</p>	-	-	<p>All: 36.0% HCP: 26.7% PCP: 50.0%</p>	<p>All: 5(1.5,7) HCP: 4(1,7) PCP: 5(2.5,7.5)</p>	<p>All: 33.3% HCP: 28.6% PCP: 40.0%</p>	<p>All: 5(2,7) HCP: 4.5(1.75,7) PCP: 5(2.5,7.5)</p>	No
<p>57. Why is there such variability in the natural progression of people with primary sclerosing cholangitis: some are very sick and require a transplant whereas others can remain relatively healthy for a long period?</p>	-	-	<p>All: 56.0% HCP: 42.9% PCP: 72.7%</p>	<p>All: 7(6,7) HCP: 6(4,7) PCP: 7(6,8)</p>	<p>All: 54.2% HCP: 38.5% PCP: 72.7%</p>	<p>All: 7(6,7) HCP: 6(4,7) PCP: 7(6,8)</p>	No
<p>58. What are the warning signals that primary sclerosing cholangitis will be aggressive or cancerous?</p>	-	-	<p>All: 57.7% HCP: 53.3% PCP: 63.6%</p>	<p>All: 7(5.75,8.25)</p>	<p>All: 60.0% HCP: 50.0% PCP: 72.7%</p>	<p>All: 7(5.5,8) HCP:</p>	No

				HCP: 7(5,8) PCP: 7(6,9)		6.5(4.75,8) PCP: 7(6,9)	
59.Does information on the impact of the complication on the people's quality of life improve the patient's informed decision- making process about treatment of liver and gallbladder diseases?	-	-	All: 46.4% HCP: 40.0% PCP: 53.8%	All: 6(4,7) HCP: 6(4,7) PCP: 6(4.5,8)	All: 44.4% HCP: 35.7% PCP: 53.8%	All: 6(4,7) HCP: 5.5(4,7) PCP: 6(5,8)	No
60.Will clinical pathways developed with patients and HCP having an equal say result in greater patient satisfaction and health in people with liver and gallbladder diseases?	-	-	All: 44.8% HCP: 33.3% PCP: 57.1%	All: 6(4.5,8) HCP: 5(4,8) PCP: 6(5,8)	All: 46.4% HCP: 35.7% PCP: 57.1%	All: 6(4.25,8) HCP: 5(3.75,8) PCP: 6(5.75,8.25)	No
61.Should high school teenagers be educated about the risks of hepatitis C?	-	-	All: 53.8% HCP: 40.0% PCP: 72.7%	All: 7(3.75,8) HCP: 5(2,7) PCP: 7(6,9)	All: 57.7% HCP: 42.9% PCP: 75.0%	All: 7(4.75,7.25) HCP: 5.5(2,7)	No

						PCP: 7(6.25,8.75)	
62.How can patients with end stage liver failure be better prepared for end of life. How can the HCP supporting them be better prepared to provide that support?	-	-	All: 65.5% HCP: 46.7% PCP: 85.7%	All: 7(6,8) HCP: 6(5,8) PCP: 7(7,9)	All: 67.9% HCP: 50.0% PCP: 85.7%	All: 7(6,8) HCP: 6.5(4.75,8) PCP: 7(7,9)	No
63.Is aggressive control of inflammation on colonic inflammatory bowel disease in primary sclerosing cholangitis associated with improved liver outcomes?	-	-	All: 48.0% HCP: 46.7% PCP: 50.0%	All: 6(5,7) HCP: 6(5,7) PCP: 6(6,8)	All: 50.0% HCP: 42.9% PCP: 60.0%	All: 6.5(5.25,7) HCP: 6(5,7) PCP: 6.5(6,8)	No
64.What is the best way to survey for cholangiocarcinoma in primary sclerosing cholangitis?	-	-	All: 61.5% HCP: 60.0% PCP: 63.6%	All: 7(5.75,8) HCP: 7(5,7) PCP: 7(6,9)	All: 60.0% HCP: 57.1% PCP: 63.6%	All: 7(6,8) HCP: 7(5,7) PCP: 7(6,9)	No
65.Should the criteria for polycystic liver disease and transplantation be changed to take into account the size the liver	-	-	All: 29.2% HCP: 13.3% PCP: 55.6%	All: 4.5(2,7) HCP: 4(2,6)	All: 30.4% HCP: 7.1% PCP: 66.7%	All: 6(3,7) HCP: 4(2,6) PCP: 6(6,7.5)	No

cysts can grow and the additional pressures on all the internal organs?				PCP: 4.5(5.5,7)			
66.Does control of colitis at the time of liver transplant reduce the risk of recurrent primary sclerosing cholangitis?	-	-	All: 36.0% HCP: 33.3% PCP: 40.0%	All: 6(5,7) HCP: 6(4,7) PCP: 6(5,8.25)	All: 33.3% HCP: 28.6% PCP: 40.0%	All: 6(5,7) HCP: 6(3.75,7) PCP: 6(5,8.25)	No
67.Are people with liver disease likely to develop other conditions, if so, what other conditions?	-	-	All: 42.9% HCP: 13.3% PCP: 76.9%	All: 6(3.25,7) HCP: 5(2,6) PCP: 6(6.5,8.5)	All: 46.4% HCP: 14.3% PCP: 78.6%	All: 6(3.25,7.75) HCP: 4.5(2,5.25) PCP: 6(6.75,8.25)	No
68.Do people with liver disease have a reduced life expectancy?	-	-	All: 30.0% HCP: 0.0% PCP: 60.0%	All: 5.5(3,8) HCP: 4(1,5) PCP: 5.5(6,9)	All: 34.5% HCP: 0.0% PCP: 66.7%	All: 6(3,8) HCP: 3.5(1.75,5.25)	No

) PCP: 6(6,9)	
69.Should transjugular intrahepatic portosystemic shunt (TIPS) be used earlier in management of variceal haemorrhage?	-	-	All: 51.9% HCP: 53.3% PCP: 50.0%	All: 7(5,7) HCP: 7(5,8) PCP: 7(5,7)	All: 55.6% HCP: 57.1% PCP: 53.8%	All: 7(6,7) HCP: 7(5.75,8) PCP: 7(5.5,7)	No
70.Should abnormal alanine transaminase (ALT) reference ranges be revised downwards in line with ACG (American College of Gastroenterology) guidance?	-	-	All: 36.0% HCP: 33.3% PCP: 40.0%	All: 6(5,7) HCP: 6(5,7) PCP: 6(5,7)	All: 37.5% HCP: 35.7% PCP: 44.4%	All: 6(5,7) HCP: 6(4.5,7.25) PCP: 6(5.875,7)	No

a Questions from 49 to 70 were collected during the first round of Delphi.

b Consensus was reached when at least 80% of Delphi-panel members scored between 7 and 9 for the specific question.

Abbreviations:

HCP = Healthcare professionals

1
2
3 IQR = interquartile range
4
5

6 PCP = Patients, carers, and public
7
8

9 References

- 10
11
12 1. Majumdar A, Roccarina D, Thorburn D, Davidson BR, Tsochatzis E, Gurusamy KS. Management of people with early- or very early-stage
13 hepatocellular carcinoma: an attempted network meta-analysis. The Cochrane database of systematic reviews. 2017;3:Cd011650. Epub 2017/03/30. doi:
14 10.1002/14651858.CD011650.pub2. PubMed PMID: 28351116.
15
16 2. Saffioti F, Gurusamy KS, Hawkins N, Toon CD, Tsochatzis E, Davidson BR, et al. Pharmacological interventions for primary sclerosing cholangitis: an
17 attempted network meta-analysis. The Cochrane database of systematic reviews. 2017;3:Cd011343. Epub 2017/04/19. doi:
18 10.1002/14651858.CD011343.pub2. PubMed PMID: 28417463.
19
20 3. Lombardi R, Onali S, Thorburn D, Davidson BR, Gurusamy KS, Tsochatzis E. Pharmacological interventions for non-alcohol related fatty liver disease
21 (NAFLD): an attempted network meta-analysis. The Cochrane database of systematic reviews. 2017;3:CD011640. Epub 2017/03/31. doi:
22 10.1002/14651858.CD011640.pub2. PubMed PMID: 28358980.
23
24 4. Rodriguez-Peralvarez M, Guerrero-Misas M, Thorburn D, Davidson BR, Tsochatzis E, Gurusamy KS. Maintenance immunosuppression for adults
25 undergoing liver transplantation: a network meta-analysis. The Cochrane database of systematic reviews. 2017;3:CD011639. Epub 2017/04/01. doi:
26 10.1002/14651858.CD011639.pub2. PubMed PMID: 28362060.
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

- 1
2
3 5. Czaja AJ, Carpenter HA, Lindor KD. Ursodeoxycholic acid as adjunctive therapy for problematic type 1 autoimmune hepatitis: a randomised placebo-
4 controlled treatment trial. *Hepatology (Baltimore, Md)*. 1999;30(6):1381-6. Epub 1999/11/26. doi: 10.1002/hep.510300603. PubMed PMID: 10573515.
5
6
7 6. Manns MP, Woynarowski M, Kreisel W, Lurie Y, Rust C, Zuckerman E, et al. Budesonide induces remission more effectively than prednisone in a
8 controlled trial of patients with autoimmune hepatitis. *Gastroenterology*. 2010;139(4):1198-206. Epub 2010/07/06. doi: 10.1053/j.gastro.2010.06.046.
9
10 PubMed PMID: 20600032.
11
12 7. Woynarowski M, Nemeth A, Baruch Y, Koletzko S, Melter M, Rodeck B, et al. Budesonide versus prednisone with azathioprine for the treatment of
13 autoimmune hepatitis in children and adolescents. *The Journal of pediatrics*. 2013;163(5):1347-53.e1. Epub 2013/07/03. doi: 10.1016/j.jpeds.2013.05.042.
14
15 PubMed PMID: 23810723.
16
17 8. Saffioti F, Gurusamy KS, Eusebi LH, Tsochatzis E, Davidson BR, Thorburn D. Pharmacological interventions for primary biliary cholangitis: an
18 attempted network meta-analysis. *The Cochrane database of systematic reviews*. 2017;3:CD011648. Epub 2017/03/30. doi:
19
20 10.1002/14651858.CD011648.pub2. PubMed PMID: 28350426.
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46